The College on Problems of Drug Dependence

85th Annual Scientific Meeting
June 17 - 21, 2023
Denver, CO

Program Book

www.cpddd.org
With a recently completed $80 million dollar renovation and located on the 16th Street Mall, the hotel offers access to some of the best attractions in Denver. The mile-long 16th Street Mall is a pedestrian promenade with shopping, dining, and entertainment.

REGISTRATION INFORMATION

Please visit the CPDD Registration desk to pick up your name badge and other meeting materials. Registration is located in the Plaza Building, Concourse Level, at the Plaza Registration desk during the following hours:

- Saturday, June 17: 12:00 pm-7:00 pm
- Sunday, June 18: 7:00 am-7:00 pm
- Monday, June 19: 7:00 am-7:00 pm
- Tuesday, June 20: 7:00 am-7:00 pm
- Wednesday, June 21: 7:00 am-3:00 pm

CONFERENCE WI-FI

Complimentary internet is available for CPDD attendees in the meeting spaces.

- Network Name: MarriottBonvoy_Conference
- Password: cpdd2023
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Information</td>
<td>4</td>
</tr>
<tr>
<td>COVID-19 Safety Protocols</td>
<td>5</td>
</tr>
<tr>
<td>2022-2023 Board of Directors</td>
<td>6</td>
</tr>
<tr>
<td>2023 Program Committee</td>
<td>7</td>
</tr>
<tr>
<td>Program Schedule</td>
<td>8</td>
</tr>
<tr>
<td>Saturday, June 17</td>
<td>8</td>
</tr>
<tr>
<td>Sunday, June 18</td>
<td>9</td>
</tr>
<tr>
<td>Monday, June 19</td>
<td>10</td>
</tr>
<tr>
<td>Tuesday, June 20</td>
<td>11</td>
</tr>
<tr>
<td>Wednesday, June 21</td>
<td>12</td>
</tr>
<tr>
<td>Plenary Sessions</td>
<td>13</td>
</tr>
<tr>
<td>Abstracts</td>
<td>19</td>
</tr>
<tr>
<td>Posters</td>
<td>55</td>
</tr>
<tr>
<td>Author Index</td>
<td>140</td>
</tr>
<tr>
<td>2022-2023 Donors</td>
<td>147</td>
</tr>
<tr>
<td>2024 Save the Date</td>
<td>Back Cover</td>
</tr>
</tbody>
</table>
QUESTIONS?
If you have questions during the conference, we encourage you to:

1) Stop by the registration desk, located in the Plaza Exhibit area in the Plaza Building, Concourse Level.
2) Email info@cpdd.org with additional question or concerns, or call (615) 432-0099.
3) Visit the Speaker Ready Room, located in Plaza Court 7, for assistance with presentation or presenter questions.

JOIN THE CONVERSATION!
CPDD is on social media, and we invite you to join the online conversation. Please follow/like the CPDD social media accounts:

@CPDDorg  @CPDDmembers  @CPDD

And don’t forget to use #CPDD23 if you post pictures or comments about the Meeting.

CPDD’S DISCLAIMER STATEMENT
Information obtained via CPDD channels, including webinars, conferences, websites, etc., is intended only for research and information purposes. CPDD cannot be held liable for the information consumed and information presented may not reflect the opinions of CPDD or its members. The content and information shared should be used at the discretion of the consumer.

Funding for this conference was made possible (in part) by 5 R13 DA 013182-15 from the National Institute on Drug Abuse.
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations, imply endorsement by the U.S. Government.
WEAR A MASK
Masks are strongly recommended at all CPDD events. Make sure and pack yours!

WEAR YOUR BADGE
A CPDD badge is required at all times for entry.

GRAB A LANYARD
Red=Keep Your Distance
Yellow=Limited Contact
Green=Handshakes & High Fives

ATTENDEES THAT EXPERIENCE SYMPTOMS OR FEEL ILL ONSITE SHOULD QUARANTINE IN THEIR GUESTROOM AND CALL JESSE HOWARD AT 606-233-3049 TO RECEIVE NEXT STEPS.
<table>
<thead>
<tr>
<th>EXECUTIVE COMMITTEE</th>
<th>BOARD MEMBERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amy Janes, PhD</td>
<td>Sudie Back, PhD</td>
</tr>
<tr>
<td>President</td>
<td>Qiana Brown, PhD</td>
</tr>
<tr>
<td></td>
<td>Kelly Dunn, MBA, PhD</td>
</tr>
<tr>
<td></td>
<td>Francesca Filbey, PhD</td>
</tr>
<tr>
<td>Deborah Hasin, PhD</td>
<td>Albert Garcia-Romeu, PhD</td>
</tr>
<tr>
<td>President-Elect</td>
<td>Cassandra Gipson-Reichardt, PhD</td>
</tr>
<tr>
<td></td>
<td>Angela Heads, PhD</td>
</tr>
<tr>
<td>Jack Bergman, PhD</td>
<td>Jermaine Jones, PhD</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Wendy Lynch, PhD</td>
</tr>
<tr>
<td></td>
<td>Silvia Martins, MD</td>
</tr>
<tr>
<td>William Stoops, PhD</td>
<td>Angela Moreland, PhD</td>
</tr>
<tr>
<td>Past-President</td>
<td>Marco Pravetoni, PhD</td>
</tr>
<tr>
<td></td>
<td>James Rowlett, PhD</td>
</tr>
<tr>
<td>Sandra Comer, PhD</td>
<td>Dace Svikis, PhD</td>
</tr>
<tr>
<td>Public Policy Officer</td>
<td>Michael Taffe, PhD</td>
</tr>
<tr>
<td></td>
<td>Erin Winstanley, PhD</td>
</tr>
</tbody>
</table>
2023 PROGRAM COMMITTEE

Chair: Kevin Freeman, PhD

MEMBERS
Marc Auriacombe, Prof Dr med
Cecilia Bergeria, PhD
Eduardo R. Butelman, PhD
Mance E. Buttram, PhD
Scott E. Hadland, MD, MPH, MS
Abenaa A. Jones, PhD
Jermaine D. Jones, PhD
Mikhail N. Koffarnus, PhD
Catalina Lopez-Quintero, MD, PhD
Carol A. Paronis, PhD
Dustin J. Stairs, PhD
Justin C. Strickland, PhD
Denise C. Vidot, PhD
Heather Burrell Ward, MD
## AGENDA

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 AM</td>
<td>ISGIDAR Annual Meeting</td>
<td>Majestic Ballroom</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Speaker Ready Room</td>
<td>Plaza Court 7</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Registration</td>
<td>Plaza Registration</td>
</tr>
<tr>
<td>01:00 PM</td>
<td>Workshop: Stressful Environments and Genetic Risk Factors Associated With Early Initiation of Alcohol and Substance Use: Findings From the ABCD Study</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>01:00 PM</td>
<td>Workshop: Evaluating Pennsylvania’s Centers of Excellence on Improving OUD Treatment Access &amp; Patient Care</td>
<td>Plaza Ballroom D</td>
</tr>
<tr>
<td>01:00 PM</td>
<td>Workshop: Sharing Your Scientific Story: Tips and Tricks for Strategically and Effectively Communicating Your Research</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>01:00 PM</td>
<td>Workshop: Pathways to Recovery and Beyond in Native American Communities</td>
<td>Governor’s Square 15</td>
</tr>
<tr>
<td>01:00 PM</td>
<td>Workshop: A View Beyond the Horizon: Innovative Methodologies and Approaches in Substance Use Disorder Research and Treatment Utilized Internationally</td>
<td>Grand Ballroom II</td>
</tr>
<tr>
<td>02:30 PM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>03:00 PM</td>
<td>Workshop: New Approaches to Culturally Appropriate Treatment and Research</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>03:00 PM</td>
<td>Workshop: Standards of Psychedelic Care: Peer &amp; Professional Providers</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>03:00 PM</td>
<td>Workshop: Epidemiology and Public Health Research Methods</td>
<td>Grand Ballroom II</td>
</tr>
<tr>
<td>03:00 PM</td>
<td>Workshop: Collaboration and Complication: Lessons Learned in Implementing Community-Engaged Research on Substance Use</td>
<td>Plaza Ballroom D</td>
</tr>
<tr>
<td>03:00 PM</td>
<td>Workshop: r/AskAcademia: Special Considerations in the Practice of Using Reddit for Substance Use Research</td>
<td>Governor’s Square 15</td>
</tr>
<tr>
<td>04:30 PM</td>
<td>National Drug Early Warning System (NDEWS) Meeting</td>
<td>Governor’s Square 16</td>
</tr>
<tr>
<td>04:30 PM</td>
<td>Workshop: NIDA Early Career Workshop</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>05:00 PM</td>
<td>Closed Abstinence-Based Recovery Meeting (NA/AA)</td>
<td>Silver</td>
</tr>
<tr>
<td>05:00 PM</td>
<td>Committee Chairs Meeting (Invitation Only)</td>
<td>Governor’s Square 10</td>
</tr>
<tr>
<td>07:00 PM</td>
<td>Opening Reception</td>
<td>Plaza Ballroom BCEF (Plenary)</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>07:00 AM</td>
<td>Registration</td>
<td>Plaza Registration</td>
</tr>
<tr>
<td>08:00 AM</td>
<td>Opening Session: Plenary, NIDA Update, and Eddy Lecture</td>
<td>Plaza Ballroom BCEF (Plenary)</td>
</tr>
<tr>
<td>08:00 AM</td>
<td>Speaker Ready Room</td>
<td>Plaza Court 7</td>
</tr>
<tr>
<td>10:15 AM</td>
<td>Mini-Symposium: Harm Reduction Utilization and Strategies</td>
<td>Grand Ballroom II</td>
</tr>
<tr>
<td>10:15 AM</td>
<td>Oral Communication: Sexual Minority Health</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>10:15 AM</td>
<td>Oral Communication: Gapapentin: Friend or Foe?</td>
<td>Governor’s Square 15</td>
</tr>
<tr>
<td>10:15 AM</td>
<td>Oral Communication: Criminal Justice: Dangers Upon Release</td>
<td>Plaza Ballroom D</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Mini-Symposium: 2022 NIDA Craving Challenge</td>
<td>Plaza Ballroom BCEF (Plenary)</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Oral Communication: Uncertainty as a Driver of SUDs</td>
<td>Governor’s Square 15</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Oral Communication: Alcohol Treatment Development</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Oral Communication: Preclinical Neuro Effects of Methamphetamine</td>
<td>Plaza Ballroom D</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Oral Communication: Juvenile Justice</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>12:15 PM</td>
<td>NIDA K12 Scholars Lunch</td>
<td>Governor’s Square 11</td>
</tr>
<tr>
<td>01:00 PM</td>
<td>Lunch Presentation: Fischman Lecture Presented by Joy Schmitz, Marian W. Fischman Lectureship Award Winner</td>
<td>Plaza Ballroom BCEF (Plenary)</td>
</tr>
<tr>
<td>02:15 PM</td>
<td>Workshop: “Pre-Addiction:” A Starting Point for a Strategic Shift Toward Earlier Intervention in Substance Use Disorders</td>
<td>Plaza Ballroom BCEF (Plenary)</td>
</tr>
<tr>
<td>02:15 PM</td>
<td>Oral Communication: E-Cigarettes: That’s Not a Thumb Drive, Mom!</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>02:15 PM</td>
<td>Oral Communication: Cocaine Science in Humans</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>02:15 PM</td>
<td>Oral Communication: Novel Stimulants and Mechanisms</td>
<td>Plaza Ballroom D</td>
</tr>
<tr>
<td>02:30 PM</td>
<td>ECMC Mentee/Mentor Mixer</td>
<td>Plaza Exhibit Networking Zone</td>
</tr>
<tr>
<td>03:15 PM</td>
<td>Networking Break</td>
<td>Plaza Exhibit Networking Zone</td>
</tr>
<tr>
<td>03:30 PM</td>
<td>CPDD Finance Committee Meeting</td>
<td>Plaza Court 5</td>
</tr>
<tr>
<td>03:45 PM</td>
<td>DAD/DADR Editorial Board Meeting (Invitation Only)</td>
<td>Governor’s Square 10</td>
</tr>
<tr>
<td>04:00 PM</td>
<td>Media Forum</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>04:00 PM</td>
<td>Policy Forum</td>
<td>Grand Ballroom II</td>
</tr>
<tr>
<td>05:15 PM</td>
<td>Poster Session 1</td>
<td>Plaza Exhibit</td>
</tr>
<tr>
<td>05:30 PM</td>
<td>CPDD Presidential Reception (Invitation Only)</td>
<td>Governor’s Square 17</td>
</tr>
<tr>
<td>06:30 PM</td>
<td>Closed Abstinence-Based Recovery Meeting (NA/AA)</td>
<td>Silver</td>
</tr>
<tr>
<td>06:45 PM</td>
<td>Pre and Post-Doctoral Networking</td>
<td>Plaza Exhibit Networking Zone</td>
</tr>
<tr>
<td>07:00 PM</td>
<td>Movie Screening and Discussion: Swallow THIS: A Documentary about Methadone and COVID-19</td>
<td>Plaza Ballroom BCEF (Plenary)</td>
</tr>
<tr>
<td>Time</td>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>---------</td>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>07:00 AM</td>
<td>07:00 PM</td>
<td>Registration</td>
</tr>
<tr>
<td>08:00 AM</td>
<td>09:00 AM</td>
<td>NIAAA Update Presented by George Koob, Director of the National Institute on Alcohol Abuse and Alcoholism</td>
</tr>
<tr>
<td>08:00 AM</td>
<td>05:00 PM</td>
<td>Speaker Ready Room</td>
</tr>
<tr>
<td>09:00 AM</td>
<td>10:00 AM</td>
<td>Oral Communication: Novel Strategies for Pain Therapeutics: Still Trying</td>
</tr>
<tr>
<td>09:00 AM</td>
<td>10:00 AM</td>
<td>Mini-Symposium: Beyond the Dichotomy</td>
</tr>
<tr>
<td>09:00 AM</td>
<td>10:00 AM</td>
<td>Oral Communication: Nicotine Reinforcement</td>
</tr>
<tr>
<td>09:00 AM</td>
<td>10:00 AM</td>
<td>Oral Communication: Sex and Gender Differences in SUDs</td>
</tr>
<tr>
<td>09:00 AM</td>
<td>10:00 AM</td>
<td>Oral Communication: Cannabis Policy and Regulation</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>10:30 AM</td>
<td>Break</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>12:00 PM</td>
<td>Symposium: Measurement of Cannabis Consumption to Determine Risk and Promote Public Health</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>12:00 PM</td>
<td>Symposium: The Intersection of Aging, Tobacco Use, and Health Equity</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>12:00 PM</td>
<td>Symposium: The Intersection of COVID-19 and Substance Use Disorders</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>12:00 PM</td>
<td>Symposium: Stimulation for the Treatment of Stimulant Use Disorder</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>12:00 PM</td>
<td>Forum: Restructuring the Pathway from Discovery to Dissemination of New Medications in the Academic Environment</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>02:00 PM</td>
<td>CPDD Early Career Investigator Travel Awards Luncheon</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>02:00 PM</td>
<td>Lunch Presentation: Presidential Symposium</td>
</tr>
<tr>
<td>02:00 PM</td>
<td>03:15 PM</td>
<td>Human Forum: Nothing About Us Without Us: Engaging Individuals with Lived Experience of Substance Use Disorders in Substance Use Research Development and Implementation</td>
</tr>
<tr>
<td>02:00 PM</td>
<td>03:15 PM</td>
<td>Animal Forum: The 3Rs Concept of Replacement: Future Tools or Political Strategy?</td>
</tr>
<tr>
<td>03:15 PM</td>
<td>03:45 PM</td>
<td>Break</td>
</tr>
<tr>
<td>03:30 PM</td>
<td>05:00 PM</td>
<td>Symposium: 10 Years Gone: Remembering Bill Woolverton Through His Impact on our Current Research Programs</td>
</tr>
<tr>
<td>03:30 PM</td>
<td>05:00 PM</td>
<td>Workshop: Early Career Member Committee: Navigating a Career in Addiction Science</td>
</tr>
<tr>
<td>03:30 PM</td>
<td>05:00 PM</td>
<td>Federal Agencies and Cannabis Research: Updates From NIH, FDA and DEA</td>
</tr>
<tr>
<td>03:30 PM</td>
<td>04:30 PM</td>
<td>Oral Communication: PrEP Among Drug Users</td>
</tr>
<tr>
<td>05:00 PM</td>
<td>06:30 PM</td>
<td>Poster Session 2</td>
</tr>
<tr>
<td>06:30 PM</td>
<td>07:30 PM</td>
<td>Primm Singleton Reception (Invitation Only)</td>
</tr>
<tr>
<td>06:30 PM</td>
<td>09:30 PM</td>
<td>Shuttle to Space Gallery Exhibition: “Art for Hope”</td>
</tr>
<tr>
<td>06:30 PM</td>
<td>07:30 PM</td>
<td>Closed Abstinence-Based Recovery Meeting (NA/AA)</td>
</tr>
<tr>
<td>06:30 PM</td>
<td>07:30 PM</td>
<td>LGBTQIA+ Networking Reception</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------------------------------------------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>07:00 AM</td>
<td>Registration</td>
<td>Plaza Registration</td>
</tr>
<tr>
<td>08:00 AM - 09:30 AM</td>
<td>Symposium: The Racist Origins and Impact of the War on Drugs</td>
<td>Grand Ballroom II</td>
</tr>
<tr>
<td>08:00 AM - 09:30 AM</td>
<td>Symposium: The Past, Present, and Future of Reinforcer Pathology Theory in Substance Use Disorder</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>08:00 AM - 09:30 AM</td>
<td>Symposium: Dysregulation of the Prefrontal Cortex in Substance Use Disorders</td>
<td>Plaza Ballroom D</td>
</tr>
<tr>
<td>08:00 AM - 09:30 AM</td>
<td>Symposium: Beyond GWAS: The Genetics and Epigenetics of Addiction</td>
<td>Governor’s Square 15</td>
</tr>
<tr>
<td>08:00 AM - 09:30 AM</td>
<td>Symposium: Not like Other Opioids: How is Fentanyl Unique?</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>08:00 AM</td>
<td>Speaker Ready Room</td>
<td>Plaza Court 7</td>
</tr>
<tr>
<td>10:00 AM - 11:30 AM</td>
<td>Symposium: Medication Development for Methamphetamine Use Disorder</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>10:00 AM - 11:30 AM</td>
<td>Symposium: The Potential of Psychedelic Therapies for Substance Use Disorders</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>10:00 AM - 11:30 AM</td>
<td>Symposium: Neuropeptides in Reward, Addiction, and Mental Health</td>
<td>Plaza Ballroom D</td>
</tr>
<tr>
<td>10:00 AM - 11:30 AM</td>
<td>Symposium: How Neuroimaging Can Be Used in Treatment Development in Drug Addiction: From FDA Standards to Clinical Applications</td>
<td>Grand Ballroom II</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Workshop: 29th Annual Contingency Management Working Group</td>
<td>Governor’s Square 15</td>
</tr>
<tr>
<td>12:15 PM</td>
<td>Symposium: In Memoriam Martin Adler</td>
<td>Plaza Ballroom BCEF (Plenary)</td>
</tr>
<tr>
<td>01:15 PM - 02:15 PM</td>
<td>Mini-Symposium: Monitoring and Diagnostic Devices for Substance Use Disorders: Challenges and Opportunities</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>01:15 PM - 02:15 PM</td>
<td>Oral Communication: SUD and Pregnancy</td>
<td>Grand Ballroom II</td>
</tr>
<tr>
<td>01:15 PM</td>
<td>Oral Communication: Minor Cannabinoids: Mild High?</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>01:15 PM</td>
<td>Oral Communication: Cocaine in Context</td>
<td>Plaza Ballroom D</td>
</tr>
<tr>
<td>01:15 PM</td>
<td>Late-Breaking Oral Session 1</td>
<td>Governor’s Square 15</td>
</tr>
<tr>
<td>02:15 PM</td>
<td>Networking Break</td>
<td></td>
</tr>
<tr>
<td>02:45 PM - 03:45 PM</td>
<td>Late-Breaking Oral Session 2</td>
<td>Governor’s Square 15</td>
</tr>
<tr>
<td>02:45 PM - 03:45 PM</td>
<td>Mini-Symposium: From Initiation to Addiction: A Measure of the Full Range of Involvement for Opioids, Cannabis, and Alcohol</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>02:45 PM</td>
<td>Oral Communication: Telehealth: Uniform Still Required</td>
<td>Grand Ballroom II</td>
</tr>
<tr>
<td>02:45 PM</td>
<td>Oral Communication: Behavioral Economics</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>02:45 PM</td>
<td>Oral Communication: Nicotine Clinical Treatments</td>
<td>Plaza Ballroom D</td>
</tr>
<tr>
<td>04:00 PM</td>
<td>CPDD Business Meeting</td>
<td>Governor’s Square 15</td>
</tr>
<tr>
<td>05:15 PM</td>
<td>Poster Session 3</td>
<td>Plaza Exhibit</td>
</tr>
<tr>
<td>05:30 PM</td>
<td>Rural Opioid Initiative Meeting (Invite Only)</td>
<td>Governor’s Square 10</td>
</tr>
<tr>
<td>06:15 PM</td>
<td>Closed Abstinence-Based Recovery Meeting (NA/AA)</td>
<td>Silver</td>
</tr>
<tr>
<td>07:00 PM</td>
<td>Awards Dinner Celebration</td>
<td>Plaza Ballroom BCEF (Plenary)</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>07:00 AM</td>
<td>Registration</td>
<td>Plaza Registration</td>
</tr>
<tr>
<td>08:00 AM</td>
<td>Symposium: Using Big Data to Understand the Role of the Gut Microbiome in Substance Use Disorders</td>
<td>Plaza Ballroom D</td>
</tr>
<tr>
<td>08:00 AM</td>
<td>Symposium: Prevention is Better than Cure: Early Intervention for Substance Use Disorders</td>
<td>Governor’s Square 15</td>
</tr>
<tr>
<td>08:00 AM</td>
<td>Symposium: Development of Fentanyl-Targeted Vaccines to Decrease Overdose Fatalities</td>
<td>Grand Ballroom II</td>
</tr>
<tr>
<td>08:00 AM</td>
<td>Symposium: Leaving No One Behind: Ending the HIV Epidemic With Targeted Interventions for People Who Use Drugs</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>08:00 AM</td>
<td>Oral Communication: Methamphetamine Science in Humans</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>08:00 AM</td>
<td>Oral Communication: Methamphetamine Science in Humans</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>08:30 AM</td>
<td>Brunch with Champions</td>
<td>Governor’s Square 14</td>
</tr>
<tr>
<td>09:30 AM</td>
<td>Symposium: Treating SUD in Patients with PTSD and Histories of Victimization</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: Driving Impairment Caused by the Use of Cannabis and Other Drugs: Recent Evidence From Human Laboratory Studies</td>
<td>Grand Ballroom II</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: A Gentle Introduction to Data Science Tools for Addiction Research: Use Cases With Examples</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: Universal Precautions: Considerations When Conducting Clinical Addiction Research in the Acute Care Hospital</td>
<td>Plaza Ballroom D</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Oral Communication: Emerging Drugs: As If There Weren't Enough Already</td>
<td>Governor’s Square 15</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>In Memoriam Mary Jeanne Kreek</td>
<td>Plaza Ballroom BCEF (Plenary)</td>
</tr>
<tr>
<td>01:00 PM</td>
<td>Oral Communication: Online Drug Marketing: Dealing in the Work-From-Home Age</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>01:00 PM</td>
<td>Oral Communication: SUD and Comorbid Anxiety</td>
<td>Grand Ballroom II</td>
</tr>
<tr>
<td>01:00 PM</td>
<td>Oral Communication: Imaging</td>
<td>Governor’s Square 15</td>
</tr>
<tr>
<td>01:00 PM</td>
<td>Oral Communication: Opioid-Stimulant Interactions: Speedballs and Goofballs</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>01:00 PM</td>
<td>Oral Communication: Digital Therapeutics: Harmful if Swallowed!</td>
<td>Plaza Ballroom D</td>
</tr>
<tr>
<td>02:00 PM</td>
<td>Poster Session 4</td>
<td>Plaza Exhibit</td>
</tr>
<tr>
<td>03:45 PM</td>
<td>Oral Communication: SUD and Suicidality</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>03:45 PM</td>
<td>Oral Communication: Understanding SUD Through Narrative Perspectives</td>
<td>Plaza Ballroom A</td>
</tr>
<tr>
<td>03:45 PM</td>
<td>Oral Communication: Delta-8-THC: Mile High?</td>
<td>Governor’s Square 15</td>
</tr>
<tr>
<td>03:45 PM</td>
<td>Oral Communication: Decision-Making in SUDs</td>
<td>Plaza Ballroom D</td>
</tr>
<tr>
<td>03:45 PM</td>
<td>Oral Communication: Novel Treatment Targets for Fentanyl and Beyond</td>
<td>Grand Ballroom II</td>
</tr>
<tr>
<td>05:00 PM</td>
<td>Closing Session and Sweepstakes</td>
<td>Plaza Ballroom A</td>
</tr>
</tbody>
</table>
SATURDAY, JUNE 17, 2023

4:30 P.M. - 7:00 P.M.

Workshop: NIDA Early Career Workshop
Plaza Ballroom A

NIDA EARLY CAREER WORKSHOP

Lindsey Friend, National Institution on Drug Abuse

The National Institute on Drug Abuse (NIDA) Early Career Workshop Summer 2023 will be held on Saturday June 17, 2023. This symposium will focus on career development and grantsmanship ideal for graduate students, postdoctoral fellows, and early-stage investigators. NIDA offers a strategic set of funding mechanisms for all early career stages. These awards are designed to facilitate continuous growth of early investigators to become career independence and to strengthen research workforce development of next generation biomedical scientists. The theme for this session is persistence in advancing career and science. Topics covered include National Institutes of Health grant mechanisms and review processes, and strategies to overcome hurdle, master grantsmanship, and tips to secure grant awards. Speakers include Program Officers, Scientific Review Officers, Research Training Officers and the Director of the Office of Diversity and Health Disparities from the National institute on Drug Abuse (NIDA). Extramural speakers include early-stage NIDA awardees and experienced training director and substance use researchers.

SUNDAY, JUNE 18, 2023

8:00 A.M. - 10:00 A.M.

Opening Session: Plenary, NIDA Update, and Eddy Lecture
Plaza Ballroom BCEF (Plenary)

NIDA UPDATE

Nora Volkow, National Institute on Drug Abuse

Scientific advances continue to broaden our understanding of the biological, developmental, and environmental elements underlying drug use and addiction and to accelerate efforts to develop targeted strategies for their prevention and treatment. At the same time, the challenges confronting the addiction field have grown both in number and in magnitude. This presentation will highlight such challenges as the growing use of fentanyl by itself or in combination with other opioids or stimulant drugs like cocaine and methamphetamine and the staggering number of overdose deaths that result. It will also focus on how NIH researchers have been using scientific advances to address the opioid crisis which has been further exacerbated by the COVID pandemic, including the development of new medications and formulations to help treat opioid use disorders and overdoses; prevention strategies to mitigate an individual’s vulnerability to addiction; and implementation science to guide optimal deployment of therapeutic interventions including the use of telehealth in diverse settings (healthcare, justice setting, rural communities).
EDDY LECTURE: WHAT HAS BRAIN IMAGING TAUGHT US ABOUT STIMULANT USE DISORDER

Edythe London, University of California Los Angeles

This session will cover scientific findings about stimulant use disorder, obtained from brain imaging research. The research findings will be presented in the historical context of the cocaine/crack epidemic of the 1980s, the surge of methamphetamine use beginning in the late 1990's and the recent surge in stimulant-related deaths. A major focus will be on taking what we know about the circuitry and neurotransmitter systems affected in designing new approaches to treatment.

1:00 P.M. - 2:00 P.M.

Lunch Presentation: Fischman Lecture Presented by Joy Schmitz, Marian W. Fischman Lectureship Award Winner
Plaza Ballroom BCEF (Plenary)

FISCHMAN LECTURE: MY 30-YEAR RESEARCH JOURNEY: HIGH-RISK SITUATIONS, COPING SKILLS, AND LESSONS LEARNED ALONG THE WAY

Joy Schmitz, University of Texas Health Science Center

This session will honor the work of Dr. Marian W. Fischman, recognizing her as an inspiring role model for women in science. The recipient of this year’s award will focus on her contributions to the field of drug abuse research and treatment, with a particular focus on her efforts to develop behavioral and pharmacological interventions for cocaine use disorder. She will conclude by highlighting her role in cultivating the next generation of women addiction researchers.

MONDAY, JUNE 19, 2023

8:00 A.M. - 9:00 A.M.

NIAAA Update Presented by George Koob, Director of the National Institute on Alcohol Abuse and Alcoholism
Plaza Ballroom BCEF (Plenary)

George Koob, National Institute on Alcohol Abuse and Alcoholism

Alcohol misuse and alcohol use disorder (AUD) are endemic societal problems that have been willingly absorbed into the social fabric of our society for generations. They cause an enormous amount of medical pathology, human suffering, loss of productivity and cost to our medical care system and the nation's economy. Alcohol misuse accounts for 30 million individuals with alcohol use disorder, 5% of cancers, 50% of liver disease deaths, and up to 25 % of pancreatitis. While efforts to employ screening, brief intervention and referral to treatment have successfully initiated screening in many situations, brief intervention and referral to treatment remain underused. Missed screening opportunities especially for some subgroups and the more widespread lack of follow up after screening contribute to a significant treatment gap: less than 10% of individuals in need of treatment receive treatment for AUD. Less than 2% receive one of the three FDA approved and effective medications for treatment of AUD. In addition, the COVID-19 pandemic has exposed some long-neglected drivers of AUD: increased drinking to cope with stress, interaction of alcohol with mental health, the role of
alcohol in women's health, alcohol and health in older adults, and understanding recovery from AUD. In the face of these challenges, a cultural change is underway as highlighted by movements to reevaluate our relationship with alcohol such as Dry January, Sober October, and the broader Sober Curious movement. Current NIAAA priorities and challenges include providing resources for the public to facilitate prevention among young adults (College Aim), to help individuals evaluate their own relationship with alcohol (Rethinking Drinking), and to assist those seeking treatment (NIAAA Treatment Navigator). Also, the Healthcare Professional Core Resource on Alcohol, launched in 2022, provides healthcare professionals with evidence-based knowledge and resources to address alcohol misuse in clinical practice.

**12:30 P.M. - 2:00 P.M.**

**Lunch Presentation: Presidential Symposium**
Plaza Ballroom BCEF (Plenary)

**PRESIDENTIAL SYMPOSIUM: THE CASE AGAINST PURITY: STUDYING THE INTERSECTION OF PSYCHIATRIC AND SUBSTANCE USE DISORDERS**
Plaza Ballroom BCEF (Plenary)
Amy Janes, NIDA

The Case Against Purity: Studying the Intersection of Psychiatric and Substance Use Disorders
*Anne Eden Evins, Massachusetts General Hospital-Psychiatry*

Beginning with the question of what can we do strategically to accelerate progress in the treatment of substance use disorders? This symposium explores from clinical and pre-clinical perspectives whether a concerted effort to study the intersection of psychiatric and substance use disorders could accelerate clinical progress. There will be discussion and Q and A led by Drs. Haney, Koob, Volkow, Evins, Khokhar, and Janes.

Cannabis Use and Schizophrenia: Cracking the Chicken or Egg Question
*Jibran Khokhar, Western University*

Although cannabis use occurs commonly in patients with schizophrenia and significantly worsen their clinical course, the neurobiological basis of cannabis use in schizophrenia is not well understood. Therefore, there is a critical need to understand the mechanisms underlying cannabis use in schizophrenia in order to identify potential targets for therapeutic intervention. Since cannabis use usually begins in adolescence, it is also important to understand the long-term effects of life-time cannabis exposure on schizophrenia- and reward-related behaviours and circuitry. Lastly, there is a need for exploring the shared genetic susceptibility for these co-occurring disorders. This talk will combine a variety of translational pre-clinical pharmacological, genetic, behavioural, electrophysiological (local field potential recordings) and magnetic resonance imaging (resting-state functional connectivity and magnetic resonance spectroscopy) approaches to study this topic with an eye toward developing better treatment approaches.

*Margaret Haney, Columbia University Irving Medical Center*  
*Nora Volkow, National Institute on Drug Abuse*  
*George Koob, National Institute on Alcohol Abuse and Alcoholism*
Federal Agencies and Cannabis Research: Updates From NIH, FDA and DEA
Grand Ballroom I

Steve Gust, Consultant, National Center on Complementary and Integrative Health
Angela Arensdorf, NIH/NCCIH

Cannabis research is subject to rapidly changing legal and regulatory requirements, while evolving findings on its potential therapeutic effects has stimulated significant changes in Federal research support. This panel will provide updates from the key Federal agencies involved in cannabis regulation and research and should provide attendees with up-to-date information relevant to researchers interested in cannabis and related constituents.

Cannabinoid Research at the NIH
David Shurtleff, NCCIH/NIH

The National Institutes of Health (NIH) support of cannabinoid and cannabis research has increased over the past few years. Several NIH Institutes, Centers, and Offices (ICOs) have a growing interest in the therapeutic potential of cannabis, cannabinoids, and related compounds as well as their adverse effects on health and society. The National Center on Complementary (NCCIH) and Integrative Health (NCCIH) has become a focal point for research on the therapeutic potential of the heretofore understudied minor cannabinoids and terpenes found in cannabis for the management of pain. Also, NCCIH has become more actively involved in coordinating activities to stimulate new research programs and coordinating various cannabis-related activities across the NIH. This presentation will provide an update on the broad landscape of cannabis-related research at the NIH, summarize new areas of research interest and investment, including those of NCCIH, and describe a new multi-NIH ICO extramural program coordinating group to foster collaboration, share information, and expand and coordinate NIH cannabis and cannabinoid research activities.

Cannabis Research Priorities at the National Institute on Drug Abuse
Susan Weiss, National Institute on Drug Abuse, National Institutes of Health

NIDA has a wide-ranging cannabis research portfolio and remains the largest funder in the US government. This includes research on the endocannabinoid system, where THC exerts its predominant effects; studies to understand the potential harms of cannabis and cannabinoid exposure throughout the lifespan; therapeutic studies on cannabinoids for treating pain, HIV, and substance use disorders; treatment research for cannabis use disorder; and epidemiology and policy research to better understand the impact of the changing cannabis laws on health outcomes and consumption patterns (e.g., choice of diverse products; multiple routes and patterns of administration).

Research on cannabis is complex and can be difficult because of the inherent variability of the plant; its multiple components with therapeutic potential and distinct mechanisms of action; the difficulty of obtaining a Schedule I registration; and up until very recently, a single source of plant material for research. The latter is expected to change with new manufacturers approved by the DEA, but there are still no assurances that the cannabis that will be available for research will reflect the diversity of products currently available to the public in States where it is legal. Federally funded researchers are prohibited from analyzing products available in state-authorized dispensaries, and therefore, must rely on participant self-report or photos of unverified product labels from dispensaries. Understanding the characteristics of products on the market - including the amount of THC, the concentration of other cannabinoids and components, and potential toxins - is important for determining and differentiating characteristics responsible for health effects.
Federal Agencies and Cannabis Research: Updates from NIH, FDA, and DEA
Matthew Strait, Drug Enforcement Administration (DEA)

Since 2016, DEA has been actively engaged in regulatory activities aimed at improving both the quality and quantity of marijuana utilized for research in the United States. DEA will provide an update of those activities, including successes and ongoing challenges. DEA will explain how it remains focused on ensuring that scientific data and evidence dictates decisions on whether marijuana should remain a schedule I controlled substance under federal law.

FDA Regulation of Cannabis and Cannabis-Derived Compounds
Katherine Bonson, US Food and Drug Administration

FDA has a well-defined role to play in the regulation and development of products containing cannabis and cannabis-derived compounds. This presentation will detail the FDA regulatory oversight of scientific investigation and new drug development with Schedule I cannabis and its derivatives and will provide a brief overview of other FDA regulatory roles for cannabis vs. hemp, particularly as impacted by the 2018 Farm Bill. With regard to potential cannabis drug products, there will be a discussion of FDA Guidance for Industry on cannabis and botanical drug development, therapeutic research areas for cannabis, IND submissions, DEA licensing of Schedule I research, and the federal process for evaluating drugs for abuse potential and scheduling them under the Controlled Substances Act.

TUESDAY, JUNE 20, 2023

12:15 P.M. - 1:15 P.M.

Symposium: In Memoriam Martin Adler
Plaza Ballroom BCEF (Plenary)

Chair: Scott Lukas, McLean Hospital, Harvard Medical School
Co-Chair: Toby Eisenstein, Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University

Speakers:
William Dewey, Virginia Commonwealth University
Toby Eisenstein, Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University
Scott Lukas, McLean Hospital, Harvard Medical School
Ellen Unterwald, Lewis Katz School of Medicine at Temple University
Seminal work performed by Dr. Mary Jeanne Kreek and colleagues demonstrate the important contribution of dysregulation of the stress-responsive hypothalamic-pituitary-adrenal axis to the acquisition and persistence of drug-seeking behaviors. Dr. Ellen Unterwald will highlight Dr. Kreek’s key findings from human and animal studies and present her own research on the role of stress-responsive mediators in cocaine seeking and relapse including analysis of sex-specific effects. Dr. Kreek’s clinical research on methadone efficacy and safety led to its FDA indication for the treatment of opioid use disorder and has resulted in life-saving and life-sustaining treatment for millions of people world-wide. Her work was also critical to identifying injection drug use as a risk factor for HIV, spurring public health approaches to drug use. Furthermore, her conceptual models of addictions entailing alterations in stress responsivity have influenced treatment approaches to opioid use disorder and alcohol use disorder and has supported increased interest in the kappa opioid system as a target for pharmacotherapy of alcohol and stimulant use disorders. Dr. Gavin Bart will use highlights from her career to illustrate her impact on contemporary clinical care and research in substance use disorders. Dr. Brian Reed will share work on diverse kappa opioid receptor ligands in animal models, in an effort to identify candidates with reduced side effect profiles, including sedation and hallucinatory-like effects, which are undesirable characteristics of some of the earlier kappa opioid receptor agonists.

46.1 Stress-Responsive Genes and Their Role in Cocaine-Seeking
Speaker: Ellen Unterwald, Lewis Katz School of Medicine at Temple University

46.2 Kappa Opioid Receptor Ligands - Structure and Signaling Relationships
Speaker: Brian Reed, Marymount Manhattan College

46.3 The Clinical Impact of Dr. Mary Jeanne Kreek
Speaker: Gavin Bart, University of Minnesota
ABSTRACT

SATURDAY, JUNE 17, 2023

1:00 P.M. - 2:30 P.M.

WORKSHOP: STRESSFUL ENVIRONMENTS AND GENETIC RISK FACTORS ASSOCIATED WITH EARLY INITIATION OF ALCOHOL AND SUBSTANCE USE: FINDINGS FROM THE ABCD STUDY
Plaza Ballroom A

Chair: Priscila Gonçalves, Columbia University
Co-Chair: Rick Cruz, Arizona State University

Early initiation of alcohol or other substance use can disrupt brain development contributing to negative individual and societal consequences. Stressful environments, including adverse childhood experiences, and high family conflict, coupled with less effective parenting, play an outsized role in the risk for early substance use initiation. This constellation of environmental influences interacts with genetics and behavioral (e.g., decision-making related to delayed reward) factors to transmit risk for early substance use. Better understanding the ecocdevelopmental pathways of early substance use risk can inform prevention efforts, which could have powerful downstream effects. This session describes novel research examining biological and environmental factors related to the prediction of early alcohol and other substance use in the large, longitudinal Adolescent Brain Cognitive Development (ABCD) Study®. The symposium is comprised of scholars from the NIDA-funded START program for URM investigators, which aims to enhance diversity among the network of scholars working with ABCD data. First, Skye Bristol will describe family conflict predictors of different alcohol expectancies. Next, Dr. Bounds will explore the combined impact of family conflict and adverse childhood experiences on future alcohol use and related risk behaviors. Dr. Ryan-Pettes will expand beyond parental monitoring and discipline by examining these influences in the context of peer affiliation, neighborhood, and environmental factors. This symposium on risk factors for early substance use will be concluded by Dr. Garcia who extends beyond environmental factors with a focus on the contribution of genetic risk factors and reward-related decision-making to alcohol and substance use risk in early adolescence.

1.1 Family Conflict as a Risk Factor for Problematic Alcohol Expectancy in the ABCD Study
Speaker: Skye Bristol, University of South Florida

1.2 Exploring the Impact of Family Conflict and Adversity on Alcohol Use and Risk Behaviors in Youth in the ABCD Study
Speaker: Dawn Bounds, University of California, Irvine

1.3 Effects of Parent Monitoring and Inconsistent Discipline on Risk for Alcohol Initiation Through Deviant Peer Affiliation in the Context of Neighborhood Variables
Speaker: Stacy Ryan-Pettes, Baylor University

1.4 Innate and Environmental Determinants of Delayed Reward Discounting in Youth Participants in the ABCD Study
Speaker: Erik Garcia, University of Nebraska Omaha

Moderator: Neo Gebru, Brown University
States have developed several responses to address the growing US opioid public health crisis. In 2016, Pennsylvania Governor Tom Wolf introduced the Centers of Excellence to increase access to evidence-based treatment services for OUD, including medications for OUD (MOUD) and care management. Amidst early program successes and planned expansions from 45 pilot treatment sites in 2020, the COVID-19 pandemic incited disruptions to healthcare services and increased overdoses. This Mini-Symposia will present the COE history and empirical results demonstrating: 1) effects of COE care management services on improving patient outcomes, 2) how COVID-19 impacted MOUD service delivery, and 3) lessons learned for future expansion.

Methods and Results:
Symposia 1: A mixed-effects Cox model with n=15,100 patients nested within n=41 treatment sites indicated an overall median retention rate of 19.4 weeks. Retention rates improved with more patients care management services and declined as sites client caseload ratios increased.

Symposia 2: Correlations between staff-administered organizational health survey scales demonstrated that organizations with greater organizational health pivoted faster (rho= -0.360, p<0.001) to COVID-19 disruptions/policy changes while maintaining higher workplace morale (r= 0.466, p=.002).

Symposia 3: Qualitative interviews with COE program staff indicated COVID-19 impacts on the processes associated with MOUD implementation, care coordination, and client confidentiality. According to participants, some policy and regulatory changes/adaptations have the potential to improve patient-level MOUD-related outcomes (e.g., telehealth, take home dosing) while others did not (e.g., urine drug screening frequency). Conclusion: Future research and policy should consider addressing organizational health to improve OUD patient-level outcomes.

2.1 The Effects of Care Management and Provider Capacity on Opioid Use Disorder Treatment Retention
Speaker: Renee Cloutier, University of Pittsburgh

2.2 The Relationship Between Organizational Health and Resiliency Among Pennsylvania’s Centers of Excellence During the COVID-19 Pandemic
Speaker: Debra Moore, University of Pittsburgh

2.3 Response to Impact of COVID-19 on Medications for Opioid Use Disorder Service Delivery at Centers of Excellence in Pennsylvania
Speaker: Rahul Amruthapuri, University of Pittsburgh, School of Pharmacy Program Evaluation and Research Unit (PERU)
ABSTRACT

1:00 P.M. - 2:30 P.M.

WORKSHOP: SHARING YOUR SCIENTIFIC STORY: TIPS AND TRICKS FOR STRATEGICALLY AND EFFECTIVELY COMMUNICATING YOUR RESEARCH
Grand Ballroom I

Chair: Rachel Evans, DHHS/NIH/NIDA

Sharing your scientific story: tips and tricks for strategically and effectively communicating your research. “Science is not finished until it’s communicated.” – Sir Mark Walport, former UK Chief scientist

The ability to effectively communicate scientific concepts and research findings to a wide range of audiences is a crucial part of the scientific process. And in a world where misinformation continues to permeate scientific discussions, and trust in science and scientists is declining across many groups, the need to deliver the right message, to the right audience, at the right time, in the right way, has never been more important. In this forum, the speakers will share strategies to help scientists move beyond communicating their findings in academic journals to reach the general public. They will discuss how to work with their research funders and the media to get attention for their scientific findings, and how to structure strong messages that will resonate with the audiences they aim to reach. The speakers will also host a robust Q and A session to answer questions from the audience.

3.1 Sharing Your Scientific Story: Tips and Tricks for Strategically and Effectively Communicating Your Research
Speaker: Magdalena Cerdá, New York University School of Medicine

3.2 Sharing Your Scientific Story: Tips and Tricks for Strategically and Effectively Communicating Your Research
Speaker: Jennifer Hobin, National Institute on Drug Abuse

3.3 Sharing Your Scientific Story: Tips and Tricks for Strategically and Effectively Communicating Your Research
Speaker: Carla Johnson, The Associated Press

1:00 P.M. - 2:30 P.M.

WORKSHOP: PATHWAYS TO RECOVERY AND BEYOND IN NATIVE AMERICAN COMMUNITIES
Governor’s Square 15

Chair: Anne Skinstad, University of Iowa

Recovery from substance use disorders (SUD) is a multi-dimensional phenomenon, and over the last two decades multiple definitions with varying overlap have been proposed. Research has also found that recovery definitions vary across social groups, including by race/ethnicity; however, scant research has focused on the ways that Native American individuals define recovery. Thus, current consensus definitions may have limited salience for Native American communities, may result in less efficacious interventions, and may partially explain persistent treatment disparities. To address the gap, this workshop intends to spur development of a culturally appropriate definition of recovery. First, Dr. Paul Gilbert will review findings from a current national US study of people in recovery, highlighting commonalities and differences across key dimensions of gender, race/ethnicity, and treatment exposure. Second, Dr. Anne Helene Skinstad and Steve Steine, MA, will introduce a translation of recovery definition into tribal and urban Indian community contexts, and summarize how results from the Virtual Native Talking Circles (VNTP), a workforce development program, contributed
to a better cultural understanding of the recovery process. Furthermore, VNCT results underscored the importance of peer support and networking, as well as providing additional culturally informed tools, and self-care measures to better prepare providers to support clients’ recovery in a culturally informed way. Non-AIAN VNCT participants reported improved cultural understanding and capacity to support their tribal clients with SUD or in recovery. Finally, Dr. Daniel V. Foster will lead a discussion with speakers and audience members on recovery meanings and pathways in an Indigenous cultural context.

4.1 What Does Recovery Mean? Ubiquitous and Unique Elements From a National U.S. Survey of Adults in Recovery
Speaker: Paul Gilbert, University of Iowa

4.2 Behavioral Health Benefits of Virtual Native American Talking Circles
Speaker: Steven Steine, ATTC/College of Public Health/University of Iowa

Discussant: Daniel Foster, Included Health

1:00 P.M. - 2:30 P.M.

WORKSHOP: A VIEW BEYOND THE HORIZON: INNOVATIVE METHODOLOGIES AND APPROACHES IN SUBSTANCE USE DISORDER RESEARCH AND TREATMENT UTILIZED INTERNATIONALLY
Grand Ballroom II

Chair: Laura Brandt, City College of New York

While substance use disorders (SUD) pose a challenge to public health worldwide, context-specific aspects of these challenges require context-specific solutions. Therefore, unique innovations are brought about by unique regional or local challenges. At the same time, owing to political and regulatory barriers, these innovations may not be available in other settings/countries. This workshop, hosted by CPDD’s International Committee, brings together researchers with diverse cultural and professional backgrounds with the aim to enrich our shared understanding of SUD-related issues and address inadequacies in the implementation of existing evidence-based approaches into practice.

Towards the goal of providing insight into methodological and treatment innovations from international contexts, this workshop will be structured in two parts. Part 1 will consist of 15-minute panel presentations: (1) Eugenia Oviedo-Joekes will present scientific evidence from Canada on injectable opioid agonist treatment, and injectable hydromorphone in particular, as a promising treatment option for severe opioid use disorder; (2) Thiago Fidalgo will discuss challenges related to collecting epidemiological data in low- and middle-income countries and lessons learned from conducting a longitudinal field survey in Brazil; (3) Min Zhao will describe digital medicine approaches and a Community-based Addiction Rehabilitation Electronic System as alternative/complementary care models in China, in the context of limited mental health resources; and (4) Suzanne Nielsen will discuss a collaborative prescriber-pharmacist model of care in Australia as a low-threshold approach to improve access to SUD treatment. Part 2 will be an interactive discussion, and we particularly encourage international attendees to share their diverse experiences and regional innovations.

5.1 “Injectable Opioid Agonist Treatment – Implementing Evidence-Based Approaches into Practice for Opioid Use Disorder in Canada”
Speaker: Eugenia Oviedo-Joekes, School of Population and Public Health, University of British Columbia
5.2 Challenges Related to Conducting Epidemiological Surveys in Low- And Middle-Income countries: Lessons Learned from Field Work in Brazil
Speaker: Thiago Fidalgo, Universidade Federal de Sao Paulo

5.3 Early learnings from a hybrid implementation-effectiveness study of pharmacist-prescriber collaborative care for opioid dependence, and other clinical innovations in Australia
Speaker: Suzanne Nielsen, Monash University

3:00 P.M. - 4:30 P.M.

WORKSHOP: NEW APPROACHES TO CULTURALLY APPROPRIATE TREATMENT AND RESEARCH
Grand Ballroom I

Chair: A. Kathleen Burlew, University of Cincinnati

New Approaches to Culturally Appropriate Treatment and Research. A compelling body of research suggests that generic treatments may not adequately address risk, protective, and contextual factors related to substance use treatment among specific racial/ethnic minoritized (REMs) groups. Moreover, novel approaches may be required to promote REM recruitment and retention into research. The mission of the Minority Interest Group (MIG) of NIDA's National Drug Abuse Treatment Clinical Trials Network is to promote research that advances the science of REM substance use. Consistent with that mission, MIG members will present novel strategies for recruiting, retaining, and treating REMs.

Aims: 1) To share culturally-appropriate approaches for engaging/retaining REMs in substance use research. 2) To describe treatment approaches that incorporate syndemic factors related to the etiology and treatment of substance use among REMs.

Both Drs. Obel and Cain will share efforts to increase the recruitment and retention of REMs into substance use research. Dr. Obel's team has developed an evidence-based manual for recruiting and retaining REMs into research. Dr. Cain will describe her team's use of community-engaged culturally appropriate strategies to recruit and retain urban REMs in substance use treatment research.

Both Drs. Moreland and Bryant will share culturally appropriate treatment research. Dr. Moreland will describe research identifying and addressing decision-making about buprenorphine among REMs. Utilizing the ADAPT-ITT framework, Dr Bryant will describe the adaptation of an intervention to more effectively respond to substance use and discrimination distress simultaneously.

Dr. Jordan, the discussant, will address the conclusions and implications for future research.

6.1 The Cultural Adaptation Process of a Substance Use Intervention for Black Justice-Involved Youth Using the Adapt-ITT Model (Phase 1): Lessons Learned
Speaker: Brittany Bryant, Medical University of South Carolina

6.2 Culturally Appropriate Approaches for Recruitment and Retention of African Americans in SUD Treatment:
Speaker: Gloria Cain, Howard University College of Medicine

6.3 Are Minority Patients With Opioid Use Disorder More Likely to Decline Buprenorphine in the ED? Exploring Reasons That People Accept and Decline Buprenorphine
Speaker: Angela Moreland, Medical University of South Carolina
ABSTRACT

6.4 Innovative Methods for Increasing Recruitment & Retention in Research (RCTs & Non-RCTs) among African American Communities in the United States (US).
Speaker: Geoffrey Obel, University of Texas Southwestern Medical Center At Dallas
Discussant: Caravella McCuistian, Department of Psychiatry and Behavioral Sciences, School of Medicine, University of California San Francisco

3:00 P.M. - 4:30 P.M.

WORKSHOP: STANDARDS OF PSYCHEDELIC CARE: PEER & PROFESSIONAL PROVIDERS
Plaza Ballroom A

Chair: Brian Anderson, University of California, San Francisco
Co-Chair: Jennifer Mitchell, University of California San Francisco

As the use of psychedelics like psilocybin, MDMA, and ayahuasca becomes more prevalent across the US due to the advancement of clinical drug development and drug policy reforms (e.g., decriminalization and legalization), providers of psychedelics and psychedelic-informed care have been developing standards of good practices with these substances. This includes providers from peer-based (12 step recovery fellowships), professional/therapeutic, and religious settings. Three national organizations that have generated standards of care for the safe use of psychedelics in their respective settings present information on their organizations, their processes of generating these standards, and comments specifically on what their memberships have learned about the apparent risks and benefits of using psychedelics as part of the care of persons suffering from addictions.

7.1 Psychedelics in Recovery: Mutual Aid for Psychedelic Integration
Speaker: Kevin Franciotti, Kevin Franciotti Counseling

7.2 Developing Standards of Practice Within the American Psychedelic Practitioners Association Part 2
Speaker: Stephen Xenakis, American Psychedelic Practitioners Association (APPA)
Discussant: Peter Hendricks, The University of Alabama At Birmingham

3:00 P.M. - 4:30 P.M.

WORKSHOP: EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH METHODS
Grand Ballroom II

Chair: Howard Chilcoat, Indivior, Inc.
Co-Chair: Maria Parker, Indiana University - Bloomington

This proposal is for a continuation of the annual CPDD Epidemiology and Public Health Research Methods evening workshop series that was launched nearly 20 years ago. This year’s workshop will focus on geospatial analytical approaches of interest to those conducting epidemiologic, prevention, and clinical research in the field of substance use and related disorders. Topics to be discussed include: 1) Jamie Humphrey, RTI - Spatial heterogeneity in county-level racial residential segregation and overdose mortality rates of opioids, synthetic opioids, and psychostimulants with abuse potential. Using multiscale geographically weighted regression models, spatially-explicit measures of racial residential segregation, and smoothed overdose mortality rates,
this presentation will explore the presence and scale of spatial heterogeneity in the relationship between structural racism and three overdose mortality rates in US counties, 2020: any opioids, synthetic opioids, and psychostimulants with abuse potential. 2) Richard Sadler, Michigan State University - Geospatially-Informed Strategies to Address Mental Health and Substance Use Disparities in Flint, Michigan. This talk will explore the creation of a community-informed GIS-based healthfulness index and the use of standard hot spot analyses to understand and act upon geographic disparities uncovered in the Strengthening Flint Families (SFF) and the Resiliency in Communities After Stress and Trauma (ReCAST) programs. 3) Erik Nelson, Brigham Young University - Placing drug use into context. This presentation will discuss the impact of social and environmental conditions that promote (impede) drug use. It will also explore methods for measuring and analyzing these factors using geospatial techniques.

8.1 Spatial Heterogeneity in County-Level Racial Residential Segregation and Overdose Mortality Rates of Opioids, Synthetic Opioids, and Psychostimulants With Abuse Potential, 2020
Speaker: Jamie Humphrey, RTI International

8.2 Geospatially-Informed Strategies to Address Mental Health and Substance Use Disparities in Flint, Michigan
Speaker: Richard Sadler, Michigan State University College of Human Medicine

8.3 Placing Drug Use Into Context
Speaker: Erik Nelson, Brigham Young University

3:00 P.M. - 4:30 P.M.

WORKSHOP: COLLABORATION AND COMPLICATION: LESSONS LEARNED IN IMPLEMENTING COMMUNITY-ENGAGED RESEARCH ON SUBSTANCE USE
Plaza Ballroom D

Chair: Devin Banks, University of Missouri--St. Louis

Advocates, policy makers, patients, and recently, NIDA have called for the inclusion of people with lived experience in the conceptualization and realization of addiction science. Perhaps more than ever, research teams are including patient and community consultants and advisory boards in their research. However, most research training paradigms do not prepare investigators to effectively collaborate with people with lived experience. This is especially true when working with communities who experience other intersecting forms of stigma, such as racial stigma, who have often been considered “hard to reach” populations. This symposium will share lessons learned from community-engaged NIH- and foundation-funded research projects with specific focus on minoritized people with lived experience. Presenters will demonstrate how their research designs, data collection, and interpretation of qualitative and quantitative findings developed based on the feedback of people with lived experience with substance use (disorder).

Attendees will increase their knowledge of different approaches to community-engaged research and strategies for addressing common challenges that emerge when collaborating with stakeholders outside the academy. This knowledge will support investigators in not only engaging with minoritized people with lived experience, but developing long-term, bidirectional relationships.

Specifically, presentations will include practical strategies for: 1) building trusted partnerships and developing a Community Advisory Board in communities that have been previously exploited by research and/or policy; 2) recruiting, engaging, and retaining minoritized research participants; 3) developing effective, culturally-appropriate recovery interventions and education; and 4) incorporating insights of community members into data interpretation and clinical and policy recommendations.
ABSTRACT

9.1 We see the Value in the Hood: Developing Reciprocal Research Partnerships in an Exploited Community
Speaker: Maria Paschke, University of Missouri - St. Louis

9.2 Blind Spots in Ivory Towers: Considerations for Recruiting Black American Research Participants
Speaker: Danelle Stevens-Watkins, University of Kentucky

9.3 The Role of Cultural Humility in Community-Engaged Research
Speaker: Alexandria Bauer, Rutgers University

9.4 From Relapse Prevention to Recovery Planning: Community-Based Participatory Research to Address Substance Use on a Rural American Indian Reservation
Speaker: Monica Skewes, Montana State University

Moderator: Devin Banks, University of Missouri--St. Louis

3:00 P.M. - 4:30 P.M.

WORKSHOP: R/ASKACADEMIA: SPECIAL CONSIDERATIONS IN THE PRACTICE OF USING REDDIT FOR SUBSTANCE USE RESEARCH
Governor’s Square 15

Chair: Savannah Brenneke, Johns Hopkins Bloomberg School of Public Health
Co-Chair: Meredith Meacham, University of California San Francisco

Interest in the use of social media platforms for substance use research has been on the rise, with Reddit emerging as one of the most rapidly growing platforms studied. To date, however, standards for the practice of collecting, analyzing, and disseminating findings from these highly unstructured data are lacking, contributing to concerns around the validity and ethics of using such data in the field. Therefore, there is a need for researchers across the fields of health and social sciences, computer science and engineering, to share lessons learned and work towards establishing best practices. This symposium will focus on phases of the research process using Reddit data, moving from defining Reddit data and conceptualizing research questions, to data collection and management, analysis and inference, and ending at dissemination. Speakers will present their original research, with special attention to a phase of the research process and challenges they face. Dr. Amanda Bunting will discuss the nature of Reddit data and the conceptualization of research questions that can be asked within the data. Ms. Alexandra DeLucia will present on the use of Natural Language Processing (NLP) for the extraction of data from Reddit, providing the perspective of computer science in the application of computational methods for data harvesting and management. Ms. Savannah Brenneke’s work will explore analytical approaches commonly found in the literature, including inferences drawn from them. Lastly, Dr. Nicholas Proferes will cover the ethical considerations in the decision to use Reddit for research and their implications for the dissemination of findings.

10.1 Rapid Use of Reddit to Understand Emerging Drug Use Trends
Speaker: Amanda Bunting, New York University School of Medicine

10.2 r/AskAComputerScientist: Processing Reddit Data for the Social Sciences
Speaker: Alexandra DeLucia, Johns Hopkins University
MINI-SYMPOSIUM: HARM REDUCTION UTILIZATION AND STRATEGIES
Grand Ballroom II

Chair: Mai Pho, The University of Chicago
Co-Chair: Judith Tsui, Department of Medicine, Division of General Internal Medicine, University of Washington

Rural areas experience high rates of drug overdose. While recent surges in overdose deaths are driven largely by highly potent fentanyl and related analogues, the rural opioid crisis is co-occurring and intertwined with evolving methamphetamine use. Overdose deaths involving methamphetamines increased by over 600% between 2007 and 2017. Harm reduction services (HRS) play a vital role in risk reduction and health promotion among rural PWUD by both figuratively and literally meeting individuals where they are in the communities and settings where they live and use drugs. Strategies include sterile equipment, overdose education and naloxone distribution (OEND), product testing for fentanyl, HIV, hepatitis C, and STI screening, sexual health supplies, linkage to substance use disorder treatment and social support. Given limited substance use disorder treatment in rural areas, efforts to improve health outcomes for people who use drugs in these settings hinge on harm reduction strategies. However, the availability of HRS is limited in rural settings compared to urban areas due to funding, marginalization, and vulnerabilities exacerbated by the COVID-19 pandemic and related mitigation strategies. This mini-symposium will explore factors associated with harm reduction practices, including naloxone use and fentanyl product testing from data collected through the Rural Opioid Initiative (ROI), a research consortium funded by NIDA, CDC, SAMHSA, and the Appalachian Regional Commission, as well as present strategies for expanding access and engagement with harm reduction services in rural settings.

11.1 Factors Associated With Possession of Naloxone Among Rural People Who Use Drugs
Speaker: Alex Rains, University of Chicago, Pritzker School of Medicine

11.2 Fentanyl Awareness and Harm Reduction Techniques to Avoid Fatal Overdose: A Qualitative Exploration of Eight Rural Settings in the United States
Speaker: Rebecca Bolinski, Southern Illinois University School of Medicine

11.3 Engagement in Harm Reduction Services through Academic and Community-Based Partnership
Speaker: Mai Pho, The University of Chicago
MINI-SYMPOSIUM: 2022 NIDA CRAVING CHALLENGE
Plaza Ballroom BCEF (Plenary)

Chair: G. Andrew James, University of Arkansas for Medical Sciences
Co-Chair: Ronald Thompson, University of Arkansas for Medical Sciences

The National Institute on Drug Abuse (NIDA) issued the “Product Prototypes to Combat Drug Craving” Challenge, which solicited working prototypes of devices intended to reduce drug craving among people with substance use disorders. The Challenge specifically sought prototypes that were easily accessible, minimally invasive, available on-demand, did not require detoxification, could be adapted for different substances, modifiable to provide tailored experiences, and suitable for patients of diverse backgrounds and different stages of recovery. This mini-symposium will discuss the inspiration behind some of the winning entries.

Richard Hanbury MBA (Healthcare) will discuss the winning entry Sana, a neuromodulation platform that provides anxiety relief on-demand and has shown a 45% reduction in anxiety during methadone withdrawal. Josh Israel (Serial Entrepreneur) will discuss the runner-up entry Hale, a vaporizer system to ease nicotine craving and withdrawal by automatically reducing nicotine use over time. Ronald G. Thompson Jr., Ph.D., will discuss the Honorable Mention entry for smartphone app OptiMAT, which seeks to reduce opioid misuse through daily monitoring of mood and craving, personalized feedback, and GPS-driven “just-in-time” intervention when participants enter areas of high contextual risk for relapse. Chair Andrew James, Ph.D., a co-creator of OptiMAT, will lead discussion on the devices’ common and unique approaches for reducing drug craving.

12.1 The Sana Wearable Neuromodulation Device for Reducing Anxiety and Drug Cravings
Speaker: Richard Hanbury, Sana Health, Inc.

12.2 Hale: Automated Nicotine Reduction Device
Speaker: Josh Israel, Hava Health, Inc.

12.3 OptiMAT: A Smartphone Application to Decrease Opioid Cravings and Optimize MAT for Opioid Use Disorders
Speaker: Ronald Thompson, University of Arkansas for Medical Sciences

2:15 P.M. - 3:45 P.M.

WORKSHOP: “PRE-ADDICTION:” A STARTING POINT FOR A STRATEGIC SHIFT TOWARD EARLIER INTERVENTION IN SUBSTANCE USE DISORDERS
Plaza Ballroom BCEF (Plenary)

Chair: Nora Volkow, National Institute on Drug Abuse
Co-Chair: George Koob, National Institute on Alcohol Abuse and Alcoholism
Discussant: A Thomas McLellan, University of Pennsylvania Perelman School of Medicine

Federal efforts to address substance use disorders (SUDs) have focused almost exclusively on those with serious, chronic addictions. Yet treatment penetration rates and treatment outcomes have been disappointing. The far larger population of those who regularly misuse substances and often transition to serious SUDs has
been largely ignored. Facing a similar situation, the diabetes field strategically moved toward identifying and intervening with early-stage diabetes - termed "pre-diabetes." That strategic change led to better prevention, longer delay in onset of serious diabetes, better treatment penetration and more effective reimbursement policies. This workshop first describes (15 minutes) how the diabetes field developed this strategy, including a commonly understood name to motivate both patients and clinicians, and creation of evidence-based medications and behavioral interventions. Finally, we offer our suggestion of the term "pre-addiction," initially defined by 2-5 DSM 5 diagnostic criteria as a starting point for the development of this concept for SUDs. The remainder of the workshop will be devoted to audience discussion and suggestions on five important and unresolved issues (12 minutes each) if this concept is to move forward.

1. What promising biological measures may improve the suggested operational definition of pre-addiction?
2. What medications might be appropriate for those with pre-addiction?
3. What behavioral interventions – including social media or internet apps - might be effective with pre-addiction?
4. How can insurers and healthcare systems facilitate studies of effectiveness and value pre-addiction interventions?
5. Are there concerns that the term pre-addiction will promote stigma?

4:00 P.M. - 5:15 P.M.

MEDIA FORUM
Grand Ballroom I

Chair: Bethea Kleykamp, BAK and Associates

Mainstream news media disseminates many problematic narratives about drug use and addiction that perpetuate stigma, discrimination, and bad policy. One way to address these shortcomings is to increase the coverage of evidence-based approaches to addiction treatment and recovery, including well-designed research studies, through collaborative efforts with subject matter experts. Unfortunately, many experts are not trained to interact with journalists or the general public about addiction science. This forum is designed to offer customized, in-person training that can help attendees develop effective science communication skills.

The Media Forum will be open to all attendees including graduate-level and early-career CPDD attendees for whom this forum could serve as a valuable career development experience. The 120-minute forum will be broken down into three components: 1) an overview of different types of science and medical writing related to substance use research and treatment (Presenter: Kleykamp; 30min); 2) tips on science communication (Presenter: Jonathan 30min) 3) tips on working with the media to communicate science (Presenter: Ashton; 30minutes); 4) trainer led small-group didactic and practice sessions (30min). The small-group trainer sessions will help attendees become aware of non-traditional avenues of disseminating their research and expertise (science journalism, regulatory writing, clinical guidelines, educational materials), sharing research accurately and concisely with the media, how to disseminate press releases, and how to pitch ideas or op-eds.

14.1 Reporting on Addiction: Science Communication
Speaker: Jonathan Stoltman, Opioid Policy Institute

14.2 Communicating Science Effectively Media Forum: Training With Reporting on Addiction
Speaker: Ashton Marra, Reporting on Addiction
Despite a longstanding prohibition on psychedelics dating back to the 1970s, scientific and public interest in these substances is growing as clinical trials suggest their promise for treating mood, anxiety, and substance use disorders. Early reports that people with severe treatment-resistant depression responded to psychedelic treatment created momentum for controlled clinical trials to establish therapeutic efficacy for other indications. The Food and Drug Administration (FDA) has granted breakthrough therapy status for psilocybin and MDMA, which means that intensive FDA guidance is provided for designing the clinical trial programs and expedited timelines are applied when FDA reviews the safety and efficacy data from the completed Phase III studies.

This Forum will present the history of the therapeutic use of hallucinogens (Jack Henningfield), the epidemiology of the current illicit use of hallucinogens (Deborah Hasin), and current regulatory perspectives on psychedelic drug development from the FDA (Marta Sokolowska) and Industry (Beatriz Rocha).

15.1 The History of Therapeutic Use: Lessons Learned From 1960s Studies, and From the Renaissance in Clinical Development Beginning in the First Decade of the 21st Century
Speaker: Jack Henningfield, Pinney Associates, Inc.

15.2 The Epidemiology of Hallucinogen/Psychedelic Use in the United States
Speaker: Deborah Hasin, Columbia University

15.3 Analyses of U.S. Trends in Non-Medical Use of Hallucinogens
Speaker: Beatriz Rocha, Fortrea

15.4 MDMA for PTSD and Psilocybin for Treatment-Resistant Depression Currently in Phase III Trials
Speaker: Marta Sokolowska, FDA

MONDAY, JUNE 19, 2023

Cannabis use and cannabis-related problems remain highly prevalent among adolescents and young adults (AYA). Burgeoning research reveals substantial disparities in problematic cannabis use between LGBTN+ (lesbian, gay, bisexual, transgender, non-binary+) AYA and their cisgender, heterosexual counterparts. However, this research has been limited by a lack of adequate sampling, leading studies to combine individuals from any LGBTN+ subgroup into a single analytic group and obfuscating heterogeneity in cannabis use behaviors across
the diverse range of identities utilized by AYA. This mini-symposium will highlight the need for scientists to expand analyses to explore differences within the LGBTN+ population by describing heterogeneity observed in cannabis use behaviors across subgroups. Talks will examine key individual, interpersonal, and structural mechanisms that may explain observed disparities within and outside the LGBTN+ population of AYA. The first speaker will present on distinct cannabis use patterns among subgroups of LGBTN+ youth from Southern California, and relatedly explore how outness (openness about one’s identity) and discrimination experiences might explain disparities in use. The second speaker will examine differences in the effects of depression and anxiety on associations between minority stressors and cannabis problems across subgroups of LGBTN+ young adults. The third speaker will examine LGBTN+ subgroup differences in reported exposure to pro-cannabis marketing, and associations with LGBTN+ disparities in cannabis use. This collection of presentations on LGBTN+ disparities in cannabis use behaviors will highlight implications for future research, treatment, and policy, providing concrete suggestions for research strategies to better understand disparities in substance use behaviors for the LGBTN+ population.

16.1 Addressing the Role of Minority Stressors: A Cross-Sectional Analysis of Cannabis Use Patterns Among LGBTN+ High Schoolers
Speaker: Tahsin Rahman, University of Southern California

16.2 Comparing the Impact of Minority Stressors and Co-Occurring Mental Health Factors on Cannabis-Related Problems in a Diverse Sample of LGBTN+ Young Adults
Speaker: Cara Struble, Geisel School of Medicine at Dartmouth

16.3 Pro-Cannabis Marketing and LGBTQ+ Disparities in Cannabis Use Among Youth and Young Adults
Speaker: Evan Krueger, Tulane University

10:30 A.M. - 12:00 P.M.

SYMPOSIUM: MEASUREMENT OF CANNABIS CONSUMPTION TO DETERMINE RISK AND PROMOTE PUBLIC HEALTH
Plaza Ballroom A

Chair: Alan Budney, Geisel School of Medicine at Dartmouth
Co-Chair: Ashley Linden-Carmichael, Penn State University

With the escalation of cannabis legalization and commercialization, the need for better public messaging and guidelines about safe vs. risky use patterns has become imperative. Efforts to develop such guidelines are hindered by a lack of valid methods for measuring diverse cannabis products and quantifying consumption of the intoxicating component of cannabis, i.e., THC. This symposium will provide data from a diverse set of studies that help move the field towards resolution of this cannabis quantification impasse. The initial presentation will showcase methods utilized in the International Cannabis Policy Study for measuring novel cannabis product consumption quantities, generating national prevalence estimates, and evaluating consumer understanding of product labels. Next, a community-based study of frequent cannabis consumers that measured quantity, frequency, potency, and dose will demonstrate how those metrics can predict risk of problematic cannabis use. Findings from an intensive ecological momentary assessment study of young adults, will show how quantity reports and their interaction with product type and route of administration relate to subjective intoxication and other adverse consequences. Last, results from a study in which milligrams of THC consumption was calculated using responses from an internet-based survey of frequent cannabis consumers will describe associations between THC amount, pattern of use, and Cannabis Use Disorder severity. A moderated discussion will
highlight how this work advances methods for measuring cannabis dose and determining its relationship to risk, and importantly, generate future innovative studies that will expedite the development of guidelines for safe and unsafe use of cannabis.

17.1 Consumption Patterns for Cannabis Products From a National Sample of Consumers in the United States: Edibles, Extracts, CBD, and Other ‘Novel’ Products
Speaker: David Hammond, University of Waterloo

17.2 Predicting Problematic Cannabis Use From Estimates of Cannabis Quantity, Frequency, Potency, and Standard Dose
Speaker: Brad Conner, Colorado State University

17.3 Measuring Cannabis Use, Subjective Experiences, and Cannabis-Related Consequences in the Moment: Associations by Cannabis Product, Route of Administration, and Other Substance Use
Speaker: Ashley Linden-Carmichael, Penn State University

17.4 Exploring the Link Between the Amount and Pattern of THC Consumption and CUD Severity in a Large Sample of Adults
Speaker: Jacob Borodovsky, Dartmouth Geisel School of Medicine

Moderator: Alan Budney, Geisel School of Medicine at Dartmouth

10:30 A.M. - 12:00 P.M.

SYMPOSIUM: THE INTERSECTION OF AGING, TOBACCO USE, AND HEALTH EQUITY
Governor’s Square 15

Chair: Bethea Kleykamp, BAK and Associates

Significance: Over the last 20-plus years, combustible cigarette prevalence has dropped to the lowest levels ever recorded for young people in the United States but has not changed for older adults (65 years+). At the same time, novel tobacco products and policies continue to evolve, and the extent to which these shifts will impact older smokers is rarely addressed. For example, although electronic nicotine delivery systems (ENDS) are the fastest-growing tobacco product category, few research studies examine their harm reduction potential among older adults. Yet, these individuals stand to gain the most from stopping their combustible tobacco use as soon as possible. In addition, many people who smoke into later decades of life have been historically minoritized, including individuals who are Black and Hispanic, have a lower socioeconomic status, and/or have more chronic health issues. Thus, aging and tobacco use is a long-standing health equity issue that continues to be overlooked in research, treatment, and policy.

Specific Aims: The primary aim of this symposium is to educate and promote discussion about older adults that use tobacco and nicotine. Four presentations will address four different tobacco products/policy initiatives, including 1) very low nicotine content cigarettes, 2) electronic cigarettes, 3) menthol and non-menthol tobacco flavoring, and 4) lung cancer screening. Given the broad focus of this symposium, we expect that it will be of great interest to clinical researchers, healthcare providers, and health policy organizations that seek to learn about tobacco-related disparities among older adults.
18.1 A Qualitative Analysis of Older Adults’ Perspectives on Very Low Nicotine Content Cigarettes
Speaker: Jessica Kulak, University at Buffalo

18.2 Expectations and Patterns of Electronic Nicotine Delivery Systems (ENDS) Use Among Older Adults who Smoke Cigarettes Within a Nationwide RCT
Speaker: Margaret Fahey, Medical University of South Carolina

18.3 Racial and Ethnic Differences in Lung Cancer Screening Eligibility and Health Services Utilization Among Older Smokers in the U.S.
Speaker: Jaqueline Avila, University of Massachusetts Boston

18.4 Representation of Older Adults in Tobacco Flavoring Research
Speaker: Bethea Kleykamp, BAK and Associates

10:30 A.M. - 12:00 P.M.

SYMPOSIUM: THE INTERSECTION OF COVID-19 AND SUBSTANCE USE DISORDERS
Grand Ballroom II

Chair: Carlos Blanco, National Institute on Drug Abuse
Co-Chair: Leonardo Angelone, DHHS/National Institute on Drug Abuse

This symposium will present a variety of epidemiological and health services responses to the intersection of the COVID-19 pandemic and substance use disorders and overdose. Dr. Ramsey will present an overview of changes in overdose deaths in New York State during COVID-19, innovative practices in the delivery of SUD treatment services during that period and lessons learned for the future. Dr. Halden will discuss the use of wastewater-based epidemiology to monitor community levels of SARS-CoV-2 as well as opioids, as well as opportunities and limits of information gleaned from wastewater analysis.

Dr. Jones will discuss a series of analyses examining use of telehealth for opioid use disorder prior to and during the COVID-19 pandemic among the Medicare population. The analyses explore use of telehealth services and impacts on receipt of medications for opioid use disorder (MOUD), MOUD retention, experiencing medically treated overdose, and overdose death.

There will be a discussion among all panelists regarding changes in Federal- and state-level legislation and regulations, innovations to increase access to MOUD, approaches to workforce support and augmentation and innovations to increase access to overdose prevention, such as naloxone distribution, syringe services programs, drug checking, and overdose prevention centers.

Throughout the symposium, there will be multiple opportunities for interaction with the audience to ensure that the approach is participative and inclusive, rather than adopting a top-down didactic approach.

19.1 COVID-19 and Substance Use: Lessons Learned and where Do We Go from Here?
Speaker: Kelly Ramsey, NYS OASAS

19.2 Examining the Relationship between Use of Emergency Authorities to Support Oud Treatment and Outcomes in the Medicare Population during the COVID-19 Pandemic
Speaker: Christopher Jones, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention
10:30 A.M. - 12:00 P.M.

SYMPOSIUM: STIMULATION FOR THE TREATMENT OF STIMULANT USE DISORDER
Plaza Ballroom D

Chair: Katrina Foster, NIH/NIDA/DTMC
Co-Chair: Jennifer Wong, National Institute on Drug Abuse

Stimulating the Brain to Treat Stimulant Use Disorder: Stimulant use disorder (StUD) is a significant public health concern. In 2020, over 5 million people aged 12 and older reported past year use of stimulants (SAMHSA, 2021). Currently, there are no FDA approved treatments for this devastating disorder despite decades of research focused on developing pharmacotherapies. Neuromodulation provides a new direction for developing treatments for StUDs. This treatment modality has already been authorized by the FDA for smoking cessation and mental health disorders, such as depression. Neuromodulation involves the alteration of nerve activity through targeted delivery of a stimulus, such as electrical or magnetic stimulation to specific brain area(s) to modulate behavior. Examples of neuromodulation include Deep Brain Stimulation (DBS), Transcranial Magnetic Stimulation (TMS) and Low-intensity Focused Ultrasound (LIFU). There are pre-clinical data demonstrating that neuromodulation is effective in reducing drug-seeking behavior (Knapp CM et al., 2009; Friedman A et al., 2010; Fakhrieh-Asl G et al., 2020). Moreover, preliminary data show that neuromodulation reduces alcohol, cocaine and methamphetamine use (da Silva MC et al., 2013; Batra et al., 2017; Hang S et al., 2020). Neuromodulation for the treatment of StUDs is in the early stages but significant advances are being made in clinical studies. This symposium focuses on compelling clinical neuromodulation data for the treatment of StUD and StUD craving from three different types of neuromodulation, as well as having the FDA provide guidance on the authorization pathway for new devices.

20.1 Low Intensity Focused Ultrasound (LIF) as a New Tool to Treat Cocaine Use Disorder
Speaker: Nassima Ait-Daoud Tiouririne, University of Virginia School of Medicine

20.2 Development of Portable Neuromodulatory Intervention to Reduce Craving in Cocaine Addiction
Speaker: Abhishek Datta, Soterix Medical

20.3 Deep Brain Stimulation for Treatment Refractory Methamphetamine Use Disorder
Speaker: Joseph Sakai, University of Colorado School of Medicine

20.4 The Approval Process for New Devices and the Data Needed for This Process
Speaker: Pamela Scott

10:30 A.M. - 12:00 P.M.

FORUM: RESTRUCTURING THE PATHWAY FROM DISCOVERY TO DISSEMINATION OF NEW MEDICATIONS IN THE ACADEMIC ENVIRONMENT
Grand Ballroom I

Chair: Charles France, University of Texas Health Science Center
Co-Chair: Jennifer Potter, University of Texas Health San Antonio
ABSTRACT

Discovery, development, dissemination, and implementation of treatments for substance use disorders (SUD) can be inefficient and ineffective, particularly in academic environments, thereby delaying the availability of medications to patients most in need. Scientific evidence clearly shows that medications can be effective for treating SUD and that with comprehensive care recovery is achievable. Despite the availability of effective medications (e.g., buprenorphine for opioid use disorder), relatively few individuals who need treatment receive a medication. Barriers to uptake of new medications include stigma surrounding SUD, misinformation, and policy regulations surrounding prescribing. One approach to mitigate these barriers is adjusting the manner by which new discoveries become treatments. This forum will discuss the potential value of bidirectional translational conversations across the spectrum of stakeholders, from drug discovery to patients, early and throughout the process of medication development, and from community-oriented solutions back to basic scientists to identify mechanisms of action. Discussion topics will include an adapted translational model for medication development for SUD, including adjusting the typical sequential process of translational science to a parallel interactive process. This model of translational research proposes that activities such as those that are typically conducted in T3 and T4 (e.g., dissemination and implementation research to address potential barriers and discover facilitators) are conducted in parallel with the earlier stages of development, starting with stage T0. Examples of current research will highlight how early engagement of implementation and dissemination research can accelerate the manner by which drugs for treating SUD become available as treatment options.

21.1 Integrated Research to Support Multi-Level Readiness for Evidence-Based Care
Speaker: Tara Karns-Wright, The University of Texas Health Science Center At San Antonio

21.2 Community Engagement to Facilitate Dissemination and Implementation of SUD Innovations
Speaker: Kasey Claborn, The University of Texas At Austin

21.3 The Impact of Physical Activity on Biological Circadian Rhythms in Early Remission From Alcohol Use Disorder
Speaker: Susette Moyers, Oklahoma State University- Center for Health Sciences

21.4 Immune Biomarkers to Accelerate Drug Discovery in Substance Use Disorders
Speaker: Elise Marino, University of Texas Southwestern Medical Center At Dallas

2:00 P.M. - 3:15 P.M.

HUMAN FORUM: NOTHING ABOUT US WITHOUT US: ENGAGING INDIVIDUALS WITH LIVED EXPERIENCE OF SUBSTANCE USE DISORDERS IN SUBSTANCE USE RESEARCH DEVELOPMENT AND IMPLEMENTATION
Grand Ballroom I

Chair: Omayma Alshaarawy, Department of Family Medicine. Michigan State University College of Human Medicine. Co-Chair: Rachel Luba, New York State Psychiatric Institute

Involving individuals with lived experience of substance use disorders (LESUD) in research is increasingly recognized as a critical strategy to reduce stigma, develop effective personalized interventions, and enhance policy recommendations. Individuals with LESUD are well-positioned to identify research challenges and intended outcomes, perform outreach activities, develop referrals, foster trust, and disseminate findings to the community. Accordingly, several organizations (e.g., SAMHSA and NIDA) now strongly encourage researchers to engage individuals with LESUD and their families in all steps of research process including grant proposal development, implementation, and review. The College of Problems on Drug Dependence Human Research Committee presents a forum focusing on guiding principles to ensure purposeful engagement of individuals...
with LESUD in SUD research. Forum speakers will give overviews of effective collaborations with organizations representing individuals with SUD, study planning, data collection methods and analysis, and dissemination of findings. The forum will provide attendees with different perspectives and best practices to collaborate with individuals with LESUD to design effective and responsive research programs and enhance clinical practice and public policy.

22.1 What do we do When Everyone With Lived Experience Wants to Help? Insights From a Recent Research Project of College Students With Histories of Addiction
Speaker: Noel Vest, Boston University

22.2 Qualitative Interviews to Inform Research on and Implementation of Effective Treatments for OUD: How Can the Perspectives of People With LESUD Shape Our Definitions of Clinically-Meaningful Outcomes?
Speaker: Manesh Gopaldas, Columbia University

22.3 Supporting Technology Use and Harm Reduction Within a Housing First Framework
Speaker: Tessa Frohe, University of Washington

2:00 P.M. - 3:15 P.M.

ANIMAL FORUM: THE 3RS CONCEPT OF REPLACEMENT: FUTURE TOOLS OR POLITICAL STRATEGY?
Grand Ballroom II

Chair: James Rowlett, University of Mississippi Medical Center

The “3Rs” concept was introduced in the 1959 by Russell and Birch, and consists of “Replacement”, “Reduction”, and “Refinement”. At present, these concepts play a central role in animal welfare and regulation of animal research worldwide. However, the concept of “replacement” (originally defined as scientific method using non-sentient material instead of conscious living vertebrates) has been used increasingly to promote the complete abolition of all animal-based research (e.g., US FDA Modernization Act passed Oct 2022 by the Senate). Nevertheless, research on alternatives to animals is a viable and active field. To discuss recent issues in the area of non-animal research alternatives, Dr. James Rowlett will introduce the topic and provide updates from the political arena. Dr. Robert Hester will discuss his use of animals for physiological research and his responsibility serving as IACUC Chair at the University of Mississippi Medical Center. He will then present how computer simulation of physiology was initially used to plan animal experiments, then his work on the development of computer simulation for understanding physiology and how investigators and companies are using physiological simulation for virtual clinical trials. Our primary goal is to provide perspectives (sometimes competing ones) on the realities of replacement, and to provide informed responses to challenges that animal research is outdated, including evidence-based knowledge for when alternatives are available and appropriate.

23.1 Non-Animal Alternatives as Political Strategy
Speaker: James Rowlett, University of Mississippi Medical Center

23.2 Animal Experimentation or Computer Simulations? Both are Needed
Speaker: Robert Hester, University of Mississippi Medical Center Department of Physiology
Considerable progress in understanding substance use disorders has been made using nonhuman animal models. This symposium will highlight the profound contributions of such research and its translational impact made by one of CPDD’s long-time members, Bill Woolverton, on the 10th anniversary of his passing. Bill was passionate about rigorous experimental designs using operant procedures, with a focus on translating these preclinical findings to clinical applications. Dr. Nader will discuss the use of concurrent food-drug schedules of reinforcement to model vulnerability to substance misuse, which began for Bill during the late 1980’s and while at the University of Chicago, and how these models can inform interpretations of reinforcing strength and intervention strategies involving polysubstance use. Dr. Rowlett will explore mechanisms of reinforcement and how they tie into, or are explained by, other pharmacological effects engendered by drugs using examples from his research using nonhuman primates, which originated after joining the Bill Woolverton Band (1993-1997) at the University of Mississippi Medical Center. Dr. Freeman will discuss the study of drugs as punishers and the translational implications of Bill’s efforts for the development of abuse-deterrent formulations for prescription drugs. Bill had a deep appreciation for the powerful role of the environment, and Dr. Huskinson will discuss environmental determinants of drug vs. non-drug choice, including delay and variable schedules of reinforcement. The session will conclude with moderated discussion of, and reflection on, Bill’s substantial legacy and the growth opportunities stemming from his impressive body of work.

24.1 Bill was Right: For Most Research Questions, Models of Reinforcing Efficacy are the Best
Speaker: Michael Nader, Wake Forest University School of Medicine

24.2 Woolverton’s “3Ms”: Monkeys, Music, and Mississippi
Speaker: James Rowlett, University of Mississippi Medical Center

24.3 Bill Woolverton and the Study of Drugs as Punishers: Translational Growth From a Bedrock of Rigor
Speaker: Kevin Freeman, University of Mississippi Medical Center

24.4 Looking out Instead of in: How Bill Inspired us to Study Context in Drug Taking
Speaker: Sally Huskinson, University of Mississippi Medical Center
ABSTRACT

Despite a wide range of career paths available to scientists in the substance use and addiction fields, knowledge on how to navigate a career can be limited. This gap in knowledge can be a function of limited access to resources, mentorship, and/or institutional knowledge. Opportunities may exist for emerging addiction scientists that are well suited for their skillsets or expertise but are otherwise inaccessible due to a lack of knowledge on how to pursue certain career paths. The purpose of this workshop is to provide early career attendees at CPDD the opportunity to hear from a diverse group of addiction scientists from a range of professions spanning academia, industry, and government agencies. This workshop will provide valuable information to early career scientists about skill sets, expertise, and experiences needed for various careers and the benefits of different career paths. Our speakers include preclinical, clinical, and epidemiological addiction scientists with experience in Industry positions, government agencies, and both research-focused and teaching-focused academic institutions. Presenters will share experiences that prepared them for their careers, describe their day-to-day work, and discuss available growth opportunities. Presentations by speakers will be followed by breakout groups to allow early career attendees to ask directed questions about specific careers. CPDD is successful, in part, because of dedicated scientists with careers in academia, industry, and government who collaborate to advance the understanding of addiction science. This workshop will provide critical insights for early career attendees, facilitate unique networking opportunities, and will ultimately enrich the future membership of CPDD.

25.1 Addiction Science Research at a Primarily Undergraduate Institution: Balancing the Classroom and Laboratory
Speaker: Ryan Lacy, Franklin and Marshall College

25.2 Federal Regulatory Scientist: Evaluating Drug Abuse-Potential
Speaker: Jovita Randall-Thompson, US Food and Drug Administration

25.3 Trading Paces: One Perspective on the Journey From Academia to Industry
Speaker: Erica Peters, Canopy Growth Corporation

25.4 The Role of the Psychiatrist in Academic Research
Speaker: Denis Antoine, Johns Hopkins University School of Medicine

25.5 Navigating Non-Academic Careers in Addiction Science
Speaker: Alexandra Duncan, The Pew Charitable Trusts

TUESDAY, JUNE 20, 2023

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: THE RACIST ORIGINS AND IMPACT OF THE WAR ON DRUGS
Grand Ballroom II

Chair: Bryon Adinoff, Doctors for Cannabis Regulation
Co-Chair: Brenda Curtis, NIH/NIDA-IRP

The Black Lives Matter (BLM) movement has raised awareness of the systemic racism embedded in the laws, institutions, and culture of the U.S. A key driver of systemic racism is the War on Drugs. Most U.S. drug laws were promoted to the public using racist arguments and have been used to disenfranchise and incarcerate millions of individuals, particularly people of color. Consequences include arrests, incarcerations, violent policing, and the lifelong effects of an arrest/prison record upon education, employment, housing, and child custody. The criminal
consequences of illicit drug use make our field of medicine unique in that suffering from an addictive illness (e.g. opioid use disorder) is punishable by law, even in the absence of harm. Moreover, criminal punishment can also exacerbate mental illness and contribute to problematic drug use. Nevertheless, addiction-related medical and research organizations by and large continue to either support drug prohibition or remain silent. In this symposium, the speakers will provide an overview of the origins and impact of drug prohibition, the centrality of race and stigma to the prohibitionist structure, and the role of the addiction research community in resolving the inherent conflict between an illicit drug use disorder as a criminal behavior vs. biologic illness. A moderated discussion will allow audience input into the role the CPDD community can play to re-orient society’s focus on drug prohibition to evidence-based drug treatment, where appropriate.

26.1 The Racist Origins and Impact of the War on Drugs  
Speaker: Maritza Perez Medina, Office of Federal Affairs

26.2 The Dehumanization of Substance Users  
Speaker: Brenda Curtis, NIH/NIDA-IRP

26.3 The Role of Addiction Researchers in Righting the Wrongs of the Drug War  
Speaker: Bryon Adinoff, Doctors for Cannabis Regulation

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: THE PAST, PRESENT, AND FUTURE OF REINFORCER PATHOLOGY THEORY IN SUBSTANCE USE DISORDER
Plaza Ballroom A

Chair: Justin Strickland, Johns Hopkins University School of Medicine  
Co-Chair: Warren Bickel, Fralin Biomedical Research Institute at VTC

Behavioral economics is an interdisciplinary field that uses psychological, economic, and neuroscience principles to inform behavioral health and decision-making science. Advances in behavioral economic research have culminated in the development of a novel conceptual framework – Reinforcer Pathology Theory. Reinforcer Pathology Theory posits that reinforcers are integrated over a temporal window that determines the relative value of drugs and prosocial alternatives such that brief, immediate, intense, and reliable reinforcers (e.g., substance use) are overvalued compared to alternatives lower in their intensity, variable in their outcome, and delayed in their value accumulation (e.g., employment). This session will trace the past, present, and future of Reinforcer Pathology Theory using data from diverse drug classes and preclinical, human laboratory, and clinical settings. We will first describe the development and evolution of Reinforcer Pathology Theory along with basic science tests of diverse phenomena explained by this theoretical framework (e.g., alternative reinforcer and satiation hypotheses). Speakers will then discuss applications of Reinforcer Pathology Theory to behavioral and medications development work in substance use disorder. These data will demonstrate improved translational potential achieved through Reinforcer Pathology Theory across a pipeline of preclinical rodent studies to the human laboratory to clinical assessment. A public health view of Reinforcer Pathology Theory will then be explained, and how these approaches have rendered novel insights to guide policy development and thus garnered widespread attention outside of academia. The session will conclude with a moderated discussion of future theory refinement and applications for new intervention contexts.

27.1 Reinforcer Pathology: Contemporary Status and Future Directions  
Speaker: Warren Bickel, Fralin Biomedical Research Institute at VTC
ABSTRACT

27.2 Understanding the Effects of Visual Exposure to Nature on Substance Demand and Discounting Using Reinforcer Pathology
Speaker: Meredith Berry, University of Florida

27.3 Applying Behavioral Economics and Reinforcer Pathology Theory to Improve Translational Medications Development
Speaker: Justin Strickland, Johns Hopkins University School of Medicine

27.4 The Historical Precedence and Translational Promise of Reinforcer Pathology Theory in Public Health Policy for Substance Use Disorder
Speaker: Derek Reed, University of Kansas

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: DYSREGULATION OF THE PREFRONTAL CORTEX IN SUBSTANCE USE DISORDERS
Plaza Ballroom D

Chair: Jacqueline McGinty, Medical University of South Carolina
Co-Chair: Kathryn Cunningham, John Sealy School of Medicine University of Texas Medical Branch

Dysregulation of the medial prefrontal cortex (mPFC) during substance use disorders (SUDs) is a major characteristic of relapse to drug seeking and the cognitive deficits that accompany relapse. However, we know little about the phenotypes that result from structure and functional mPFC deficits in impulse control and executive decision-making during SUD development. Recent evidence indicates that abused drugs disrupt regulation of mPFC pyramidal neurons by fast-spiking, parvalbumin (PV)-expressing interneurons and the perineuronal nets (PNNs) that surround them. In this symposium, a diverse panel of investigators who represent multi-disciplinary perspectives will address these issues and more. To introduce the clinical context, F. Gerard Moeller (VCU) will discuss human brain effective connectivity engaging the mPFC to gain a richer “fingerprint” of the complex neurocircuitry and behavior to develop precise diagnoses and make therapeutic decisions in SUDs. Barbara Sorg (Legacy Research Institute) will discuss the effects of repeated cocaine on PNNs and synaptic excitability of PV interneurons in the mPFC as well as the impact of mPFC PNN removal on communication between the mPFC and hippocampus during consolidation of cocaine-associated memories. Antonieta Lavin (MUSC) will discuss the role of PV-positive interneurons in METH-induced hypofrontality and its resulting cognitive deficits. Kathryn Cunningham (UT Galveston) will highlight preclinical studies of serotonin target-phenotype relationships engaging mPFC circuitry which precipitate SUD risk. Altogether this panel will highlight the importance of the relationship between specific PFC neuronal subpopulations in preclinical and clinical models that expand our understanding of clinical phenotypes of SUDs.

28.1 Human Brain Connectivity as a Fingerprint of Neurocircuitry and Behavior
Speaker: F. Gerard Moeller, Virginia Commonwealth University

28.2 Impact of Perineuronal Nets on Reconsolidation of Cocaine-Associated Memories and Prefrontal-Hippocampal Coupling During Cocaine Cue Acquisition
Speaker: Barbara Sorg, Legacy Research Institute

28.3 Chronic Methamphetamine Administration Produces Cognitive Deficits Through Augmentation of Gabaergic Synaptic Transmission in the Prefrontal Cortex
Speaker: Antonieta Lavin, MUSC, Dept. of Neuroscience
28.4 Prefrontal Cortex 5-HT2A and 5-HT2C Receptors Control Target Behaviors Allied With Cocaine Use Disorder
Speaker: Kathryn Cunningham, John Sealy School of Medicine University of Texas Medical Branch

8:00 A.M. – 9:30 A.M.

SYMPOSIUM: BEYOND GWAS: THE GENETICS AND EPIGENETICS OF ADDICTION
Governor’s Square 15

Chair: Jonathan Pollock, National Institute of Drug Abuse, National Institutes of Health
Co-Chair: Arpana Agrawal, Washington University School of Medicine

GWAS studies are rapidly identifying variants underlying addiction and complex psychiatric disorders. These variants are being found within the coding regions of genes and in non-coding regions of the genome. Understanding how these different types of variants contribute to addiction and behaviors associated with addiction requires approaches that identify functional consequences, assess gene x gene interactions within gene networks, and creation of addiction risk scores associated with these variants. In this symposium, we will discuss technologies that uncover the underlying biology of GWAS variants using three different approaches: identifying function through analysis of variant-specific chromatin changes, machine learning, and analysis of short tandem repeats.

29.1 Substance Use Disorders in 3D Genome
Speaker: Hyejung Won, University of North Carolina at Chapel Hill

29.2 Transcriptomic Profiling of the Opioid Exposed Human Ventral Midbrain at Single Nuclei Resolution
Speaker: Schahram Akbarian, Icahn School of Medicine at Mount Sinai

29.3 Systems Biology Integration of Multi-Omic Data Reveals Biological Pathways Underlying Substance Use Disorders
Speaker: Kyle Sullivan, Oak Ridge National Laboratory

29.4 The Contribution of Short Tandem Repeats to Splicing Variation in Humans
Speaker: Yang Li, University of California - San Diego

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: NOT LIKE OTHER OPIOIDS: HOW IS FENTANYL UNIQUE?
Grand Ballroom I

Chair: Kelly Dunn, Johns Hopkins University School of Medicine
Co-Chair: Andrew Huhn, Johns Hopkins University School of Medicine

Illicitly manufactured fentanyl has infiltrated and, in many places, completely replaced the heroin product in the United States and Canada. Fentanyl has many unique characteristics that distinguish it from other opioid agonists and make it a particularly nefarious compound. Specifically, the mechanisms through which fentanyl exerts effects leads to differences in its subjective effect profile and withdrawal experience and increases its lethality relative to other opioids, putting patients at extreme risk and complicating conventional treatment strategies. This symposium brings together researchers from several disciplines to discuss these unique features. First, Dr. Sandra Comer will discuss fentanyl’s unique pharmacodynamic profile relative to
other opioids. Next, Dr. Jaime Yanez-Farfan will discuss fentanyl's secondary peaking profile, an effect that is not typically observed in persons using other opioid agonists. Third, Dr. Phillip (Randy) Torralva will review preclinical evidence of the unique lethality of fentanyl-induced vocal cord (glottic) closure (FIVCC) as it relates to fentanyl overdose in humans. Finally, Dr. Kelly Dunn will present data on withdrawal and play recorded (and anonymized) conversations with persons who have lived experience with illicit fentanyl exposure to illustrate patient-reported differences in the experience of withdrawal following fentanyl versus heroin as well as during buprenorphine inductions. A panel discussion, moderated by Dr. Andrew Huhn, will focus on how these distinct features make fentanyl uniquely challenging relative to other opioids and review the epidemiological, clinical, and preclinical research that is needed to help advance the care of patients.

30.1 Pharmacology of Fentanyl and its Implications for Treatment of Opioid Use Disorder and Overdose
Speaker: Jermaine Jones, Columbia University Irving Medical Center

30.2 Multiple Peaking Phenomena in Fentanyl Disposition
Speaker: Jaime Yanez, Universidad Norbert Wiener

30.3 Preclinical Evidence of Fentanyl-Induced Vocal Cord Closure (FIVCC)- Relevance to Fentanyl Overdose in Humans
Speaker: Phillip Torralva, Oregon Health and Science University / Torralva Medical Therapeutics, INC.

30.4 Withdrawal From Fentanyl is Different: Data Presentation and First-Hand Accounts From Persons With Lived Experience
Speaker: Kelly Dunn, Johns Hopkins University School of Medicine

Moderator: Andrew Huhn, Johns Hopkins University School of Medicine

10:00 A.M. - 11:30 A.M.

INNOVATOR SYMPOSIUM: MEDICATION DEVELOPMENT FOR METHAMPHETAMINE USE DISORDER
Plaza Ballroom A

Chair: Linda Dwoskin, University of Kentucky

Methamphetamine Use Disorder (MUD) afflicts 2.6 million US citizens, caused >23,000 US deaths in 2020, and imposes an economic burden of >$600B annually. MUD is the compulsive, chronic use of methamphetamine, causing devastating health consequences (e.g., psychotic behavior, brain and heart damage, death) and harm to communities (e.g., crime, unemployment, child neglect or abuse). There are currently no FDA approved medications to treat MUD. Methamphetamine increases extracellular dopamine by inhibiting cellular uptake and reversing transport at the vesicular monoamine transporter-2 (VMAT2). Blocking methamphetamine's effects at VMAT2, and thus blocking METH-induced reward and relapse, could lead to a MUD pharmacotherapy. Our late lead preclinical candidate VMAT2 inhibitor, UKY-21, potently (Ki = 31 nM) inhibits VMAT2 function with minimal interactions at potential off targets (dopamine transporter and hERG, Ki's >100-fold higher than at VMAT2). UKY-21 evolved from a previously reported series of related VMAT2 inhibitors with poor oral bioavailability and hERG liability. Oral administration of UKY-21 in rats, potently (ID50 = 17mg/kg/d) and effectively decreases methamphetamine self-administration without the development of tolerance. In vivo selectivity for UKY-21 is supported by failure to decrease cocaine self-administration at oral doses that decrease METH self-administration. UKY-21 has high oral bioavailability (>65% in rat) and provides durable exposure in plasma and brain, consistent with once daily oral dosing. UKY-21 is well tolerated in vivo in rat and
ABSTRACT

appears to have an optimal safety pharmacology profile, including no significant hERG inhibition. Successful development of a pharmacotherapy for MUD would have a tremendously beneficial health and socioeconomic impact.

31.1 Mirtazapine for Methamphetamine Use Disorder
Speaker: Phillip Coffin, San Francisco Department of Public Health

31.2 Development of Biased Neurotensin Receptor 1 Ligands for the Treatment of Addiction
Speaker: Lauren Slosky, University of Minnesota

10:00 A.M. - 11:30 A.M.

SYMPOSIUM: THE POTENTIAL OF PSYCHEDELIC THERAPIES FOR SUBSTANCE USE DISORDERS
Grand Ballroom I

Chair: Albert Garcia-Romeu, Johns Hopkins University School of Medicine

Historically, clinical research with classic psychedelics such as LSD focused heavily on applications treating substance use disorders (SUDs). Meta-analysis of early controlled trials comparing LSD to non-psychedelic control conditions found a single high-dose LSD treatment was associated with significantly greater reductions in alcohol misuse than control. Similarly, a preliminary trial of high-dose LSD with residential treatment in formerly incarcerated men with a history of opioid dependence found significantly greater biologically verified opioid abstinence in the LSD vs. treatment-as-usual control condition up to 12 months post-treatment. These studies and anecdotal and observational reports on indigenous and naturalistic psychedelic use formed the basis for novel research on psychedelic therapies for SUD in the 21st century, with small preliminary trials of psilocybin and ayahuasca for various SUDs showing feasibility and promise. More recently, larger randomized controlled trials of psilocybin for SUD have been conducted. Published data from a placebo-controlled trial in patients with alcohol use disorder showed significantly greater reductions in heavy drinking days and daily alcohol consumption after two high doses of psilocybin with motivational enhancement therapy (MET) compared to placebo with MET. Available data from recently completed controlled trials of psilocybin-assisted treatment for tobacco and cocaine use disorder will also be discussed. Additionally, growing preclinical research is probing biological activity underlying psychedelics’ anti-addictive effects. These findings will be examined in the context of investigating psychedelic therapies and their mechanisms and exploring the ramifications for potential psychedelic-assisted treatments for SUD.

32.1 Effects of Psilocybin in Treatment-Seeking Adults With Alcohol Use Disorder
Speaker: Michael Bogenschutz, New York University Grossman School of Medicine

32.2 Psilocybin Treatment for Cocaine Use Disorder
Speaker: Peter Hendricks, The University of Alabama At Birmingham

32.3 Effects of Psychedelics in Preclinical Models of Substance Use Disorders
Speaker: Kevin Murnane, Louisiana State University Health Sciences Center - Shreveport

32.4 Psilocybin-Assisted Smoking Cessation: A Randomized Controlled Trial
Speaker: Matthew Johnson, Johns Hopkins University School of Medicine
10:00 A.M. - 11:30 A.M.

**SYMPOSIUM: NEUROPEPTIDES IN REWARD, ADDICTION, AND MENTAL HEALTH**
Plaza Ballroom D

Chair: Subramaniam Ananthan, DHHS/NIH/NIDA
Co-Chair: Lakshmi Devi, Icahn School of Medicine At Mount Sinai

Neuropeptides are known to play a central role in physiological and pathological processes relating to reward, learning, memory, stress, addiction, and neurological disorders. Peptidomic studies using mass spectroscopy and single cell transcriptional profiling are revealing a surprising prevalence of neuropeptides in brain that are positioned to broadly modulate neural activity and behavioral functions. These findings offer novel targets for therapeutics development for neurobehavioral disorders. This symposium will feature presentations on innovations and recent advances in the field of neuropeptides and their signaling mechanisms in addiction, mental health, and psychiatric disorders.

33.1 The Role of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Binge-Like Ethanol Drinking and Affective Behavior
Speaker: Jessica Barson, Drexel University College of Medicine

33.2 Extended Amygdala Neuropeptide Circuitry of Emotional Arousal
Speaker: William Giardino, Stanford University

33.3 Endogenous Opioid Peptides and Novel Neuropeptides in Addiction, Reward, and Mental Health
Speaker: Lakshmi Devi, Icahn School of Medicine At Mount Sinai

10:00 A.M. - 11:30 A.M.

**SYMPOSIUM: HOW NEUROIMAGING CAN BE USED IN TREATMENT DEVELOPMENT IN DRUG ADDICTION: FROM FDA STANDARDS TO CLINICAL APPLICATIONS**
Grand Ballroom II

Chair: Hamed Ekhtiari, University of Minnesota
Co-Chair: Sarah Yip, Yale University

As a neurobiological process, addiction involves pathological patterns of engagement with substances and a range of behaviors with a chronic and relapsing course. Neuroimaging technologies assess brain activity, structure, physiology, and metabolism at scales ranging from neurotransmitter receptors to large-scale brain networks, providing unique windows into the core neural processes implicated in substance use disorders. Identified aberrations in the neural substrates of reward and salience processing, response inhibition, interoception, and executive functions with neuroimaging can inform the development of pharmacological, neuromodulatory, and psychotherapeutic interventions to modulate the disordered neurobiology. Neuroimaging measures can facilitate the development of a range of biomarkers that may prove useful in the arsenal of addiction treatments in the coming years. There is evidence that these markers of large-scale neural structure and activity may indicate vulnerability or separate disease subtypes, predict response to treatment, or provide objective measures of treatment response or recovery. Neuroimaging biomarkers can also suggest novel targets for interventions. Closed or open loop interventions can integrate these biomarkers with neuromodulation in real-
time or offline to personalize stimulation parameters and deliver precise intervention. Given the sheer diversity and rapid advances in neuroimaging in recent years, this symposium will provide an overview of neuroimaging modalities in addiction, potential neuroimaging biomarkers, and future directions and challenges in bringing these putative biomarkers from the bench to the bedside. At the end, we will discuss an executive pathway to support FDA qualification for neuroimaging biomarkers in certain contexts of use and how other labs can contribute in this collective effort.

34.1 From Neuroimaging Markers to Biomarkers in Treatment Development
Speaker: Lara Ray, University of California Los Angeles

34.2 Brain-Based Predictive Modeling of Addiction
Speaker: Sarah Yip, Yale University

34.3 Neuroimaging as a Response Biomarker in Drug Development
Speaker: Joseph Schacht, University of Colorado School of Medicine

34.4 Neuroimaging as a Target Biomarker in Neuromodulation
Speaker: Hamed Ekhtiari, University of Minnesota

10:00 A.M. - 11:30 A.M.

WORKSHOP: 29TH ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP
Governor’s Square 15

Chair: Matthew Novak, Johns Hopkins University School of Medicine
Co-Chair: Diann Gaalema, University of Vermont

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the discussion and dissemination of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 29th annual meeting of the CM Working Group, junior and senior researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input and providing opportunities for junior and senior researchers to interact. As the goal for this working group has always been to provide an informal outlet for discussion of CM data, names of presenters are not included with this submission. Rather, participants and topics will be chosen during the Spring of 2023 to capture the most current data in contingency management research for presentation at our annual working group.
MINI-SYMPOSIUM: MONITORING AND DIAGNOSTIC DEVICES FOR SUBSTANCE USE DISORDERS: CHALLENGES AND OPPORTUNITIES
Grand Ballroom I

Chair: Stacie Gutowski, National Institute on Drug Abuse, National Institutes of Health
Co-Chair: Kelly Dunn, Johns Hopkins University School of Medicine

Medical devices can serve as tools for monitoring patients and/or diagnosing drug overdose to provide innovative solutions in the management of substance use disorders. New developments in hospital-based monitoring options can provide personalized pain management and medication dosing to reduce opioid exposure. Beyond the clinical environment, novel technological developments have led to monitoring for a wide range of real-time physiologic parameters in daily life including respiratory rate, blood oxygen saturation, heart rate, and electrodermal activity through wearable devices and accompanying mobile phone applications. These devices can be utilized by patients to provide instantaneous monitoring of the patient experience, such as identifying when a person is experiencing stress or anxiety and subsequently providing real-time options for social support, geo-located interventions (e.g., meetings, treatment centers), cognitive behavioral therapies through clinician or chat bot interactions. Additionally, medical devices are being developed to focus on the detection of opioid-induced respiratory depression, to monitor and possible alert bystanders and/or caregivers and allow for a timely administration of naloxone. As these devices are developed, we must discuss and understand the challenges and opportunities about which measures are most useful and the types of data output and alerts that will be accepted in this patient population.

36.1 Monitoring and Diagnostic Devices for Substance Use Disorders: Challenges and Opportunities
Speaker: David Reeser, OpiAID, Inc.

36.2 An EEG Biomarker for Opioids: Insights From the Operating Room to aid in the Opioid Crisis
Speaker: Patrick Purdon, Harvard Medical School

36.3 Wearable and On-Body Devices for Detection of Opioid Overdose
Speaker: Michael Hite, Ayuda Medical

MINI-SYMPOSIUM: FROM INITIATION TO ADDICTION: A MEASURE OF THE FULL RANGE OF INVOLVEMENT FOR OPIOIDS, CANNABIS, AND ALCOHOL
Grand Ballroom I

Chair: Ty Ridenour, RTI International
Co-Chair: Lissette Saavedra, RTI International

This mini symposium will present an innovative measure of the full developmental continuum of substance use (SU) involvement from pre-initiation through physiological dependence onto which numerous other SU measures could be mapped. This measure could help delineate which stages of progression from earlier to later involvement are impacted by specific environmental risks, genetic mechanisms, and underlying neurophysiology as well as when and for whom prevention and treatment programs are most impactful. Involvement was tested
using items on initiation, regular use, and SU disorder (SUD) criteria available in many commonly used datasets. Methods: National Survey on Drug Use and Health (NSDUH) datasets 2016-2019 (N=225,622) were analyzed using moderated non-linear factor analysis and traditional psychometric analyses to evaluate “anchor items” for recreating involvement measures in other datasets for alcohol, cannabis, prescription opioids, and heroin. NSDUH data represent noninstitutionalized U.S. civilians, ages 12 or older. Sample composition was 52.2% female; 58.3% non-Hispanic White, 12.8%, non-Hispanic Black and 18.5% Hispanic; and 21.5% with an income below 2 times the poverty level. Results: Psychometrics in the general population and an elevated risk subsample supported involvement measures for each substance and overall SU involvement. Greater involvement with each substance was associated with SUDs of the same or other drugs (e.g., cocaine), major depression, risk taking, criminal behavior, and suicidality. Conclusions: Panelists will present study results; methods to create involvement measures in other datasets illustrated using NIH HEAL datasets; and how involvement could shed light on SUD etiology, prevention, treatment, and recovery.

37.1 Substance Use Involvement Associations With Risk Factors and Psychopathology
Speaker: Barrett Montgomery, RTI International

37.2 Development and Psychometrics of Substance Use Involvement Measures With Nonlinear Moderated Factor Analysis
Speaker: Alexandra Tonigan, RTI International

37.3 Substance Use Involvement Replication in Other Datasets and Potential Research Directions Illustrated With Heal Initiatives Studies
Speaker: Ty Ridenour, RTI International

WEDNESDAY, JUNE 21, 2023

SYMPOSIUM: USING BIG DATA TO UNDERSTAND THE ROLE OF THE GUT MICROBIOME IN SUBSTANCE USE DISORDERS
Plaza Ballroom D

Chair: Susan Wright, NIDA/NIH
Co-Chair: Kiran Vemuri, National Institute of Drug Abuse/NIH/DHHS

Substance use disorders (SUDs) continue to be a significant public health challenge with negative health, social, and economic consequences. They are known to co-occur at high prevalence with several mental health disorders and can involve several different substances, including cocaine, opiates, cannabinoids, nicotine, and alcohol. While much SUD research has focused on the neurologic and genetic components of usage behavior, there is increasing interest in the role of the gut microbiome in the pathogenesis of SUD. With the continuous collection of large volumes of various data types, researchers are trying to facilitate microbiome research by building large reference data sets to serve as a foundation for new technologies and data analysis tools. This session will explore current research providing evidence that the gut microbiome is involved in SUDs and the challenges and opportunities for understanding the role of the microbiome in health. Accordingly, the symposium will address key knowledge gaps in the field while describing relationships between the gut microbiome and various addiction or addiction-related behaviors. The panel will also discuss relevant models of drug-seeking behavior along with metagenomics, metabolomics, and proteomics approaches to identify...
molecular signatures underlying gut microbiome affects, including biomarkers that covary in the context of SUD.

38.1 Using Big Data to Understand the Role of Gut Microbiome in Substance Use Disorder
Speaker: Jason Bubier, The Jackson Laboratory

38.2 The Gut Microbiome in Modulating Binge Drinking
Speaker: Yanjiao Zhou, UConn Health

38.3 Utilizing Multi-Omics Approaches to Identify Molecular Signatures of Gut-Brain Signaling in Models of Fentanyl Use Disorder
Speaker: Drew Kiraly, Wake Forest School of Medicine

38.4 The Microbiome as a Risk Factor in Opioid Use Disorders
Speaker: Jennifer Whistler, Center for Neuroscience

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: PREVENTION IS BETTER THAN CURE: EARLY INTERVENTION FOR SUBSTANCE USE DISORDERS
Governor’s Square 15

Chair: Gillinder Bedi, The University of Melbourne
Co-Chair: Carlos Blanco, National Institute on Drug Abuse

Substance use disorders (SUD) commonly emerge during adolescence/young adulthood, a critical period of neurobiological and psychosocial development. Onset of SUD during this period confers risk of harm to the developmental trajectory, setting the stage for a cascade of future difficulties. Without intervention, SUDs can develop into chronic conditions, requiring multiple episodes of care. Yet, delayed treatment remains the norm and most treatments are targeted to the severe end of the SUD spectrum. There is a need to refocus intervention efforts towards the early stages of SUD to disrupt progression to more severe SUD and prevent adverse health outcomes. This symposium will provide an overview of the current limited evidence guiding early intervention strategies for SUD. We will review the clinical staging model in psychiatry and developments in early intervention psychiatry, assessing the utility of these frameworks for clinical addiction science. Early intervention depends on the presence of well-delineated early clinical phenotypes: the second speaker will use epidemiological data to assess whether clinical high-risk states for SUD can be identified. The second section of the symposium will present emerging evidence on early intervention methods. This will include data on implementation of screening, brief intervention and referral to treatment for adolescents in pediatric medical and school settings, and opportunistic early intervention in college students and youth presenting for emergency care. Speakers will highlight the potential for early intervention to modify negative effects of SUD across the life course, and the clear need for further research to enable these impacts to be realised.

39.1 Early Intervention for Substance Use Disorders: Lessons From Clinical Staging and Early Intervention Psychiatry
Speaker: Gillinder Bedi, The University of Melbourne

39.2 Is There a Clinical High Risk State for Substance Use Disorder? An Epidemiological Perspective
Speaker: Carlos Blanco, National Institute on Drug Abuse
ABSTRACT

39.3 Implementing SBIRT for Adolescent Substance Use in Pediatric Medical and School Settings
Speaker: Christopher Hammond, Johns Hopkins University School of Medicine

39.4 Opportunistic Early Intervention for Problematic Substance Use in Young People via University and Emergency Services
Speaker: Leanne Hides, University of Queensland

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: DEVELOPMENT OF FENTANYL-TARGETED VACCINES TO DECREASE OVERDOSE FATALITIES
Grand Ballroom II

Chair: Drew Townsend, NIDA DTMC
Co-Chair: Jason Sousa, National Institute on Drug Abuse

Opioid-related fatalities have become the most common cause of death for Americans between 18-45 years of age. This surge in deaths may be attributable to the adulteration of illicit drugs (heroin, cocaine, methamphetamine) with fentanyl, leading to the unintentional exposure of illicit drug users to this highly potent opioid. Recent findings suggest that fentanyl-targeted vaccines can confer robust protection against fentanyl and structurally similar opioids. However, it is critical that the durability of fentanyl-targeted vaccines is closely examined preclinically to identify the most promising candidates for clinical testing. The aims of this symposium, organized by NIDA's Division of Therapeutics and Medical Consequences, include 1) educating the audience on the mechanisms of the leading anti-opioid vaccination strategies, 2) provide the current state of the science of opioid-targeted vaccines, and 3) discuss practical considerations of opioid vaccine development (e.g., preclinical vs. clinical endpoints, gaining IND approval, manufacturing). These goals will be accomplished by highlighting three approaches for vaccination under preclinical consideration and conclude with a preview of how these vaccines may be tested under human-laboratory conditions. The first speaker will share findings with a fentanyl-conjugated vaccine, a conventional and well-established approach for vaccination. The second speaker will share findings with a monoclonal vaccination approach for fentanyl. The third speaker will share data related to a novel “nanoparticle vaccine” approach. Finally, potential challenges to the forward translation of opioid-targeted vaccines towards clinical evaluation will be discussed.

40.1 Translation of Vaccines and Antibody Based Strategies Against Fentanyl and its Analogs
Speaker: Marco Pravetoni, University of Washington School of Medicine

40.2 Development of CSX-1004 Monoclonal Antibody for Treatment and Prevention of Fentanyl Overdose
Speaker: Paul Bremer, Cessation Therapeutics

40.3 Hybrid Nanoparticle as a Platform for Vaccine Development Against Opioids and Other Psychoactive Compounds
Speaker: Chenming Zhang, Virginia Tech

40.4 Clinical Testing of Opioid Vaccines: Lessons Learned
Speaker: Sandra Comer, Columbia University and NYSPI
Co-Presenter: Rachel Luba, New York State Psychiatric Institute
8:00 A.M. - 9:30 A.M.

SYMPOSIUM: LEAVING NO ONE BEHIND: ENDING THE HIV EPIDEMIC WITH TARGETED INTERVENTIONS FOR PEOPLE WHO USE DRUGS
Grand Ballroom I

Chair: Joy Schmitz, University of Texas Health Science Center
Co-Chair: Angela Heads, The University of Texas Health Science Center At Houston

In 2019, the US announced a plan to End the HIV Epidemic by 2030. People who use drugs (PWUD) are disproportionately affected by the epidemic, due in part to low rates of HIV testing and insufficient access to HIV prevention and care services. Consequently, many PWUD do not benefit from highly efficacious HIV prevention and treatment interventions, such as pre-exposure prophylaxis (PrEP) and antiretroviral therapies (ART). Effectively ending the HIV epidemic involves improving HIV prevention and treatment outcomes for PWUD so that no one is left behind. In this symposium, speakers will present progress being made in the development of integrated interventions, encompassing a range of substances of abuse, treatment delivery modalities, and affected populations. Dr. Christopher Kahler will present findings from a factorial randomized controlled trial of telehealth interventions to reduce substance use in men who have sex with men (MSM) living with HIV. Dr. Glenn-Milo Santos will discuss the use of intermittent naltrexone with an in-the-moment ecological momentary intervention to increase PrEP and ART adherence in MSM who use methamphetamine. Research presented by Dr. Adam Carrico will focus on optimizing contingency management to improve HIV prevention and care with sexually minority men who use stimulants. Finally, Dr. Jennifer Jain will present an intervention approach that addresses stigma-related barriers to HIV care engagement among racially diverse women living with HIV who use drugs. Drs. Joy Schmitz and Angela Heads will summarize the talks and moderate a discussion on research priorities for addressing the intersection of substance use and HIV.

41.1 Leaving No One Behind: Ending the HIV Epidemic With Targeted Interventions for People who Use Drugs
Speaker: Christopher Kahler, Brown University School of Public Health

41.2 Pharmacotherapy With an Ecological Momentary Intervention to Increase Pre-Exposure Prophylaxis and Anti-Retroviral Therapy Adherence Among Men who Have Sex With Men who Use Methamphetamine
Speaker: Glenn-Milo Santos, University of California San Francisco

41.3 Optimizing the Benefits of Contingency Management for HIV Prevention and Care With Sexual Minority Men who Use Stimulants
Speaker: Adam Carrico, University of Miami

41.4 WISH: Women, Intersectionality, Substance Use, and HIV
Speaker: Jennifer Jain, University of California, San Francisco
SYMPOSIUM: TREATING SUD IN PATIENTS WITH PTSD AND HISTORIES OF VICTIMIZATION
Grand Ballroom I

Chair: Carrie Mulford, National Institute on Drug Abuse, National Institutes of Health

PTSD and SUD commonly co-occur, with approximately 30% of youth and 50% of adults with PTSD also meeting criteria for SUD. Traumatic experiences are risk factors for the development of SUD. Moreover, the co-occurrence of PTSD and SUD is associated with more severe symptoms and worse clinical outcomes. This panel will present research demonstrating that integrated treatment of comorbid PTSD and SUD, is feasible and effective in reducing symptoms of both disorders. The first presentation will identify neurobiology and symptomatology common to comorbid PTSD and SUD and review the clinical impact of co-occurring disorders. The second presenter will summarize results from the Collaboration Leading to Addiction Treatment and Recovery from Other Stresses (CLARO) study, a randomized controlled trial comparing the effectiveness of collaborative care for patients with co-occurring OUD, PTSD and/or depression. In this presentation, the authors will describe and compare adult patients who have OUD and co-occurring PTSD with and without traumatic experiences of victimization. The third presentation will provide an overview of research on Risk Reduction through Family Therapy (RRFT), including preliminary findings from an ongoing effectiveness implementation trial in adolescent outpatient clinics. RRFT is an integrative, exposure-based treatment for youth that incorporates best-practice interventions for PTSD, SUD, and related health risk behaviors. The final presentation will present preliminary outcomes from an RCT examining the efficacy Concurrent Treatment of PTSD and Substance Use Using Prolonged Exposure - Adolescent (COPE-A), a 16-session intervention, on substance use and PTSD outcomes for adolescents and young adults.

42.1 Comorbid Ptsd and Substance Use disorders: Shared Symptomatology and Neurobiology
Speaker: Jesse Hinckley, University of Colorado School of Medicine

42.2 Challenges in Addressing Victimization for People who Have Opioid Use Disorder and Probable PTSD
Speaker: Lisa Meredith, RAND
Co-Presenter: Grace Hindmarch, RAND Corporation

42.3 Advancing Treatment for Adolescents with Co-Occurring Substance Use Disorders (SUDs) and Posttraumatic Stress Disorder (PTSD): Risk Reduction through Family Therapy
Speaker: Zachary Adams, Indiana University School of Medicine

Moderator: Devin Banks, University of Missouri--St. Louis
10:00 A.M. - 11:30 A.M.

SYMPOSIUM: DRIVING IMPAIRMENT CAUSED BY THE USE OF CANNABIS AND OTHER DRUGS: RECENT EVIDENCE FROM HUMAN LABORATORY STUDIES
Grand Ballroom II

Chair: Tory Spindle, Johns Hopkins University School of Medicine
Co-Chair: Carlos Zamarripa, Johns Hopkins University School of Medicine, Department of Psychiatry

The global expansion of cannabis legalization for medical and “recreational” purposes has created an urgent need for research on cannabis-induced driving impairment. Controlled studies demonstrate that cannabis can impair driving performance and epidemiological evidence shows that: 1) driving under the influence of cannabis is increasing, and 2) cannabis-positive drivers have an increased crash risk. However, there are currently no validated methods to detect cannabis-impaired drivers and novel approaches are sorely needed. Further, many novel cannabis products (e.g., edibles) have emerged that remain understudied. Finally, given the heterogeneity in cannabis users, there is a need to characterize impairment among different groups (e.g., medical vs recreational users) and to evaluate individual differences in impairment. This symposium includes four presentations describing data from human laboratory studies featuring sophisticated driving simulators. Dr. Austin Zamarripa will present a study evaluating the individual and interactive effects of cannabis edibles and alcohol on driving performance. Dr. Thomas Arkell will present research on the effects of real-world medical cannabis use on driving/cognitive performance. Dr. Jan Ramaekers will present data showing neural mechanisms underlying individual differences in cannabis-induced impairment. Lastly, Dr. Amie Hayley will describe a novel impairment-detection approach (Driver Monitoring Systems, DMS) that evaluates fitness to drive using eye-tracking; the effectiveness of DMS at detecting drug/alcohol-induced impairment and future applications of this technology will be discussed. Dr. Tory Spindle will synthesize findings from these studies and facilitate an interactive discussion, with an emphasis on U.S. and global policy implications and possible future directions in the driving impairment field.

43.1 Individual and Interactive Effects of Oral Cannabis Products (i.e., “Edibles”) and Alcohol on Driving Impairment
Speaker: Carlos Zamarripa, Johns Hopkins University School of Medicine, Department of Psychiatry

43.2 Acute Effects of Medicinal Cannabis on Driving and Cognitive Function: Real-World Evidence
Speaker: Thomas Arkell, Centre for Human Psychopharmacology, Swinburne University of Technology

43.3 Neural Mechanisms Underlying Cannabis-Induced Driving Impairment: The Impact of Tolerance and Individual Differences
Speaker: Jan Ramaekers, Maastricht University

43.4 Driver Monitoring Systems (DMS): Next Generation Methods to Manage Driver Impairment
Speaker: Amie Hayley, Swinburne University of Technology

Moderator: Tory Spindle, Johns Hopkins University School of Medicine
10:00 A.M. - 11:30 A.M.

SYMPОSIUM: A GENTLE INTRODUCTION TO DATA SCIENCE TOOLS FOR ADDICTION RESEARCH: USE CASES WITH EXAMPLES
Plaza Ballroom A

Chair: Gabriel Odom, Florida International University
Co-Chair: Raymond Balise, University of Miami
Discussant: Daniel Feaster, University of Miami Miller School of Medicine

Writing and publishing fully replicable scientific analyses is the goal for addiction research, but because of limitations in common software (e.g., copying and pasting numbers between SAS/Excel and Word) researchers do not have the easy-to-use tools to build fully reproducible workflows. In this workshop, participants will be shown how to use free (open source) software tools, including REDCap, R/RStudio, Quarto, and Zotero, to build a completely reproducible pipeline from data collection to manuscript publication. We will present general-purpose software add-ons (the Tidyverse, tidyREDCap, and rUM R Packages) in addition to other user-friendly software tools designed to aid addiction science researchers (R Packages including DOPE, ctn0094data, ctn0094DataExtra, and CTNote). We will give examples of how we write our manuscripts: starting with data curation in REDCap; data wrangling, preprocessing, and engineering in RStudio with tidyREDCap and the Tidyverse; specific tasks related to addiction data with DOPE, ctn0094DataExtra, and CTNote; managing our research bibliographies with Zotero, and creating publication-ready manuscripts with Quarto and rUM. Some of our examples will use the data sets from the Clinical Trials Network, namely CTN-0027, CTN-0030, and CTN-0051, as harmonized during the CTN-0094 project.

10:00 A.M. - 11:30 A.M.

SYMPОSIUM: UNIVERSAL PRECAUTIONS: CONSIDERATIONS WHEN CONDUCTING CLINICAL ADDICTION RESEARCH IN THE ACUTE CARE HOSPITAL
Plaza Ballroom D

Chair: Michelle Lofwall, University of Kentucky, College of Medicine
Co-Chair: Laura Fanucchi, University of Kentucky, College of Medicine

Hospitalizations for consequences of opioid use disorder (OUD), such as overdose and severe infections associated with injection drug use, are increasing with the opioid epidemic. Persons with OUD hospitalized with significant medical consequences are a unique population with complex needs both during and after hospitalization. Though there has been recent attention to the need to screen, diagnose, and initiate medications for OUD in hospitals, and also facilitate linkage to continued care in the community, there is a lack of evidence informing best practices, and major gaps in the care continuum post-discharge. Clinical research that involves persons with OUD and other substance use disorders in acute care hospitals, and that addresses the specific implementation issues in that setting is challenging but urgently needed. Investigators must navigate myriad factors that affect recruitment, enrollment, and adverse event monitoring, such as changes in clinical care and participant medical complexity. In addition, to be successful, research teams must frequently communicate with and coordinate among various multidisciplinary members of clinical teams and hospital administration. Furthermore, stigma related to persons with OUD and medications for OUD is common in general healthcare settings, and complicates interactions between researchers and the clinical team. During this session we will explore challenges, successes, and lessons learned in initiating, recruiting, enrolling, and randomizing medically
complex, hospitalized patients with opioid use disorder through the lens of two ongoing clinical trials. We will also discuss a hybrid implementation-effectiveness trial evaluating the roll-out of an addiction consultation service in a large health care system.

45.1 Conducting a Randomized Controlled Trial in Hard to Control Hospital Settings: Lessons Learned From the B-OPAT Trial (Buprenorphine plus Outpatient Parenteral Antibiotic Therapy)
Speaker: Laura Fanucchi, University of Kentucky, College of Medicine

45.2 Inpatient and out of Treatment: The Ins and Outs of Addiction Research in Hospitals
Speaker: Gavin Bart, University of Minnesota

45.3 Understanding the Implementation and Effectiveness of Addiction Consult Services: Partnering With a Large Public Hospital System to Conduct a Pragmatic Trial of Addiction Consult Services in 6 Urban Hospitals
Speaker: Jennifer McNeely, New York University Grossman School of Medicine
SUNDAY, JUNE 18, 2023

POSTER SESSION 1

S1. Substance Use Patterns and Impulsivity Among Bariatric Surgery Patients
Rachel Arnold¹, Dace Svikis¹
¹Virginia Commonwealth University

S2. Sex Differences in Acute Pharmacological Stress-Induced Mood and Opioid-Seeking Behavior
Tabitha Moses¹, Mark Greenwald²
¹Wayne State University School of Medicine, ²Wayne State University, Dept of Psychiatry and Behavioral Neurosciences

S3. Sex Differences in Adversity and Risk for Future Alcohol Use in Youth in the ABCD Study
Dawn Bounds¹, Sarah Rodrigues¹, Sanghyuk Shin¹
¹University of California, Irvine

S4. Amyloid Pet and Diffusion Kurtosis Imaging for Alcohol Use Disorder
Kyoji Okita¹, Noriko Sato¹, Yoko Shigemoto¹, Mitsuru Syakadou¹, Yumi Saito¹, Toshihiko Matsumoto¹
¹National Center of Neurology and Psychiatry

S5. Alcohol Cue Reactivity in Virtual, Video Game Environments
Timothy Regan¹, Deicy De la Ossa Brown², Christopher Burrows³, Hart Blanton³, Sherece Fields²
¹Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, ²Department of Psychological and Brain Sciences, Texas A and M University, ³Department of Communication, Texas A and M University

S6. Investigating the Association Between Discrimination, Internalizing Symptoms, and Alcohol Use Among Latino/a Immigrant Parent in the United States
Miracle Macias¹, Tara Bautista¹, Sumeyra Sahbaz², Yesenia Cruz Carrillo¹, Seth Schwartz³, Pablo Montero-Zamora³
¹Northern Arizona University, ²Oklahoma State University, ³University of Texas at Austin

S7. Realist Evaluation of the Impact, Viability, and Transferability of an Alcohol Harm Reduction Support Program Based on Mental Health Recovery: The Vitae Study: First Results
Sarah Moriceau¹, Marc Auriacombe¹, Fuschia Serre¹, Judith Martin-Fernandez¹, Nolwenn Stevens³, Linda Cambon¹
¹Universite de Bordeaux

S8. SBI Tech Michigan: Optimizing Implementation of Screening and Brief Intervention for Excessive Alcohol Use Among Women of Reproductive Age
Amy Loree¹, Hsueh-Han Yeh¹, Farah Elsiss¹, Celeste Zabel¹, Logan Zelenak¹, Sarah Moore¹, Gregory Goyert¹, Jessica Beatty², Poonam Yadav², Melissa Riba², Steven Ondersma⁴
¹Henry Ford Health, ²Wayne State University, ³Center for Health and Research Transformation, ⁴Michigan State University
Jijiang Wang1, Yue-Lin Zhuang1, Anthony Gamst1, Katherine Braden1, Shu-Hong Zhu1
1UC San Diego

S10. Provider-Patient Alliance and Trauma Among Pregnant People With Opioid Use Disorder
Gustavo Angarita1, Kathryn Gilstad-Hayden2, Kimberly Yonkers2, Ariadna Forray1
1Yale School of Medicine, 2Yale University Department of Psychiatry

S11. Cannabis Use and Mental Health Coping Behavior Among Minority Women During the COVID-19 Pandemic: Results From the COVID-19 Cannabis Health Study
Bria-Necole Diggs1, Ranya Marrakchi El Fellah1, Cynthia Lebron2, Sitara Weerakoon3, Sarah Messiah4, Denise Vidot2
1University of Miami Miller School of Medicine, 2University of Miami School of Nursing and Health Studies, 3Yale University School of Medicine, 4University of Texas Health Science Center

S12. Trends in the Co-Use of Cannabis and Prescription Psychotherapeutic Drugs in the United States
Hosam Elbaz1, Omayma Alshaarawy2
1Department of Pharmacology and Toxicology, Michigan State University College of Osteopathic Medicine., 2Department of Family Medicine. Michigan State University College of Human Medicine.

Ofir Livne1, Carol Malte2, Yoanna McDowell2, Mark Olfson3, Melanie Wall3, Katherine Keyes4, Magdalena Cerda5, Silvia Martins1, Andrew Saxon6, Zachary Mannes7, David Fink8, Salomeh Keyhani9, Deborah Hasin1
1Columbia University, 2VA Puget Sound Health Care System, 3Columbia University and NYSPI, 4Columbia University Mailman School of Public Health, 5Department of Population Health, NYU School of Medicine, 6Veterans Affairs Puget Sound Healthcare System, 7Columbia University, Mailman School of Public Health, 8New York State Psychiatric Institute, 9University of California, San Francisco

S14. Aerobic Exercise During Adolescence Protects Against Anxiety Disorders in the United States
Whitney Cordoba-Grueso1, Karla I. Galaviz2, Maria A. Parker2
1Indiana University, 2Indiana University - Bloomington

S15. Factors Related to Cannabis Use in Individuals Over 65
Lauren Russell1, Alison Oliveto1
1University of Arkansas for Medical Sciences

S16. Factors Associated With Risk for Cannabis Use Disorder Among Adults Using Medical Marijuana in Florida
Robert Cook1, Hannah J Fechtel1, Ruba Sajdeya1, Gabriel Spandau1, Yan Wang1
1University of Florida

S17. Evaluation of the Pharmacokinetic and Pharmacodynamic Profile of Cannabigerol (CBG) in Human Subjects
David Wolinsky1, Elise Weerts2, Marcel O. Bonn-Miller Bonn-Miller3, Matthew Feldner3, Ryan Vandrey2, Cecilia Bergeria2
1Johns Hopkins University School of Medicine, Department of Psychiatry, 2Johns Hopkins University School of Medicine, 3Canopy Growth Corporation
S18. Neural Correlates of Controllable Negative Life Events and Their Relationships With Cannabis and Alcohol Use Initiation
Yihong Zhao¹, Marc Potenza², Susan Tapert³, Martin Paulus⁴
¹Columbia School of Nursing, ²Yale University School of Medicine, ³University of California San Diego, ⁴Laureate Institute for Brain Research

S19. Neural Reward Reactivity to Delta-9-Tetrahydrocannabinol (THC) among Young Adults as a Function of Lifetime Cannabis Use Frequency
Julia Brooks¹, Zoa Glab², Rebecca Denson¹, Natania Crane²
¹University of Illinois At Chicago, ²Psychiatric Institute, University of Illinois At Chicago

S20. Identifying Brief Intervention Factors to Improve Cannabis Related Outcomes in Adolescents and Emerging Adults: A Systematic Review
Kathryn Gex¹, Ruschelle Leone², Jenna Aungst³, Kevin Branson¹, Kevin Gray¹, Rachel Tomko¹
¹Medical University of South Carolina, ²Georgia State University, ³Lincoln Memorial University

S21. A Human Laboratory Study Investigating the Influences of Sex on the Acute Pharmacological Effects of a Range of Smoked Cannabis Doses
Madison Wright¹, Justin Matheson², Bernard Le Foll¹, Bruna Brands³
¹University of Toronto, ²Centre for Addiction and Mental Health, ³Health Canada

S22. Results of Pilot Randomized Controlled Trial of Cognitive Behavioral Therapy for Insomnia to Reduce Cannabis Use
Mark Ilgen¹, J. Todd Arnedt¹, Deirdre Conroy¹, Emily Yeagley¹, Kipling Bohnert²
¹University of Michigan, ²Michigan State University

S23. Adolescents’ Online Searches for Marijuana Information: Results From a Random Sample of Middle and High School Students in Los Angeles County
Shuwen Li¹, Yue-Lin Zhuang¹, Adam Cole², Shu-Hong Zhu¹
¹University of California - San Diego, ²Ontario Tech University

S24. Domestic Cannabis Cultivation: Results of the Georgian (country) Sample of the Transnational Online Survey of Cannabis Growers
Irma Kirtadze¹
¹Illia State University

S25. Differences in Immediate Memory Performance Between Individuals Living With and Without Cannabis Use Disorder in Young Adult HBCU Undergraduates
Emma Quarles¹, Larry Keen¹
¹Virginia State University

S26. Cannabis Retail Staff Perspectives on Trustworthiness of Social Media Information: A Qualitative Study
Meredith Meacham¹, Danielle Schell², Coye Cheshire²
¹University of California San Francisco, ²University of California Berkeley
S27. THC/CBD Vapor Self-Administration in Female Rats Results in Spatial Memory Deficits and Increases Methamphetamine Self-Administration
Jordan Carter¹, Samuel Wood¹, Caroline Limbaker², Ayteria Crow¹, Carmela Reichel¹
¹Medical University of South Carolina

S28. Open Board

S29. Cigarillo Purchasing and Pack Sizes by Their Use as Blunts
Brian Fairman¹
¹University of Arkansas for Medical Sciences

S30. Likelihood and Duration of Breastfeeding by Maternal Smoking and Drinking Change During Pregnancy
Yukiko Washio¹, Ashton Raines², Mengxi Li³, Shaopeng Pei⁴, Shantae Taylor¹, Zugui Zhang⁵
¹RTI International, ²Drexel University, ³University of Delaware, ⁴University of Delaware, ⁵Christiana Care

S31. Sex-Specific Associations Between Childhood Trauma and Tobacco Use Outcomes
Alexandra Palmisano¹, Elizabeth Schwartz², Mehmet Sofuoglu³
¹Yale University School of Medicine, ²West Haven VA, Yale School of Medicine, and Yale University, ³Yale University

S32. The Impact (or Lack Thereof) of Moving to Remote Study Procedures on Quit Attempts in an NRT Sampling Intervention
Elizabeth Hawes¹, Andrew Bontemps¹, Andres Azuero¹, Matthew Carpenter², Peter Hendricks³, Adrienne Lahti¹, Karen Cropsey¹
¹The University of Alabama At Birmingham, ²Medical University of South Carolina

S33. Tobacco Use and Sleep Problems in the Population Assessment of Tobacco and Health (PATH) Study
Jocelyn Hansson¹, Halle Thomas¹, Samantha Bauer¹, Leslie Lundahl², David Ledgerwood¹
¹Wayne State University, ²Wayne State University School of Medicine

S34. Optimizing the Training Conditions of Rats in Nicotine Drug Discrimination Studies
Nana Kofi Kusi-Boadum¹, Nathalie Sumien¹, Michael Forster¹
¹University of North Texas Health Science Center

S35. Is Resilience Enough? Resilience Processes to Intersectional Stigma Among People who Inject Drugs (PWID) in Appalachia Ohio
Kathryn Lancaster¹, Anna D. Sucaldito², Stacy Endres-Dighe¹, Renee McDowell¹, Ashleigh LoVette¹, William C. Miller¹, Vivian F. Go³
¹The Ohio State University, ²Wake Forest University, ³University of North Carolina at Chapel Hill

S36. Examining Population Trends in the Association Between Mental Health and Psychedelic Use
Daniel Grossman¹, Melissa Bradley¹, Alex Clain², Greg Pavela³, Peter Hendricks¹
¹The University of Alabama At Birmingham, ²Northwestern University
S37. Prevalence of Comorbid Substance Use Disorders Among People With Opioid Use disorder: A Systematic Review and Meta-Analysis
Thomas Santo, Gabrielle Campbell, Natasa Gisev, Lucy Thi Tran, Daniel Martino-Burke, Jack Wilson, Samantha Colledge-Frisby, Brodie Clark, Louisa Degenhardt
1National Drug and Alcohol Research Centre, UNSW Sydney, 2School of Psychology, University of Queensland, 3Matilda Centre, The University of the Sydney, 4National Drug Research Institute, Curtin University

Erin Annunziato, John Pamplin, Seth Prins, Pia Mauro
1Columbia University

S39. Overdose Death Rates Among Racial Minority Women in Wisconsin: Changes During the COVID-19 Pandemic
Alexa Lopez, Jeneile Luebke, Hanan Abusbaitain
1University of Wisconsin-Milwaukee, 2University of Wisconsin-Madison

S40. Syndemic Profiles and Opioid-Related Mortality among People Initiating Chronic Episodes of Prescription Opioid Use in BC, Canada
Mohammad Karamouzian, Younathan Abdia, James Wilton, Naveed Janjua, Jane Buxton, Roy Pursell
1Centre of Drug Policy Evaluation, St. Michael’s Hospital, 2BC Centre for Disease Control, Vancouver, British Columbia, 3School of Population and Public Health, UBC

S41. Sex Differences in Non-Fatal Overdose Rates: A Population-Based Administrative Health Records Study in British Columbia, Canada
Megan Marziali, Katherine Kooij, Jason Trigg, Michael Budu, Viviane Lima, Julio Montaner, Robert Hogg
1Columbia University Medical Center, 2Simon Fraser University, British Columbia, Canada, 3British Columbia Centre for Excellence in HIV/AIDS, British Columbia, Canada

S42. Oud Treatment, Harm Reduction Service Engagement, and Sexually Transmitted Infection Risk Among Men and Women who Use Illicit Opioids in New York City
Joy Scheidell, Muthoni Mahachi, Maria Khan, Holly Hagan, Alex S. Bennett, Luther Elliott
1University of Central Florida, 2New York University, 3New York University Grossman School of Medicine

S43. Open Board

S44. Prescription Opioid Tapering Patterns Prior to Discontinuation of Long-Term, High-Dosage Treatment Episodes Among Adult Medicaid Enrollees
Hillary Samples, Nicole Kennelly, Arthur Robin Williams, Mark Olfson, Stephen Crystal
1Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, 2Rutgers Institute for Health, Health Care Policy and Aging Research, 3Columbia University Division on Substance Use Disorders, 4Columbia University and NYSPI, 5Rutgers University

S45. Transition Strategies to Link Patients With Substance Use Disorders From Acute Care to Community-Based Treatment Settings: A Scoping Review
Noa Krawczyk, Bianca Rivera, Ji Chang, Margaux Grivel, Yu-Heng Chen, Suhas Nagappala, Honora Englander, Jennifer McNeely
1NYU Grossman School of Medicine, 2New York University Grossman School of Medicine, 3NYU Global School of Public Health, 4Temple University, 5Oregon Health and Science University
S46. Impact of Oat Initiation During Acute Hospitalization on Readmission, Overdose, and Mortality Among People With Opioid Use Disorder
Tamara Mihic1, Nadia Fairbairn1, Janet Mok2, Michelle Cui2, Seonaid Nolan1, Eugenia Socías1
1University of British Columbia, 2British Columbia Centre on Substance Use

S47. Trends in Buprenorphine Dosage and Days Supplied for New Treatment Episodes, 2010-2019
Alyssa Tilhou1, Eleanor Murray2, Jiayi Wang3, Benjamin Linas, MD MPH1, Laura White2, Jeffrey Samet3, Marc Larochelle3
1Boston Medical Center, 2Boston University School of Public Health, 3Boston University School of Medicine

S48. Barriers and Facilitators to Integrating Medications for Opioid Use Disorder (MOUD) and HIV Pre-Exposure Prophylaxis (PrEP) for Adolescents and Young Adults (AYA)
Maria Herrera1, Kaja Darien1, Sarah Wood2, Scott Hadland3, David Metzger2, Nadia Dowshen2
1Children’s Hospital of Philadelphia, 2Perelman School of Medicine at the University of Pennsylvania, 3Harvard Medical School

S49. Removal of Medicaid Prior Authorizations for Buprenorphine did Not Result in a Substantial Change in Prescriptions
Paul Christine1, Marc Larochelle2, Lewei (Allison) Lin3, Jonathan McBride3, Renuka Tipirneni3
1Boston Medical Center, 2Boston University School of Medicine, 3University of Michigan

S50. Effectiveness of Rapid Inpatient Initiation of Methadone for Pregnant Women With Opioid Use Disorder
Dennis Hand1, Amulya Raju1, Ryan Sholes1, Neel Iyer1, Vanessa Short1, Meghan Gannon1, Diane Abatemarco1, Rupsa Boeligi1
1Thomas Jefferson University

S51. Qualitatively Exploring Pharmacist and Patient Needs to Design a Patient-Centered Pharmacy-Based Opioid Misuse Screening and Brief Intervention
Deepika Rao1, Olayinka Shiyanbola2, James Ford2
1Dartmouth College, 2University of Wisconsin - Madison

S52. Opioid Prescribing Trajectories in Veterans With and Without Substance Use Disorder
Anne Black1, Sydney Axson2, Jessica Merlin3, Karl Lorenz4, William Becker2
1VA Connecticut Healthcare System, 2Yale University, 3University of Pittsburgh School of Medicine, 4Stanford University

S53. Investigation of Life Events Associated With Development of OUD in Young Adults: A Longitudinal Study of a High-Risk Clinical Population
Grace Blake1, Jarrod Ellingson1, Kristen Raymond2, Soo Rhee3, Michael Stallings2, Tamara Wall4, Christian Hopfer5, Jesse Hinckley5
1University of Colorado Anschutz Medical Campus, 2University of Colorado, 3University of Colorado Boulder, 4University of California San Diego, 5University of Colorado School of Medicine
S54. Social Determinants of Health and Quality of Care Among Patients With Opioid Use Disorder Receiving Treatment in Rural Primary Care Settings
Huyen Pham¹, Allison Ober², Yuhui Zhu¹, Zhe Fei³, Laura-Mae Baldwin⁴, Larissa Mooney⁵, Yih-Ing Hser⁵
¹Semel Institute - UCLA, ²RAND Corporation, ³University of California, Los Angeles, ⁴University of Washington Department of Family Medicine, ⁵Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles

S55. Prevalence of Opioid Use Disorder and Overdose Rates Among People With Mental Illness in New York State
Felipe Castillo¹, Qingxian Chen², Nancy Covell¹, Manesh Gopaldas¹, Emily Leckman-Westin², Edward V Nunes³, Frances R Levin¹, Molly Finnerty¹
¹Columbia University and New York State Psychiatric Institute, ²New York State Office of Mental Health, New York

S56. Changes in Buprenorphine Prescribing After X-Waiver Exemptions: An Interrupted Time Series Analysis
Payel Roy¹, Katie Suda², Jing Luo¹, MyoungKeun Lee², Joel Anderton², Donna Olejniczak², Jane Liebschutz¹
¹UPMC/University of Pittsburgh, ²University of Pittsburgh

S57. Assessment of Treatment Retention Rates and Factors Affecting Retention on Opioid Agonist Maintenance Treatment Among Adolescents: A Retrospective Cohort Study From India
Pooja Shakya¹, Jaswant Jangra², Roshan Bhad², Ravindra Rao³
¹All India Institute of Medical Sciences New Delhi, ²All India Institute of Medical Science New Delhi, ³Department of Psychiatry and National Drug Dependence Treatment Centre (NDDTC), AIIMS, New Delhi, INDIA

S58. Examining the Relationship Between Childhood Trauma and Behavioral Economic Indices Among Individuals who use Opioids
Andrea Vasquez Ferreiro¹, Shahar Almog¹, Meredith Berry¹
¹University of Florida

S59. Fentanyl Concentrations and Withdrawal in Illicit Fentanyl Exposure
Helen Bird¹, William Clarke¹, Melanie Baime¹, Prem Umang Satyavolu¹, Rachel Burns¹, Kelly Dunn¹, Andrew Huhn¹
¹Johns Hopkins University School of Medicine

S60. Prolonged Exposure Therapy for Individuals with Co-Occurring Posttraumatic Stress Disorder and Opioid Use Disorder: A Randomized Clinical Trial
Kelly Peck¹, Jillian Giannini¹, Rebecca Cole¹, Gary Badger¹, Letizia Mosca¹, Stacey Sigmon¹
¹University of Vermont

S61. Racial/Ethnic Differences in Treatment-Related Barriers and Facilitators Among Patients Initiating Medication for Opioid Use Disorder (MOUD) as Part of Comprehensive Patient Navigation Programs
Caravella McCuistian¹, Maria Olivas¹, Alexandra Haas¹, Emily Dauria², Valerie Gruber³, Paula Lum³, J. Konadu Fokuo², D. Andrew Tompkins¹
¹Department of Psychiatry and Behavioral Sciences, School of Medicine, University of California San Francisco, ²Department of Behavioral and Community Health Sciences, University of Pittsburgh, School of Public Health, ³Department of Medicine, School of Medicine, University of California, San Francisco, ⁴Department of Psychiatry, College of Medicine, University of Illinois at Chicago
S62. Implementation of a “Tele-Peer” Model to Expand Access to Medications for Opioid Use Disorder (MOUD) in a Rural Emergency Department (R-ED) in South Carolina
Sarah Gainey¹, Lindsey Jennings¹, Suzanne Lane¹, Angela Moreland¹, Karen Hartwell², Louise Haynes¹, Kathleen Brady¹
¹Medical University of South Carolina, ²Medical University of South Carolina; Ralph H. Johnson VAMC

S63. Effects of a Comprehensive Patient Navigation Program on High-Cost Healthcare Utilization Among Patients Enrolled in Project HOUDINI LINK (Hospital Opioid Use Disorder treatment INITiation and LINKage to Care)
Kendall Islam¹, Maria Olivas¹, Alexandra Haas¹, Alexander Bazazi¹, D. Andrew Tompkins¹
¹University of California San Francisco School of Medicine

S64. Preliminary Evidence of Lower Kappa Opioid Receptor Availability in Opiate Use Disorder: An Exploratory ¹¹C-EKAP Positron Emission Tomography Study in Humans
Henrique Oliva¹, Ansel Hillmer², Marcella Mignosa¹, Yiyun Henry Huang², Richard Carson², Sarah Yip¹, David Matuskey², Gustavo Angarita¹
¹Yale University School of Medicine, ²Yale University

S65. Data-Driven Selection of Regions of Interest (ROIs) for fMRI Opioid Cue Reactivity: Using Systematic Review, Bold Signal Intensity and Test-Retest Reliability Data
Hamed Ekhtiari¹, Arshiya Sangchooli², Sara Jafakesh³, Rayus Kuplicki⁴
¹University of Minnesota, ²Melbourne University, ³University of Shiraz, ⁴Laureate Institute for Brain Research

S66. The Substance Abuse Self-Stigma Scale: Reliability Among Veterans With Co-Occurring Chronic Pain and Opioid Use Disorder
Verlin Joseph¹, Frank Schwebel², Zachary Schmidt³, Juliana Bondzie⁴, Brian Bosari³, Joannalyn Delacruz⁵, David Moniz-Lewis¹, Megan Kiolac², Kevin Vowles¹, Katie Wiltczewz²
¹University of New Mexico, ²Center on Alcohol, Substance Use, and Addictions (CASAA), ³New Mexico Veterans Affairs, ⁴VA Puget Sound Health Care System, ⁵San Francisco Veterans Affairs Health Care System, ⁶University of California San Francisco

S67. Transition to Antagonist Treatment in the Age of Fentanyl
George Woody¹, Sabrina Poole¹, Evgeny Krupitsky², Kyle Kampman³
¹Perelman School of Medicine at the University of Pennsylvania, ²V. M. Bekhterev National Medical Research Center for Psychiatry and Neurology, ³University of Pennsylvania

S68. Within-Subject Variations in Opioid Sensitivity Across Patient-Reported Outcomes, Observer-Ratings, Physiological Endpoints, and Analgesic Responses
Caitlyn Durgin¹, Andrew Huhn², Cecilia Bergeria², Patrick Finan³, Claudia Campbell², Denis Antoine², Kelly Dunn²
¹Pinney Associates, ²Johns Hopkins University School of Medicine, ³University of Virginia

S69. Sociodemographic Differences in Engagement With a Mobile Application to Support Recovery From Opioid and Stimulant Use Disorders in Missouri
Hannah Szlyk¹, Lindsey Filiatreau¹, Xiao Li³, Alex Ramsey³, Patricia Cavazos⁴
¹Washington University School of Medicine, Department of Psychiatry, ²Washington University in St. Louis, ³Washington University School of Medicine, ⁴Washington University St. Louis
POSTERS

S70. Open Board

S71. Association Between Ongoing Illicit Fentanyl Use and Risk for Non-Fatal Overdose Among Patients Treated With Opioid Agonist Therapy in Canada
Kenneth Lee¹, Sophie Zhao², Tazmin Merali³, Chris Fraser⁴, Jan Kozicky⁵, Brian Conway⁶
¹University of Western Ontario Faculty of Medicine, ²Indivior, Inc., ³Drug Intelligence Inc, Toronto, ON Canada, ⁴COOL-AID Community Health Centre, ⁵Indivior Canada, ⁶Vancouver Infectious Diseases Center and Simon Fraser University, Vancouver BC, Canada

S72. The Association of Self-Report Adherence to Hepatitis C (HCV) Direct-Acting Antiviral (DAA) Therapy With Measured Adherence and Sustained Virologic Response Among People Who Inject Drugs (PWID) Receiving Opioid Agonist Therapy
Snehal Lopes¹, Irene Pericot-Valverde¹, Julia Arnsten², Paula Lum², Lynn Taylor⁴, Shruti H Mehta⁵, Judith Tsui⁶, Judith Feinberg⁷, Arthur Kim⁸, Brianna Norton⁹, Kimberly Page¹⁰, Moonseong Heo¹¹, Alain Litwin¹²
¹Clemson University, ²Montefiore Medical Center, ³University of California San Francisco School of Medicine, ⁴University of Rhode Island, ⁵Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, ⁶Department of Medicine, Division of General Internal Medicine, University of Washington, ⁷West Virginia University School of Medicine, ⁸Massachusetts General Hospital, ⁹Albert Einstein College of Medicine and Montefiore Medical Center, ¹⁰University of New Mexico, ¹¹University of South Carolina School of Medicine

S73. Prevalence of Secondary Health Diagnoses Among Persons Presenting in Texas Hospitals With an Opioid or Stimulant Diagnosis Compared to General Population
J. Michael Wilkerson¹, Cecilia M Ganduglia Cazaban¹, Regina M Hansen¹, Caroline M Schaefer¹, Elizabeth M Caballero¹, David Adzrago¹, Kathryn R. Gallardo¹, Sheryl McCurdy²
¹The University of Texas Health Science Center at Houston, ²University of Texas Health Science Center

S74. Sex Trafficking Experiences and Substance Use Patterns Among Incarcerated Women Who Use Opioids
Martha Tillson¹, Jaxin Annett¹, Megan Dickson¹, Matt Webster¹, Carrie Oser¹, Michele Staton²
¹University of Kentucky, ²University of Kentucky, College of Medicine

S75. Rapid Jail-Based Implementation of Overdose Education and Naloxone Distribution (OEND) in Response to the COVID-19 Pandemic
Carrie Oser¹, Margaret McGladrey², Marisa Booty¹, Hilary Surratt¹, Hannah Knudsen¹, Patricia Freeman¹, Danelle Stevens-Watkins¹, Monica Roberts¹, Michele Staton³, April Young⁴, Emma Draper⁵, Sharon Walsh¹
¹University of Kentucky, ²University of South Florida, ³University of Kentucky, College of Medicine, ⁴University of Kentucky, College of Public Health, ⁵Williams College

S76. A Consistent Decrease of Opioid Misuse Among Young Americans: A Pseudo-Cohort Analysis of Use Patterns From the National Household Survey on Drug Use and Health
Georgiy Bobashev¹, Lauren Warren², Joella Adams¹
¹RTI International

S77. Exploring the Relationship Between Readiness to Change and Engagement with Substance Use Disorder Treatment Among People who Inject Drugs
Lauren Crimmins¹, Edward Suarez Jr.², Renae Schmidt², Viviana Horigian²
¹Brigham and Women's Hospital, ²University of Miami Miller School of Medicine
S78. Adoption and Reach of Overdose Education and Naloxone Distribution in Kentucky During Wave 1 of the Healing Communities Study
Hannah Knudsen¹, Patricia Freeman¹, Carrie Oser¹, Doug Oyler¹, Sharon Walsh¹
¹University of Kentucky

S79. A Qualitative Study Examining Factors Influencing Access to Opioid Agonist Treatment Among a Sample of People who Use Drugs in Rural and Remote Canada
Kate Hodgson¹, Manal Mansoor², Ellery Cleaveland³, Thomas Kerr¹, Geoff Bardwell⁴
¹University of British Columbia, ²University of British Columbia Faculty of Medicine, ³Lift Community Services, ⁴University of British Columbia, BC Centre on Substance Use

S80. Using Implementation Facilitation to Implement Interim Methadone in Opioid Treatment Programs
Shannon Mitchell¹, Karen Burruss-Cousins¹, Julia Jester², Jan Gryczynski³, Melanie Whitter³, Douglas Fuller³, Caroline Halsted³, Robert Schwartz¹
¹Friends Research Institute, ²Mid Shore Pro Bono, ³National Association of State Alcohol and Drug Abuse Directors, Inc.

S81. Factors Associated With Patient Referral From Rural Primary Care Clinics to Vendor-Based Telemedicine for Opioid Use Disorder Treatment
Chunqing Lin¹, Yuhui Zhu², Megan Black³, Sarah Clingan⁴, Huyen Pham², Larissa Mooney⁴, Yih-Ing Hser⁴
¹David Geffen School of Medicine at UCLA, ²Semel Institute - UCLA, ³Semel Institute for Neuroscience and Human Behavior at UCLA, ⁴Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles

S82. Predictors and Correlates of Hepatitis C Incidence Among Young People who Inject Drugs in the Chicago Metropolitan Area
Mary Mackesy-Amiti¹, Basmattee Boodram²
¹University of Illinois at Chicago, School of Public Health, ²University of Illinois at Chicago

S83. Calcium Imaging of Central Amygdala Activity After Escalation of Fentanyl Self-Administration
Samantha Malone¹, Pavel Ortinski², Michael Bardo¹
¹University of Kentucky College of Arts and Sciences, Department of Psychology, ²University of Kentucky College of Medicine, Department of Neuroscience

S84. Lived Experiences of Addiction Counselors: A Protocol Exploring Stigma in a Time of Regulatory Change Within Opioid Treatment Programs
Kathryn Eggert¹, Lynn Madden¹, Beth Mabry², Ermonda Gjoni-Markaj¹, Kim Hoffman³, Kimberly DiMeola⁴, Erica Cannata¹, Scott Farnum³, Gretchen Hermes⁵, Declan Barry⁵
¹APT Foundation, Inc., ²Antioch University, ³Oregon Health and Science University, ⁴APT Foundation, ⁵Yale University School of Medicine
S85. Pharmacy-Level Barriers to Buprenorphine Dispensing: Evidence From the Medicaid Distributed Research Network in Five States
Patricia Freeman1, Lindsey Hammerslag2, Michael Sharbaugh3, Katherine Ahrens4, Anna Austin5, Adam Gordon6, Lindsay Allen7, Andrew Barnes8, Julie Donohue9, Jeffery Talbert2
1University of Kentucky, 2College of Medicine, University of Kentucky, 3University of Pittsburgh, 4Muskie School of Public Service, University of Southern Maine, 5Injury Prevention Research Center, Gillings School of Public Health, University of North Carolina, 6University of Utah School of Medicine and VASLCHCS, 7Feinberg School of Medicine, Northwestern University, 8School of Medicine Health Behavior and Policy, Virginia Commonwealth University

S86. Changes in Opioid and Other Analgesic Prescribing Following Voluntary and Mandatory Prescription Drug Monitoring Program Implementation: A Time Series Analysis
Suzanne Nielsen1, Louisa Picco2, Grant Russell1, Christopher Pearce2, Nadine Andrew1, Dan Lubman3, Simon Bell1, Rachel Buchbinder1, Ting Xia1
1Monash University, 2Outcome Health, 3Turning Point

S87. Naloxone Distribution in the Emergency Department: Program Evaluation of the University of Washington Harborview Medical Center Emergency Department’s Response to Washington State Bill 5195
Sophie Morse1, Canada Parrish, PhD2, Callan E. Fokele, MD MS3, Chris Craft2, Sarah Leyde, MD2, Arvin R. Akhavan, MD MPA2, Elinor Sveum, MD, Timothy Fredrickson, RN2, Lauren Whiteside, MD MSc2
1University of Washington School of Medicine, 2University of Washington, 3University of Washington at Harborview Medical Center

S88. Photovoice – a Methodology to Engage People With Lived Experience in Order to Understand Contextual Drivers of the Opioid Epidemic and Promote Community Activism
Peter Balvanza1, Alyssa Curran2, Anna Martin1, Carolyn Damato-MacPherson1, Randy Gratton3
1Boston Medical Center, 2WMTC, 3BHN

S89. Perceptions of Racism’s Impact on Drug Use Among African Americans Using Opioids
Natalie Malone1, Gabriella Pitcher1, Danelle Stevens-Watkins2
1University of Kentucky, 2University of Kentucky, Center on Drug and Alcohol Research

S90. Referral Appointment Wait-Times and Arrival for Patients Accessing Medication for Opioid Use Disorder (MOUD) in an Emergency Department (ED)
Suzanne Lane1, Lindsey Jennings1, Sarah Gainey1, Angela Moreland1, Karen Hartwell2, Louise Haynes1, Kathleen Brady1
1Medical University of South Carolina, 2Medical University of South Carolina; Ralph H. Johnson VAMC

S91. Advantages and Disadvantages of Online Networking Among Those Engaged in Opioid Misuse
Erin Kasson1, Hannah Szlyk1, Xiao Li1, Aishwarya Rajamahanty1, Nina Kaiser1, Patricia Cavazos-Rehg1
1Washington University School of Medicine Department of Psychiatry

S92. Pain in Opioid Use Disorder Recovery: Is Pain Severity or Chronicity a Stronger Predictor of Health Outcomes?
William Craft1, Allison Tegge1, Candice Dwyer1, Devin Tomlinson1, Diana Keith2, Liqa Athamneh1, Jeffrey Stein1, Anne Le Moigne1, Angela DeVeaugh-Geiss3, Howard Chilcoat3, Warren Bickel1
1Fralin Biomedical Research Institute at Virginia Tech Carilion, 2Behavioral Psychopharmacology Research Laboratory, McLean Hospital, Belmont, MA; Department of Psychiatry, Harvard Medical School, Boston, MA, 3Indivior, Inc.
S93. Open Board

S94. Patient Perspectives on an Open Access Model for Methadone Treatment: A Research and Process Improvement Protocol
Lynn Madden¹, Scott Farnum², Kathryn Eggert², Erica Cannata², Gretchen Hermes³, Kimberly DiMeola¹, Kim Hoffman⁴, Declan Barry³
¹APT Foundation, ²APT Foundation, Inc., ³Yale University School of Medicine, ⁴Oregon Health and Science University

S95. Mobile Units Improve Access to Medications for Opioid Use Disorder: A Qualitative Implementation Study
Avik Chatterjee¹, Trevor Baker¹, Maria Rudorf¹, Galya Walt², Caroline Stotz³, Anna Martin¹, Elizabeth Kinnard¹, Ann McAlearney¹, Julie Bosak¹, Bethany Medley³, Jeffrey Samet⁴, Karsten Lunze⁴
¹Boston Medical Center, ²Harvard T.H. Chan School of Public Health, ³Columbia School of Social Work, ⁴Boston University School of Medicine

S96. The Pharmacist-Integrated Medication Treatment for Opioid Use Disorder (PriMO) Model: Operationalizing an Effective Clinical Care Model to Assess Feasibility in Diverse Care Settings
Felicity Homsted¹, Trip Gardner², Noah Nesis², Frank R. McGrady², David Fiellin³, Paul Joudrey⁴, Bethany McLeman³, Phoebe Gauthier³, Sarah K. Moore⁵, Lisa Marsch⁵, Udi Ghitza⁶, Deepika Rao⁷
¹FQHC 340B Compliance, ²Penobscot Community Health Care, ³Yale University School of Medicine, ⁴University of Pittsburgh, ⁵Geisel School of Medicine at Dartmouth College, ⁶National Institute of Drug Abuse, National Institutes of Health, ⁷Dartmouth College

S97. Initiation and Retention in Medications for Opioid Use Disorder (MOUD) Among Women: A Multi-Paneled Qualitative Study of Women in Recovery, Women who Terminated Treatment, and the Professionals who Serve Them
Hannah Apsley¹, Robert Schwartz², Hobart Cleveland¹, Eric Harrison¹, Kristina Brant¹, Sarah Brothers¹, Abenaa Jones¹
¹Pennsylvania State University, ²Friends Research Institute

S98. More Stress Than You Know: A Qualitative Study of Client Experiences Navigating MOUD Treatment
Jodie Dewey¹, Dennis Watson², Monte Staton³
¹Chestnut Health System’s Lighthouse Institute, ²Chestnut Health Systems, ³University of Illinois at Chicago

S99. Patient Perceptions of Integrating Meditation-Based Interventions in Office-Based Opioid Treatment With Buprenorphine: A Mixed-Methods Survey
Babak Tofighi¹, Christina Marini¹, Joshua D. Lee¹, Eric Garland²
¹New York University School of Medicine, ²University of Utah

S100. Vulnerability to Hyperalgesia and Hyperkatifeia Drives Addiction-Like Behaviors
Renata Marchette¹, Emma Frye¹, Lyndsay Hastings¹, Erika Carlson¹, Leandro Vendruscolo¹, Hugo Tejeda², George Koob¹
¹National Institute on Drug Abuse, Intramural Research Program, ²National Institute of Mental Health, Intramural Research Program

S101. Ventilatory Effects of Fentanyl, Heroin, and D-Methamphetamine, Alone and in Mixtures, in Male Rats
Takato Hiranita¹, Nicholas Ho¹, Charles France¹
¹UT Health San Antonio
S102. **NMRA-140, a Novel and Selective Kappa Opioid Receptor Antagonist: Mode of Action Profiling Studies Demonstrate No Opioid Agonist Properties Implicated in Opioid-Related Abuse**
Filomene Morrison¹, Lori Jean Van Orden², Karla Zeitz², David Heal³, Sharon Smith³, Tanya Wallace²
¹Neumora Therapeutics, ²Neumora Therapeutics Inc., ³DevelRx Ltd.

S103. **Extended Access to Fentanyl Self-Administration During Pregnancy: Effects on Dams and Offspring**
Barrett Aldridge¹, Isaac Johnson², DONNA Platt², Daniela Rüedi-Bettschen²
¹University of Mississippi Medical Center, ²University of Mississippi Medical Center, Dept. of Psychiatry and Human Behavior

S104. **Estradiol Enhances the Development of Addition-Like Features in a Female Rat Model of Opioid Use Disorder**
Eleanor Towers¹, Ben Setaro¹, Wendy Lynch¹
¹University of Virginia

S105. **Acute Effects of Oral 3,4-Methylenedioxymethamphetamine (MDMA) and Delta-9-Tetrahydrocannabinol (THC) on Intrinsic Functional Connectivity**
Tonisha Kearney-Ramos¹, Xuejun Hao¹, Margaret Haney², Gillinder Bedi³
¹Columbia University Medical Center, ²Columbia University Irving Medical Center, ³The University of Melbourne

S106. **Reduced Demand for Substances Following Visual Exposure to Natural Versus Built Stimuli**
Shahar Almog¹, Andrea Vásquez Ferreiro¹, Ali Yurasek¹, Meredith Berry¹
¹University of Florida

S107. **Anger Across Substance Use Disorders: Results From the National Epidemiologic Survey on Alcohol Use and Related Conditions-III**
Krista Miloslavich¹, Margaret Wardle¹
¹University of Illinois Chicago

S108. **Drug Decriminalization in the United States: Emerging Models, Implementation Experiences and Implications for Health and Racial Equity**
Saba Rouhani¹, Leanne Zhang², Abigail Winiker², Catherine Tomko², Bradley Silberzahn³, Susan Sherman⁴, Sachini Bandara²
¹New York University School of Global Public Health, ²Johns Hopkins Bloomberg School of Public Health, ³University of Texas at Austin, ⁴Department of Health, Behavior and Society, Bloomberg School of Public Health

S109. **Cross-Spouse Relationships Between Drug Use and Marital Functioning Among Reserve and National Guard Soldiers and Their Spouses**
Bonnie Vest¹, Rachel Hoopsick², D. Lynn Homish¹, Gregory Homish¹
¹State University of New York at Buffalo, ²University of Illinois Urbana-Champaign

S110. **Brandeis/Harvard Spire Center: SUD Systems Performance Improvement Research and Engagement**
Sharon Reif¹, Haiden Huskamp², Constance Horgan³
¹Brandeis University, Heller School for Social Policy and Management, Institute for Behavioral Health, ²Harvard Medical School, Department of Health Care Policy, ³Brandeis University, Heller School for Social Policy and Management
S111. Regional Differences of Self-Reported Past-12-month Marijuana, Psilocybin, and Cocaine Use: Results From NDEWS Rapid Street Reporting 2021-2022
Nae Won¹, Anna Wang¹, Joseph Palamar², Nicole Fitzgerald¹, MeLisa Creamer³, Catherine Striley¹, Linda Gottler¹
¹University of Florida, ²New York University School of Medicine, ³National Institute on Drug Abuse

S112. Toxicology Testing Inequities During the Birthing Hospitalization and Impact of an Institutional Intervention
Leah Habersham¹, Angela Bianco¹, Candice Woolfolk², Toni Stern¹, Joanne Stone¹, Yasmin Hurd¹
¹Icahn School of Medicine At Mount Sinai, ²Washington University in St. Louis

S113. Provider Perspectives on Facilitators and Barriers to Providing HIV Pre-Exposure Prophylaxis (PrEP) in Hospital-Based Addiction Treatment Bridge Clinics to Women Sex Workers who Use Drugs
Miriam Harris¹, Emma Weinberger², Mary Althoff³, Samantha Paltrow-Krulwich⁴, Jessica Taylor⁵, Abigail Judge⁶, Jeffrey Samet⁷, Christine Gunn⁸, Alexander Walley⁹
¹Boston University, ²Boston Medical Center, ³AIDS Action Committee, ⁴Harvard School of Public Health, ⁵Boston University School of Medicine, ⁶Massachusetts General Hospital

S114. Initial Results of the First Momentary-Assessment Study of U.S. Adults who Use Kratom
Kirsten Smith¹, Leigh Panlilio², Jeffrey Feldman³, Kelly Dunn³, Albert Garcia-Romeu³, Oliver Grundmann⁴, Abhisheak Sharma⁵, Jeffrey Rogers⁶, Christopher McCurdy⁷, David Epstein²
¹National Institute on Drug Abuse, Intramural Research Program, ²NIDA Intramural Research Program, ³Johns Hopkins University School of Medicine, ⁴College of Pharmacy, Dept. Medicinal Chemistry, Univ. FL, ⁵University of Florida, ⁶SDSU/UCSD Joint Program in Clinical Psychology

S115. Screening Test for Drug Abuse Among Blood Donors in the West Bank, a Cross-Sectional Study
Ashraf Awad¹, Maytham Khatatbeh¹, Mahmoud Matar¹, Saed Abed¹, Majdi Dwikat¹, Basma Damiri²
¹An-Najah National University, ²School of Medicine and Health Sciences, An-Najah National University

S116. Laws Limiting Access to SNAP Benefits for People With Felony Drug Convictions
Hridika Shah¹, Alex McCourt¹, Sachini Bandara¹
¹Johns Hopkins Bloomberg School of Public Health

S117. Exploring Substance Use Among LGB Adults Through the National Institutes of Health All of Us Research Program
Stephen Lippi¹, Matthew Perez¹, Jennifer Potter¹, Tara Karns-Wright¹
¹The University of Texas Health Science Center At San Antonio

S118. Untargeted Umbilical Cord Testing to Detect Novel Psychoactive Substances
Marcela Smid¹, Joseph Worden², Melissa Hughes³, Gwen McMillin⁴
¹University of Utah Health, ²University of Utah School of Medicine, ³ARUP Lab, ⁴ARUP

S119. Safety and Tolerability of Ascending Doses of ENA-001: A Novel Respiratory Stimulant, for the Intended Management of Pharmacologically-Induced Respiratory Depression
Errol Gould¹, Thomas Miller¹, Joseph Pergolizzi¹
¹Enalare Therapeutics
S120. Sociodemographic Correlates of a Substance-Related Diagnosis and Associations With the Number of Emergency Department Visits Using Electronic Health Record Data From 2012-2019
Wayne Kepner¹, Natasia Courchesne², Carla Marienfeld²
¹SDSU/UCSD Joint Program, ²University of California San Diego

S121. The Application of Positive Psychology to Substance Use, Addiction, and Recovery Research: An Updated Systematic Review
Hannah Carlon¹
¹University of New Mexico

S122. Caregiver Recommendations for Contingency Management in Juvenile Probation
Logan Jackson¹, Meghan Morrison¹, Phillippe B. Cunningham², Jeff Randall³, Colleen Halliday-Boykins², David Ledgerwood³, Stacy Ryan-Pettes¹
¹Baylor University, ²Medical University of South Carolina, ³Wayne State University

S123. Associations Between Daily Coffee Consumption and Personal and Family Alcohol, Drug and Mental Health Problems in College Students: Looking Separately at Rapid and Slow Caffeine Metabolizers
Dace Svikis¹, Pamela Dillon¹, Alexis Edwards¹, Kathryn Polak¹, Leroy Thacker¹, David Pomm¹, Danielle Dick², Kenneth Kendler¹
¹Virginia Commonwealth University, ²Rutgers University

S124. Characteristics of People With Early Psychosis and Substance Use Problems
Megan Liew¹, Mary Grace Shinners¹, Justin Shepherd², Roger Weiss³, Julie McCarthy³
¹McLean Hospital, ²McLean Hospital, University of Houston, ³McLean Hospital, Harvard Medical School

S125. Socioeconomic Marginalization and Overdose Risk: A Gender-Stratified Repeated Measures Latent Class Analysis Among Men and Women who Use Drugs
Sanjana Mitra¹, Lindsey Richardson², Michelle Cui³, Mark Gilbert⁴, Kanna Hayashi⁵, M-J Milloy⁶, Thomas Kerr³
¹Centre on Drug Policy Evaluation, ²University of British Columbia, ³BC Centre on Substance Use, ⁴British Columbia Centre on Substance Use, ⁵BC Centre for Disease Control, ⁶Simon Fraser University

S126. Exploring Future Research Needs for Pharmaceutical Pain Management Among Black/Hispanic Populations With Opioid Use Disorder and Liver Disease
Autumn Barnes¹, Lissette Saavedra¹, Ty Ridenour¹, Amber Jarnecke²
¹RTI International, ²Medical University of South Carolina

S127. Substance Co-Exposure Among Women With Opioid Use During Pregnancy
Michael Kuzniewicz¹, Cynthia Campbell¹, Sandra Comer², Monique Heddderson¹, Lisa Croen¹, Eileen Walsh¹, Sherwan Li¹, Sam Pimentel³, Lena Sun⁴
¹Kaiser Permanente Northern California, ²Columbia University Irving Medical Center and the New York State Psychiatric Institute, ³University of California, Berkeley, ⁴Columbia University

S128. How Common is Fentanyl Contamination of Methamphetamine? Attitudes, Self-Reported Exposures, and Toxicology Data From Persons who Use Methamphetamine
Raminta Daniulaityte¹, Lance Ruhter¹, Matthew Juhascik², Sydney Silverstein³
¹Arizona State University, ²Montgomery Co. Coroner’s Office, ³Boonshoft School of Medicine Wright State University
S129. Combinations of Drugs Among Maryland Overdose Decedents
Catherine Tomko¹, Kristin Schneider¹, Masoumeh Amin-Esmaeili¹, Ryoko Susukida¹, Taylor Parnham¹, Ju Nyeong Park², Renee Johnson¹
¹Johns Hopkins Bloomberg School of Public Health, ²Alpert Medical School, Brown University

S130. Characterizing Methamphetamine Use Among Opioid Agonist Therapy-Seeking Adults With Prescription-Type Opioid Use Disorder in Canada
Jenna Langlois¹, Nadia Fairbairn¹, Didier Jutras-Aswad², Bernard Le Foll³, Ron Lim⁴, M. Eugenia Socias¹
¹University of British Columbia, ²Université de Montréal, ³University of Toronto, ⁴University of Calgary

S131. The Interplay of Temporal Contexts With Social and Physical Contexts on Alcohol and Marijuana Use and Related Consequences
Brooke Arterberry¹, Brian Calhoun², Christine Lee², Megan Patrick¹
¹University of Michigan, ²University of Washington

S132. HIV Pre-Exposure Prophylaxis Awareness, Use, Willingness, and Physician Engagement Across Sexually and Gender Diverse Veterans who Use Drugs
Ariana Gross¹, Olivia V. Fletcher², Amy J. Kennedy³, Emily C. Williams⁴
¹University of Washington School of Medicine, ²Health Services Research and Development Center of Innovation for Veteran-Centered and Value-Driven Care, VA Puget Sound Health Care System, 1660 S Columbia Way, Seattle, WA, 98108, USA, ³Veterans Affairs Puget Sound Health Care System, 1660 S Columbia Way, Seattle WA, 98102, ⁴University of Washington School of Public Health, Department of Health Systems and Population Health

S133. Time-To-COVID-19 Vaccination by HIV Viral Load Among People who Inject Drugs in Baltimore, Maryland
Pieter Baker¹, Javier Cepeda¹, Becky Genberg¹, Shruti H Mehta¹, Gregory Kirk¹, Kenneth Feder¹, Jing Sun¹, Jacqueline Rudolph¹, Jacquie Astemborski¹
¹Johns Hopkins Bloomberg School of Public Health

S134. A Pilot Trial of Integrated Intervention Strategies to Optimize Prep Care Among PWID in Rural Kentucky
Hilary Surratt¹, Cole Derossett¹, Laura Fanucchi², Christie Green³, Jennifer Havens², Rebecca Rains³, Michele Staton³, Philip Westgate³
¹University of Kentucky, ²University of Kentucky, College of Medicine, ³Cumberland Valley District Health Department, ⁴Knox County Health Department
S135. Differences in Hepatitis C Virus (HCV) Testing and Treatment by Opioid, Stimulant, and Polysubstance Injection Among People who Inject Drugs (PWID) in Rural U.S. Communities
Angela Estadt1, William C. Miller2, David Kline3, Judith I. Tsui4, April M. Young5, Hannah Cooper6, P. Todd Korthuis7, Judith Feinberg6, Gordon Smith9, Mai T. Pho10, Wiley Jenkins11, Peter D. Friedmann12, Ryan P. Westergaard13, Vivian F. Go14, L. Sarah Mixson15, Daniel Brook16, Kelsa Lowe13, Christopher B. Hurt17, Dylan Rice18, Kathryn E. Lancaster2
1College of Public Health, The Ohio State University, 2The Ohio State University, College of Public Health, Division of Epidemiology, 3Wake Forest University School of Medicine, Division of Public Health Sciences, Department of Biostatistics and Data Science, 4University of Washington, Division of General Internal Medicine, 5University of Kentucky, Department of Epidemiology, Center on Drug and Alcohol Research, 6Emory University, Rollins School of Public Health, 7Oregon Health and Science University, Department of Medicine, Section of Addiction Medicine, 8West Virginia University School of Medicine, Departments of Behavioral Medicine and Psychiatry and Medicine/Infectious Diseases, 9West Virginia University School of Public Health, Department of Epidemiology and Biostatistics, 10University of Chicago, Department of Medicine, 11Southern Illinois University, School of Medicine, 12University of Massachusetts Medical School-Baystate and Baystate Health, 13University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Division of Infectious Disease, 14University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Health Behavior, 15University of Washington, Department of Medicine, 16The Ohio State University, College of Medicine, 17University of North Carolina at Chapel Hill School of Medicine, Institute for Global Health and Infectious Diseases, 18University of Massachusetts Chan School of Medicine

S136. Trends in Past-Month Alcohol and Tobacco Co-Use Among Older Adults in the US Between 2002-2019
Pia Mauro1, Sarah Gutkind1, Benjamin Han2, Guadalupe Antonio-Lopez3, Silvia Martins1, Katherine Keyes1, Daniel Giovenco1
1Columbia University, 2University of California - San Diego, 3Mount Holyoke College

S137. Examining Polysubstance Overdose Patterns and Demographic Correlates: A Latent Class Analysis in St. Louis, Missouri
Julia Richardson1, Kanila Brown1, Melissa Nance1, Devin Banks1, Ryan Carpenter1, Rachel Winograd1
1University of Missouri-St. Louis

S138. Preferences for Abstinence-Based Recovery and Public Stigma Toward Substance Use
Diamond Meadows1, Bruce Taylor2, Kelly Moore1
1East Tennessee State University, 2NORC at the University of Chicago

S139. The Effect of Opioid-Stimulant Co-Use on Tonic and Cue Induced Cravings
Martin Hochheimer1, Andrew Huhn2
1Department of Psychiatry, Johns Hopkins University School of Medicine, 2Johns Hopkins University School of Medicine

S140. I Crave Not to Feel Uncomfortable: Craving for Opioids and Cannabis Among Patients With Chronic Pain
Johannes Thrul1, Courtney Nordeck2, Janardan Devkota1, Chung Jung Mun3, Kelly Dunn4, Vadim Zipunnikov1, Ryan Vandrey4, Patrick Finan5
1Johns Hopkins Bloomberg School of Public Health, 2Friends Research Institute, 3Arizona State University, 4Johns Hopkins University School of Medicine, 5University of Virginia
S141. Trajectories of Substance Abuse Treatment Usage: A 9-Year Longitudinal Approach Using Latent Class Growth Analysis and Multichannel Sequence Analysis
Ignacio Borquez¹, Magdalena Cerda¹, Andrés Gonzáles-Santa Cruz², Ignacio Madero-Cabib³, Alvaro Castillo-Carniglia²
¹Department of Population Health, NYU School of Medicine, ²Universidad Mayor, ³Instituto de Sociología and Departamento de Salud Pública, Pontificia Universidad Católica de Chile

S142. Delay Discounting, Pain Catastrophizing, and Quality of Life Among Individuals in Recovery From Substance Use Disorder: A Reinforcer Pathology Perspective
Candice Dwyer¹, William Craft², Liqa Athamneh³, Yu-Hua Yeh², Warren Bickel⁴
¹Virginia Tech, ²Fralin Biomedical Research Institute at Virginia Tech Carilion, ³Fralin Biomedical Research Institution, ⁴Fralin Biomedical Research Institute at VTC

S143. Traumatic Events, Chronic Pain, and Multiple Substance Use in Women With Poly-Substance Use Disorder
Nia Fogelman¹, Marshall Tate³, Stephanie Wemm¹, Erin Vacey², Suraj Bera², Gretchen Hermes¹, James Swain², Helen Fox², Rajita Sinha¹
¹Yale University School of Medicine, ²Stony Brook University School of Medicine

S144. Motivation to Seek Mental Health Services Young Black Men
Carolyn Bazan¹, Alexandria Bauer¹
¹Rutgers University

S145. The Potential of Virtual Reality to Treat Substance Use Disorders
Sarah Clingan¹, Lin Chunqing¹, Guo Freeman², Larissa Mooney², Yih-Ing Hser¹
¹Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles, ²Human-Centered Computing Division, School of Computing, Clemson University

S146. A Multi-Phased Study to Develop a Novel Measure of Polysubstance Use
Amanda Bunting¹
¹New York University School of Medicine

S147. Characteristics of Substance Use Disorder Treatment Facilities That Provide Tailored Mental Health Treatment
Orrin Ware¹, Kelly Dunn²
¹University of North Carolina at Chapel Hill, ²Johns Hopkins University School of Medicine

Peter Driezen¹, Karin Kasza², Shannon Gravely³, Andrew Hyland², David Hammond⁴, Richard O’Connor², Geoffrey Fong¹, Mary Thompson¹, Nicolas Schlienz⁵, Danielle Smith²
¹University of Waterloo, ²Roswell Park Comprehensive Cancer Center, ³University of Waterloo, Canada, ⁴University of New York at Buffalo

S149. Perceived Stigma on the Emotional Wellbeing Among Latinx With Substance Use Disorders: The Mediated Roles of Self-Stigma and Self-Efficacy
Coralee Perez-Pedrogo¹, Bianca Y. Planas-Garcia², Jose Noel Caraballo³, Carmen E. Albizu-Garcia³
¹University of Puerto Rico, Medical Sciences Campus and Albizu University, ²University of Puerto Rico, Medical Sciences Campus and Albizu University, ³University of Puerto Rico, Medical Sciences Campus
S150. Barriers to Enrolling Monolingual Spanish-Speaking Primary Care Patients in a Screening and Brief Intervention (SBI) RCT to Reduce Risky Drug Use: Lessons Learned From the Quit-Mobile Study
Leticia Cazares1, Dallas Swendeman2, Lillian Gelberg3, Stephanie Sumstine4, Amanda Sirisoma2, Cristina Batarse2, Cristina Hernandez2, Melvin Rico1, Mani Vahidi1, Andrea Bañuelos Mota1
1David Geffen School of Medicine at UCLA, 2University of California Los Angeles, 3University of California Los Angeles, Department of Family Medicine, 4University of California Los Angeles, Department of Psychiatry and Biobehavioral Sciences

S151. Optimizing Recovery Funding: A National Look at Strategies for State Funding of Recovery Support Services for Substance Use Disorders
Zoe Murphy1, Rebecca Boss2, Neil Campbell2, Victor Capoccia2, Colette Croze2, Jordan Gulley2, Crystal Jeffers3, Adam Viera3, Laurie Krom3
1University of Missouri- Kansas City, 2Technical Assistance Collaborative, 3University of Missouri-Kansas City

S152. Associations of Sleep Quality and Perceived Stress With Discounting and Quality of Life in Substance Use Disorder Recovery
Yu-Hua Yeh1, Michelle Zheng2, Allison Tegge1, Liqa Athamneh1, Roberta Freitas-Lemos1, Candice Dwyer1, Warren Bickel1
1Fralin Biomedical Research Institute at Virginia Tech Carilion, 2Civil and Environmental Engineering Department, University of California, Los Angeles

S153. Examining Quality of Life in a Sample of U.S. Veterans Seeking Treatment for Substance Use
Cory Stanton1, Austin Hahn2, Stefan Kertesz2, Elizabeth Santa Ana4
1Ralph H. Johnson VA Medical Center, 2Medical University of South Carolina, 3Birmingham VA Medical Center, 4Medical University of South Carolina and Charleston VAMC

S154. Health Justice Coordination for Increased Access to Health and Social Services for People With Drug Use Disorders in Contact With the Criminal Justice System
Anja Busse1, Sanita Suhartono1, Nicola Singleton2, Dagmar Hedrich3, Jee Aei Lee1, Sven Pfeiffer1, Giovanna Campello1
1United Nations Office on Drugs and Crime, 2King’s College London, 3Freelance Consulting Drug Policy and Demand Reduction

S155. Recovery Support Services Research Priorities Developed by People With Lived Expertise
Eden Buell1, Patrick Hibbard1, Ashli Sheidow1, Michael McCart1, Tess Drazdowski1
1Oregon Social Learning Center

S156. Lifetime Depression and Psilocybin Mushroom Use in U.S. Adults, 2008–2019
Lauren Gorfinkel1, Julia Bujno2, Claire Walsh2, Dvora Shmulewitz3, Deborah Hasin3
1The University of British Columbia, 2New York State Psychiatric Institute, 3Columbia University

S157. Developing Core Consensus Measures for Assessment of Psilocybin Services
P. Todd Korthuis1, Kim Hoffman1, Adrianne Wilson-Poe2, Jason Luoma3, Alissa Bazinet4, David Morgan5, Sarann Bielavitz1, Dennis McCarty1, Christopher Stauffer6
1Oregon Health and Science University, 2Legacy Research Institute, Legacy Health, 3Portland Psychotherapy Clinic, Research, and Training Center, 4Sequoia Center, 5Department of Sociology, Portland State University, 6Portland VA Medical Center; Oregon Health and Science University
S158. Psychedelic Drug Abuse Potential Assessment Challenges to Scientific Validity and Real World Predictiveness: Current Approaches and Research Gaps
Jack Henningfield¹, August Buchhalter², Caitlyn Durgin³, Ryan Lanier⁴, Judy Ashworth¹

S159. Ayahuasca-Assisted Addiction Treatment in Peru: Results, Challenges, and Promises From a Multi-Year, Mixed-Methods Study at Takiwasi Center
Olivia Marcus¹, Sara García Arce², Ariane Spitalier³, Anja Loizaga-Velder⁴, Fernando Mendive⁵, Brian Rush⁶
¹New York University, ²Independent researcher, ³Autonomous University of Barcelona, ⁴National Autonomous University of Mexico, ⁵Independent Researcher, ⁶University of Toronto

S160. Sex Differences Are Associated With Perceived Changes in Baseline and Post-Acute Religious Beliefs Among Ayahuasca Users
Yitong Xin¹, Roland Griffiths², Alan K. Davis¹
¹The Ohio State University, ²Johns Hopkins University

S161. Physical Dependence-Like Effects of Acute Benzodiazepine Treatment in Rhesus Monkeys
Eliseu Moreira¹, Joseph T. Talley Talley², Heather H. Hembree Hembree², Lais Berro², James Rowlett²
¹University of Mississippi Medical Center, Dept. of Psychiatry and Human Behavior, ²University of Mississippi Medical Center

Karla Wagner¹, Phillip Coffin², Phillip Fluty³, Leo Beletsky⁴, Kimberly Page⁵
¹University of Nevada School of Public Health, ²San Francisco Department of Public Health, ³The Mountain Center Harm Reduction Center, ⁴Northeastern University, ⁵University of New Mexico

S164. Comparison Between Original and Adaptive Form of Cocaine Purchase Task
Fatima Quddos¹, Devin Tomlinson¹, Kirstin Gatchalian¹, Warren Bickel¹
¹Fralin Biomedical Research Institute at VTC

S165. Resting-State Electroencephalogram Markers of Sleep Quality in Cocaine Use Disorder
Heather Webber¹, Danielle Kessler², Joy Schmitz¹, Robert Suchting¹, Scott Lane¹
¹University of Texas Health Science Center, ²Drexel University College of Medicine at Tower Health

S166. Randomized Controlled Trial Testing the Efficacy of a Remote Caffeine Reduction Intervention
Dustin Lee¹, Labos Breanna¹, Roland Griffiths²
¹Johns Hopkins University School of Medicine, ²Johns Hopkins University

S167. Resilience as a Mediator of Amphetamine Dependence and Psychiatric Symptoms in Deferred Prosecuted Individuals who Use Amphetamine in Taiwan
Chia-Chun Hung¹, Ming-Chyi Huang², Lian-Yu Chen², Kuen-Hong Wu³, Cheng-Yi Huang⁴, Yung-Lien Lai⁵, Su-Chen Fang⁶, Chuan-Hsi Chen⁷, Chun Lin², Yang-Lin Lin³, Yi-Jia Wu², En Chao¹, Lien-Wen Su⁸, Tony Szu-Hsien Lee¹
¹National Taiwan Normal University, ²Taipei City Hospital, ³Taoyuan Psychiatric Center, ⁴Bali Psychiatric Center, ⁵Central Police University, ⁶Mackay Medical College, ⁷National Taipei University, ⁸Taipei Medical University-Shuang Ho Hospital
S168. Estimating Human Doses of Stimulant-Like New Psychoactive Substances Based on Invitro Monoamine Transporter Data
Matthew Baggott1, Donna Walther2, Dino Luethi3, Jeremy Coyle4, Matthias Liechti4, Michael Baumann5
1Tactogen Inc, 2NIDA Intramural Research Program, 3University Hospital Base, University of Basel, and Medical University of Vienna, 4University Hospital Basel and University of Basel, 5NIDA, Intramural Research Program

S169. Vitamin D Deficiency in a Series of Heavy Drinkers Admitted for Hospital Treatment
Daniel Fuster1, Julia Casado2, Anna Hernández-Rubio2, Xavier Garcia-Calvo2, Robert Muga1, Paola Zuluaga2
1Hospital Universitari Germans Trias i Pujol, 2Internal Medicine Service. Hospital Universitari Germans Trias i Pujol

S162. Open Board

MONDAY, JUNE 19, 2023

POSTER SESSION 2

M1. Increased Risk of Mortality From Polysubstance Use Among Hospitalized Patients With Opioid Use Disorder
Karli Hochstatter1, Courtney Nordeck1, Shannon Mitchell1, Robert Schwartz1, Christopher Welsh2, Jan Gryczynski1
1Friends Research Institute, 2University of Maryland School of Medicine

M2. Pupilometer to Predict Postoperative Opioid-Induced Respiratory Depression in Children
Jeffrey Oliver1, Charles Abramson1, Claudio Privitera1, Senthilkumar Sadhasivam2
1NeurOptics Inc, 2UPMC, University of Pittsburgh

M3. A Virtual Reality Recovery Support Intervention for Opioid Use DISORDER: Efficacy Testing and Development
Brandon Oberlin1, Andrew Nelson2, Megayn Lewandowski1, Yitong Shen1
1Indiana University School of Medicine, 2Half Full Nelson, LLC; Relate XR, LLC

M4. Small Business Program: Implementation of a Technological Solution to Support Treatment for Opioid Use Disorder in the Primary Care Setting
Mariah Kalmin1, Bengisu Tulu2, Omar Nieto3, Alycia Quick4, Allison Rosen5, Li Li5, Dominic Trupiano4, Steve Jenkins4, Steve Shoptaw5
1RAND Corporation, 2Worcester Polytechnic Institute, 3UCLA, 4Q2i, 5University of California Los Angeles

M5. Transcutaneous Auricular Neurostimulation (tAN): An Emerging Treatment Strategy to Combat the Opioid Crisis
Navid Khodaparast1, Melanie McWade1, Caroline Benner1, Alejandro Covalin1
1Spark Biomedical, Inc.

M6. Proof of Concept of Regional Oximetry to Detect Opioid Induced Respiratory Depression, Signifying Possible Overdose
Desislava Hite1, Michael Hite1
1Ayuda Medical
M7. Development and Validation of a Reasons for Electronic Cigarette Use Questionnaire
David Ledgerwood¹, Danishi Bedi¹, Mannat Bedi¹, Ciara Cannoy¹, Krithika Prakash², Alanna Foulon¹, ShayLin Excell¹, Leslie Lundahl¹
¹Wayne State University, ²Eastern Michigan University

M8. Digital Motivation and Prediction Platform to Improve Treatment Retention and Reduce Relapse in Opioid Use Disorder
Jeremy Guttman¹, Debarati Bhanja², Jane Liebschutz³, Carolanne Semancik⁴, Kamaneeya Kalaga⁵, Bilal Stambouli¹
¹Biomotivate, ²Penn State College of Medicine, ³University of Pittsburgh, ⁴Glenbeigh Hospital, ⁵Carnegie Mellon University

M9. Reduce Return to Use: Personalized AI for Individuals in Recovery
Ellie Gordon¹, Whitney Menarcheck¹
¹Behaivior

M10. Small Business Program: Scalable Cue-Induced Craving Neurofeedback for Opioid Use Disorder Treatments
Scott Burwell¹, Flavio Da Silva¹, Justin Anker²
¹Neurotype Inc., ²University of Minnesota

M11. OpiAID: A Data Driven Approach to Treating Opioid Dependence
Christopher Evonko¹, David Reeser², Tyler Sugden², Jesse Shaw², Wendy Washington¹, David MacQueen¹
¹University of North Carolina Wilmington, ²OpiAID

Gregg Siegel¹, Richard Priesmeyer², Leslie Siegel¹, Tara Karns-Wright³, Van King⁴, Katherine Dondanville⁴, Jennifer Potter⁴
¹Biomedical Development Corporation, ²St. Mary’s University, ³The University of Texas Health Science Center At San Antonio, ⁴University of Texas Health San Antonio

Cynthia Jimes¹, Marlene Lira¹, M. Justin Coffey¹
¹Workit Health

M14. NIDA-Funded Small Business Companies Successfully Contribute to NIH Heal Initiative
Jia Bei Wang¹, Leonardo Angelone¹, Stacie Gutowski¹, Tam Nguyen¹, Yordan Kostov¹, Elena Kousta¹, Sara Lioi¹
¹NIDA, NIH

M15. A Digital Health App for Opioid Treatment Programs: The Sonara Health Platform for Video Observed Methadone Take-Homes
Michael Giles¹, Kshitij Verma¹, Omer Kaplan¹, Dongseok Choi², Kim Hoffman², Katharina Wiest³, Dennis McCarty²
¹Sonara Health, ²Oregon Health and Science University, ³Pacific Vascular Specialists
M16. Wearable Immunosensor Array for Rapid Opioids Detection
Igor levitsky¹, Nantaniel Cady², Natalia Tokranova³, Albert Lampher¹
¹Emitech, Inc., ²Albany Polytechnic institute, ³Albany Polytechnic Institute

M17. Development of a Community-Based Wastewater Surveillance System to Measure Opioid, Stimulant and Medications for Opioid Use Disorder in the COVID-19 Pandemic
Peter Chai¹, Gordon Getzinger², Joji Suzuki¹, Alex Buben², Matthew Boyce², Kait Hess², Kelly Wahl², Mariana Matus², Timothy Erickson¹
¹Brigham and Women's Hospital, Harvard Medical School, ²Biobot Analytics

M18. Targeting a Non-Opioid Signaling Pathway to Reverse Opioid-Induced Respiratory Depression
Andy Chang¹, Alexandra Scharr², Ethan Garcia¹, Terra Lin¹, Deomar Arizabal¹
¹University of California, San Francisco, ²Olfa Thera, Inc.

M19. Novel Maintenance Therapeutic for Opioid Use Disorder
Don Gehlert¹, Douglas Crawford¹, William Schmidt¹, Neil Schwartz¹
¹Epiodyne

M20. Brief Xenon Gas Inhalation Attenuates Naltrexone-Precipitated Morphine Withdrawal Symptoms in Morphine-Dependent Mice
Marc Kaufman¹, Edward Meloni¹, Dilin Meloni¹, Carol Paronis¹, Vlad Bogin²
¹McLean Hospital, Harvard Medical School, ²Nobilis Therapeutics, Inc., Portland OR

M21. Development of Dual MOR Agonist/DOR Antagonists as Novel Treatments for Opioid Use Disorder
Annie Pasternak¹, Jeffrey Reich²
¹Sparian Biosciences, ²Sparian Biosciences, Inc.

M22. Incentivized Collaborative Care to Disseminate Contingency Management via Buprenorphine Treatment
Sean Regnier¹, Rosemarie Davidson², Hayley Brown², David Gastfriend³, Anthony DeFelio²
¹University of Kentucky, College of Medicine, ²Western Michigan University, ³Dynam Health, Inc.

Joseph Jones¹
¹United States Drug Testing Laboratories

John Timberlake¹, Kenneth Stoller², Thomas King¹, Christy Corey¹
¹Berkshire Biomedical, ²Johns Hopkins University School of Medicine

Thomas King¹, Christy Corey¹, Kenneth Stoller², John Timberlake¹
¹Berkshire Biomedical, ²Johns Hopkins School of Medicine
M26. Identification of Epigenetic Biomarkers Associated With Prenatal Exposure to Substances of Abuse
Aileen Baldwin¹, Joseph Jones¹
¹United States Drug Testing Laboratories, Inc.

M27. The NIDA Cause of Death Elucidated (CODE) Initiative: Developing Innovative Postmortem Toxicology Testing Devices to Reduce the Undercounting of Drug Overdose Deaths
Tam Nguyen¹, Yordan Kostov¹, Sara Lioi¹, Leonardo Angelone³, Elena Koustita¹
¹DHHS/National Institute on Drug Abuse

M28. RA cHealth: A Digital Tool to Support Peer Recovery-Based Treatment for Substance Use Disorder and to Reduce Digital Inequity
Stephanie Carreiro¹, Rebecca Leach¹, Melissa Taylor¹, Joshua Stapp², Nicole Gilbertson², Megan Reinhardt², Premananda Indic³
¹University of Massachusetts Medical School, ²RAE Health, ³Department of Electrical Engineering, The University of Texas at Tyler

M29. The Vox Venturi Device: Portable Breath-Based THC and Opioid Detection
Jake Golde¹, Scott Lukas², Arash Aslani¹, Ken Markoski¹, Joe Santos³, Jane McNeil²
¹Vox Biomedical, ²McLean Hospital, Harvard Medical School, ³DRAPER

M30. A Three Phase Program of Research Investigating a Digital Intervention for Substance Use Delivered via a Relational Agent, “Woebot”
Athena Robinson¹, Maddison Pirner¹, Sarah Pajarito¹, Amy Chieng², Erin Vogel², Jessie Moore², Alison Darcy¹, Judith Prochaska²
¹Woebot Health, ²Stanford University Stanford Prevention Research Center

M31. Novel ‘Agnostic’ Pharmacologic Approach to Polysubstance Overdose
Thomas Miller¹, Amanda Bunting², Michael Schatman³, Joseph Pergolizzi¹, Alfred Schweikert¹, Frank Diana¹, Robert Colucci⁴, Herm Cukier¹, Daniel Motto¹, Marty Lutz¹, Errol Gould¹, Robert Raffa¹
¹Enalare Therapeutics, ²NYU Langone Health, ³NYU Grossman School of Medicine, ⁴NEMA Research

M32. A Novel Approach to Treat Fentanyl Intoxication
Shekar Shetty¹, Xinhua Li², Mitchell Zakin², Piercen Oliver²
¹Clear Scientific Inc., ²Clear Scientific Inc

M33. Using MegaSyn Generative Machine Learning to Identify Psychoplastogens for Opioid Abuse Treatment
Joshua Harris¹, Jacob Gerlach¹, Fabio Urbina¹, Sean Ekins¹
¹Collaborations Pharmaceuticals, Inc.

M34. AI/ML-Driven in Silico Identification of Blood-Brain Barrier Permeable Compounds
Maksim Khotimchenko¹, Kaushik Chakravarty¹, Courtney Miller², Yogesh Bundey¹, Roshan Bhave¹, Szczepan Baran¹, Jyotika Varshney¹
¹Verisim Life, ²The Scripps Research Institute, Department of Neuroscience
Artin Perse¹, Catherine Stanger², Bridget Skidmore³, Erin Winstanley⁴
¹Levl, ²Dartmouth College, Geisel School of Medicine, Department of Psychiatry, ³West Virginia University, WVU Medicine Children's Hospital, ⁴West Virginia University, Department of Behavioral Medicine and Psychiatry

M36. Novel Neurotheranostic for MR Imaging of Dopamine Transporters (DAT) and Treatment of Dopaminergic Neurodegeneration in Methamphetamine Use Disorder (MUD)
Gordana Vitaliano¹, Christopher Adam², Gonzalo Zeballos², Kyoko Ohashi¹, Franco Vitaliano³
¹McLean Hospital, Harvard Medical School, ²McLean Hospital, ³EXQOR

M37. Development of Dual “Atypical” DAT Inhibitor/Sigma Receptor Antagonists as Novel Treatments for Stimulant Use Disorder
Jeffrey Reich¹, Christopher McCurdy²
¹Sparian Biosciences, Inc., ²University of Florida

M38. You Can See that the Culture is Definitely Changing: Peer-Facilitated Telemedicine Hepatitis-C Treatment for People who Use Drugs
Kim Hoffman¹, Soomin Shin², Gillian Leichtling², Hunter Spencer¹, Tonhi Gailey¹, Andrew Seaman¹, P. Todd Korthuis¹
¹Oregon Health and Science University, ²Comagine Health

M39. Patient- And Clinician-Level Factors for Virtual and In-Person Substance Use Disorder Treatment Retention
Michael Parks¹, Justine Welsh², Lance Waller³, Siara Sitar⁴, Jackie Braughton¹, Samantha Patton⁵, Quyen Ngo¹
¹Hazelden Betty Ford Foundation, ²Emory University School of Medicine Department of Psychiatry and Behavioral Services, ³Emory University Rollins School of Public Health Department of Biostatistics and Bioinformatics, ⁴Emory University School of Medicine, Department of Psychiatry and Behavioral Services, ⁵Emory University, Department of Psychiatry and Behavioral Sciences

M40. Persistent Anxiety is Associated With Reporting At-Risk Drinking During COVID-19 Among Women in a Community Setting
Alyssa Berger¹, Linda Cottler¹
¹University of Florida

M41. Open Board

M42. Substance Use Patterns and Access to Services in Humanitarian Settings: A Formative Research Study
Stephanie Haddad¹, Mbaita Shawa², Jeremy Kane¹, Bertha Bwalya³, Megan Sienkiewicz¹, Grace Kilbane¹, Veronica Chibemba², Princess Chiluba², Nkumbu Mtongo², Kristina Metz⁴, Mildred Chibwe², Namuchana Mubabati², Allan Zulu³, Ravi Paul⁵, Zaliwe Banda⁴, Henry Loongo³, Muzi Kamanga⁵, M. Claire Greene¹
M43. Preliminary Evidence That Individuals With Remitted Alcohol Use Disorder and Major Depressive Disorder Exhibit Enhanced Neural Responses to Reward: An EEG Study
Natania Crane1, Lilian Li2, Julia Brooks3, Stewart Shankman2
1Psychiatric Institute, University of Illinois At Chicago, 2Northwestern University, 3University of Illinois At Chicago

M44. Fluoxetine in the Relapse Prevention of Alcoholism
John Sullivan1, Donald Jasinski2
1none, 2Johns Hopkins Bayview Medical Center

M45. Differences in Psychopathology, Substance Use, and Social Support Among Adolescents With Versus Without Lifetime Alcohol Use
Carol Vidal1, Caroline Brooks2, Eric Strain2
1Department of Psychiatry, Johns Hopkins University School of Medicine, 2Department of Psychiatry, Johns Hopkins University, 3Johns Hopkins University School of Medicine

M46. Ageing With an Alcohol Problem is Not What I Envision: Reclaiming Agency in Shaping Personal Ageing Trajectory and Recovery From an Alcohol Problem
Wossenseged Birhane Jemberie1, Fredrik Stenman2, Malin Eriksson1, Anders Hammarberg2
1Umea University, Faculty of Social Sciences, 2Karolinska Institutet, Department of Clinical Neuroscience

M47. Parent Influence and Alcohol Use by Youth With Chronic Medical Conditions
Jessica Calihan1, Machiko Minegishi2, Elissa Weitzman3
1HHMI, Children’s Hospital - Boston, 2Division of Adolescent/Young Adult Medicine, Boston Children’s Hospital, 3Department of Pediatrics, Harvard Medical School, Boston, Massachusetts; Division of Adolescent/Young Adult Medicine, Boston Children’s Hospital, Boston, Massachusetts; Computational Health Informatics Program, Boston Children’s Hospital, Boston, Massachusetts.

M48. Chronic Alcohol Self Administration Induces Extracellular Matrix Abnormalities in the Hippocampus of Non-Human Primates
Jake Valeri1, Charlotte Stiplosek1, Donna Platt1, Kathleen A Grant2, Barbara Gisabella1, Harry Pantazopoulos1
1University of Mississippi Medical Center, 2Oregon National Primate Research Center

M49. Molecular Signaling Pathways in the Hippocampus of Rhesus Monkeys With Chronic Alcohol Use
Tanya Pareek1, Donna Platt1, Kathleen Grant2, Barbara Gisabella1, Harry Pantazopoulos1
1University of Mississippi Medical Center, 2Oregon Health and Science University

M50. Common and Distinct Associations Between Baseline Impulsivity and Longitudinal Development of Positive and Negative Alcohol Expectancies in the Adolescent Brain Cognitive Development (ABCD) Cohort
Faith Adams1, Iliyan Ivanov1, Muhammad Parvaz1
1Icahn School of Medicine At Mount Sinai

M51. Gender, Mental Health, and Cannabis Use Amongst Students in the United States During the Pandemic: Results From the COVID-19 Cannabis Health Study
Ana Borja1, Marvin Reid2, Layan Ibrahim3, Nicole O’Dell4, Deanna Uddin5, Denise Vidot5
1Syracuse University, 2The University of the West Indies, Mona, 3Vanderbilt University School of Medicine, 4University of Miami Miller School of Medicine, 5University of Miami School of Nursing and Health Studies
M52. Effects of Cannabidiol and Morphine on Antinociception Across Multiple Modalities
Leslie Lundahl¹, Mark Greenwald²
¹Wayne State University School of Medicine, ²Wayne State University, Dept of Psychiatry and Behavioral Neurosciences

M53. White Matter Structural Organization Alterations in People Living With HIV With Heavy Cannabis Use
Ryan Bell¹, Sheri Towe¹, Syam Gadde¹, Amelia Costello², Christina Meade³
¹Duke University School of Medicine, ²Duke University

M54. Chronic Disease Symptoms Self-Managed with Cannabis during the COVID-19 Pandemic: Results From the COVID-19 Cannabis Health Study
Nicole O’Dell¹, Marvin Reid², Jessica Islam³, Marlene Camacho-Rivera⁴, Denise Vidot⁵
¹University of Miami Miller School of Medicine, ²The University of the West Indies, Mona, ³Moffitt Cancer Center, ⁴SUNY Downstate Health Sciences University, ⁵University of Miami School of Nursing and Health Studies

M55. Primary Form of Cannabis Use and Recent Negative Affect Symptoms
Anita Cservenka¹
¹Oregon State University

M56. Characteristics Associated With Cannabis Dispensary Purchasing Among a Representative Sample of Adults in the United States who Use Cannabis
Matthew Myers¹, Kipling Bohnert²
¹Michigan State University College of Human Medicine, ²University of Michigan and Department of Veterans Affairs

M57. Age and Pandemic-Related Stress among Cannabis Consumers in First Year of COVID-19 Pandemic: Preliminary Results from the COVID-19 Cannabis Health Study
Layan Ibrahim¹, Marvin Reid², Nicole O’Dell³, Audrey Harkness⁴, Denise Vidot⁵
¹Vanderbilt University School of Medicine, ²The University of the West Indies, Mona, ³University of Miami Miller School of Medicine, ⁴University of Miami School of Nursing and Health Studies

M58. Applying the Observational-Implementation Hybrid Approach to Collect Implementation Data on the Use of Evidence-Based Practices to Support Reductions in Cannabis Use among Black Sexual Minority Men and Transgender Women
Justin Knox¹, Silvia Martins¹, Elvin Geng²
¹Columbia University, ²Washington University in St Louis

M59. Cannabis Use in Adolescence and the Later Onset of Bipolar Disorder: A Systematic Review and Meta-Analysis of Prospective Cohort Studies
Naonori Yasuma¹, Kotaro Imamura², Kazuhiro Watanabe³, Mako Iida⁴, Ayumi Takano⁵
¹Ageonomori clinic, ²Department of Digital Mental Health, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ³Department of Public Health, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ⁴Department of Psychiatric Nursing, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁵Department of Mental Health and Psychiatric Nursing, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
M60. Cannabis Use Disorder Symptom Profiles Among Individuals Reporting Past-year Cannabis Use in the United States
Angela DeVeau-Geiss1, John Mariani2, Beth Reboussin3, Howard Chilcoat4
1Indivior, Inc., 2Columbia University Irving Medical Center, New York State Psychiatric Institute, 3Wake Forest University School of Medicine, 4Indivior, Inc; Johns Hopkins Bloomberg School of Public Health

M61. Sex Differences in Prospective Trajectories of Alcohol but Not Marijuana Use Following Trauma
Robyn Ellis1, R. Kathryn McHugh1, William Davie2, Charis Wiltshire2, Samuel McLean3, Kerry Ressler1, Tanja Jovanovic2, Antonia Seligowski1
1McLean Hospital - Harvard Medical School, 2Wayne State University School of Medicine, 3University of North Carolina-Chapel Hill

M62. Pilot Trial of a Behavioral Economic Intervention to Promote Cannabis-Free Activities for Non-Treatment Seeking Adults With Cannabis Use Disorder
Lara Coughlin1, Erin Bonar1, Joshua Wieringa1, Alyssa Augustiniak1, Grant Goodman1, Rachel Girard2, Lewei (Allison) Lin1
1University of Michigan, 2University of Rhode Island

M63. Mobile EEG Correlates of Frequent Cannabis Use are Sex- and Age-Dependent
Conor Murray1, Ziva Cooper1
1University of California, Los Angeles

M64. Cannabis Reduction is Associated With Improved Functional Outcomes: An Aggregated Analysis From Seven Cannabis Treatment Trials
Erin McClure1, Brian Neelon1, Rachel Tomko1, Kevin Gray1, Aimee McRae-Clark1, Nathaniel Baker1
1Medical University of South Carolina

M65. Examining the Effects of Marijuana Use on Cognition in Persons With and Without HIV
Sheri Towe1, Christina Meade1
1Duke University School of Medicine

M66. Hippocampal Subfield Volume as a Function of Cannabis Use and Cannabis Use Disorder
Alexandre Guerin1, Xuejun Hao2, Margaret Haney3, Suzette Evans4, Gillinder Bedi5
1University of Melbourne, 2Columbia University Medical Center, 3Columbia University Irving Medical Center, 4NYSPI and Research Foundation for Mental Hygiene, 5The University of Melbourne

M67. Open Board

M68. Individuals with Cannabis Use Disorder Display Altered Parasympathetic Hrv during Waking and Sleeping Hours Relative to Light Cannabis Users.
Morgan Pearlman1, Stephanie Wemm1, Morgan Pearlman1, Jennifer Liston1, Rajita Sinha1
1Yale University School of Medicine
M69. Extended-Release Mixed Amphetamine Salts for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder: A Pilot, Randomized Double-Blind, Placebo-Controlled Trial
Frances Levin1, John Mariani2, Martina Pavlicova3, C. Jean Choi4, Cale Basaraba4, Amy Mahony4, Daniel Brooks4, Christina Brezing5, Nasir Naqvi5
1Columbia University Irving Medical Center/ New York State Psychiatric Institute, 2Columbia University and New York Psychiatric Institute, 3Columbia University, 4New York State Psychiatric Institute, 5Columbia University and NYSPI

M70. Cannabis Use Frequency’s Positive Associations With Blood Pressure Among Young Adult African American Students
Alexis Morris1, Larry Keen1
1Virginia State University

M71. Marijuana Use Among Asian American Adolescents: An Analysis of Specific Ethnic Groups
Ting Luo1, Jijiang Wang1, Yue-Lin Zhuang1, Shu-Hong Zhu1
1University of California - San Diego

M72. State Cannabis Legalization and Changes in Cannabis Use as Determined by Biologic Testing in Emergency Department Patients in the U.S. Veterans Health Administration, 2008 to 2019
David Fink1, Hillary Samples2, Andrew Saxon3, Carol Malte4, Melanie Wall5, Deborah Hasin6
1New York State Psychiatric Institute, 2Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, 3Veterans Affairs Puget Sound Health Care System, Seattle, 4Center of Excellence in Substance Abuse Treatment and Education, Veterans Affairs Puget Sound Health Care System, 5Columbia University and NYSPI, 6Columbia University

M73. Preliminary Evidence for Altered Sleep Patterns in Cannabis Users
Tracy Brown1, Alessandra Stagni1, Shakti Anand1, Mihir Shah1, Francesca Filbey1
1University of Texas at Dallas

M74. The Adolescent Path? Anhedonia and Cannavaping Use
Cynthia Ortiz1, Peter Hendricks1
1The University of Alabama At Birmingham

M75. Co-Occurrence of Cannabis Use and Cigarette Smoking Accelerates Epigenetic Age
Brooklyn Bradley1, Youshu Cheng1, Xiaoyu Liang2, Rajita Sinha1, Ke Xu1
1Department of Psychiatry, Yale University, New Haven, CT, 2Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

M76. Place Conditioning With Δ9-THC Following Chronic Δ9-THC Exposure During Adolescence
Sarah Withey1, Stephen Kohut1, Brian Kangas1, Jack Bergman1
1McLean Hospital / Harvard Med School

Kai-Hsiang Kang1, Wei-Ting Chen2, Yuan-Chun Liao2, Wei J. Chen3
1Center for Neuropsychiatric Research, National Health Research Institutes, Taiwan, 2Division of Controlled Drugs, Food and Drug Administration, Taiwan, 3National Taiwan University College of Public Health
M78. Emotion Regulation Expectancies and Smoking Cessation Factors: An Ecological Momentary Assessment Study During a Practice Quit Attempt
Raina Pang1, Shirlene Wang1, Chyna Tucker1, Lori Zadoorian1, Andrea Weinberger2, Lina D’Orazio1, Matt Kirkpatrick1
1University of Southern California, 2Yeshiva University

M79. Pharmacological Manipulation of Temporal Brain State Dynamics During Rest
Justine Hill1, Betty Jo Salmeron1, Thomas Ross1, Amy Janes2
1National Institute on Drug Abuse, Neuroimaging Research Branch, 2National Institute on Drug Abuse

M80. Opioid Withdrawal Symptoms and Reasons for Discontinuation of Low-Dose Buprenorphine Induction for Treatment of Opioid Use Disorder in Hospitalized Patients
Catherine Chen1, Chelsea Markle1, Judith Tsui1, Elenore Bhatraju1
1University of Washington/Harborview Medical Center

M81. Examining the Relationship of Concurrent Obesity and Tobacco Use Disorder on the Development of Substance Use Disorders and Psychiatric Conditions: Findings From the NESARC-III
Logan Fields1, Walter Roberts2, Isabella Schwing1, Michael McCoy1, Sherry McKee3
1Arcadia University, 2Yale University School of Medicine, 3Yale School of Medicine

M82. Preference for Waterpipes Among Female Patrons of Open-Air Bars in Lagos, Nigeria
Olanrewaju Onigbogi1, Omobola Ojo2, Modupe Onigbogi3
1University of Lagos, College of Medicine, 2Federal Medical Center Abeokuta, 3University of Texas Health Sciences Houston

M83. Effects of Nicotine Dose in Cigarettes on Symptoms of Depression and Anxiety
Diann Gaalema1, Jennifer Tidey2, Stacey Sigmon1, Sarah Heil1, Dustin Lee3, Michael DeSarno1, Stephen Higgins1
1University of Vermont, 2Brown University, 3Johns Hopkins University School of Medicine

M84. Latinx Combustible Cigarette Smokers Versus Dual Users: Differences in Alcohol and Drug Use Problem Severity
Justin Shepherd1, Bryce Clausen1, Michael Zvolensky1
1University of Houston

M85. Gender Differences in Smoking Dependence Motives
Dominique Black1, Andrew Bontemps1, Karen Gamble1, S. Justin Thomas1, Karen Cropsey1
1The University of Alabama At Birmingham

M86. Identifying Vape-Related Content on TikTok Using Automatic Clustering
Grace Kong1, Tanvi Anand2, Rachel Ouellette1, Juhan Lee3, Dhiraj Murthy3
1Yale University School of Medicine, 2Cockrell School of Engineering, University of Texas at Austin, 3School of Journalism and Media, University of Texas at Austin

M87. Relationships Between Socioeconomic Position and Quitting Smoking Among Pregnant Women: A Longitudinal Assessment From Waves 1–5 of the Population Assessment of Tobacco and Health Study
Loren Kock1, Stephen Higgins1, Fang Fang Chen1, Sarah Heil1
1University of Vermont
M88. Chronic Nicotine Use Induces a Unique Neuroimmune Landscape That Critically Impacts Aberrant Accumbens Synaptic Plasticity
Emma Bondy1, Shailesh Khatri1, Percell Kendrick2, Michael Scofield3, Cassandra Gipson-Reichardt1
1University of Kentucky, 2University of Kentucky, College of Medicine, 3Medical University of South Carolina

M89. Nicotine Self-Administration Differentially Modulates Ventral Tegmental and Medial Habenular Neuronal Excitability
Nathan Olszewski1, Brandon Henderson1
1Joan C. Edwards School of Medicine, Marshall University

M90. Incidence of Opioid Misuse by Cigarette Smoking Status in the United States
Maria Parker1, Raul Cruz1, Joanna Streck2, Andrea Weinberger3
1Indiana University - Bloomington, 2Harvard Medical School/Massachusetts General Hospital, 3Yeshiva University

M91. Proximity to Low Barrier Resources for Alabamians Hospitalized With Injection Drug Use
Kelly Gagnon1, John Bassler2, Ariann Nassel3, Emma Kay4, Ellen Eaton1
1Division of Infectious Diseases, The University of Alabama At Birmingham, 2School of Public Health, The University of Alabama At Birmingham, 3Lister Hill Center for Health Policy, The University of Alabama At Birmingham, 4Magic City Research Institute

M92. Patient Characteristics Associated With Retention on XR-NTX in the CTN-0051 Trial
Onumara Opara1, Kaitlyn Ohrtman1, Miranda Greiner1, Matisyahu Shulman2, Tse-Hwei Choo3, Martina Pavlicova4, Aimee Campbell5, John Rotrosen6, Edward Nunes7
1NYSPI/Columbia University, 2Columbia University and New York State Psychiatric Institute, 3Columbia University Mailman School of Public Health, 4Columbia University, 5Columbia University Irving Medical Center and New York Psychiatric Institute, 6New York University School of Medicine, 7Columbia University and New York State Psychiatric Institute

M93. Changes in Mentalization, Cognition, and Catastrophizing Scores During Methadone Maintenance Treatment
Einat Peles1, Shlomit Zorani2, Miriam Adelson2
1Tel Aviv Sourasky Medical Center, 2Adelson Clinic, Tel Aviv Medical Center

M94. Examining Protective Behavioral Strategies and Harm Reduction Service Utilization Among Individuals who Use Opioids
Rachel Luba1, Suky Martinez2, Manesh Gopaldas1, Sandra Comer3
1New York State Psychiatric Institute, 2Columbia University and New York State Psychiatric Institute, 3Columbia University and NYSPI

M95. Early Non-Adherence Among Individuals Initiating Low Barrier Buprenorphine Treatment in an Office-Based Setting
Karen Dugosh1, Michelle Lent2, Brook Burkley1, Conor Millard1, James McKay2, Kyle Kampman3
1Public Health Management Corporation, 2Philadelphia College of Osteopathic Medicine, 3University of Pennsylvania
M96. Predictors of Study Treatment Attendance Among Individuals With Opioid Use Disorder Reporting Perceived Social Isolation
Lisham Ashrafioun, Nicholas Allan, Jonathan Umansky, Tamara Bilinski, Tracy Stecker
1University of Rochester, 2Ohio State University, 3VA Center of Excellence for Suicide Prevention; Medical University of South Carolina

M97. Explainable Machine Learning Elucidates the Affective, Cognitive, and Social Factors Driving Non-Medicinal Opioid Use in Young Adults
Andrea Maxwell, Gregory Niklason, Sisi Ma, Anna Zilverstand
1University of Minnesota, Medical Scientist Training Program, Graduate Program in Neuroscience, 2University of Minnesota, Department of Psychiatry, 3University of Minnesota, Institute for Health Informatics

M98. Comparisons Between Prescription Opioid Formulations and Risk for New-Onset Affective Disorders in Chronic Pain Patients
David Houghton, Christopher Lewis
1University of Texas Medical Branch

M99. An Implementation Science Framework to Contextualize an Innovative Intervention Integrating Medications for Opioid Use Disorders in the Probation System
Amelia Bailey, Siena Napoleon, Augustine Kang, Rosemarie Martin
1Brown University, 2Brown University School of Public Health

M100. History of Traumatic Events and Opioid Use Among Justice Involved Mothers
Michele Staton, Martha Tillson, Mary Levi, Carl Leukefeld, Matt Webster, Carrie Oser
1University of Kentucky, College of Medicine, 2University of Kentucky

M101. Comparison of Symptom Networks in Younger Adults vs. Middle and Older Adults With Past 12-Month Non-Medical Use of Prescription Pain Relievers
Alyssa Falise, Sara Nutley, Catherine Striley, Catalina Lopez-Quintero
1University of Florida

M102. Characteristics of Adults Who Used Opioids Nonmedically From the NDEWS Rapid Street Reporting, 2021 to 2022
Anna Wang, Nae Won, Nicole Fitzgerald, Joseph Palamar, MeLisa Creamer, Catherine Striley, Linda Cottler
1University of Florida, 2New York University School of Medicine, 3National Institute on Drug Abuse

M103. Naloxone Usage Over Time as Reported to the National Poison Data System (NPDS)
Evelyn Fox, Richard Dart, Alicia Dalton, Jennifer Jewell, Joshua Black
1Rocky Mountain Poison and Drug Safety
M104. Screening for Co-Morbid OUD, PTSD, and Depression in a Primary Care Setting: Recruitment Results From a Randomized Clinical Trial
Christina Crowley1, Jessica Anderson2, Cristina Murray-Krezan3, Mary Carmody2, Lina Tarhuni2, Christina Phillips2, Kirsten Becker4, Lauren Kelly4, Colleen McCullough4, Beth Ann Griffin4, Kimberly Page2, Michael Schoenbaum5, Miriam Komaromy6, Katherine E. Watkins4
1Frederick S. Pardee RAND Graduate School, RAND Corporation, 2Department of Internal Medicine, University of New Mexico Health Sciences, 3Department of Medicine, University of Pittsburgh School of Medicine, 4RAND Corporation, 5National Institute of Mental Health, 6Grayken Center for Addiction, Boston Medical Center, Boston University

Kevin Xu1, Davida Schiff2, Hendree Jones3, Caitlin Martin4, Jeannie Kelly1, Laura Bierut1, Ebony Carter1, Richard Grucza5
1Washington University School of Medicine, 2Mass General Hospital for Children, 3University of North Carolina at Chapel Hill, 4Virginia Commonwealth University, 5St Louis University School of Medicine

M106. Reduction in Substance Use-Related Harms Among a Cohort of People Receiving Injectable Opioid Agonist Treatment in Ontario, Canada
Tinkhani Mbichila1, Mohammad Karamouzian2, Zachary Bouck1, Ahmed Bayoumi3, Bijan Rafat1, Carman Brown1, Shaun Hopkins4, Ayden Scheim5, Dan Werb1
1Centre on Drug Policy Evaluation, 2Centre of Drug Policy Evaluation, St. Michael’s Hospital, 3MAP Centre for Urban Health Solutions, 4Toronto Public Health, 5Dornsife School of Public Health, Drexel University

M107. Attitudes Toward Naloxone Uptake for Opioid Overdose Prevention Among People who Use Opioids in the Southeastern U.S.
Mylinh Le1, Tanja Laschober2, Susan Tross3, Margaret Paschen-Wolff4, Melissa Ertl5, Lynette Wright6, Mary Hatch7
1University of Washington School of Medicine, 2University of Washington, Addictions, Drug and Alcohol Institute, 3Columbia University, 4Columbia University Medical Center, 5Columbia University and New York State Psychiatric Institute, 6University of Washington Alcohol and Drug Abuse Institute, 7University of Washington, Department of Psychiatry and Behavioral Sciences

M108. Screening for Opioid Use Disorder at Public Sexual Health Clinics
Jan Gryczynski1, Courtney Nordeck1, Kristi Dusek1, Anjalee Sharma1, Mishka Terplan1, Elizabeth Gilliams2
1Friends Research Institute, 2Baltimore City Health Department
M109. Feasibility and Outcomes of a Community-Pharmacist Led Program to Treat Hepatitis C Virus Among Persons who Inject Drugs
Judith Tsui1, Alex J. Gojic1, Kathleen A. Pierce2, Elyse L. Tung3, Nancy C. Connolly4, Andrea C. Radick1, John D. Scott1, Ryan N. Hansen4, Joanne D. Stekler5, Sarah V. Marchetti6, Robert H. Kubiniec7, Regan R. Hunt8, Elizabeth J. Austin9, Emily C. Williams10, Sara N. Glick11
1Department of Medicine, Division of General Internal Medicine, University of Washington, 2Kelley-Ross Pharmacy Group, 3Kelley-Ross Pharmacy Group; Department of Pharmacy, University of Washington, 4Kelley-Ross Pharmacy Group; Department of Pharmacy, University of Washington; Department of Health Systems and Population Health, University of Washington, 5Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, 6Hepatitis Education Project, 7Evergreen Treatment Services, 8Des Moines University College of Osteopathic Medicine, 9Department of Health Systems and Population Health, University of Washington, 10Department of Health Systems and Population Health, University of Washington; Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, Health Services Research and Development, VA Puget Sound, 11Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington; HIV/STD Program, Public Health - Seattle and King County

M110. Performance of a Brief Substance Use Symptom Checklist (SUSC) for Identifying Substance Use Disorder Among Primary Care Patients With or at Elevated Risk for Opioid Use Disorder
Emily Williams1, Theresa Matson2, Kevin Hallgren3, Malia Oliver4, Katharine Bradley2
1Veterans Affairs Puget Sound Health Services Research and Development, 2Kaiser Permanente Washington Health Research Institute, 3University of Washington

M111. A Retrospective Chart Review of Hormonal Contraceptives and Compliance With Medication for Opioid Use Disorder in Adolescents and Young Adults
Stephanie Mallahan1, Andrea Bonny2, Brittney Manos2, Erin Mcknight2, Alicia Allen1
1University of Arizona, College of Medicine, 2Nationwide Children’s Hospital

M112. Emergency Department and Hospital Admissions With Injecting-Related Infections in a Cohort of People who Inject Drugs
Samantha Colledge-Frisby1, Stephanie Curtis2, Andrew Stewardson2, Joe Doyle2, Peter Higgs3, Matthew Hickman4, Lisa Maher5, Mark Stooke5, Paul Dietze1
1National Drug Research Institute, Curtin University, 2Monash University, 3Burnet Institute, 4Bristol University, 5Kirby Institute

M113. The Relationship Between Medical and Recreational Cannabis Legalization With Opioid Misuse Among Individuals Reporting Medically Recommended Cannabis Use
Silvia Martins1, Emilie Bruzelius1, Christine Mauro1, Julian Santaella-Tenorio2, Anne Boustead3, Magdalena Cerdá2
1Columbia University, 2New York University, 3University of Arizona

M114. Punitive Policies and Stigma in Health and Social Service Settings as Drivers of Perinatal Overdose: A Qualitative Exploration in New York City
Brooke West1, Bethany Medley1, Jaih Craddock2, Talia Z. Nadel1, Morgan Philbin1, Pia Mauro1
1Columbia University, 2University of California, 3University of California San Francisco

M115. Sex and Age Differences in Suicide Attempts Among Opioid Overdose-Related 911 Dispatches
Andrew McCabe1, Linda Cottler1
1University of Florida
M116. Assessment of Risky Sexual Practices Among Married Males Seeking Treatment for Opioid Dependence in India
Ankita Chattopadhyay1, Mahadev Sen2, Nishtha Chawla3, Ragul Ganesh4, Suraj Verma3, Siddharth Sarkar5, Atul Ambekar6
1All India Institute of Medical Sciences, New Delhi, 2Institute of Human Behaviour and Allied Sciences (IHBAS), New Delhi, 3All India Institute of Medical Sciences (AIIMS), New Delhi, 4All India Institute of Medical Sciences (AIIMS), Jammu, 5National Drug Dependence Treatment Centre, AIIMS, New Delhi, India, 6National Drug Dependence Treatment Centre

M117. The Interaction Between Anhedonia and Impulsivity in Opioid Use Disorder
Nicole Kouri1, Tabitha Moses2, Leslie Lundahl2, Mark Greenwald3
1Wayne State University, 2Wayne State University School of Medicine, 3Wayne State University, Dept of Psychiatry and Behavioral Neurosciences

M118. Patient Characteristics of Fentanyl Positive Individuals With Opioid Use Disorder
Miranda Greiner1, Mei-Chen Hu2, Matisyahu Shulman3, Kathryn Hefner4, Onumara Opara5, Kenzie Potter6, Kaitlyn Ohrman6, Udi Ghitza7, Edward Nunes1, Adam Bisaga7
1Columbia University and New York State Psychiatric Institute, 2Columbia University and NYSPi, 3Columbia University and New York State Psychiatric Institute, 4Emmes Data and Statistics Center, NIDA CTN, 5NYSPi, 6National Institute of Drug Abuse, National Institutes of Health, 7Columbia University Division on Substance Use Disorders

M119. Predictors of Treatment Drop-Out and Termination Among Those With Opioid Use Disorder
Nicholas Weaver1
1The University of Texas At Austin

M120. Examining Predictors of the Routes of Administration of Opioids Among Adolescents in the United States
Enya Vroom1, Skye Bristol2, Micah Johnson2
1University of Florida, 2University of South Florida

M121. Opioid-Related Poisoning in Kentucky Medicaid Beneficiaries Receiving Buprenorphine, Methadone or Naltrexone
Lindsey Hammerslag1, Svetla Slavova2, Feitong Lei2, Emily Slade2, Michelle Lofwall3, Laura Fanucchi3, Heather Bush2, Patricia Freeman4, Sharon Walsh3, Jeffery Talbert3
1University of Kentucky, 2University of Kentucky, College of Public Health, 3University of Kentucky, College of Medicine, 4University of Kentucky, College of Pharmacy

M122. Patient Reported Insights to Guide Development and Implementation of Sleep Interventions in the Opioid Use Disorder Treatment Setting
Michelle Eglovitch1, Anna Beth Parlier-Ahmad1, Sajanee Chithranjan1, Saisriya Kolli1, Catherine Legge1, Stephanie Violante1, Joseph Dzierzewski2, Caitlin Martin1
1Virginia Commonwealth University, 2National Sleep Foundation
M123. Neural and Longitudinal Mechanisms Mediating Drug-Related Optimism Bias in Opioid Addiction
Emmanuel Alvarez¹, Maëlle Gueguen², Syed Sawar³, Julia Kong², Sahar Hafezi², Darla Bonagura⁴, Anna Konova³
¹Rutgers Robert Wood Johnson Medical School, ²Department of Psychiatry, UBHC, and Brain Health Institute, Rutgers University – New Brunswick, ³Rutgers University Center for Cognitive Science, Rutgers University–New Brunswick, NJ, ⁴Department of Psychology, University of Tennessee – Knoxville

M124. Associations Between Suvorexant and Biological and Self-Reported Stress in a Randomized Trial in Persons With Opioid Use Disorder
Greer McKendrick¹, Charlotte Clapham², Vadim Zipunnikov², Patrick Finan², Kelly Dunn¹, Andrew Huhn¹
¹Johns Hopkins School of Medicine, ²Johns Hopkins University

M125. Cannabis Use Disorder Treatment Preferences: A Pilot Survey in People who Currently Use Cannabis
Joshua Lile¹, David Cox¹, Marcel O. Bonn-Miller Bonn-Miller², Thomas Shellenberg¹, William Stoops¹, Justin Strickland³
¹University of Kentucky, College of Medicine, ²Canopy Growth Corporation, ³Johns Hopkins University School of Medicine

M126. Safety and Subjective Reinforcing Effects of Lorcaserin on Oxycodone in Adults With Opioid Use Disorder
Taylor Ochalek¹, Kathryn Polak¹, Lori Keyser-Marcus¹, Kathryn Cunningham², Caitlin Martin¹, F. Gerard Moeller¹
¹Virginia Commonwealth University, ²University of Texas Medical Branch

M127. Preliminary Effectiveness of Remote Opioid Overdose and Naloxone Administration Training and Impact of Naloxone Possession on Opioid Use
Karen Cropsey¹, Michelle Sisson¹, Andres Azuero¹, Keith Chichester¹, Michael Businelle², Richard Shelton¹, Matthew Carpenter³
¹University of Alabama at Birmingham, ²University of Oklahoma Health Sciences Center, ³Medical University of South Carolina

M128. Impact of an Addiction Consultation Team on the Initiation of Medication for Opioid Use Disorder and Readmissions for Patients With Substance Use Disorders
Adrianna Kehne¹, Colin Macleod², Michelle Braunger², Jillian DiClemente², Emily McCall², Yolanda Preston², Nathan Menke², Pooja Lagisetty²
¹University of Michigan/VA Ann Arbor Healthcare System, ²University of Michigan

M129. Reasons for Past Abortions Among Women in Treatment for Opioid Use Disorder
Roxanne Harfmann¹, Sarah Heil¹, Lindsay Cannon², Yasamin Kusunoki³, Vanessa Dalton³, Lauren MacAfee¹
¹University of Vermont, ²University of Wisconsin, ³University of Michigan

M130. Successful Integration of Care for Patients With Serious Injection-Related Infections and Substance Use Disorder in a Tertiary Care Hospital
Clinton Cooper¹, Judith Feinberg²
¹West Virginia Univ. School of Medicine, ²West Virginia University School of Medicine

M131. Connection, Navigation, Engagement in Care and Treatment (ConNECT) for Opioid Use Disorder
Alia Al-Tayyib¹, Ryan Loh¹, Joshua Blum¹, Deborah Rinehart¹, Scott Simpson¹, Sarah Rowan¹, Jason Haukoos¹
¹Denver Health and Hospital Authority
M132. Depression Profiles and Hepatitis C Treatment Outcomes Among Persons who Inject Drugs: The Hero Study
Snehal Lopes1, Irene Pericot-Valverde1, Judith Feinberg2, Shadi Nahvi3, Paula Lum4, Lynn Taylor5, Judith Tsui6, Shruti H Mehta7, Brianna Norton8, Arthur Kim9, Julia Arnsten9, James Thrasher10, Kimberly Page11, Moonseong Heo1, Alain Litwin12
1Clemson University, 2West Virginia University School of Medicine, 3Montefiore Medical Center, 4University of California San Francisco, 5University of Rhode Island, 6Department of Medicine, Division of General Internal Medicine, University of Washington, 7Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, 8Montefiore Medical Center, 9Massachusetts General Hospital, 10University of South Carolina, 11University of New Mexico, 12University of South Carolina School of Medicine

M133. Iron Depositions in Prefrontal Cortex Influences the Effectiveness of Cortical Paired Associative Stimulation in Heroin-Dependent Patients: A Randomized Sham-Controlled Study
Tianzhen Chen1, Haoye Tan2, Hang Su1, Haifeng Jiang1, Min Zhao3
1Shanghai Mental Health Center, 2Heidelberg University, 3Shanghai Jiao Tong University School of Medicine

M134. A Novel 3 mg Naloxone Nasal Spray for the Over-the-Counter Market
Judy Ashworth1, Vicki G Davis2, Richard Mannion2, Michael Hufford3
1Pinney Associates, Inc., 2Harm Reduction Therapeutics, Inc., 3Harm Reduction Therapeutics

M135. Counselor Terminological Preferences for “Craving,” “Euphoria,” and “Withdrawal” Among Patients Receiving Methadone Treatment
Marina Gaeta Gazzola1, Mark Beitel2, Kendall Buck3, Katharine Cammack3, Gul Saeed4, Kathryn Eggert5, Teresa Roehrich5, Lynn Madden6, Declan Barry7
1NYU Langone Medical Center/NYC Health and Hospitals Bellevue Hospital Center, 2Yale University, APT Foundation, 3The University of the South, 4APT Foundation, Inc., Yale University School of Medicine, 5APT Foundation, Inc., 6APT Foundation, 7Yale University School of Medicine

M136. Psychosocial and Drug Use Characteristics in Persons With Opioid Use Disorder and Chronic Pain
Kaylin Sweeney1, Ramzi W. Nahhas2, Sydney Silverstein3, Chung Jung Mun4, Raminta Daniulaityte1
1Arizona State University, 2Wright State University, 3Boonshoft School of Medicine Wright State University, 4Johns Hopkins Bayview Medical Center

M137. Substance Use Stigma and Abstinence Self-Efficacy Among Justice-Involved Women Who Use Opioids
Matt Webster1, Martha Tillson1, Michele Staton2
1University of Kentucky, 2University of Kentucky, College of Medicine

M138. Neighborhood Racial and Ethnic Segregation is Associated With Opioid Deaths, With or Without Access to Facilities Offering Affordable Medication for Opioid Use Disorder
Michael Williams1, Justin Manjourides1, Danielle Haley1
1Northeastern University

M139. Non-Fatal Drug Overdose Among Persons who Inject Drugs During First Two Years of the COVID-19 Pandemic in New York City: Prevalence, Risk
Jonathan Feelemyer1, Chenziheng (Allen) Weng2, Courtney McKnight2, Don Des Jarlais3
1New York University School of Medicine, 2New York University College of Global Public Health, 3New York University School of Global Public Health
M140. Trends in Use of Prescribed “Safer Supply” Opioids Among People Living with HIV and Opioid Use Disorder in Vancouver, Canada

Neasa Coll¹, Hudson Reddon², M-J Milloy³
¹University of British Columbia Faculty of Medicine, ²BCCSU, ³BCCSU, University of British Columbia

M141. EMS Calls for Naloxone Administration and Implementation of EMS-Specific Overdose Prevention Strategies Across Maryland

Catherine Tomko¹, Masoumeh Amin-Esmaeili¹, Ryoko Susukida¹, Taylor Parnham³, Ju Nyeong Park², Renee Johnson¹
¹Johns Hopkins Bloomberg School of Public Health, ²Alpert Medical School, Brown University

M142. Opioid Use Disorder Treatment in Medicaid Managed Care Plans

Amanda Myers¹, Christina Andrews², Dominic Hodgkin³, Constance Horgan³, Cindy Thomas¹, Maureen Stewart¹, Sharon Reif¹
¹Brandeis University, ²University of South Carolina, ³Brandeis University, Heller School for Social Policy and Management, ⁴Brandeis University, Heller School for Social Policy and Management, Institute for Behavioral Health

M143. Characteristics Associated With Opioid Use Disorder Care Post-COVID-19 Public Health Emergency: A Cohort Study

Steffani Bailey¹, Jennifer Lucas¹, Shuling Liu¹, Miguel Marino³, Rebecca Cantone¹, Brian Garvey¹, Laurel Hallock-Koppelman¹
¹Oregon Health and Science University

M144. Challenges Linking Clients to Medication for Opioid Use Disorder (MOUD) From Emergency Department (ED) Settings

Molly Gallivan¹, Anna Ross², Amanda Fallin-Bennett³, Christopher Cook¹, Michelle Lofwall⁴, Devin Oller⁴, John Lauckner¹, Shelley Elswick², Sharon Walsh³, Laura Fanucchi⁴
¹University of Kentucky, Substance Use Priority Research Area, ²Voices of Hope, ³University of Kentucky, ⁴University of Kentucky, College of Medicine

M145. Assessing Provider Readiness to Implement Pre-Exposure Prophylaxis for HIV Prevention and Medications for Opioid Use Disorder Among People who Inject Drugs

Eleanor Pickering⁵, Minhee Sung⁵, Genie Bailey³, Marianne Buchelli⁴, Daniel Davidson¹, Mark Jenkins⁵, Betsey John⁵, Jennifer Kolakowski⁷, Leah Maier⁸, Elizabeth Porter⁹, Oscar Rojas Perez¹⁰, Carla Rash¹¹, E. Jennifer Edelman⁵, Adam Viera¹
¹Yale School of Public Health, ²Yale University School of Medicine and VACHS, ³Stanley Street Treatment and Resources, Inc., ⁴Connecticut Department of Public Health, ⁵Connecticut Harm Reduction Alliance, ⁶Massachusetts Department of Public Health, ⁷Recovery Network of Programs, Inc., ⁸Apex Community Care, ⁹Yale University School of Medicine, ¹⁰Yale School of Medicine, ¹¹UConn School of Medicine

M146. Effectiveness of Family Intervention Addressing Expressed Emotions in Recipients of Opioid Substitution Therapy: A Randomised Controlled Study

Vasudha Singh¹, Gauri Kaloiya¹, Atul Ambekar¹, Ravindra Rao², Ashwani Mishra¹
¹National Drug Dependence Treatment Centre, ²National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi
M147. Assessing the Impact of Medical Expenditure Supplements Program on the Enrolling and Retention of Patients Attending Methadone Maintenance Treatment Clinics in Taiwan: An Interrupted Time Series Analysis
Yu-Chu Chung1, Yu-Chi Tung2, Sheng-Chang Wang1, Wei J. Chen1
1Center for Neuropsychiatric Research, National Health Research Institutes, 2Institute of Health Policy and Management, National Taiwan University

M148. State Licensure Policy as an Innovative Tool for Mainstreaming Medications for Opioid Use Disorder
Alene Kennedy-Hendricks1, Minna Song1, Alex McCourt1, Matthew Eisenberg1, Brendan Saloner1
1Johns Hopkins Bloomberg School of Public Health

M149. Attitudes and Beliefs About Vermont’s 2021 Buprenorphine Decriminalization Law Among Residents who Use Illicit Opioids
Kenneth Feder1, Samantha Harris1, Lauren Byrne1, Samantha Miller1, Sheree Sodder1, Vanessa Berman2, Amy Livingston2, Jessica Edwards2, Shane Hartman2, Olivia Sugarman2, Hridika Shah1, Justin Xu1, Jewyl Raikes1, Sabrina Gattine1, Brendan Saloner1
1Johns Hopkins Bloomberg School of Public Health, 2Pacific Institute for Research and Evaluation

M150. Self-Identified Stage in Recovery and Substance Use Behaviors Among Pregnant and Postpartum Women and People With Opioid Use Disorder
Patricia Cavazos1, Xiao Li2, Hannah Szlyk3, Anna Constantino-Petit2, Erin Kasson3, Devin Banks4
1Washington University St. Louis, 2Washington University School of Medicine, Department of Psychiatry, 3Washington University School of Medicine Department of Psychiatry, 4University of Missouri--St. Louis

M151. Life Still Exists: Describing the HIV Risk Environment for Women who Inject Drugs-Living With HIV in Kenya
Myla Lyons1, John Sauceda2, Brandon L. Guthrie3, Loice Mbogo4, Betsy Sambai5, Jane M. Simon6, Aliza Monroe-Wise7, David Bukusi8, William Sinkele9, Esther Gitau9, Helgar Musyoki10, Rose Bosire11, Joshua Herbeck12, Carey Farquhar13, Natasha Ludwig Barron14
1University of Michigan/VA Ann Arbor Healthcare System, 2Department of Medicine, Division of Prevention Science, University of California, San Francisco, 3Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA; Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA, 4Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA; University of Washington Global Assistance Program-Kenya, Nairobi, Kenya, 5University of Washington Global Assistance Program-Kenya, Nairobi, Kenya, 6Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA; Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA; Department of Psychology, University of Washington, Seattle, WA, USA; Department of Gender, Women and Sexuality Studies, University of Washington, Seattle, WA, USA, 7Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA, 8VCT and HIV Care, Kenyatta National Hospital, Nairobi, Kenya, 9Support for Addictions Prevention and Treatment in Africa (SAPTA), Nairobi, Kenya, 10National AIDS and Sexually Transmitted Infection Control Programme (NASCOP), Kenyatta Ministry of Health, Nairobi, Kenya, 11Centre for Public Health Research, Kenya Medical Research Institute, Nairobi, Kenya, 12Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA, 13Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA; Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA, 14Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA
**M152. Transgenerational Effects of Parental Fentanyl Dependence on Sleep and Cognition During Adolescence**  
Marissa Jones¹, Brooke Schmeichel¹  
¹East Tennessee State University, James H. Quillen College of Medicine

**M153. Discriminative Stimulus and Antinociceptive Effects of Six Novel Fentanyl Analogs**  
Michael Gatch¹, Jeanne Priddy¹, Ritu Shetty¹  
¹University of North Texas Health Science Center

**M154. Abstinence Following Paternal Morphine Exposure Mitigates Increased Morphine Reinforcing Efficacy in Offspring**  
Dana Zeid¹, Andre B. Toussaint¹, Mathieu Wimmer¹  
¹Temple University

**M155. Effects of Opioids on the Synaptic Density in Rodents: A Systematic Review and Meta-Analysis**  
Henrique Oliva³, Tiago Paiva Prudente², Marc Potenza¹, Gustavo Angarita¹  
¹Yale University School of Medicine, ²Universidade Federal de Goias

**M156. Buprenorphine Decreases Fentanyl Vapor Self-Administration More Effectively in Opioid Dependent Rats**  
Emma Frye¹, Lyndsay Hastings¹, Renata Marchette¹, Caroline Smith¹, Brendan Tunstall², Janaina Vendruscolo¹, George Koob¹, Leandro Vendruscolo¹  
¹National Institute on Drug Abuse, Intramural Research Program, ²University of Tennessee Health Science Center - Memphis

**M157. The Creation of a Web-Based, Interactive, Cost-Effectiveness Calculator for Bystander Naloxone Distribution Programs**  
Hannah Wang¹, Margaret Moore¹, Sierra Castedo de Martell¹, H. Shelton Brown, III¹  
¹UTHealth School of Public Health

**M158. The Growth Hormone Secretagogue Receptor Inverse Agonist/Antagonist PF5190457 Suppresses Fentanyl Intake and Seeking in Rats**  
Noelle Anastasio¹, Robert Fox¹, F. Gerard Moeller², Kathryn Cunningham³  
¹John Sealy School of Medicine University of Texas Medical Branch, ²Virginia Commonwealth University

**M159. Opposing Genetic Influences on Opioid Overdose and Self-Administration in Rats**  
Ken Grasing¹, Alok De¹  
¹Kansas City VA Medical Center

**M160. The Impact of Heroin Self-Administration on CRF1 and CRF2 Expression Within the Nigrostriatal and Mesocorticolimbic Systems**  
Ewa Galaj³, Eddy Barrera², Hayley Lenhard¹, Apoorva Vashisht², Zhi-Bing You³, Robert Ranaldi⁴  
¹Colgate University, ²CUNY Graduate Center, ³NIDA IRP, ⁴Queens College

**M161. Modulation of Estradiol Signaling in the Amygdala Impacts Heroin Extinction Memory Recall in a Sex-Specific Manner**  
Jordan Carter¹, Caitlyn Costa², Carmela Reichel²  
¹Department of Neuroscience, Medical University of South Carolina, ²Medical University of South Carolina, Department of Neurosciences
M162. Phytochemical Composition of Fresh Kratom Leaves Collected in the Northern Region of Malaysia
Thiruventhan Karunakaran1, Vicknasingam Kasiather1, Marek Chawarski2
1Center for Drug Research, Universiti Sains Malaysia, 2Yale School of Medicine

M163. Acceptability of Psychedelic Therapy Differs Among Social workers, Psychiatrists, and Psychologists in the United States
Stacey B. Armstrong1, Adam Levin2, Yitong Xin1, Jordan Horan3, Jason Luoma4, Paul Nagib2, Brian Pilecki4, Alan Davis1
1The Ohio State University, 2Ohio State University, College of Medicine, 3Independent Researcher, 4Portland Psychotherapy Clinic, Research, and Training Center

M164. Experimental Approaches to Screen for Efficacy of Novel Psychedelics
Sharon Smith1, Jane Gosden1, David Heal1
1DevelRx Ltd

M165. Physiological Effects of Psilocybin, Psilocetin, and DOI in Rats
Shelby McGriff1, Grant Glatfelter1, David Manke2, Andrew Chadeayne3, Charles Schindler1, Michael Baumann1
1NIDA, Intramural Research Program, 2University of Massachusetts Dartmouth, 3CaaMTech, Inc.

M166. Involvement of 5-HT2A and 5-HT1A Receptors in the Pharmacological Effects of 5-MeO-DMT Analogs in Male C57BL/6J Mice
Grant Glatfelter1, Antonio Landavazo2, Bruce Blough2, Michael Baumann1
1NIDA, Intramural Research Program, 2RTI International

M167. Adverse Childhood Experiences, Substance Use, and Mental Health Conditions Among Men who Have Sex With Men
Lian-Yu Chen1, Li-Yuan Chen2, Yung-Hsiang Chen1, Ming-Chyi Huang1, Nai-Ying Ko3
1Taipei City Hospital, 2Changhua Christian Children's Hospital, 3National Cheng Kung University

M168. Severity of Stimulant Use Disorder by Type of Stimulant
Ty Schepis1, Kennedy S. Werner2, Olivia Figueroa2, Vita McCabe4, John Schulenberg4, Philip Veliz2, Timothy Wilens5, Sean Esteban McCabe2
1Texas State University, 2Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing, 3St. Joseph Mercy Hospital, 4University of Michigan, 5Massachusetts General Hospital

David Heal1, Jane Gosden1, Sharon Smith1
1DevelRx Ltd
POSTER SESSION 3

T1. Alcohol Use and Substance Use Treatment Engagement Among Patients With Alcohol-Associated Cirrhosis in Three Hospital-Based Hepatology Practices
Hannah Snyder1, Derek Satre2, Martha Shumway2, Steven Batki3, Michael Ostacher4, D. Andrew Tompkins5, Alexander Monto5, Robert Wong4, Ramsey Cheung4, Priti Parekh6, William Hua7, Denissa Widiarto8, Seo Yoon Eli Oh8, Meimei Liao8, Mandana Khalili9
1University of California, San Francisco Department of Family and Community Medicine, 2Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, 3UCSF and San Francisco VA Medical Center, 4Stanford University School of Medicine and Palo Alto VA Medical Center, 5University of California, San Francisco, School of Medicine, 6Palo Alto VA Medical Center, 7UCSF Weill Institute for Neurosciences, 8University of California, San Francisco, 9University of California San Francisco

T2. Recreational Cannabis Legislation and Binge Drinking in U.S. Adolescents and Adults between 2008-2019
Priscila Gonçalves1, Emilie Bruzelius1, Natalie Levy1, Luis Segura1, Ofir Livne1, Sarah Gutkind1, Anne Boustead2, Deborah Hasin1, Pia Mauro1, Diana Silver3, James Macinko4, Silvia Martins1
1Columbia University, 2University of Arizona, 3New York University, 4University of California, Los Angeles

T3. Hepatitis C and HIV Among Substance Users in Mizoram, Northeast India
Lalchhanhima Ralte1
1Presbyterian Hospital

T4. Evaluation of a Functional Assessment Tool for Alcohol Use
Haily Traxler1, Mark Rzeszutek1, Sean Regnier1, Mikhail Koffarnus1
1University of Kentucky, College of Medicine

T5. fMRI and Eye-Tracking During Pavlovian Conditioned Approach: Measuring Sign- And Goal-Tracking in Humans
Lora Cope1, Ryan Klaus1, Mary Soules1, Ha Jung1, Scott Peltier1, Jonathan Morrow1
1University of Michigan

T6. Results From a Phase 2, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group Study of Sunobinop in Subjects who are Experiencing Insomnia During Recovery From Alcohol Use Disorder
Nelson Sessler1, Stephen Harris1, Mingyan Zhou1, Garth Whiteside1, Ellie He1, Valentine Pascale1, Alessandra Cipriano1, Steven Ripa1, Russell Rosenberg2
1Imbrium Therapeutics, 2Neurotrials Research

T7. Body Mass Index in Alcohol Withdrawal: Predictive or Protective?
Alice Ely1, Krystal Hunter2, Brian Schonewald2, Matthew Salzman3
1Cooper Medical School of Rowan University, 2Cooper University Health Care, 3Addiction Medicine, Cooper University Health Care
T8. Association of Baseline Fentanyl Use and Opioid Withdrawal Symptoms During Inpatient Buprenorphine Initiation in a Large Multisite Detoxification Trial
Matisyahu Shulman¹, Miranda Greiner², Mei-Chen Hu³, Onumara Opara⁴, Kenzie Potter⁵, Kaitlyn Ohrtman⁵, Edward Nunes², Adam Bisaga⁶
¹College of Physicians and Surgeons, Columbia University/NYSPI, ²Columbia University and New York State Psychiatric Institute, ³Columbia University and NYSPI, ⁴NYSPI/Columbia University, ⁵NYSPI, ⁶Columbia University Division on Substance Use Disorders

T9. Auditing Measures of Harmful Alcohol Use in Transgender and Non-Binary Communities: A Systematic Review
Ana Chapa Motemayor¹
¹VCU Medical College

T10. Age of Onset of Cannabis Use Predicts Anxiety, Psychoticism, and Anger-Hostility Mental Health Symptoms in Severe Concurrent Disorder Inpatients
Karina Thiessen¹, Tanisse Teale², Karling R. Luciani¹, Chris Schütz¹
¹University of British Columbia, ²University of British Columbia, Faculty of Medicine

T11. Correlates of Resilience in Transitional Age Youth Experiencing Homelessness
Colin Burke¹, Sylvia Lanni¹, Maura DiSalvo¹, Peter Ducharme², Timothy Wilens¹
¹Massachusetts General Hospital, ²Bridge Over Troubled Waters

T12. Characterizing Medical Cannabis Use Among Medical Users in Florida Using Cannabis for Sleep Reasons and Reporting Poor Sleep.
Juan G Perez-Carreno¹, Robert L Cook¹, Yan Wang¹, Krishna Vaddiparti¹, Ruba Sajdeya¹, Hannah J Fechtel¹, Catalina Lopez-Quintero¹
¹University of Florida

Andrew Derminassian¹, Matthew Nickel², Karl Alcover³
¹Keck School of Medicine, University of Southern California, ²College of Arts and Sciences, Gonzaga University, ³Uniformed Services University of the Health Sciences

T14. The Relationship Between High-Potency Cannabis Use and Health-Related Factors: A Systematic Review of Experimental and Observational Studies
Stephanie Lake¹, Conor Murray¹, Beau Kilmer², Ziva Cooper¹
¹University of California, Los Angeles, ²RAND Drug Policy Research Center

T15. Cannabis Use for Medical Symptoms: Patterns Over the First Year of Use
Jodi Gilman¹, Kevin Potter², Randi Schuster², Anne Eden Evins¹, Bettina Hoeppner²
¹Massachusetts General Hospital-Psychiatry, ²Massachusetts General Hospital/Harvard Medical School, ³Harvard Medical School, Massachusetts General Hospital

T16. A Cohort Sequential Analysis of Developmental Changes in Cannabis Use Practices and Problematic Cannabis Use Among Young Adult Users From Age 18 to 22 in Los Angeles
Carolyn Wong¹, Omolola Odejimi², Bridgid Conn¹, Janna Ataiants³, Ekaterina Fedorova³, Meagan Suen², Alisha Osorno², Susie Choi², Stephen Lankenau³
¹Children’s Hospital Los Angeles and University of Southern California, ²Children’s Hospital Los Angeles, ³Drexel University Dornsife School of Public Health
T17. Sex Differences in the Prospective Association of Intra-Individual Reaction Time Variability in Stroop and Hazardous Cannabis Use at Six Months
Elsie Xu Yan1, Margaret Bedillion1, Eric Claus1, Cynthia Huang-Pollock1, Emily Ansell1
1Penn State University

T18. Is Drowsiness After Cannabis Use Predictive of Magnitude of Driving Impairment
Timothy Brown1, Thomas Burt1, Rose Schmitt1, Gary Gaffney1, Gary Milavetz1
1The University of Iowa

T19. Relationship Between Blood THC and Metabolite Concentrations and Rapidly Collected and Analyzed Breath Samples in Healthy Volunteers After Smoking Marihuana
Scott Lukas1, Mia Brousseau1, Samantha Kalmar1, Jane McNeil1, Gordana Vitaliano1, Jake Golde2, Joe Santos3, Arash Asiani2, Ken Markoski2
1McLean Hospital, Harvard Medical School, 2Vox Biomedical, 3DRAPER

T20. Factors Associated With Self-Reported Cannabis Use Problems Among People With HIV Screened in Primary Care
Maha Mian1, Varada Sarovar2, Tory Levine2, Alexandra Lea2, Amy Leibowitz2, Mitchell Luu2, Kelly Young-Wolff2, Michael J. Silverberg2, Derek Satre3
1University of California - San Francisco, Department of Psychiatry, 2Division of Research, Kaiser Permanente Northern California, Oakland CA, 3Division of Research, Kaiser Permanente Northern California, Oakland CA; University of California - San Francisco, Department of Psychiatry

T21. Post-Stress Late Positive Potential Prospectively Predicts Cannabis Use Disorder Severity in Cannabis Using Women
Thomas Preston1, Richard Macatee1
1Auburn University

T22. Emerging Sex Differences in Current Tobacco and Marijuana Use Trends Among Members of a Community Engagement Program in Florida
Vijaya Seegulam1, Catherine Striley1, Linda Cottler1
1University of Florida

T23. Sex Differences in Cortical Thickness in Cannabis Use Disorder
Erin Martin1, Laura Campbell1, Kathryn Thorn1, Gregory Sahlem2, Aimee McRae-Clark1, Andreana Benitez1
1Medical University of South Carolina, 2Stanford University

T24. Cannabis Use Effects on Reaction Time in Daily Versus Occasional Users
Alexis Krause1, Samantha Bothwell2, Julia Wrobel2, Tim Brown3, Sarah Limbacher2, Ashley Brooks-Russell2
1University of Colorado Anschutz Medical Campus, Children’S Hospital, 2University of Colorado Anschutz Medical Campus, 3University of Iowa

T25. A Prospective Investigation of Emergency Department Patients With Suspected Cannabinoid Hyperemesis Syndrome
Rachel Wightman1, Jane Metrik2, Timmy Lin3, Yu Li2, Adina Badea4, Alexandra Collins2, Francesca Beaudoin2
1Rhode Island Hospital/Alpert Medical School of Brown University, 2Brown University School of Public Health, 3Brown Emergency Medicine, 4Rhode Island Hospital
T26. Alcohol First, Cannabis Last: Identification of an Especially Risky Use Pattern Among Individuals who Co-Use Alcohol and Cannabis
Hollis Karoly¹, Mark Prince¹, Bradley Conner¹
¹Colorado State University

T27. Positive Association Between Self-Reported Autonomic Symptoms and Hazardous Cannabis Use Scores in a Community-Based Sample of Adults
Larry Keen¹
¹Virginia State University

T28. Common Barriers to Risky Cannabis Use Reduction Among Adult FQHC Primary Care Patients in Los Angeles County
Quynh Vo¹, Amanda Sirisoma², Maria Vasquez², Cristina Batarse², Ishika Seth², Stephanie Sumstine³, Leticia Cazares¹, Melvin Rico¹, Dallas Swendeman³, Lillian Gelberg¹
¹University of California Los Angeles, Department of Family Medicine, ²University of California Los Angeles, ³University of California Los Angeles, Department of Psychiatry and Biobehavioral Sciences

Margaret Bedillion¹, Emily Ansell¹
¹Penn State University

Nicole Fitzgerald¹, Nae Won¹, Anna Wang¹, Joseph Palamar², MeLisa Creamer³, Catherine Striley¹, Linda Cottler¹
¹University of Florida, ²New York University School of Medicine, ³National Institute on Drug Abuse

T31. Towards the Understanding of Smoking Reduction in a Home Use Test Paradigm
Hui Cheng¹, Joshua Karelitz², Elizabeth Becker²
¹Altria Client Services, LLC, ²Altria Client Services

T32. Associations Between Cigarette Smoking, Weight Status, and Mortality Among U.S. Adults
Luis Mestre¹, Maria Parker²
¹Indiana University, ²Indiana University - Bloomington

T33. Investigating Sex Differences in the Relations Between Parent/Guardian Promotion of Tobacco Abstinence, and Tobacco Use in a Nationally Representative Sample of Black Adolescents
Wynta Alexander¹, Adriana Espinosa¹, Lesia M. Ruglass², Fiona N. Conway³, Christine Sheffer⁴
¹The Colin Powell School at The City College of New York, ²The City College of New York, CUNY, ³Steve Hicks School of Social Work at The University of Texas at Austin, ⁴Roswell Park Comprehensive Cancer Center

T34. Cigarette Smoking and Executive Function: Experimental Effects of Very-Low-Nicotine-Content Cigarettes
Brian Katz², William Middleton¹, Diann Gaalema¹, Jennifer Tidey², Stacey Sigmon¹, Sarah Heil¹, Dustin Lee³, Michael DeSarno¹, Stephen Higgins¹
¹University of Vermont, ²Brown University, ³Johns Hopkins University School of Medicine
T35. Modeling Common and Patient-Specific Resting-State Connectivity to Predict Craving and Smoking Cessation Treatment Response
Laura Murray¹, Blaise Frederick², Amy Janes³
¹McLean Hospital/Harvard Medical School, ²McLean Hospital, Harvard Medical School, ³National Institute on Drug Abuse

T36. Feasibility and Acceptability of an Ecological Momentary Intervention of Implementation Intentions Delivered by Text Message to Reduce Cigarette Smoking
Elizabeth Saunders¹, Jesse Boggis¹, Lisa Marsch¹, Nico Agosti¹, Shea Lemley¹
¹Geisel School of Medicine at Dartmouth

T37. Fine-Grained Patterns of Combusted Cigarette and E-Cigarette Use Among Dual Users Who Intend to Quit Smoking
Rhiannon Wiley¹, William Middleton¹, Shannon O’Connor¹, Joan Skelly¹, Stacey Sigmon¹, Elias Klemperer²
¹University of Vermont, ²University of Vermont College of Medicine

T38. Differential Reward Processing Across Adolescent Temperamental Profiles Associated With Increased Risk of Substance Use
Patricio Viera Perez¹, Sarah Hartmann¹, Timothy Hayes¹, Elisa Trucco¹, Matthew Sutherland¹
¹Department of Psychology, Florida International University, Miami, FL

T39. Study of Impulsiveness and Aggression in Patients With Opioid Dependence: Comparison With Healthy Controls
Rahul Mathur¹, Siddharth Sarkar², Muzaffar Ahmad Pandit³, Raka Jain⁴, Yatan Pal Singh Balhara²
¹MBBS, MD, ²National Drug Dependence Treatment Centre, AIIMS, New Delhi, India, ³All India Institute of Medical Sciences New Delhi, India, ⁴All India Institute of Medical Sciences

T40. Trauma-Related Shame Predicts Daily Non-Medical Prescription Opioid Use and Motives for Use Among Individuals with PTSD
Tanya Saraiya¹, Teresa Lopez-Castro², Alyssa Jones³, Caitlyn Hood⁴, Jessica Flores⁴, Chrystal Badour⁴
¹Rutgers University, ²The City University of New York, ³Ralph H. Johnson Veterans Affairs Medical Center, ⁴University of Kentucky

T41. Access to Medications for Opioid Use Disorders: A Multi-Site Comparison of Qualitative Evidence With Stakeholders
Augustine Kang¹, Anthony Surace¹, Lauren Perron², Jennifer Wood², John Fritsche¹, Alice Cates³, Lauren Brinkley-Rubenstein³, Rosemarie Martin¹
¹Brown University School of Public Health, ²Temple University, ³Duke University

T42. Treatment Setting Among Individuals With Opioid Use and Criminal Legal Involvement, Housing Instability, or Medicaid Insurance, 2015-2020
Riley Shearer¹, Benjamin Howell², Utsha Khatri³, Tyler Winkelman⁴
¹The University of Minnesota, ²Yale University School of Medicine, ³Icahn School of Medicine at Mount Sinai, ⁴Health, Homelessness, and Criminal Justice Lab, Hennepin Healthcare Research Institute
T43. Women and Medications for Opioid Use Disorder: Contributors to Treatment Success From the Perspectives of Women in Recovery, Women With Past Attempts in Drug Treatment, and Health and Criminal Justice Professionals
Emma Skogseth¹, Robert Schwartz², Eric Harrison¹, Kristina Brant³, D. Max Crowley¹, Abenaa Jones¹
¹Pennsylvania State University, ²Friends Research Institute, ³Department of Agricultural Economics, Society, and Education, Pennsylvania State University

T44. Geographic Variations in Fentanyl Positive Urine Drug Screens in the United States, 2021
Erin Winstanley¹, Brian Hendricks², Jane Liebschutz³, Cristina Murray-Krezan⁴, Jeremiah Bertz⁵, Yanping Liu⁶, Galen Switzer³, Sarah Kawasaki⁸
¹West Virginia University, Department of Behavioral Medicine and Psychiatry, ²West Virginia University, ³University of Pittsburgh, ⁴University of Pittsburgh School of Medicine, ⁵National Institute on Drug Abuse, Intramural Research Program, ⁶NIH, ⁷Penn State College of Medicine

T45. Changing Characteristics of HIV/AIDS Epidemic in Malaysia
Vicknasingam Kasinather¹, Ravi Ramadah², Darshan Singh¹, Weng-Tink Chooi¹, Norzarina Mohd Zaharim¹, Marek Chawarski³
¹Universiti Sains Malaysia, ²National Anti-Drugs Agency Malaysia, ³Yale School of Medicine

T46. A Longitudinal Analysis of Time in Buprenorphine Treatment States and Stratification by Hazardous Alcohol Use, Cocaine Use and Alcohol or Cocaine Use Disorders Among People with HIV
Jarratt Pytell¹, Anthony Fojo², Jeanne Keruly², LaQuinta Snow², Sean Falade-Nwulia³, Richard Moore², Geetanjali Chander³, Catherine Lesko⁴
¹University of Colorado Denver School of Medicine; Department of General Internal Medicine, ²Johns Hopkins University School of Medicine, ³University of Washington Seattle, School of Medicine, ⁴Johns Hopkins Bloomberg School of Public Health

T47. Assessing the Add-On Impact of Accessibility Enhancement Program on the Alleviation of Participant Reduction in Methadone Maintenance Treatment Clinics in Taiwan: An Interrupted Time Series Analysis
Wei J. Chen¹, Yu-Chu Ella Chung², Yu-Chi Tung³, Sheng-Chang Wang¹
¹National Health Research Institutes, ²Center for Neuropsychiatric Research, National Health Research Institutes, Taiwan, ³Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan and Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan

T48. Naloxone Expansion is Not Associated With Increases in Adolescent Heroin Use and Injection Drug Use: Evidence From 44 U.S. States
Emilie Bruzelius¹, Magdalena Cerdá², Corey Davis³, Victoria Jent², Katherine Wheeler-Martin², Christine Mauro⁴, Stephen Crystal⁵, Katherine Keyes¹, Hillary Samples⁶, Deborah Hasin⁴, Silvia Martins⁴
¹Columbia University Mailman School of Public Health, ²New York University School of Medicine, ³Network for Public Health Law, ⁴Columbia University, ⁵Rutgers University, ⁶Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research

T49. Neighborhood and Individual Disparities in Community-Based Naloxone Access
Elizabeth Nesoff¹, Silvia Martins²
¹University of Pennsylvania Perelman School of Medicine, ²Columbia University
T50. Receipt of Prescribed Opioids and Benzodiazepines After Non-Fatal Overdose and Risk of Subsequent Overdose
Benjamin Howell1, Anne Black2, Hsiu-ju Lin3, Grau Lauretta4, Robert Heimer5, Kathryn Hawk6, Gail D’Onofrio1, David Fiellin1, William Becker5
1Yale University School of Medicine, 2VA Connecticut Healthcare System, 3State of Connecticut, 4Yale School of Public Health, 5Yale University, 6Yale University School of Medicine, Department of Emergency Medicine

T51. Evaluating Changes in Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder Before and During the COVID-19 Pandemic
Anh Nguyen1, Ingrid Binswanger2, Komal Narwaney1, Stanley Xu3, David McClure4, Deborah Rinehart5, Jason Glanz1
1Kaiser Permanente Colorado, 2Kaiser Permanente Colorado/Colorado Permanente Medical Group, 3Kaiser Permanente Southern California, 4Marshfield Clinic Research Institute, 5Denver Health and Hospital Authority

T52. Implementing a Patient-Centered, Rapid-Access Substance Use Treatment Program in Primary Care
Scott Jeansonne1, Alex R. Dopp2, Christina Phillips3, Marion Cook4, Laura Brown4, Miriam Komaromy3, Kimberly Page3, Katherine Watkins2
1First Choice Community Healthcare, 2RAND Corporation, 3Department of Internal Medicine, University of New Mexico Health Sciences, 4University of New Mexico Health Sciences Center, 5Grayken Center for Addiction, Boston Medical Center

T53. Disparities in the Hepatitis C Virus Cascade of Care Among Reproductive Age Women With Opioid Use Disorder
Breanne Biondi1, Benjamin Buzzee2, Claudine Lavarin1, Sara Lodi3, Rachel Epstein4
1Boston University School of Public Health, 2Boston Medical Center, Section of Infectious Diseases, 3Boston University School of Public Health, Dept of Biostatistics, 4Boston University School of Medicine, Department of Medicine, Section of Infectious Diseases

T54. Prescribed Opioids and Neurocognitive Status Among Elderly American Indians: Data From the Strong Heart Study
Che Ross1, Judith Tsui1, Andrea C. Radick MPH1, Jason Deen1, Dedra Buchwald2, Astrid Suchy-Dicey2
1University of Washington School of Medicine, 2Washington State University

T55. Open Board

T56. Prospective Acceptability of Digital Phenotyping Among Pregnant and Parenting People With Opioid Use Disorder
Elizabeth Charron1, Ashley White2, Kristi Carlston2, Walitza Abdullah3, Jacob Baylis2, Stephanie Pierce1, Adam Gordon4, Elizabeth Krans5, Marcela Smid6, Gerald Cochran7
1University of Oklahoma Health Sciences Center, 2University of Utah School of Medicine, 3University of Pittsburgh School of Medicine, 4University of Utah SoM and VASLCHCS, 5University of Pittsburgh, 6University of Utah Health, 7University of Utah

T57. Toward a More Complete Comparative Epidemiology of Heroin Use: Female-Male Variations in Using Once and Only Once
Barrett Montgomery1, Olga Vsevolozhskaya2, James Anthony3
1RTI International, 2University of Kentucky, 3Michigan State University
T58. Initiations of Safer Supply Hydromorphone Increased During the COVID-19 Pandemic in Ontario: An Interrupted Time-Series Analysis
Samantha Young1, Tara Gomes2, Gillian Kolla3, Daniel McCormack4, Zoë Dodd5, Janet Raboud6, Ahmed Bayoumi5
1British Columbia Centre on Substance Use, 2Li Ka Shing Knowledge Institute, St. Michael’s Hospital, 3University of Victoria, 4ICES, 5MAP Centre for Urban Health Solutions, 6University of Toronto

T59. Initial Validation and Characterization of a Measure to Assess Attitudes Toward Medications for Opioid Use Disorder for Outpatient Populations
Michael Bushey1, Kurt Kroenke1
1Indiana University School of Medicine

T60. Opioid Agonist Treatment Modifications During COVID-19 Pandemic
Beth Sproule1, Jessica Stovel1, Julia Saragosa2, Helen Huynh2, Francesca Di Paola1, Bruna Brands3, Maria Zhang1
1Centre for Addiction and Mental Health, 2University of Toronto, 3Health Canada

T61. Utilization of Medication for Opioid Use Disorder for Hospitalized Patients at 6 New York City Public Hospitals With an Addiction Consultation Service
Yasna Rostam Abadi1, Carla King2, Noa Appleton3, Medha Mazumdar3, Jasmine Fernando3, Adetayo Fawole3, Roopa Kalyanaraman Marcello4, Caroline Cooke4, Johanna Dolle4, Charles Barron4, Jennifer McNeely3
1NYU School of Medicine, 2NYU Grossman School of Medicine - NY Health + Hospitals, 3NYU Grossman School of Medicine, 4NYC Health + Hospitals

T62. An Emulated Trial of Buprenorphine-Naloxone Versus Extended-Release Naltrexone Following Medically Managed Opioid Withdrawal
Marc Larochelle1, Shapei Yan2, Paul Christine2, Heather Hsu2, Benjamin Bovell-Ammon2, Radhika Puppala2, Dana Bernson3, Jane Liebschutz4, Alexander Walley1, Patricia Novo3, Joshua Lee6, John Rotrosen7, Sara Lodi8
1Boston University School of Medicine, 2Boston Medical Center, 3Massachusetts Department of Public Health, 4University of Pittsburgh, 5New York University School of Medicine, 6New York University Grossman School of Medicine, 7Department of Psychiatry, NYU Langone School of Medicine, New York, NY, United States, 8Boston University School of Public Health

T63. Association of Prescribed Oral Stimulants on Cocaine Use Among Patients Enrolled in Opioid Agonist Treatment: A Retrospective Longitudinal Cohort Study
Mark Tatangelo1, Farah Tahsin2, Kristen Morin3, David Marsh3
1ICES North, 2University of Toronto, 3Northern Ontario School of Medicine

T64. Patient Navigation Promotes Substance Use Disorder Treatment Retention Among Hospital Patients Experiencing Homelessness
Courtney Nordeck1, Johannes Thrul2, Christopher Welsh3, Shannon Mitchell1, Robert Schwartz1, Kevin O’Grady2, Jan Gryczynski1
1Friends Research Institute, 2Johns Hopkins Bloomberg School of Public Health, 3University of Maryland School of Medicine, 4University of Maryland, College Park
T65. Developing a Novel High-Fidelity Overdose Simulation Model
Laura Brandt1, Gabriella Horton2, Allen Yang3, Suky Martinez4, Samantha Chong4, Kellie Bryant5
1City College of New York, 2Johns Hopkins University School of Medicine, 3Geisel School of Medicine at Dartmouth, 4Columbia University and New York State Psychiatric Institute, 5Columbia School of Nursing

T66. Impact of Cannabidiol on Reward- And Stress-Related Neurocognitive Processes Among Individuals with Opioid Use disorder: A Pilot, Double-Blind, Placebo-Controlled, Cross-Over Trial
Joji Suzuki1, Sara Prostko1, Veronica Szpak1, Peter Chai2, Primavera Spagnolo1, Saeed Ahmed3, Roger Weiss4
1Brigham and Women's Hospital, 2Brigham and Women's Hospital, Harvard Medical School, 3Rutland Regional Medical Center, 4McLean Hospital

T67. Preliminary Evidence of Heterogeneity in the Opioid Withdrawal Syndrome
Suky Martinez2, Laura Brandt2, Andrew Huhn3, Jermaine Jones3, Kelly Dunn3
2Columbia University Vagelos College of Physicians and Surgeons, 3City College of New York, 4Johns Hopkins University School of Medicine

T68. Clinical Profiles of Individuals With Primary Heroin and Primary Prescription Opioid Use
Sara Witcraft1, Tanya Saraiya2, Charli Kirby1, Amber Jarnecke1
1Medical University of South Carolina, 2Rutgers University, Medical University of South Carolina

T69. Open Board

T70. Bystander Preference for Naloxone Products
Katherine Marks1, Doug Oyler1, Feitong Lei1, Justin Strickland2, Jody Jaggers3, Monica Roberts1, Chase Barnes4, Patricia Freeman1
1University of Kentucky, 2Johns Hopkins University School of Medicine, 3Kentucky Pharmacy Education and Research Foundation, 4Kentucky Department for Public Health

T71. Open Board

T72. Impact of Medication-Based Treatment on Healthcare Utilization Among Individuals With Opioid Use Disorder: A Secondary Analysis of the X:BOT Clinical Trial
Manesh Gopaldas1, Kevin Wenzel2, Aimee Campbell3, Ali Jalali4, Marc Fishman2, John Rotrosen5, Edward Nunes6, Sean Murphy4
1Columbia University, 2Mountain Manor Treatment Center/Maryland Treatment Centers, 3Columbia University Irving Medical Center and New York Psychiatric Institute, 4Weill Cornell Medical College, 5New York University School of Medicine, 6Columbia University and New York State Psychiatric Institute

T73. Application of the Multiphase Optimization Strategy (MOST) to Optimize HIV Prevention Targeting People on Medication for Opioid Use Disorder (MOUD) who Have Cognitive Dysfunction: A Study Protocol
Michael Copenhaver1, Colleen Mistler1, Roman Shrestha1
1University of Connecticut
T74. Patient Navigation for Pregnant Persons With Opioid Use Disorder: Results of a Multisite Pilot Study
Gerald Cochran¹, Marcela Smid², Elizabeth Krans³, Ziji Yu¹, Elizabeth Charron⁴, Akiko Okifuji¹, Adam Gordon⁵, Brad Lundahl¹, John Silipigni⁶, Benjamin Haaland⁷, Ralph Tarter³
¹University of Utah, ²University of Utah Health, ³University of Pittsburgh, ⁴University of Oklahoma HCS, ⁵University of Utah SoM and VASLCHCS, ⁶University of Pittsburgh School of Medicine, ⁷University of Utah School of Medicine

T75. Greater Ethnic Identity and Lower Perceived Stigmatization Relate to Lower Compulsive Craving Behaviors in Individuals in Recovery From Opioid Use Disorder
Chrysantha Davis¹, Breanna McNaughton¹, Abigail Pleiman¹, Megan Posey², Rayus Kuplicki¹, Hun-Wen Yeh¹, Natosha Markham¹, Martin Paulus¹, Jennifer Stewart²
¹Laureate Institute for Brain Research, ²Laureate Institute for Brain Research and The University of Tulsa

T76. Development and Clinical Feasibility of an Abbreviated Addiction-Focused Phenotyping Battery Piloted in a Female OUD Sample Receiving Buprenorphine Treatment
Anna Parlier-Ahmad¹, Michelle Eglovitch¹, Catherine Legge¹, Lori Keyser-Marcus¹, James Bjork¹, Amanda Adams¹, Tanya Ramey², F. Gerard Moeller¹, Caitlin Martin¹
¹Virginia Commonwealth University, ²NIDA

T77. Open Board

T78. The Effect of Prolonged Exposure Therapy on Posttraumatic Stress Disorder Symptom Clusters in Individuals With Opioid Use Disorder
Jillian Giannini¹, Rebecca Cole¹, Gary Badger¹, Letizia Mosca¹, Stacey Sigmon¹, Kelly Peck¹
¹University of Vermont

T79. Engagement in OUD Treatment 6 Months After Community-Based Intervention
Cecile Denis¹, Peter Smith¹, Kyle Kampman¹, Jose Benitez², Karen Dugosh³, David Metzger⁴
¹University of Pennsylvania, ²Prevention Point Philadelphia, ³Public Health Mangement Corporation, ⁴University of Pennsylvania, Department of Psychiatry

T80. Outcomes of the Community-Based Medication-First Program for Opioid Use Disorder: A Multisite Hybrid Implementation Study
Caleb Banta-Green¹, Mandy Owens¹, Jason Williams¹, Anthony Floyd¹, Jeanne Sears¹, Wendy Williams-Gilbert¹, Susan Kingston²
¹University of Washington

T81. Characterization of Peer Support Services for Substance Use Disorders in 11 U.S. Emergency Departments in 2020: Findings From a Nida Clinical Trials Network Study Site Selection Process
Angela Moreland¹, Lindsey Jennings¹, Laura Lander², Tricia Lawdahl³, Erin McClure¹, Jenna McCauley¹, Louise Haynes¹, Tim Matheson⁴, Richard Jones⁵, Thomas Robey⁶, Sarah Kawasaki⁷, Phillip Moschella⁸, Amer Raheemullah⁹, Suzette Miller¹⁰, Gina Gregovich¹¹, Deborah Waltman¹², Kathleen Brady¹, Kelly Barth¹
¹Medical University of South Carolina, ²West Virginia University Rockefeller Neurosciences Institite, ³FAVOR Upstate, ⁴San Francisco Department of Public Health, ⁵Heritage Health Solutions, ⁶Washington State University, ⁷Penn State College of Medicine, ⁸Prisma Health, ⁹Stanford Health Care, ¹⁰Mercy Health, ¹¹University of Utah, ¹²Deaconess Hospital
**T82. Buprenorphine Versus Methadone for the Treatment of Opioid Dependence: A Systematic Review and Meta-Analysis of Randomised and Observational Studies**
Louisa Degenhardt¹, Brodie Clark², Georgina Macpherson², Oscar Leppan², Suzanne Nielsen³, Emma Zahra², Briony Larance⁴, Jo Kimber², Daniel Martino-Burke², Matthew Hickman⁵, Michael Farrell¹
¹National Drug and Alcohol Research Centre, ²National Drug and Alcohol Research Centre, UNSW Sydney, ³Monash University, ⁴University of Wollongong, ⁵University of Bristol

**T83. Effects of Intervention on Methamphetamine Use and Mental Health Outcomes Among Patients on Methadone who Use Methamphetamine in Vietnam**
Diep Bich Nguyen¹, Trang Thu Nguyen¹, Thuy Thi Thanh Dinh¹, Huy Duc Do¹, Van Thi Hai Hoang¹, Vi Thi Tuong Vu², Truc Thanh Thai², Dung Van Do², Michael Li², Steven Shoptaw², Giang Minh Le³
¹Hanoi Medical University, ²Hochiminh City University of Medicine and Pharmacology, ³University of California, Los Angeles

**T84. Effects of Co-morbid Health Conditions on Health-Related Quality of Life Among Recovery Residents With an Opioid Use Disorder in Texas**
Elizabeth Obekpa¹, Sheryl McCurdy², David Adzrago³, Kathryn R. Gallardo³, J. Michael Wilkerson³
¹The University of Texas Health Science Center At Houston, ²University of Texas Health Science Center, ³The University of Texas Health Science Center at Houston

**T85. Aspects of Interorganizational Collaboration in Linking Justice-Involved Persons With Opioid Use Disorder Treatment: A Qualitative Exploration of the Community Supervision and Treatment Provider Relationship**
Lauren Perron¹, Gerald Stahler¹, Jennifer Wood¹, Steven Belenko¹
¹Temple University

**T86. Effects of Chronic Naltrexone Treatment on Relapse-Related Behavior and Neural Responses to Fentanyl in Awake Squirrel Monkeys**
Sarah Withey¹, Harshawardhan Deshpande², Lei Cao³, Jack Bergman⁴, Stephen Kohut¹
¹McLean Hospital, Harvard Medical School, ²Harvard Medical School McLean Hospital, ³McLean Hospital, ⁴McLean Hospital / Harvard Med School

**T87. Long-Term Relationship Between Opioid Use and Change in HIV Disease Severity: A Prospective Cohort Study**
Fiona Bhendoekhan¹, Coraline Danieli², Michal Abrahamowicz², Brandon D.L. Marshall¹, M-J Milloy³
¹Brown University School of Public Health, ²McGill University Health Centre, ³University of British Columbia

**T88. Harm Reduction in the Field: First Responders’ Perceptions of Opioid Overdose Interventions**
Callan Fockele¹, Tessa Frohe², Owen McBride¹, David Perlmutter³, Brenda Goh³, Will Williams⁴, Courteney Wettmann⁴, Nathan Holland⁴, Jenna van Draanen⁵
¹University of Washington Department of Emergency Medicine, ²University of Washington Department of Psychiatry and Behavioral Sciences, ³University of Washington Department of Health Systems and Population Health, ⁴Research with Expert Advisors on Drug Use (READU), ⁵University of Washington Department of Health Systems and Population Health and Department of Child, Family, and Population Health Nursing

**T89. Take-Home Methadone Research From 2020 Through 2022: A Narrative Review**
Javier Ponce Terashima¹, Kim Hoffman², Ximena Levander², Dennis McCarty²
¹Yale University School of Medicine Department of Psychiatry, ²Oregon Health and Science University
T90. Impact of an Opioid Use Disorder Treatment Implementation Intervention Among Patients With and Without Co-Occurring Substance Use Disorders in the Veterans Health Administration
Madeline Frost¹, Carol Malte², Eric Hawkins², Joseph Glass³, Kevin Hallgren⁴, Emily Williams⁵
¹VA Puget Sound Health Services Research and Development, ²Center of Excellence in Substance Addiction Treatment and Education, Veterans Affairs Puget Sound Health Care System, ³Kaiser Permanente Washington Health Research Institute, ⁴University of Washington School of Medicine, Department of Psychiatry and Behavioral Sciences, ⁵University of Washington School of Public Health, Department of Health Systems and Population Health

T91. Justice Community Opioid Innovations Network Linkage Facilitation
Lynda Stein¹, Linkage Facilitation Group¹
¹University of Rhode Island

T92. COVID-19 Vaccination and HIV Transmission Among Persons who Inject Drugs During the First Two Years of the COVID-19 Pandemic in New York City
Don Des Jarlais¹, Chenziheng (Allen) Weng², Jonathan Feelemyer³, Courtney McKnight⁴
¹New York University School of Global Public Health, ²New York University College of Global Public Health, ³New York University School of Medicine

T93. Readiness to Implement Contingency Management to Promote PrEP Initiation and Adherence Among People who Inject Drugs
Adam Viera¹, Eleanor Pickering¹, Minhee Sung², Genie Bailey³, Marianne Buchelli⁴, Daniel Davidson¹, Mark Jenkins⁵, Betsey John⁶, Jennifer Kolakowski⁷, Leah Maier⁸, Elizabeth Porter⁹, Oscar Rojas Perez¹⁰, E. Jennifer Edelman¹¹, Carla Rash¹²
¹Yale School of Public Health, ²Yale University School of Medicine and VACHS, ³Stanley Street Treatment and Resources, Inc., ⁴Connecticut Department of Public Health, ⁵Connecticut Harm Reduction Alliance, ⁶Massachusetts Department of Public Health, ⁷Recovery Network of Programs, Inc., ⁸Apex Community Care, ⁹Yale University School of Medicine, ¹⁰Yale School of Medicine, ¹¹UConn School of Medicine

T94. A Summary of Opioid Recovery Funds: Settlements Between Pharmaceutical Companies and Governments Regarding Their Role in the Opioid Epidemic
Jermaine Jones¹, Sara Calvin², Nathan Driskill³, Holly Hagle⁴, Kerri Hayes⁵, Sazid Khan⁶, Michael Knabel⁷, Kiersten Johnson⁸, Brent Moore⁹, Zoey Logan⁹, Zuleyma Serpas⁹, Shelby Webb⁹, Camara Wooten², Frances Levin¹, Kathryn Cates-Wessel³
¹Columbia University Irving Medical Center, ²RTI International, ³Opioid Response Network, American Academy of Addiction Psychiatry, ⁴Yale University School of Medicine

T95. A Time Series Analysis of Nonfatal and Fatal Drug Overdose Outcomes for the Surveillance of Drug Overdose Outbreaks
Thomas Patton¹, Christos Lazarou², Sharon Trillo-Park¹, Steffanie Strathdee¹, Annick Borquez¹, Annick Borquez³
¹University of California, San Diego, ²University of York, ³University of California San Diego

T96. Changes in Opioid Agonist Treatment Initiation Following Voluntary and Mandatory Prescription Drug Monitoring Program Implementation: A Time Series Analysis
Louisa Picco¹, Ting Xia¹, Simon Bell¹, Dan Lubman², Rachelle Buchbinder¹, Suzanne Nielsen¹
¹Monash University, ²Turning Point
T97. Policies Relevant to the Healing Communities Study Kentucky Site Implementation
Anita Silwal1, Jeffery Talbert2, Christopher Cook3, Daniel R. Harris4, Daniel T. Redmond5, Molly Gallivan6, Drew Speer4, Patricia R. Freeman7, Katherine R. Marks9, Laura Fanucchi10, Sharon Walsh10, Michelle Lofwall10
1University of Kentucky, College of Communication and Information, Substance Use Priority Research Area, 2University of Kentucky, Division of Biomedical Informatics, College of Medicine, Institute for Biomedical Informatics, Center for Clinical and Translational Sciences, 3University of Kentucky, Substance Use Priority Research Area, 4University of Kentucky, Center for Clinical and Translational Sciences, Department of Pharmacy Practice and Science, College of Pharmacy, 5University of Kentucky, Institute for Biomedical Informatics, 6University of Kentucky, Substance Use Priority Research Area (SUPRA), 7University of Kentucky, Department of Pharmacy Practice and Science, College of Pharmacy, 8University of Kentucky, Department of Behavioral Science, 9University of Kentucky, Department of Internal Medicine, Center on Drug and Alcohol Research, 10University of Kentucky, Department of Behavioral Science, College of Medicine, Center on Drug and Alcohol Research

T98. Open Board

T99. Perceptions of Syndromic Surveillance to Prevent Overdose in Lowell, Massachusetts: Qualitative Perspectives of Community Leaders and People who Use Drugs
Kevin Cyr1, Shikhar Shrestha1, Thomas Stopka1, Jennifer Pustz1
1Tufts University School of Medicine

T100. Preparing Recovery Coaches to Discuss Medication for Opioid Use Disorder (MOUD): An Interactive Training and Competency
Trevor Moffitt1, Amanda Fallin-Bennett2, Anna Ross3, Molly Gallivan4, Jeremy Byard5, Jimmy Chadwell3, Christopher Cook4, John Lauckner4, Laura Fanucchi6, Devin Oller6, Sharon Walsh1, Michelle Lofwall6
1University of Kentucky, 2University of Kentucky, Voices of Hope, 3Voices of Hope, 4University of Kentucky, Substance Use Priority Research Area, 5Louisville Recovery Community Connection, 6University of Kentucky, College of Medicine

T101. The Primary Care Opioid Use Disorders Treatment (PROUD) Trial
Paige Wartko1, Abigail Matthews2, Jennifer Bobb3, Denise Boudreau4, Jennifer McCormack5, David Qiu6, Onchee Yu1, Noorie Hyun1, Amy Lee1, Cynthia Campbell7, Andrew Saxon8, David Liu9, Andrea Altschuler7, Jeffrey Samet10, Angela Stotts11, Jordan Braciszewski12, Mark Murphy13, Julia Arnsten14, Viviana Horigian15, Jose Szapocznik16, Joseph Glass17, Ryan Caldeiro18, Rebecca Phillips3, Mary Shea3, Katharine Bradley3
1Kaiser Permanente Health Research Institute, 2The Emmes Company, 3Kaiser Permanente Washington Health Research Institute, 4Genetech, 5The Emmes Company, LLC, 6Wharton School, University of Pennsylvania, 7Kaiser Permanente Northern California, 8Veterans Affairs Puget Sound Healthcare System, 9National Institute on Drug Abuse, National Institutes of Health, 10Boston University School of Medicine, 11University of Texas Health Science Center, 12Henry Ford Health System, 13MultiCare Institute for Research and Innovation, 14Montefiore Medical Center, 15Miller School of Medicine, University of Miami, 16University of Miami, 17Kaiser Permanente Washington Health Research Institute, 18Kaiser Permanente Washington

T102. Understanding the Needs of Women in Treatment for Opioid Use Disorder to Inform the Development of a Gender-Specific Digital Intervention
Dawn Sugarman1, Emily A. Levine2, Callie Wang3, Lisa Marsch4, Roger Weiss1, Shelly Greenfield1
1McLean Hospital - Harvard Medical School, 2McLean Hospital, 3University of Central Florida, 4Geisel School of Medicine at Dartmouth
T103. Implementation of Virtual Contingency Management Within a Statewide Opioid Treatment Program Provider Network in Texas
Carma Deem Bolton1, Michele Green2, Tara Karns-Wright1, Jennifer Potter3
1The University of Texas Health Science Center At San Antonio, 2WEconnect Health Management, 3University of Texas Health San Antonio

T104. Facilitators of and Barriers to Buprenorphine-Naloxone Initiation for People With Opioid Use Disorder in the Emergency Department: A Scoping Review
Nikki Bozino1, Erin Grennell2, Charlene Soobiah3, Christine Bucago4, Terri Rodak5, Michelle Klaiman6, Brittany Poynter7, Dominick Shelton7, Elizabeth Schoenfeld8, Csilla Kalocsai9
1Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 2Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, 3Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada, 4Department of Emergency Medicine, Centre for Addiction and Mental Health, Toronto, Ontario, Canada, 5CAMH Library, Department of Education, Centre for Addiction and Mental Health, Toronto, Ontario, Canada, 6Department of Emergency Medicine, St. Michael’s Hospital, Unity Health Toronto, Toronto, Ontario, Canada, 7Department of Emergency Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, 8Department of Emergency Medicine, University of Massachusetts Medical School - Baystate Campus, Springfield, Massachusetts, USA, 9Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

T105. Prescription Opioid Dose Reductions and Potential Adverse Events: A Multi-Site Study in Eight U.S. Health Systems
Verena Metz1, Thomas Ray1, Vanessa Palzes1, Ingrid Binswanger2, Andrea Altschuler1, Susan Andrade3, Robin Clark4, Irina Haller5, Rulin Hechter6, Douglas Roblin7, Steffani Bailey8, Dennis McCarty9, Kari Stephens10, Andrea Rubinstein11, Ruchir Karmali12, Cynthia Campbell1
1Kaiser Permanente Northern California, Division of Research, Center for Addiction and Mental Health Research, Oakland, CA, United States, 2Kaiser Permanente Colorado, 3Meyers Primary Care Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, 4Department of Family Medicine and Community Health, University of Massachusetts Chan School of Medicine, Worcester, Massachusetts, 5Essentia Institute of Rural Health, Duluth, Minnesota, 6Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, 7Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland, 8Department of Family Medicine, Oregon Health and Science University, Portland, Oregon, 9OHSU-PSU School of Public Health, Portland, Oregon, and Division of General and Internal Medicine, School of Medicine, Oregon Health and Science University, Portland, Oregon, 10Department of Family Medicine, University of Washington, Seattle, Washington, 11Department of Pain Medicine, The Permanente Medical Group, Santa Rosa, California, 12Mathematica, Oakland, California

T106. Barriers to Retention in Inpatient and Residential Drug Treatment Among Persons who Use Opioids in the Rural U.S.
Lyndsey Mixson1, Thomas Stopka2, Minh Powell3, Gillian Leichtling4, Angela Estadt5, John Bressett6, William Zule7, John Pearce3, Eric Romo8, Peter Friedmann9, Suzan Walters10, Joseph Delaney11, Heidi Crane12, Rob Fredericksen3
1University of Washington/Harborview Medical Center, 2Department of Public Health and Community Medicine, Tufts University, 3University of Washington, 4Comagine Health, 5Ohio State University, 6Department of Public Health and Recreations Professions Southern Illinois University at Carbondale, 7RTI International, 8University of Massachusetts Medical School, 9Baystate Health, 10New York University, 11University of Manitoba, 12University of Washington at Harborview Medical Center
T107. Perceived Importance of Counseling Among Patients Receiving Methadone Treatment
Mark Beitel1, Gul Saeed2, Marina Gaeta Gazzola3, Kathryn Eggert4, Teresa Roehrich4, Lynn Madden5, Declan Barry6
1Yale University, APT Foundation, 2APT Foundation, Inc., Yale University School of Medicine, 3NYU Langone Medical Center/NYC Health and Hospitals Bellevue Hospital Center, 4APT Foundation, Inc., 5APT Foundation, 6Yale University School of Medicine

T108. Exploring Long-Term Trajectories of Quality of Life for People who are Treated With Methadone
Anjalee Sharma1, Jan Gryczynski2, Trenette Goings3, Robert Schwartz2
1Johns Hopkins School of Medicine, 2Friends Research Institute, 3University of North Carolina at Chapel Hill

T109. Substance Use Screening Rates and Screening Results Among Adult Primary Care Patients With Mental Health Conditions and Substance Use-Related Medical Conditions
Jennifer McNeely4, Aimee Wahle2, Margaret Kline2, Clayton Snyder3, Sarah E. Wakeman4, Timothy Wilens4, Joseph Kanny5, Richard Rosenthal6, Noa Appleton1, Sarah Farkas1, Carmen Rosa7, Seth Pitts2, Martina Pavlicova8, John Rotrosen1, Leah Hamilton9
1New York University Grossman School of Medicine, 2The Emmes Company, 3New York State Psychiatric Institute, 4Massachusetts General Hospital, 5Icahn School of Medicine at Mount Sinai, 6Renaissance School of Medicine, Stony Brook University, 7National Institute of Drug Abuse, National Institutes of Health, 8Mailman School of Public Health, Columbia University, 9Kaiser Permanente, Washington Health Research Institute

T110. Socioeconomic Status Differences in U.S. Multiracial Adolescents’ Substance Use and Mental Health Problems
Audrey Hai1, Catalina Lopez-Quintero2, Amanda Elton2, Juan Perez-Carreño2
1Tulane University, 2University of Florida

T111. The ATTC Network: 30 Years of Supporting EBP Implementation in SUD Treatment and Recovery Services
Maxine Henry1, Lena Marceno2, Holly Hagle1, Laurie Krom1
1University of Missouri-Kansas City, 2Altarum Institute

T112. State Laws Regulating Provision of Incentives Related to Substance Use
Barbara Andraka-Christou1, Michelle Williams1, Scott Buksbaum1, Josie Karkkainen1, Bradley Stein2, Sydney Batchelder3, Kelly Peck3, Sarah Heil3, Richard Rawson4, Sarah Jacobs5, Stephen Higgins3, Stacey Sigmon1
1University of Central Florida, 2RAND Corporation, 3University of Vermont, 4UCLA Integrated Substance Abuse Programs, 5Parthenon Management

T113. Comparing mHealth Use and Acceptability in Individuals Engaged in Treatment for Substance Use Disorders Prior to and After the Start of COVID-19
Emily A. Levine1, Hannah Shapiro1, R. Kathryn McHugh2, Roger D. Weiss2, Shelly F. Greenfield2, Dawn E. Sugarman2
1McLean Hospital, 2McLean Hospital, Harvard Medical School

T114. Introducing a Socio-Ecological Model of Collegiate Recovery Programs
Noel Vest1, Sierra Castedo de Martell2, Emily Hennessy3
1Boston University, 2UTH Health School of Public Health, 3Massachusetts General Hospital and Harvard Medical School
T115. An Intervention Module for Methamphetamine Use in Youths Utilizing Mobile Smartphone Technology
Suzaily Wahab¹, Amirul Danial Azmi¹, Mohammad Faidzul Nasrudin², Muhamad Afiq Zulkifly¹, Nor Ba'yah Abdul Kadir³, Norhayati Ibrahim⁴, Normah Mustaffa⁵, Siti Rahmah Awang⁶, Noor Alaudin Abdul Wahab⁴, Mohd Juzaiddin Ab Aziz²
¹Universiti Kebangsaan Malaysia Medical Centre, ²Faculty of Information Science and Technology, Universiti Kebangsaan Malaysia, ³Faculty of Social Sciences and Humanities, Universiti Kebangsaan Malaysia, ⁴Faculty of Health Sciences, Universiti Kebangsaan Malaysia, ⁵Azman Hashim International Business School, Universiti Teknologi Malaysia

T116. Inclusion of Community Members in Initial Design Stages of Technology-Based Interventions Addressing Topics Including Substance Use and HIV: A Systematic Review
Mary-Andrée Ardouin-Guerrier¹, German Rivera-Castellar², Juan Esteban Baus¹, Alex S. Bennett¹, Brent Gibson³, Selena A. Gilles⁴, Ian Aronson²
¹NYU School of Global Public Health, ²New York University, ³Community Research, ⁴NYU Rory Meyers College of Nursing

T117. Long-Term Mortality After Drug Use-Associated Endocarditis is High and Differs by Race and Sex: Results of a Statewide Study
Asher Schranz¹, Mary Figgatt¹, Vivian Chu², Li-Tzy Wu², David Rosen¹
¹University of North Carolina at Chapel Hill, ²Duke University School of Medicine

T118. Kratom Use and Adverse Events: Findings From the NDEWS Rapid Street Reporting Study
Catherine Striley¹, Anna Wang¹, Nae Won¹, Nicole Fitzgerald¹, Linda Cottler¹
¹University of Florida

T119. Familiarity With Substances and Adolescent Substance Use
Devika Bhatia¹, Benjamin Lewis², Hugh Farrior², Andrew Moore², Sara Jo Nixon²
¹University of Colorado School of Medicine, ²University of Florida College of Medicine

T120. Patterns and Clinical Correlates of Depressive Symptoms, Pain Impact, and Sleep Disturbance Among Patients in Residential Substance Use Treatment
Jennifer Ellis¹, Jill Rabinowitz², Patrick Finan³, Neha Skandan¹, Justin Strickland¹, J. Greg Hobelmann⁴, Andrew Huhn¹
¹Johns Hopkins University School of Medicine, ²Johns Hopkins Bloomberg School of Public Health, ³Johns Hopkins Hospital, ⁴Ashley Treatment Center

T121. Black Market Drug Purchases as Reported to Real-Time Monitoring Website, StreetRx
Brooke E. Kritikos¹, Kyle A. Beekman¹, Annika M. Czizik¹, Richard C. Dart¹, Joshua C. Black¹
¹Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, CO, USA

T122. The Controlled Substances Act Regulations on Schedule I Researcher Registrations and the Need to Investigate New Substances of Abuse
Theresa Carbonaro¹, William Heuett¹, Terry Boos¹
¹The United States Department of Justice

T123. Open Board
T124. Assessing Amygdala Habituation as it Relates to Substance-Use Disorder Vulnerability, Using Data From the ABCD Study®
Paul Regier¹, Yousef Khan², Virgilio Gonzenbach², Elizabeth Sweeney², Russell Shinohara², Anna Rose Childress²
¹University of Pennsylvania, ²University of Pennsylvania Perelman School of Medicine

T125. Marijuana Vaping Exceeds Nicotine Vaping Among California Youth: Results of a Statewide Survey
Angelina Van Dyne¹, Jijiang Wang², Shu-Hong Zhu²
¹UCSD, ²University of California - San Diego

T126. High Blood Pressure Among Psilocybin and Cannabis Consumers During the COVID-19 Pandemic: An Analysis of the COVID-19 Cannabis Health Study
Denise Vidot¹, Bria-Necole Diggs², Amrit Baral², Michaela Larson², Sitara Weerakoon³, Moudou Baquai⁴, Ramessu Iyi⁵, Michelle Weiner⁵, Marlene Camacho-Rivera⁶, Sarah Messiah⁷
¹University of Miami School of Nursing and Health Studies, ²University of Miami Miller School of Medicine, ³Yale University School of Medicine, ⁴TaMerrian Institute, ⁵Spine and Wellness Centers of America, ⁶SUNY Downstate Health Sciences University, ⁷University of Texas Health Science Center

Abenaa Jones¹, Riley Shearer², Joel Segel³, Alexis Santos-Lozada¹, Tyler Winkelman⁴
¹Pennsylvania State University, ²The University of Minnesota, ³Penn State, ⁴Health, Homelessness, and Criminal Justice Lab, Hennepin Healthcare Research Institute

T128. Unmet Social Gender Affirmation as a Driver of Drug Use Among Transgender Women: The Need for Policy and Protections
Tiffany Glynn¹, Don Operario², Conall O’Cleirigh³, Adam Carrico⁴, Steven Safren⁵
¹Harvard Medical School/Massachusetts General Hospital/Brigham and Women’s Hospital, ²Rollins School of Public Health at Emory University, ³Harvard Medical School/Massachusetts General Hospital, ⁴University of Miami Miller School of Medicine, ⁵University of Miami

T129. Prevalence of Psilocybin and Cannabis Concurrent Use During the COVID-19 Pandemic: An Analysis of the COVID-19 Cannabis Health Study
Denise Vidot¹, Amrit Baral², Bria-Necole Diggs³, Sitara Weerakoon⁴, Moudou Baquai⁵, Ramessu Iyi⁶, Michelle Weiner⁶, Sarah Messiah⁷
¹University of Miami School of Nursing and Health Studies, ²Miller School of Medicine, University of Miami, ³University of Miami Miller School of Medicine, ⁴Yale University School of Medicine, ⁵TaMerrian Institute, ⁶Spine and Wellness Centers of America, ⁷University of Texas Health Science Center

T130. Open Board

T131. Injecting Partnership Interpersonal Factors Predict Partnership Needle Sharing
Maia Scarpetta¹, Yea-Hung Chen¹, Torstein Neilands¹, Judy Tan¹, Julie Bruneau², Kimberly Page³, Meghan D. Morris¹
¹UCSF, ²Université de Montréal, ³University of New Mexico
T132. Poly-Substance Use Characterization in an Urban Cohort of Substance Users in Philadelphia, PA
Livio Azzoni¹, David Metzger², Amy Jessop³, Rachel Holbert⁴, Madison Scialanca³, Karam Mounzer⁴, Emily Hiserodt¹, Cecile Denis⁵, Luis J. Montaner¹
¹The Wistar Institute, ²University of Pennsylvania, Department of Psychiatry, ³Prevention Point, Philadelphia, ⁴Philadelphia FIGHT, ⁵University of Pennsylvania

T133. Cigarette and E-Cigarette Use Trajectories and Prospective Prescription Drug Misuse Among Adolescents and Young Adults
Moriah Harton¹, Dong-Chul Seo³, Rebecca Evans-Polce², Ivana Nguyen¹, Maria Parker¹
¹Indiana University, ²University of Michigan

T134. Disparities in Use of Syringe Services Programs in King County, WA
Katheryn Salow¹, Sara Glick²
¹University of Washington School of Medicine, ²University of Washington

T135. The Association Between Psychosocial Syndemic Conditions and Chemsex Among Men who Have Sex With Men Seeking PrEP in Thailand
Awirut Oon-arom¹, David Grelotti², Kriengkrai Srithanaviboonchai³, Sung-Jae Lee⁴, Chaisiri Angkurawaranon⁵, Sherry Larkins⁶
¹Department of Psychiatry, Faculty of Medicine, Chiang Mai University, ²Department of Psychiatry, University of California San Diego, USA, ³Research Institute of Health Science, Chiang Mai University, ⁴Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (UCLA) David Geffen School of Medicine, USA, ⁵Department of Family Medicine, Faculty of Medicine, Chiang Mai University, ⁶Integrated Substance Abuse Programs, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), USA

T136. Missed Opportunities for HIV Prevention and Treatment for Hospitalized People who Inject Drugs
Ellen Eaton¹, John Bassler², Myles Prados³, Kedarius Ingram³, William Bradford³, Kelly Gagnon³
¹UAB, ²School of Public Health, The University of Alabama At Birmingham, ³Division of Infectious Diseases, The University of Alabama At Birmingham

T137. Health and Social Service Providers’ Perspectives on Peer Distribution of HIV Self-Test Kits With Pre-Exposure Prophylaxis Information Among People who Inject Drugs in San Diego County, California
Angela Bazzi¹, Chad Valasek², William Eger², Tara Stamos-Buesig³, Alicia Harvey-Vera⁴, Carlos Vera⁴, Jennifer Syvertsen⁵, Erik Storholm⁶, Steffanie Stratthdee⁷, Heather Pines⁸
¹University of California, San Diego, ²University of California - San Diego, ³Harm Reduction Coalition of San Diego, ⁴University of California San Diego, ⁵University of California, Riverside, ⁶San Diego State University

T138. Am I in Recovery? Bayesian Network Analysis to Understand Mental Models of Adolescent Recovery
Janaka Kosgolla¹, Doug Smith¹, Reinhart Crystal¹, Evans Jennifer¹
¹University of Illinois Urbana-Champaign

T139. Identifying Neurocognitive Mechanisms Underlying the Effects of Structural Racism on Risk for Substance Misuse Using the ABCD Study
Micah Johnson¹, Wesley Thompson²
¹University of South Florida, ²University of California, San Diego
T140. The Effect of Mental Illness on High-Risk Opioid Prescribing for Clients With Comorbid Pain and Alcohol Use Disorder in New York State
Zackary Falls¹, Chi-Hua Lu², Gail Jette³, Walter Gibson², Edward Bednarczyk², David Jacobs², Peter Elkin¹, Kenneth Leonard⁴
¹University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, ²University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, ³Division of Outcomes, Management, and Systems Information, Office of Addiction Services and Supports, ⁴Clinical and Research Institute on Addictions, University at Buffalo

T141. Evaluation of the Risk of Psychoactive Substance Use and Eating Attitudes and Behaviors Among Palestine Refugees in the North of the West Bank
Ali Shakhshir¹, Nashat Khelfeh², Adnan Mousa², Ibraheem AbuAlrub², Ali Hamad², Marah Hunjul², Fayez Mahamid³, Basma Damiri⁴
¹Department of Medicine, Faculty of medicine and health Sciences, An-Najah National University, Nablus, 44839, Palestine, ² Medicine and Health Sciences Faculty, Department of Medicine, An-Najah National University, Nablus, 00970, Palestine, ³Department of Psychology, An-Najah National University, Nablus, Palestine, ⁴Medicine and Health Sciences Faculty, Drug, and Toxicology Division, An-Najah National University, Nablus, 00970, Palestine

T142. Polysubstance Use Among Patients With Opioid Use Disorder in Rural Primary Care Clinics
Yuhui Zhu¹, Laura-Mae Baldwin², Larissa Mooney³, Andrew Saxon⁴, Emily Kan⁵, Yih-Ing Hser³
¹Semel Institute - UCLA, ²University of Washington Department of Family Medicine, ³Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles, ⁴Veterans Affairs Puget Sound Health Care System, Seattle, ⁵University of California, Los Angeles

T143. Abuse Potential Similarities Between Hypnotic Classes: Real-World Data
Margaret Moline¹, Jocelyn Cheng¹, Caitlyn Durgin², Steve Pype², August Buchhalter², Jack Henningfield²
¹Eisai, Inc., ²Pinney Associates, Inc.

T144. Open Board

T145. Self-Perception of Smoking Status and Co-Use of Cannabis and Narcotic Pain Medication
Andrew Bontemps¹, S. Justin Thomas¹, Karen Gamble¹, Karen Cropsey¹
¹The University of Alabama At Birmingham

T146. The Role of Past Substance Use on ART Adherence Among Black People with HIV
Vanessa Serrano¹, Jessica Montoya², Elizabeth Pasibanodya³, David Moore²
¹University of California, San Diego, ²University of California, San Diego, La Jolla, CA, USA, ³Rehabilitation Research Center, Santa Clara Valley Medical Center, San Jose, CA, USA

T147. Evaluating Patient Perspectives on Mixed Virtual and In-Person Group Settings
Tyler Oesterle¹, Victor Karpyak¹, Scott Breitinger¹
¹Mayo Clinic, Dept. Psychiatry and Psychology
T148. Results from a Randomized Clinical Trial to Optimize Community Wise to Reduce Alcohol and Substance Misuse (ASM) Among Formerly Incarcerated Men in Urban Communities
Liliane Windsor1, Ellen Benoit2, Carol Lee3
1The University of Illinois at Urbana-Champaign, 2North Jersey Community Research Initiative, 3University of Michigan Medical School

T149. Motivation and Context of Concurrent Stimulant and Opioid Use Among Persons who Use Drugs in the Rural United States: A Multi-Site Qualitative Inquiry
Rob Fredericksen1, David Colston2, Adams Sibley2, Robin Baker3, Sarah Mixson1, Angela Estadt4, Suzan Walters5, John Bresett6, Ximena Levander3, Gillian Leichtling7, Minh Powell1, John Pearce1, Thibaut Davy-Mendez2, Bridget Whitney1, Joseph Delaney8, Heidi Crane1, Judith Tsui1
1University of Washington, 2University of North Carolina, 3Oregon Health Sciences University, 4Ohio State University, 5New York University, 6Southern Illinois University, 7Comagine Health, 8University of Manitoba

T150. Substance Use, Psychiatric Disorders, and the COVID-19 Vaccine: A Quality Improvement Project
Zoe Karavolis1, Emily Thacker2, Maureen Reynolds3, Ralph Tarter3, Antoine Douaihy4
1University of Pittsburgh Medical Center, 2UPMC Western Psychiatric Hospital, 3University of Pittsburgh, 4UPMC-Western Psychiatric Hospital

T151. Understanding Ketamine Use in Treatment-Seeking Persons With Opioid Use Disorder
Corinne Chandler1, Matthew Ellis2, Mance Buttram1
1University of Arkansas, 2Washington University in St. Louis

T152. HIV and Hepatitis C Virus-Related Misinformation Remains a Challenge to Improved Clinical Outcomes Among Persons who use Drugs During the U.S. Opioid Overdose Crisis
Alejandro De La Hoz Gomez1, Kristin Graves, BA2, Judith A. Bernstein, PhD3, Sabrina A. Assoumou, MD, MPH2
1Boston Medical Center, 2Boston University School of Medicine, 3Boston University School of Public Health

T153. Open Board

T154. Optimizing Recovery Funding: Barriers to Acquiring Funding Among Organizations in the Ecosystem of Recovery
Stephanie Spitz1, Tyler Myroniuk2, Enid Schatz2, Deena Murphy3, Stephanie Bage3, Laurie Krom3, Adam Viera4
1Peer Recovery Center of Excellence, 2University of Missouri-Columbia, Department of Public Health, 3University of Missouri-Kansas City, 4Yale School of Public Health

T155. Changes in Prevalence of Substance Use Among Patients of Community Health Centers in Los Angeles Over Time: Comparative Analysis From 2013 to 2022
Daisy Hernandez-Casas1, Melvin Rico2, Stephanie Sumstine3, Amanda Sirisoma1, Maria Vasquez1, Jack Tsai4, Armen Arshakyan5, Dallas Swendeman1, Lillian Gelberg2
1University of California, Los Angeles, 2University of California, Los Angeles, Department of Family Medicine, 3University of California, Los Angeles, Department of Psychiatry and Biobehavioral Sciences, 4TCC Family Health, 5Saban Community Clinic

T156. Momentary Latent Class Membership to Predict Self-Efficacy and Subsequent Substance Use
Danny Wang1, Samuel Stull1, Michael Dennis2, Christy Scott2, Stephanie Lanza3
1The Pennsylvania State University, 2Chestnut Health Systems, 3The Pennsylvania State University, Department of Biobehavioral Health
T157. Applying Theory of Planned Behavior to Predict Online Addiction Treatment Intention During COVID-19
Hagit Bonny-Noach1, Dudi Gold2, Ariel Caduri3
1Department of Criminology, Ariel University and Board member of ILSAM-The Israeli Society of Addiction Medicine, 2M.A., Director of “Gold Center”- An outpatient treatment center and Board member of ILSAM-The Israeli Society of Addiction Medicine, 3Ph.D, Head of Knowledge Development, Israel Authority for prevention of Violence, Alcohol and Drug Abuse - National Authority for Community Safety-Ministry of Public Security

T158. Differences in Acute and Enduring Effects of MDMA vs. Classic Psychedelics in People With Eating Disorders
Natalie Gukasyan1, Erin Wang1, Alan K. Davis2, Colleen Schreyer1, Angela Guarda1, Roland Griffiths3
1Johns Hopkins Hospital, 2Ohio State University, 3Johns Hopkins University

T159. Open Board

T160. Acute Psychedelic Effects and Clinical Outcomes Are Associated With Therapeutic Alliance Among Participants Receiving Psilocybin Therapy
Alan Davis1, Adam Levin2, Rafaelle Lancelotta3, Nathan Sepeda4, Natalie Gukasyan2, Sandeep Nayak5, Frederick Barrett6, Roland Griffiths4
1The Ohio State University, 2Ohio State University, College of Medicine, 3Ohio State University, 4Johns Hopkins University, 5Johns Hopkins Hospital, 6Johns Hopkins University School of Medicine

T161. Essential Experimental Screening to Evaluate the Safety of Novel Psychedelics
Jane Gosden1, Sharon Smith1, Christopher Atterwill1, David Heal1
1DevelRx Ltd

T162. Drug Overdose Risk Following Benzodiazepine Treatment in Young Adults With Depression or Anxiety Disorders
Greta Bushnell1, Moira Rynn2, Deborah Hasin3, Katherine Keyes3, Tobias Gerhard1, Magdalena Cerda4, Mark Olfson3
1Rutgers University, 2Duke University, 3Columbia University, 4New York University

T163. Latent Class Analysis of Psychosocial Factors Among People Living with HIV who Use Substances
Daniel Feaster1, Renae Schmidt1, Rui Duan2, Sharleen Traynor3, Carly Davis4, Sophia Gonzalez4, Derrick Forney1, Lisa Metsch5, Daniel Feaster1
1University of Miami Miller School of Medicine, 2University of Miami, 3Durham Technical Community College, 4Miller School of Medicine, University of Miami, 5Columbia University

T164. Care Utilization Among Patients With Stimulant Use Disorder During COVID-19: A National Cohort Study of US Veterans
Lewei (Allison) Lin1, Madeline Frost2, Lan Zhang3, Lara Coughlin1
1University of Michigan, 2University of Washington School of Public Health, Department of Health Systems and Population Health
**POSTERS**

**T165. The Development of a Knowledge, Attitude, and Practice Questionnaire for Methamphetamine Use**
Amirul Danial Azmi¹, Suzaily Wahab², Nor Ba’yah Abdul Kadir³, Noor Alaudin Abdul Wahab³, Rogayah Abdul Razak⁴
¹Universiti Kebangsaan Malaysia Medical Centre, ²Faculty of Social Sciences and Humanities, Universiti Kebangsaan Malaysia, ³Faculty of Health Sciences, Universiti Kebangsaan Malaysia, ⁴Faculty of Social Science and Liberal Arts, UCSI University

**T166. Treatment Outcomes From Computerized CBT for Substance Use Disorders Among People With Criminal Justice Involvement**
Jennifer Loya¹, Theresa Babuscio¹, Charla Nich¹, Brian Kiluk¹
¹Yale University School of Medicine

**T167. Impact of Methamphetamine Use on Cardiovascular Risk and Deprivation: Objective Assessment Using Wearable Activity Tracker and Mobile Application**
Ayumi Takano¹, Koki Ono², Makito Sato³, Masaki Onuki³, Jun Sese³, Toshihiko Matsumoto⁴
¹Department of Mental Health and Psychiatric Nursing, Tokyo Medical and Dental University, ²Department of Clinical Information Engineering, The University of Tokyo, Tokyo, ³Humanome Lab., Inc., ⁴Department of Drug Dependence Research, National Institute of Mental Health, National Center of Neurology and Psychiatry

**T168. An Evaluation of the “Critical Period” in Contingency Management**
Sean Regnier¹, Thomas Shellenberg¹, Mikhail Koffarnus¹, Joshua Lile¹, Craig Rush¹, William Stoops¹
¹University of Kentucky, College of Medicine

**T169. Correlates of Methamphetamine Use for Self-Treatment of Attention Deficit/Hyperactivity Disorder**
Patricia Timmons¹, Sydney Silverstein², Raminta Daniulaityte¹
¹Arizona State University, ²Boonshoft School of Medicine Wright State University

**WEDNESDAY, JUNE 21, 2023**

**POSTER SESSION 4**

**W1. Historical Trauma, Racial Identity, and Binge Drinking Among Black Young Adults**
Chantel Ebrahimi¹, Lillian Polanco-Roman¹, Denise Hien²
¹The New School, ²Rutgers Center of Alcohol and Substance Use Studies Studies, Graduate School of Applied and Professional Psychology

**W2. Open Board**

**W3. Is the Whole Greater Than the Sum of Its Parts? Examining How Dosage of Intervention Components From the Sacramento Neighborhood Alcohol Prevention Project Affect Child Abuse and Neglect**
Bridget Freisthler¹, Yun Ye¹
¹The Ohio State University

**W4. A Therapeutic Workplace for Adults With Alcohol Use Disorder who are Experiencing Homelessness**
Matthew Novak¹, August Holtyn¹, Forrest Toegel², Kenneth Silverman³
¹Johns Hopkins University School of Medicine, ²Northern Michigan University, ³Johns Hopkins University
W5. Association of Phosphotidylethanol (PEth) Levels With Severity of Alcohol Dependence in Treatment Seeking Patients of Alcohol Dependence: An Exploratory Study
Abhishek Gupta¹, Raka Jain², Biswadip Chatterjee³
¹AIIMS DELHI, ²All India Institute of Medical Sciences, ³National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences, New Delhi - 110029

W6. Mediation Effect of the Alcohol Reinforcement Value on the Association Between Poor Sleep Quality and Problematic Drinking Among Adolescents
Clara Sancho-Domingo¹, Jose Luis Carballo¹, Ainhoa Coloma-Carmona¹, Antonia Pelegrín Muñoz¹, Carlos Van-der Hofstadt Román¹
¹Miguel Hernández University

W7. Combined Multiomics of Comorbid Alcohol Use Disorder and Depression
Eric Vallender¹, Jon Person², Gouri Mahajan¹, James Overholser², George Jurjus³, Lesa Dieter², Grazyna Rajkowska¹, Craig Stockmeier¹
¹University of Mississippi Medical Center, ²Case Western Reserve University, ³Louis Stokes Cleveland VA Medical Center

W8. Increasing Capacity of International Researchers and Universities Through Collaboration
Carly Searcy¹, Stephen Asatsa²
¹International Consortium of Universities for Drug Demand Reduction, ²The Catholic University of Eastern Africa

W9. The Potential Moderating Effects of Alcohol Use Severity and Reinforcer Valuation on Suicidal Thoughts and Behaviors
Mark Rzeszutek¹, Mikhail Koffarnus¹
¹University of Kentucky, College of Medicine

W10. Exploring the Relationships Between Dimensions of Adverse Childhood Experiences and Cannabis Use Outcomes
Catalina Lopez-Quintero¹, Martha Castañeda¹, Juan Perez-Carreño¹
¹University of Florida

W11. A Prospective Study on Changes in Alcohol, Cannabis, and Tobacco Use From Before to During the COVID-19 Pandemic
J. Megan Ross¹, Jesse Hinckley¹, Jarrod Ellingson¹, Stephanie Zellers², Matt McGue², Robin Corley³, Scott Vrieze², Soo Rhee⁴, Sylia Wilson², John Hewitt⁵, William Iacono², Christian Hopfer⁶
¹University of Colorado Anschutz Medical Campus, ²University of Minnesota, ³Institute for Behavioral Genetics, ⁴University of Colorado Boulder, ⁵University of Colorado, ⁶University of Colorado School of Medicine

W12. An Analysis of Gender Differences in Cannabis Use Frequency Among People With Mental Health Disorders Pre- And Post-Recreational Cannabis Use Legalization: A Repeated Cross-Sectional Survey
Maryam Sorkhou¹, Elle Wadsworth², Faith Rodas³, David Hammond⁴, Tony George⁵
¹University of Toronto and CAMH, ²University of Waterloo, ³McMaster University, ⁴University of Waterloo, ⁵University of Toronto
W13. Using Self-Reported Hits and Grams to Estimate Cannabis Consumption in Milligrams of THC
Mohammad Habib1, Jacob Borodovsky2, Cara Struble3, Deborah Hasin4, Dvora Shmulewitz4, Claire Walsh5, Ofir Livne6, Efrat Aharonovich7, Alan Budney3
1Dartmouth College, 2Dartmouth Geisel School of Medicine, 3Geisel School of Medicine at Dartmouth, 4Columbia University, 5New York State Psychiatric Institute, 6Mailman School of Public Health, Columbia University, 7Columbia University Irving Medical Center

W14. Behavioral and Psychosocial Predictors of Cannabis Use Among Youth During the COVID-19 Pandemic
Kerry Flannagan1, Marushka Silveira2, Colm Everard1, Heather Kimmel1, Satoko Kuramoto-Crawford4, Daniela Marshall1, Wilson Compton4, Melissa Creamer4
1National Institute of Drug Abuse, National Institutes of Health; Kelly Government Solutions, 2National Institute of Dental and Craniofacial Research, National Institutes of Health; Kelly Government Solutions, 3National Institute of Drug Abuse, National Institutes of Health, 4National Institute on Drug Abuse, National Institutes of Health

Zachary Mannes1, Carol Malte2, Andrew Saxon3, Deborah Hasin4
1Columbia University, Mailman School of Public Health, 2Center of Excellence in Substance Abuse Treatment and Education, Veterans Affairs Puget Sound Health Care System, 3Veterans Affairs Puget Sound Healthcare System, 4Columbia University

W16. Rising Solitary Cannabis Use Among Young Adults Over Time: Investigating Cannabis Practices, Motivations, and Demographic Factors
Stephen Lankenau1, Ekaterina Fedorova1, Janna Ataiants1, Bridgid Conn2, Carolyn Wong3
1Drexel University Dornsife School of Public Health, 2Children's Hospital Los Angeles, 3Children's Hospital Los Angeles and University of Southern California

W17. Social Role Protective Factors in Risky Substance Use Among a Community Sample of Emerging Adults
Melissa Fenton1, Piyush Chaudhari1, Linda Cottler1, Catherine Streiley1
1University of Florida

W18. The Left Dorsolateral Prefrontal Cortex Modulates the Perception of Low Dose THC Effects in Individuals With Problematic Cannabis Use
Miranda Ramirez1, Preston Tolbert2, Brady Stamper2, Caroline Sumner1, Joshua Lile2, Michael Wesley2
1University of Kentucky, College of Arts and Sciences, 2University of Kentucky, College of Medicine

W19. Investigating the Simultaneous Effects of Cannabidiol Isolate and Caffeine
Morgan Ferretti1, Noah Gustin2, Rachel Zindler2, Caroline Sokol2, Avery Knowlton2, Kate Porter2, Olivia Carmack2, Ethan Hoffman2, Matthew Feldner2, Marcel Bonn-Miller3, Jessica Irons2
1University of Arkansas, 2James Madison University, 3Canopy Growth Corporation

W20. Modular-Level Alterations in Functional Brain Connectivity Associated With Cannabis Use
Christina Meade1, Ryan Bell1, Sheri Towe1, Kareem Al-Khalil1, Jessica Cohen2, Syam Gadde4, Shana Hall1
1Duke University School of Medicine, 2University of North Carolina at Chapel Hill
W21. Concurrent and Prospective Relations Between Aberrant Stress-Induced Frontal Alpha Asymmetry and Cannabis Use Disorder
Brandon Schermitzler¹, Richard Macatee¹
¹Auburn University Department of Psychological Sciences

W22. Attitudes and Beliefs of Prenatal Cannabis Use: Assessing the Reliability of the Perceptions of Prenatal Cannabis Use Measure and Comparing Perceptions Between Locations
Anna Wiese¹, Judy Chang², Jeanelle Sheeder³, Nancy jallo¹, Lisa Brown¹, Nicole Karjane¹, Divya Sharma¹, Enkelejda Ngjelina¹, Dace Svikis¹
¹Virginia Commonwealth University, ²University of Pittsburgh, ³University of Colorado Denver

W23. Effect of Acute THC, Sex, and Lifetime Cannabis Use on Neural Reward Activation
Rebecca Denson¹, Zoa Glab², Julia Brooks¹, Natania Crane²
¹University of Illinois At Chicago, ²Psychiatric Institute, University of Illinois At Chicago

Gregory Sahlem¹, Nathaniel Baker², Brian Sherman², Amanda Wagner², Brendan Wong¹, Margaret Caruso³, Lauren Campbell², Irakli Kaloani¹, TJ Ford¹, Haroon Musli¹, Andrew Geoly¹, Nolan Williams¹, Ian Kratter¹, Andrew Manett², Suzanne Kerns², E. Baron Short², Robert Malcolm², Therese Killeen², Mark George², Aimee McRae-Clark²
¹Stanford University, ²Medical University of South Carolina, ³Auburn University

W25. Motives Behind Frequency of Cannabis Use – a Comparison of Regular and Occasional Young Adult Cannabis Users
Anna Li¹, Zoa Glab², Rebecca Denson³, Shahd Smadi², Julia Brooks³, Natania Crane²
¹University of Illinois At Chicago College of Medicine, ²Psychiatric Institute, University of Illinois At Chicago, ³University of Illinois At Chicago

W26. Measuring Cannabis Reinforcement Among Young Adults: A Mixed Methods Examination
Neo Gebru¹, Tyler G. James², Ricarda Foxx³, Michelle Castro⁴, Ali Yurasek³
¹Brown University, ²University of Michigan, ³University of Florida, ⁴University of Colorado

W27. Changes in State Medical Cannabis Registration and in Daily Medical Cannabis Sales from 2018-2021
Benjamin Roman¹, Eve Barton¹, Savannah Poling¹, Madeline Meier¹
¹Arizona State University

W28. It’s Just, Like, a Younger Guy Thing to Smoke Weed: Gendered Cannabis Norm Perceptions Among Treatment-Seeking Adults
Justin Matheson¹, Madison Wright¹, Tara Marie Watson¹, Beth Sproule¹, Bernard Le Foll¹, Bruna Brands²
¹Centre for Addiction and Mental Health, ²Health Canada

W29. Prevalence of Cannabis Use Disorder Among Primary Care Patients who Use Cannabis for Medical Only, Nonmedical Only, or Both Reasons
Gwen Lapham¹, Theresa Matson¹, Jennifer Bobb¹, Casey Luce¹, Malia Oliver¹, Leah Hamilton¹, Katharine Bradley¹
¹Kaiser Permanente Washington Health Research Institute
W30. Hair Testing: From Drug Monitoring to Harm Reduction Tool
Daniel Martins¹, Alberto Salomone², João Matias³
¹Kosmicare/University of Porto, ²University of Turin, ³EMCDDA

W31. The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis
Lamia Haque¹, David Fiellin², Kendall Bryant³, E. Jennifer Edelman², Amy Justice³, Joseph Lim⁴, Vincent Lo Re III⁵, Brandon Marshall⁷, Tamar Taddei⁵, Janet Tate⁵, Jeanette Tetrault¹, Emily Williams⁶, Kathleen McGinnis⁹, E. Jennifer Edelman¹⁰
¹Yale School of Medicine, ²Yale School of Medicine, Yale School of Public Health, ³National Institute of Drug Abuse, National Institutes of Health, ⁴Yale School of Medicine, Yale School of Public Health, VA Connecticut Healthcare System, ⁵Yale School of Medicine, VA Connecticut Healthcare System, ⁶Perelman School of Medicine, University of Pennsylvania, ⁷Brown University School of Public Health, ⁸University of Washington School of Public Health, Department of Health Systems and Population Health, ⁹VA Connecticut Healthcare System, ¹⁰Yale University School of Medicine

W32. How Did the Removal of IQOS® Tobacco Heating System (THS) from the Market Impact Tobacco Harm Reduction?
Brendan Noggle¹, Andrea Vansickel¹
¹Altria Client Services LLC

W33. Open Board

W34. Treatment Engagement, Cigarette Smoking, and Quit Attempts One Month After a Randomized Controlled Trial of E-Cigarette Reduction Among Dual Users
Marc Jerome Feinstein¹, Joan Skelly², Stephen Higgins³, Elias Klemperer⁴
¹Univ. of Vermont College of Medicine, ²Vermont Center on Behavior and Health, ³University of Vermont, ⁴University of Vermont College of Medicine

W35. Nicotine Use and Metabotropic Glutamate Receptor 5 (mGluR5) in Individuals With Major Depressive and Post Traumatic Stress Disorders
Stephen Baldassarri¹, Ruth Asch¹, Ansel Hillmer¹, Robert Pietrzak¹, Nicole DellaGioia¹, Irina Esterlis¹, Margaret Davis¹
¹Yale University

W36. Cooling Flavors Use and E-Cigarette Nicotine Dependence Among Youth
Wei Li¹, Danielle Davis¹, Krysten Bold¹, Deepa Camenga¹, Asti Jackson¹, Grace Kong¹, Juhan Lee¹, Meghan Morean¹, Akshika Sharma¹, Suchitra Krishnan-Sarin¹
¹Yale University School of Medicine

W37. Actual Use Study of Nicotine Pouches Among U.S. Adult Smokers
Tiffany Parms¹, Erin Evans¹, Patrudu Makena¹, Mandara Shetty², Rachel Hart², Peter Chen¹, Kristen Prevette¹, Christine Campbell¹, Krishna Prasad², Sarah Baxter-Wright¹, Kristen Jordan¹
¹RAI Services Company, ²British American Tobacco

W38. Open Board
POSTERS

W39. Self-Reported Opioid Overdose via 120-Day Timeline Follow-Back and Documented Overdose Medical Encounters Among Opioid Overdose Survivors
Rachel Smith1, Nicole C. McCann2, Adam Majeski1, Vanessa M. McMahan3, Sarah Kosakowski1, Sarah L. Johns1, Shae Wolfe1, Sarah Brennan3, Phillip Coffin3, Alexander Walley1
1Grayken Center for Addiction and Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine; Boston University School of Medicine and Boston Medical Center, Boston MA, 2Boston University School of Public Health, Department of Health Law, Policy and Management, Boston, MA, 3Center on Substance Use and Health, San Francisco Department of Public Health, San Francisco, CA

W40. High Threshold Prescribing Practices Associated with Increased Termination of Care: Results From a Survey of Michigan Buprenorphine Prescribers
Omeid Heidari1, Valencia Lyle2, Samantha Harris3, Eric Hulsey2, Kate Boulton2, Brendan Saloner3, Jason Gibbons3
1University of Washington, 2Vital Strategies, 3Johns Hopkins Bloomberg School of Public Health

W41. Cumulative Vulnerabilities: An Investigation of Lifetime Substance Use Among Individuals in Recovery From Opioid Use Disorder
Devin Tomlinson1, Allison Tegge2, Roberta Freitas-Lemos1, William Craft3, Anne Le Moigne4, Angela DeVeau-Gaiss4, Howard Chilcoat4, Stephen Higgins5, Warren Bickel6
1Fralin Biomedical Research Institute at Virginia Tech Carilion, 2Virginia Tech Carilion Research Institute, 3Fralin Biomedical Research Institute at VTC, Roanoke, VA, 4Indivior, Inc., 5University of Vermont, 6Fralin Biomedical Research Institute at VTC

W42. Criminal Justice Involvement as Trauma: The Role of Recidivism and Reentry on Substance Use Trajectories Among Women With Substance Use Disorders
Sienna Strong-Jones1, Derek Kreager2, Jennie Noll1, Samantha Ellner3, Amanda Ferrara4, Miranda Kaye4, Kristina Brant5, Melissa Kusi-Amanfang6, Abenaa Jones1
1Department of Human Development and Family Studies, Pennsylvania State University, 2Department of Sociology and Criminology, Pennsylvania State University, 3Department of Educational Psychology, Counseling, and Special Education College of Education, Pennsylvania State University, 4Survey Research Center, Pennsylvania State University, 5Department of Agricultural Economics, Society, and Education, Pennsylvania State University, 6Department of Psychology, Northwestern University

W43. The Impact of CDC’s Opioid Prescribing Guideline on Racial Disparities in Discontinuation of Opioid Treatment in the United States
Huiru Dong1, Erin Stringfellow1, Mohammad Jalali1
1Harvard Medical School

W44. Association of Medications for Mood/Anxiety Disorders With Fatal and Non-Fatal Opioid Overdose
Nadia Fairbairn1, Alexis Crabtree2, Christian Schutz3, Tae Woo Park4, Eugenia Socias5, Janet Mok6, Zishan Cui6, Lianping Ti5
1University of British Columbia, 2BC Centre for Disease Control, 3Institute of Mental Health, Department of Psychiatry, Faculty of Medicine, University of British Columbia, 4Department of Psychiatry, Boston University School of Medicine, Boston Medical Center, United States of America; Grayken Center for Addiction, Boston Medical Center, United States of America, 5Department of Medicine, University of British Columbia, St. Paul’s Hospital, Vancouver, British Columbia, Canada, 6British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada
W45. Risk Factors for Misuse Versus Abuse of Opioids and Sedatives
Nicole Schow1, Elizabeth Bemis2, Karilynn Rockhill2, Joshua Black1, Richard Dart2
1Rocky Mountain Poison and Drug Safety, 2Rocky Mountain Poison and Drug Center

W46. Examining Drug Overdose Mortality Ratios and Their Intersection With Substance Use Disorder-Related Services Across Diverse Communities in a Segregated Metropolitan Area
Fahimeh Mohebbi1, Rina Ghose2, Amir Masoud Forati3, John Mantsch4
1University of Wisconsin-Milwaukee, 2Department of Geography, University of Wisconsin - Milwaukee, 3University of Wisconsin - Milwaukee, 4Medical College of Wisconsin, Pharmacology and Toxicology

W47. Using Spatial Social Network Analysis to Study the Journey to Overdose Deaths
Amir Masoud Forati1, Rina Ghose2, Fahimeh Mohebbi3, John Mantsch4
1University of Wisconsin - Milwaukee, 2Department of Geography, University of Wisconsin - Milwaukee, 3University of Wisconsin-Milwaukee, 4Medical College of Wisconsin, Pharmacology and Toxicology

W48. The Development of a Conceptual Model to Assess Intersectional Stigma’s Role in Shaping Rural Primary Care Providers’ Decisions to Implement Harm Reduction, Buprenorphine, and HIV Prevention
Phil Marotta1, Kaileigh Backes1, Miryam Baied1, Lindsey Filiatreau1, Rachel Winograd2, Hilary Reno1, Katie Wang3, Robert Heimer3, Cindy McDannold4, Patricia Cavazos1
1Washington University in St. Louis, 2University of Missouri St. Louis, 3Yale University, 4Missouri Primary Care Association

W49. Estimating the Impact of Diverted Buprenorphine on Population Opioid Overdose Incidence Using an Agent-Based Model
Joella Adams1, Michael Duprey1, Sazid Khan1, Jessica Cance1, Donald Rice2, Georgiy Bobashev1
1RTI International, 2Brown University

W50. Perceptions of Overdose Response Hotlines Among a Sample of People in Treatment for Substance Use Disorder
Rachel Gicquelais1, Rachel Chenoweth1, Nora Jacobson1, Caitlin Conway1, Carmen Skarlupka2, Oona Krieg3, Gina Bryan1
1University of Wisconsin - Madison, 2Never Use Alone, 3Brave co-op

W51. The Impact and Evolution of Structural Vulnerabilities Throughout Substance Use Initiation, Treatment, and Recovery: Perspectives From Providers and Women With Opioid Use Disorder
Eric Harrison1, Kristina Brant1, Hobart Cleveland1, Marinda Kaye1, Hannah Apsley1, Emma Skogseth1, Abenaa Jones1
1Pennsylvania State University

W52. They Don’t Care who you are, They’re Only There to Help you: Barriers and Facilitators to Accessing Syringe Service Programs (SSPs) Among People who Inject Drugs (PWID) in Appalachia Ohio
Stacy M. Endres-Dighe1, Ana D. Sucaldito2, Renee McDowell1, Cathy Neal1, Anyssa Wright1, William C. Miller1, Vivian F. Go3, Kathryn E. Lancaster1
1The Ohio State University, 2Wake Forest University, 3University of North Carolina
W53. Socioeconomic Status and HIV Severity Among People With HIV who Inject Drugs in St. Petersburg, Russia
Bulat Idrisov¹, Jenna Van Draanen¹, Sara Lodí², Karsten Lunze³, Simeon Kimmel³, Emily Quinn², Ve Truong³, Elena Blokhina⁴, Natalia Gnatienko⁵, Evgeny Krupitsky⁶, Jeffrey Samet³, Emily Williams¹
¹University of Washington, ²Boston University School of Public Health, ³Boston Medical Center, ⁴Pavlov University, ⁵Boston Medical Center

W54. Frequency of Fentanyl Injection is Associated with Hepatitis C Status: A Cross-Sectional Study
Ahmed Bayoumi¹, Khuloud Aldhaheri¹, Kolla Gillian², Flores Brian³, Kenny Kathleen⁴
¹University of Toronto, ²University of Victoria, ³Unity Health Toronto, ⁴University of Manitoba

W55. Fentanyl Route of Administration and Overdose Risk: A Preliminary Analysis of Baseline Data From a Cohort of Overdose Survivors in San Francisco and Boston
Phillip Coffin¹, Vanessa McMahan¹, Sarah Brennan¹, Mackenzie Robinson¹, Andrew Rolles², Sarah Kosakowski², Miriam Harris³, Alexander Walley⁴
¹San Francisco Department of Public Health, ²Boston Medical Center, ³Boston University, ⁴Boston University School of Medicine

W56. An Observational Study of Medication for Opioid Use Disorder Prescribing Practices During Pregnancy
Camille Cioffi¹, Anne Martinez Acevedo², Menolly Kauffman², Miguel Marino², Kea Parker², Mishka Terplan³, Stephan Linder²
¹University of Oregon, ²Oregon Health and Science University, ³Friends Research Institute

W57. Characterizing Empirically-Derived Sub-Groups of Latinx PWID Living Along the US-Mexico Border for HIV and HCV Prevention
Natasha Ludwig-Barron¹, John Sauceda¹, Jorge Salazar², Jorge Puentes³, Lidia Rodriguez-Garcia¹, Rebeca Ramos⁴, Maria Elena Ramos Rodríguez⁵, Julia Lechuga³
¹Department of Medicine, Division of Prevention Science, University of California, San Francisco, ²Department of Medicine, Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, ³Department of Public Health Sciences, University of Texas, El Paso, ⁴Alliance of Border Collaboratives, ⁵Programa Compañeros, A.C.

W58. Benzodiazepine, Z-Drug, and Sleep Medication Prescriptions in Male and Female People With Opioid Use Disorder and Comorbid Insomnia: An Analysis of Multi-State Insurance Claims
Caitlin Martin¹, Hetal Patel², Joseph Dzierewski³, F. Gerard Moeller¹, Laura Bierut⁴, Richard Grucza⁵, Kevin Xu⁴
¹Virginia Commonwealth University, ²Washington University, ³National Sleep Foundation, ⁴Washington University School of Medicine, ⁵St Louis University School of Medicine

W59. Trauma and Craving Among Those Reentering From the Criminal Justice System With Opioid Use Disorder: Treatment Implications
Michael Fendrich¹, Cindy Dubuque-Gallo², Beth Russell², Crystal Park²
¹Advocate Aurora Research Institute, ²University of Connecticut

W60. Neurofunction and Insomnia Symptoms Among Women in Treatment for Opioid Use Disorder
Augustus White¹, Michelle Eglovitch¹, Anna Beth Parlier-Ahmad¹, Jospeh Dzierewski², F. Gerard Moeller¹, Caitlin Martin¹
¹Virginia Commonwealth University, ²National Sleep Foundation
W61. Absorption of Naloxone in Patients Prescribed Buprenorphine/Naloxone – a Retrospective Analysis
Domenic Ochal\textsuperscript{1}, Tyler Oesterle\textsuperscript{2}
\textsuperscript{1}Mayo Medical School, \textsuperscript{2}Mayo Clinic, Dept. Psychiatry and Psychology

W62. Opioid Use and Treatment Retention Outcomes Among Patients Initiating Methadone Versus Buprenorphine Treatment in Rural Practices
Lisa Khairy\textsuperscript{1}, Leslie Kenefick\textsuperscript{1}, Luke Hall\textsuperscript{1}, Kibeom Kwon\textsuperscript{1}, Nicole Limberg\textsuperscript{1}, Sterling McPherson\textsuperscript{1}, Andre Miguel\textsuperscript{1}
\textsuperscript{1}Elson S. Floyd College of Medicine

W63. Impact of Covid-Related Policy Changes on Retention and Adverse Events Amongst new Methadone Maintenance Intakes
Arthur Robin Williams\textsuperscript{1}, John Rotrosen\textsuperscript{2}, Noa Krawczyk\textsuperscript{3}, Mei-Chen Hu\textsuperscript{4}, Lexa Harpel\textsuperscript{5}, Nicole Aydinoglo\textsuperscript{6}, Magdalena Cerda\textsuperscript{7}, Edward Nunes\textsuperscript{7}
\textsuperscript{1}Columbia University Division on Substance Use Disorders, \textsuperscript{2}Department of Psychiatry, NYU Langone School of Medicine, New York, NY, United States, \textsuperscript{3}NYU Grossman School of Medicine, \textsuperscript{4}Columbia University and NYSPI, \textsuperscript{5}Research Foundation for Mental Hygiene, \textsuperscript{6}Department of Population Health, NYU School of Medicine, \textsuperscript{7}Columbia University and New York State Psychiatric Institute

W64. Nondrug Reward and Recovery From Addiction: Socio-Spatial Contexts, Interindividual Heterogeneity, and Change Over Time
Samuel Stull\textsuperscript{1}, Stephanie Lanza\textsuperscript{2}, David Epstein\textsuperscript{3}
\textsuperscript{1}The Pennsylvania State University, \textsuperscript{2}The Pennsylvania State University, Department of Biobehavioral Health, \textsuperscript{3}NIDA Intramural Research Program

W65. Trends in Buprenorphine Prescribing in a National Network of Community Health Centers
Daniel Hartung\textsuperscript{1}, Robert Voss\textsuperscript{2}, Steffani Bailey\textsuperscript{3}, Nathalie Huguet\textsuperscript{3}, Irina Chamine\textsuperscript{3}, John Muench\textsuperscript{3}
\textsuperscript{1}Oregon State University, \textsuperscript{2}OCHIN, \textsuperscript{3}Oregon Health and Science University

W66. The Dynamics of Craving and Willingness-To-Pay for Drugs and Food in Daily Life
Sergej Grunevski\textsuperscript{1}, Emmanuel Alvarez\textsuperscript{1}, Emma Schweitzer\textsuperscript{1}, Julia Kong\textsuperscript{1}, Sahar Hafezi\textsuperscript{1}, Maelle Guegen\textsuperscript{1}, Anna Konova\textsuperscript{1}
\textsuperscript{1}Department of Psychiatry, UBHC, and Brain Health Institute, Rutgers University – New Brunswick

W67. Pain Catastrophizing Moderates the Relationship Between Chronic Pain and Insomnia Severity in Persons With Opioid Use Disorder
Melanie Baime\textsuperscript{1}, Prem Umang Satyavolu\textsuperscript{1}, Andrew S Huhn\textsuperscript{1}, Jennifer D Ellis\textsuperscript{1}
\textsuperscript{1}Johns Hopkins Bayview Medical Center

W68. Greater Coupling of Pain Intensity and Opioid Craving After Delaying Methadone Dose Among Veterans With Opioid Use Disorder
Robert MacLean\textsuperscript{1}, Suzanne Spinola\textsuperscript{1}, Brian Pittman\textsuperscript{2}, Julia Meyerovich\textsuperscript{1}, Sara Szollosy\textsuperscript{1}, Noah Wolkowicz\textsuperscript{3}, Mehmet Sofuoglu\textsuperscript{4}
\textsuperscript{1}VA Connecticut Healthcare System, \textsuperscript{2}Yale University School of Medicine, \textsuperscript{3}VA Connecticut Healthcare, Yale Medical School, \textsuperscript{4}Yale University
W69. An Intervention to Reduce the Stigma of Substance Use and Criminal Involvement Among Criminal Legal Staff: Feasibility, Acceptability, and Preliminary Effectiveness
Kelly Moore
East Tennessee State University

W70. Gender Differences in Substance Use Treatment Interest
Bailey Pridgen, Andrew Bontemps, Michelle Sisson, Karen Cropsey
The University of Alabama At Birmingham

W71. Adapting to the Fentanyl Epidemic: Rapid Qualitative Observations and Derived Protocol Modifications From the Emergency Department Longitudinal Integrated Care (ED-LINC) Randomized Clinical Trial
Lauren Whiteside, Kayla Lovett, Lawrence Palinkas, Field Craig, Mark McGovern, Caleb Banta-Green, Douglas Zatzick
University of Washington, University of Southern California, University of Texas, El Paso, Stanford University School of Medicine

W72. The Cost Effectiveness of Interim Buprenorphine Treatment Vs. Waitlist Control for Opioid Use Disorder: An Analysis of Three Randomized Trials
Sydney Batchelder, Eric Ross, Kelly Peck, Stacey Sigmon
University of Vermont, University of Vermont Health Network

W73. Effects of Opioid Use Disorder and Withdrawal on Striatal Reward Prediction Errors During Decision-Making
Michael Wesley, Joshua Beckmann, Shanna Babalonis, Joseph Alcorn, Kevin Hatton, Hays Lon, Miranda Ramirez, Craig Rush, William Stoops, Joshua Lile
University of Kentucky, University of Kentucky, College of Medicine, University of Kentucky, College of Arts and Sciences

W74. A Mobile Health Tool to Capture Social Determinants of Health and Their Impact on HIV Treatment Outcomes Among People Who Use Drugs
Caitlin Conway, Ryan Westergaard, Olivia Vjorn, Andrew Genz, Gregory Kirk, Rachel Gicquelais
University of Wisconsin - Madison, Johns Hopkins Bloomberg School of Public Health

W75. Association Between Social Exposure and Substance Use Among Youth in the Legal System
Yang Yang, Danica Knight
Texas Christian University

W76. Open Board

W77. Peer Intervention to Link Overdose Survivors to Treatment (PILOT): Study Protocol of a Multi-Site, Randomized Controlled Trial in the National Institute on Drug Abuse Clinical Trials Network
Carrie Papa, Erin McClure, Louise Haynes, Tim Matheson, Jenna McCauley, Rich Jones, Tricia Lawdahl, Kathleen Brady, Kelly Barth
Medical University of South Carolina, San Francisco Department of Public Health, YouTurn Health, FAVOR Upstate
W78. Nomi™ SMRxT Bottles Track Daily Medication Intake Patterns in Chronic Pain Patients Prescribed Opioids
Christina Merritt1, Sierra Miller1, Jonathan Hommel1, Denise Wilkes1, Kathryn Cunningham1, David Houghton1
1John Sealy School of Medicine University of Texas Medical Branch

W79. Mobile Medication Adherence Platform for Buprenorphine (MAP4BUP): A Phase I Feasibility, Usability, and Efficacy Randomized Clinical Trial
Sterling McPherson1, Crystal Smith1, Luke Hall1, Andre Miguel1, Theresa Bowden2, Abigail Keever1, Alex Schmidt1, Katie Olson3, Nicole Rodin4, Michael McDonell1, John Roll1, Jeff LeBrun5
1Washington State University Elson S. Floyd College of Medicine, 2Washington State University College of Nursing, 3Ideal Option, 4Washington State University College of Pharmaceutical Sciences and Pharmacy, 5Optimize Health

W80. Buprenorphine-Naloxone vs. Extended-Release Naltrexone for Opioid Use Disorder in People With Recent Criminal Legal Involvement: A Secondary Analysis of the X:BOT Randomized Controlled Trial
Dylan Balter1, Lisa Puglisi1, James Dzira2, David Fiellin1, Benjamin Howell1
1Yale University School of Medicine, 2Yale University School of Public Health

W81. Implementation Facilitation Improves Clinician Readiness to Provide Emergency Department-Initiated Buprenorphine in Four Urban Academic Centers
Kathryn Hawk1, Gail D’Onofrio2, Marek Chawarski3, Edouard Coupert2, Ethan Cowan3, Leslie Curry4, Caroline Freiermuth5, Michael Lyons6, Alexandra Murphy7, Patrick O’Connor2, Lynne Richardson3, Richard Rothman8, Lauren Whiteside9, Joseph Williams1, David Fiellin2, E. Jennifer Edelman2
1Yale University School of Medicine, Department of Emergency Medicine, 2Yale University, School of Medicine, 3Ichan School of Medicine at Mount Sinai, Department of Emergency Medicine, 4Yale University, School of Public Health, 5University of Cincinnati, Department of Emergency Medicine, 6University of Cincinnati, College of Medicine, 7Yale University, Department of Emergency Medicine, 8Yale University School of Medicine, Department of Emergency Medicine, 9Yale University School of Medicine, Department of Emergency Medicine, 10University of Washington

W82. Variation in Psychosocial Symptom Change: A Preliminary Examination of Veterans in Early Medication Treatment for Opioid Use Disorder
Noah Wolkowicz1, Mehmet Sofuoglu2, Joao De Aquino3, Robert MacLean4
1VA Connecticut Healthcare, Yale Medical School, 2Yale University, 3Yale University School of Medicine, 4VA Connecticut Healthcare System

W83. Ethical and Methodological Challenges in Studying Discontinuation of Medications for Opioid Use Disorder
Roger Weiss1, Edward Nunes2, Patricia Novo2, Matisyahu Shulman3, Genie Bailey5, Scott Provost1, Sarah Meyers-Ohki3, David Liu4, John Rotrosen7
1McLean Hospital, 2Columbia University and New York State Psychiatric Institute, 3New York University School of Medicine, 4College of Physicians and Surgeons, Columbia University/NYSPI, 5Stanley Street Treatment and Resources, Inc., 6National Institute on Drug Abuse, National Institutes of Health, 7Department of Psychiatry, NYU Langone School of Medicine, New York, NY, United States

W84. Profiles of Risk and Protection Among People who Use Illicit Opioids in NYC: A Latent Class Analysis
Luther Elliott1, Alex S. Bennett2, Joy Scheidell3
1New York University, 2New York University College of Global Public Health, 3University of Central Florida
W85. The Role of Law Enforcement Officers in Overdose Response: Insights From a Qualitative Study With People who Use Drugs and Law Enforcement Officers
Sydney Silverstein1, Tasha Perdue2, Darwin Baluran2, Ejuan Kendrick2, Kaylee Larsen1, Nathaniel Mack2, Russell Hassan2
1Boonshoft School of Medicine Wright State University, 2The Ohio State University

W86. A Care Cascade Analysis of Opioid Use Disorder Services Provided in Jail
Daniel Hoover1, Alicia Feryn1, Melanie Menear2, Lee Eby2, Elizabeth Waddell3
1Oregon Health and Science University, 2Clackamas County Jail, 3OHSU-Portland State University School of Public Health

W87. Community Focused Technical Assistance: A Multifaceted Approach to Address Opioid-Related Overdoses
John Lauckner1, Michelle Lofwall2, Laura Fanucchi2, Christopher Cook1, Sharon Walsh3, Molly Gallivan1, Jordan Kelsch4, Devin Oller2
1University of Kentucky, Substance Use Priority Research Area, 2University of Kentucky, College of Medicine, 3University of Kentucky, 4University of Kentucky Substance Use Research Priority Area (SUPRA)

W88. Factors Associated With Sleep Health Among Community Recruited People who Inject Drugs in Los Angeles, CA and Denver, CO, 2021-22
Avaion Ruth1, Karen Corsi2, Kelsey Simpson3, Patricia Wilkins2, Jesse Goldshear4, Eric Kovalsky2, Dustin Duncan2, Ricky Bluthenthal3
1University of Southern California, 2Department of Psychiatry, University of Colorado Denver School of Medicine, 3University of Southern California, Keck School of Medicine, 4Keck School of Medicine University of Southern California, 5Department of Epidemiology, Mailman School of Public Health, Columbia University

W89. Fentanyl Test Strip Knowledge and Attitudes Among Patients in the Emergency Department who Use Drugs
Megan Reed1, Anne Siegler2, Tracy Esteves Camacho1, Kory London1, Kevin Schaeffer1, Kristin Rising2
1Thomas Jefferson University, 2Independent Researcher

W90. Open Board

W91. Patient Experiences With Buprenorphine Following Discontinuation of Long-Term Opioid Therapy
Jessica Wyse1, Sarah Ono1, Belle Zaccari2, Jennette Lovejoy3, Noah Jacobson2, ayushi gulati2, Tiona Wu4, Taylor levine5, Amie Goerlich2, Travis Lovejoy2
1Oregon Health and Science University, 2VA Portland Health Care System, 3University of Portland, 4VA Potland Health Care System

W92. Primary Care Team Perspectives on Approaches to Engaging Patients in Treatment for Opioid Use Disorder
Elizabeth Austin1, Jessica Chen1, Elena Soyer1, Bulat Idrisov2, Elsa Briggs1, Anna Ratzliff2, Monica Ruiz2, Emily Williams3, Ulrich Koch4
1University of Washington School of Public Health, Department of Health Systems and Population Health, 2University of Washington School of Medicine, Department of Psychiatry, 3George Washington University, Milken Institute School of Public Health, 4George Washington University School of Medicine and Health Sciences, Department of Clinical Research and Leadership

W93. The Relationship between Substance Use and Remote Hiv Testing among Men at Risk for Hiv
Bethany McLeman1, Kathleen Bell1, Kyle Moon1, Chantal Lambert-Harris1, Haiyi Xie1, Lisa Marsch1
1Geisel School of Medicine at Dartmouth College
W94. Intersectional Stigma and Aging Among Older Adults With Opioid Use Disorder
Benjamin Han¹, Mirella Orozco¹, Mari Miyoshi¹, Heidi Doland¹, Alison Moore¹
¹University of California - San Diego

W95. Hopelessness and Impulsivity and Recent Non-Fatal Overdose Among Overdose Survivors who Actively Use Nonprescribed Opioids in San Francisco and Boston
Vanessa McMahan¹, Xochitl Luna Martí¹, Emily Pope¹, Shae Wolfe², Adam Majeski², Gabriela Reed², Alexander Walley², Phillip Coffin¹
¹Center on Substance Use and Health, San Francisco Department of Public Health, ²Grayken Center for Addiction and Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Boston Medical Center and Boston University School of Medicine

W96. Scaling up Opioid Agonist Therapies in Ukraine Before the War: Implementation Factors Related to Disruptions From Legislative Reform and COVID-19
Lynn Madden¹, Roman Ivasiy², Maxim Polonsky³, Scott Farnum⁴, Samy Galvez³, Anna Meteliuk⁵, Daniel J. Bromberg⁶, Frederick Altice³
¹APT Foundation, ²Yale Medical School, ³Yale University School of Medicine, ⁴APT Foundation, Inc., ⁵Alliance for Public Health of Ukraine, ⁶Yale School of Public Health

W97. Open Board

W98. Effects of the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain: A Scoping Review
Katherine Warren¹, Sooyeon Kho², Scott G. Weiner³, Carol Mita¹, Molly Franke¹, Shelly Greenfield⁴
¹Harvard Medical School, ²Brigham and Women's Hospital, ³Brigham and Women's Hospital, Harvard Medical School, ⁴McLean Hospital, Harvard Medical School

W99. Barriers and Facilitators to the Prescription Monitoring Program in Harris County, TX: Preliminary Findings
Alejandro Betancur¹, J. Michael Wilkerson², Niles Zoschke², David Adzrago²
¹The University of Texas Health Science Center At Houston, ²The University of Texas Health Science Center at Houston

W100. Impact of a Brief Educational Intervention on Preferences for Medications for Opioid Use Disorder
Pooja Lagisetty¹, Adrianne Kehne², Stephanie Slat¹, Colin Macleod¹, Amy Bohnert¹
¹University of Michigan, ²Center for Clinical Management and Research, Ann Arbor Veterans Health Administration

W101. Moderate-Vigorous Physical Activity and Opioid Use Status
Elizabeth Lee¹, Andrew Bontemps¹, S. Justin Thomas¹, Karen Gamble¹, Karen Cropsey¹
¹The University of Alabama At Birmingham

W102. What Makes an Emergency Department Peer? Characteristics of Effective Peer Recovery Support Specialists in an Ed-Based Post-Overdose Intervention
Mia Kirk¹, Karla Wagner²
¹University of Nevada, Reno School of Public Health, ²University of Nevada School of Public Health
W103. Feasibility of Ecological Momentary Assessment With People who Inject Drugs: A Pilot Study
Kristina Phillips1, Trent Lalonde2, Michael Phillips3, Catherine Erickson1, Jonathan Lai1, Michael Stein4
1Kaiser Permanente Hawaii, Center for Integrated Health Care Research, 2Colorado Department of Early Childhood, 3University of Hawai’i – Manoa, Office of Public Health Studies, 4Boston University, School of Public Health

W104. Open Board

W105. Exploring the Impact of the COVID-19 Pandemic on MOUD Retention in a Sample of Rural Primary Care Patients
Stacy Calhoun1, Huiying Guo2, Zhe Fei1, Laura-Mae Baldwin3, Allison Ober4, Megan Black2, Sarah Clingan2, Emily Kan1, Chunqing Lin5, Huyen Pham6, Yuhui Zhu6, Larissa Mooney2, Yih-Ing Hser2
1University of California, Los Angeles, 2Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles, 3University of Washington Department of Family Medicine, 4RAND Corporation, 5David Geffen School of Medicine at UCLA, 6Semel Institute - UCLA

W106. Peer Support for Individuals Presenting in Emergency Departments Following Opioid Overdose: Association of Program Implementation With Drug Treatment Initiation and Repeat Overdose
Peter Treitler1, Anna Kline1, Nina Cooperman2, Stephen Crystal1, Kristen Lloyd1, Sujoy Chakravarty1, Joel Cantor1, Cory Morton1, Kristen Powell3
1Rutgers University, 2Rutgers Robert Wood Johnson Medical School, 3Rutgers, The State University of New Jersey

W107. Access to Tablet Injectable Opioid Agonist Therapy in Rural and Smaller Urban Settings in British Columbia: A Qualitative Study
Geoff Bardwell1, Jeanette Bowles2, Manal Mansoor2, Dan Werb3, Thomas Kerr2
1University of Waterloo, 2British Columbia Centre on Substance Use, 3University of California San Diego

W108. Expanding Medication for Opioid Use Disorder (MOUD) Treatment in Rural Health Care Systems: A Case Example
Christopher Cook1, Lisa Childress2, Stacy Caudill2, Wes Romanello2, Debbie Duckworth3, Jennifer Miles1, Sharon Walsh4, Laura Fanucchi4, Devin Oller4, Michelle Lofwall4
1University of Kentucky, Substance Use Priority Research Area, 2King’s Daughters Medical Center, 3University of Kentucky, Specialty Pharmacy and Infusion Services, 4University of Kentucky, College of Medicine

W109. Barriers and Facilitators to Expanding Buprenorphine Treatment for Opioid Use Disorder in Jail Settings
Jordan Kelsch1, Margaret McGladrey2, Carrie Oser3, Laura Fanucchi4, Sharon Walsh5, Marisa Booty1, Michelle Lofwall5
1University of Kentucky Substance Use Research Priority Area (SUPRA), 2University of South Florida, Department of Mental Health Law and Policy, College of Behavioral and Community Sciences, 3University of Kentucky, Dept. of Sociology, College of Arts and Science, Center on Drug and Alcohol Research, 4University of Kentucky, Dept. of Internal Medicine, Center on Drug and Alcohol Research, 5University of Kentucky, Dept. of Behavioral Science, Center on Drug and Alcohol Research
W110. Associations Between Receipt of Government Assistance and Past-Year Substance Use Treatment Utilization Among People With Alcohol or Drug Use Disorders in the United States, 2015-2019
Sarah Gutkind1, Morgan Philbin2, Pia Mauro1
1Columbia University, 2University of California San Francisco

W111. Craving Persistence Over 3 Months: An Early and Predictive Marker of Addiction?
Emmanuelle Baillet1, Cassandre Romao1, Fuschia Serre2, Sarah Moriceau2, Marc Auriacombe1
1University of Bordeaux, 2Universite de Bordeaux

W112. Drug Checking in the Fentanyl Era: Awareness, Interest, and Utilization Among People who Inject Drugs in San Diego County, California
Katie Bailey1, Annick Borquez2, Daniela Abramovitz2, Irina Artamanova2, Peter Davidson2, Tara Stamos-Buesig3, Carlos Vera2, Thomas Patterson2, Jaime Arredondo4, Jessica Kattan5, Sayone Thihalolipavan5, Steffanie Strathdee2
1University of California San Diego and San Diego State University, 2University of California San Diego, 3Harm Reduction Coalition of San Diego, 4British Columbia Centre on Substance Use, 5County of San Diego Health and Human Services

W113. Psychosocial Functioning and Health Service Utilization Among Psychiatric Subgroups in a Substance-Using Homeless Population: A Cluster Analysis of the at Home/Chez Soi Study in Vancouver, BC
Thomas Wen-Chi Chao1, Suky Martinez2, Jane J. Kim1, Christian G. Schütz1
1University of British Columbia, 2Columbia University Vagelos College of Physicians and Surgeons

W114. Transcultural Translation and Adaptation of the Universal Treatment Curriculum for Fostering Professional Treatment Workforce for Substance Use Disorders in Taiwan
An-Nie Chung1, Li-Ching Wang1, Yu-Chu Ella Chung1, Pei-Hsuan Lin1, Kai-Hsiang Kang1, Ya-Wen Yang1, Yi-Ya Lai1, Yen-Feng Lin1, Sheng-Chang Wang1, Wei J. Chen2
1Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Miaoli County, Taiwan, 2Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Miaoli County, Taiwan; Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan; Department of Psychiatry, College of Medicine and National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan

W115. Prevalence of Cannabis, Nicotine, and Alcohol Use and Associations With Psychological and Diabetes Distress Among Young Adults With Type 1 Diabetes
Enzo Plaitano1, Catherine Stanger1
1Dartmouth College

W116. Emotion Dysregulation Fully Mediates the Relationship between Stress and Impulsivity in Inpatients With Co-Occurring Substance Use and Mental Health Disorders
Stefanie Todesco1, Thomas Wen-Chi Chao1, Chris Schütz2
1University of British Columbia
W117. Dynamic Modeling on the Health Outcomes for People With First-Time Offense of Different Illicit Drugs in Taiwan With Implications for Policy
Chi-Ya Chen1, Shang-Chi Wu1, Lian-Yu Chen2, Hsien-Ho Lin3, Yu-Chi Tung4, Wei J. Chen5
1Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan, 2Taipei City Hospital, 3National Taiwan University, 4Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan and 5Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan

W118. Co-Use of Harm Reduction and Addiction Treatment Services Associated With Decreased Non-Fatal Overdose in Catalonia
Todd Korthuis1, Ibrahim Sonmez2, Xavier Majó3, Albert Espelt4, Mercè Meroño5, Francina Fonseca6, Joan Colom2, Jordi Casabona7, Cinta Folch7, REDAN Study Group8
1Oregon Health and Science University, Portland, OR USA, 2CEEISCAT, 3Sub-direcció General de Drogodependències, Agència de Salut Pública de Catalunya, Barcelona, Spain, 4Departament de Psicobiologia i Metodologia en Ciències de la Salut, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain, 5Fundació Àmbit Prevenció, Barcelona, Spain, 6Institut de Neuropsiquiatria i Addiccions (INAD)- Hospital del Mar Medical Research Institute-IMIM, Barcelona, Spain / Medicine and Health Sciences Department. Universitat Pompeu Fabra, Barcelona, Spain, 7CEEISCAT; Centre d’Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Departament de Salut, Generalitat de Catalunya, Badalona, Spain; Institut d’Investigació Germans Trias i Pujol (IGTP), Badalona, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, 8-

W119. Associations Between Kratom-Related State Policy Environments and Kratom Use in a Nationally Representative Population in the United States
Mance Buttram1, Matthew Ellis2, Joshua Black3
1University of Arkansas, 2Washington University in St. Louis, 3Rocky Mountain Poison and Drug Safety

W120. Adaptation of a Digital Intervention to Reduce Substance Use and Increase Contraceptive Access Among Women Involved in Criminal Legal Systems
Melissa Slavin1, Chermaine Black4
1Columbia University School of Social Work

W121. Earlier Substance Use and Differential Rates by Substance Class for Youth With Combined Externalizing Disorders and Family History of Substance Use Disorders
Michael Smoker1, Olivia Murray1, Michael Peck1, Leslie Hulvershorn1
1Indiana University School of Medicine

W122. Diabetes Management in Patients With Substance Use Disorder Served in a Network of Federally Qualified Health Centers in Florida: A Retrospective Analysis Using EHR Data
Viviana Horigian1, Renae Schmidt1, Rui Duan2, Daniel Parras2, Katherine Chung-Bridges2, Jacob Batycki3, Kevin Espinoza1, Peyman Taghioff1, Sophia Gonzalez2, Carly Davis1, Daniel Feaster1
1Miller School of Medicine, University of Miami, 2Health Choice Network, 3Ross School of Medicine
W123. Enhancing Integration of Substance Use Research Among BIRCWH Scholars: The BIRCWH Scholars Innovation Program (BSIP) Needs Assessment
Karen Hartwell¹, Jacqueline McGinty², Constance Guille², Aimee McRae-Clark¹, Amanda Wagner², Jenna McCauley², Kathleen Brady²
¹Medical University of South Carolina; Ralph H. Johnson VAMC, ²Medical University of South Carolina

W124. A Preliminary Evaluation of the Cost-Effectiveness of Long-Term Post-Treatment Peer Recovery Support Services in the United States
Sierra Castedo de Martell¹, Margaret Brannan Moore², Hannah Wang², H. Shelton Brown, III²
¹JEAP Initiative, ²UTHealth School of Public Health

W125. California’s Drug Medi-Cal Organized Delivery System Implementation: Substance Use Services Evolution From 2017-2021, Key Lessons Learned and Systems Improvements From the 1115 Demonstration Project
Rama Khalsa¹, Vandana Joshi², Samantha Fusselman³, Patrick Zarate³
¹UCLA, ²University of California - Los Angeles, ³Behavioral Health Concepts

W126. Understanding Cannabis Use Among Teens who Vape Nicotine
Danielle Davis¹, Ran Wu¹, Krysten Bold¹, Grace Kong¹, Meghan Morean¹, Suchitra Krishnan-Sarin¹
¹Yale University School of Medicine

W127. Supportive Services Program Utilization Among Substance Use Treatment Clients Using Big Data
Vandana Joshi¹, Tina Kim², Rama Khalsa¹, Brittany Bass¹
¹University of California - Los Angeles, ²Los Angeles County, Dept of Public Health, Substance Abuse Prevention and Control

W128. Using an Environmental Scan to Organize Substance Use Prevention Resources to Address the Social Determinants of Health
Holly Hagle¹, Cara Alexander², Ingrid Donato², Thia Walker², Rachel Witmer³, Rory McKeown³
¹UMKC, ²SAMHSA, CSAP, ³UMKC, PTTC

W129. Avoidance of Racial Trauma Exposure and Concurrent Substance Use Among Racial/Ethnic Minoritized Young Adults
Kaytryn Campbell¹, Devin Banks², Kari Thompson³, Kathryn Howell³
¹University of Missouri - St. Louis, ²University of Missouri--St. Louis, ³University of Memphis
W130. Illicit Drug Use in Adolescents Versus Adults Among Those With Use of Other Psychoactive Substance or Depressive Symptoms: A Conditional Prevalence Analysis of the 2014 and 2018 National Survey of Substance Use in Taiwan
1Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan, 2Department of Addiction Psychiatry and Kunming Prevention and Control Center, Taipei City Hospital, Taipei, Taiwan, 3School of Big Data Management, Soochow University, Taipei, Taiwan, 4Department of Psychiatry, College of Medicine, National Taiwan University Hospital and School of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 5Department of Health Care and Management, Chung Shan Medical University, Taichung, Taiwan, 6Department of Public Health, College of Medicine, Tzu Chi University, Hualien, Taiwan, 7Institute of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan, 8Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan

W131. Polygenic Risk for Alcohol, Cannabis, and Opioid Use Disorder as Predictors of Age of Initiation in a Community Sample
David Sosnowski, Jill Rabinowitz, Kenneth Feder, Nicholas Ialongo, Brion Maher
1Johns Hopkins Bloomberg School of Public Health

Danielle Smith, Pete Driezen, Shannon Gravely, Nicolas Schlienz, David Hammond, Andrew Hyland, Richard O’Connor, Geoffrey Fong, Mary Thompson, Karin Kasza
1Roswell Park Comprehensive Cancer Center, 2University of Waterloo

W133. Polysubstance Use Trends in a Large Urine Drug Testing (UDT) Database: A Latent Class Analysis
Barrett Bolin, Penn Whitley, Eric Dawson, Kelly Olson, Steven Passik, Angela Huskey
1Millennium Health, LLC

W134. Pandemic Era Changes in Drug Use and Harm Reduction Behavior Among People who Use Drugs in Rural Illinois
Alex Rains, Ellen Almirol, Erin Augustine, Kyle Miller, Elizabeth Salisbury-Afshar, Wiley Jenkins, Mai Pho
1University of Chicago, Pritzker School of Medicine, 2The Chicago Center for HIV Elimination, University of Chicago, Chicago, IL, 3Department of Population Science and Policy, SIU School of Medicine, 4Departments of Family Medicine and Community Health and Population Health Sciences, University of Wisconsin School of Medicine and Public Health, 5Department of Medicine, University of Chicago

W135. Prevalence of Polysubstance Use Diagnoses in Electronic Health Records Data for Patients Hospitalized With Opioid Use Disorder or Opioid Poisoning at six NYC Public Hospitals
Carla King, Yasna Rostam Abadi, Noa Appleton, Medha Mazumdar, Jasmine Fernando, Adetayo Fawole, Roopa Kalyanaraman Marcello, Caroline Cooke, Johanna Dolle, Charles Barron, Jennifer McNeely, Yasna Rostam Abadi
1NYU Grossman School of Medicine, 2NYC Health + Hospitals, 3NYU School of Medicine
W136. Open Board

W137. Prep Experience and Willingness in Substance-Using MSM in Higher Incidence Southern U.S. Cities: NIDA Clinical Trials Network Study
Susan Tross1, Tanja Laschober2, Margaret Paschen-Wolff3, Melissa Ertl4, C. Mindy Nelson5, Lynette Wright6, Daniel Feaster5, Colby Hankey7, David Meche8, Chloe Lancaster8, Josh Fegley9, Mauda Monger11, Christina Woodhouse12, David Forrest5, Mary Hatch2
1Columbia University Irving Medical Center/NYS Psychiatric Institute, 2University of Washington, Addictions, Drug and Alcohol Institute, 3Columbia University Medical Center, 4Columbia University and New York State Psychiatric Institute, 5University of Miami Miller School of Medicine, 6University of Washington Alcohol and Drug Abuse Institute, 7Aspire Health Partners, 8Louisiana State University School of Social Work, 9University of South Florida, 10Tulane University School of Social Work, 11My Brother's Keeper Inc., 12Jasmyn Inc.

Mary Hatch1, Tanja Laschober2, Margaret Paschen-Wolff3, C. Mindy Nelson4, Melissa Ertl5, Lynette Wright2, Daniel Feaster4, Susan Tross5
1University of Washington Addictions, Drug and Alcohol Institute, Department of Psychiatry and Behavioral Sciences, Seattle, WA, 2University of Washington, Addictions, Drug and Alcohol Institute, Department of Psychiatry and Behavioral Sciences, 3Division on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center at New York State Psychiatric Institute, New York, New York, 4Department of Public Health Sciences, University of Miami Miller School of Medicine, 5HIV Center for Clinical and Behavioral Studies, Division of Gender, Sexuality, and Health, Department of Psychiatry, New York State Psychiatric Institute and Columbia University, New York, New York

W139. Childhood Aggression and Adolescent Substance Use Initiation
Nora Satybaldiyeva1, Erin Delker1, Gretchen Bandoli1
1UC San Diego

W140. Substance Use in Pregnancy is Associated With Attention Deficit Hyperactivity Disorder in Childhood: Findings From the Adolescent Brain Cognitive Development Study
Jennie Ryan1, Philip Veliz2
1Thomas Jefferson University, 2Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing

W141. Positive Methamphetamine Urinalysis Result During Treatment Intake is Not Associated With Worst Treatment Outcomes Amongst Opioid Users Initiating Medication-Assisted Opioid Treatment in Rural Communities
Leslie Kenefick1, Lisa Khairy1, Luke Hall1, Nicole Limberg1, Kibeom Kwon1, Sterling McPherson1, Andre Miguel1
1Elson S. Floyd College of Medicine

W142. Attachment Insecurity Predicts Poly-Substance use in Individuals With Opioid Use Disorder Reporting Loneliness
Matthew Snyder1, Lisham Ashrafioun2, Tracy Stecker3, Nicholas Allan4, Jonathan Umansky5
1Syracuse University, 2University of Rochester, 3VA Center of Excellence for Suicide Prevention; Medical University of South Carolina, 4Department of Psychiatry and Behavioral Health, Ohio State University, 5University of Rochester Rochester, NY
W143. Habitual Use of Tobacco and Alcohol on Tendency of Depression and Anxiety Evidence from 27,942 Taiwan Biobank Participants
Shaw-Ji Chen  
1Taitung MacKay Memorial Hospital

W144. Association of Opioid Analgesics, Benzodiazepines, Gabapentinoids, and Opioid Agonist Treatment With Mortality Among Individuals With Opioid Dependence
Chrianna Bharat1, Natasa Gisev2, Sebastiano Barbieri2, Timothy Dobbins3, Sarah Larney4, Luke Buizen1, Louisa Degenhardt1  
1National Drug and Alcohol Research Centre, 2Centre for Big Data Research in Health, UNSW Sydney, Sydney, Australia, 3School of Population Health, UNSW Sydney, Sydney, Australia, 4Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) and Department of Family Medicine and Emergency Medicine, Université de Montréal

W145. Rates of Medication Prescription, Mental Health Disorder, and HCV Diagnoses Among Patients With Comorbid Alcohol and Opioid Use Disorder in Rural Primary Care Clinics
Emily Kan1, Laura-Mae Baldwin2, Larissa Mooney3, Andrew Saxon4, Yuhui Zhu5, Yih-Ing Hser6  
1University of California, Los Angeles, 2University of Washington, 3Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles, 4Veterans Affairs Puget Sound Healthcare System, 5Semel Institute - UCLA, 6UCLA Integrated Substance Abuse Programs

W146. Is Abstinence From Alcohol and Smoking Associated With Better Mood Among People With HIV?
Christina Freibott1, Breanne Biondi1, Sowmya Rao1, Elena Blokhina1, Greg Patts1, Julienne Dugas1, Sally Bendiks1, Evgeny Krupitsky4, Natalie Chichetto5, Jeffrey Samet6, Matthew Freiberg7, Michael Stein1, Hilary Tindle7  
1Boston University School of Public Health, 2First Pavlov State Medical University, 3Boston Medical Center, 4V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, 5University of Florida - Department of Epidemiology, 6Boston University School of Medicine, 7Vanderbilt University Medical Center

W147. Neural and Behavioral Habituation to Sad Infant Stimuli in Mothers who Use Substances
Li Yan McCurdy1, Sarah Yip1, Patrick Worhunsky1, Sohye Kim2, Lane Strathearn3, Marc Potenza1, Linda Mayes1, Helena Rutherford1  
1Yale University School of Medicine, 2University of Massachusetts Medical School, 3University of Iowa, Stead Family Department of Pediatrics

W148. Development of Text Message-Based Intervention Content for People who Inject Drugs: Opportunities and Challenges
Ian Aronson1, Alex S. Bennett2, Selena A. Gilles3, Mary-Andrée Ardouin-Guerrier4, Juan Esteban Baus4, Brent Gibson5  
1New York University, 2New York University College of Global Public Health, 3NYU Rory Meyers College of Nursing, 4NYU School of Global Public Health, 5Community Research
W149. Motives and Experiences of Psychedelic and Cannabis Co-Use Among Emerging Adult Cannabis Users: A Qualitative Analysis
Bridgid Conn1, Alisha Osornio2, Meagan Suen2, Susie Choi2, Omolola Odejimi2, Janna Ataiants3, Ekaterina Fedorova3, Stephen E. Lankenau3, Carolyn F. Wong2
1Children’s Hospital Los Angeles and University of Southern California, 2Children’s Hospital Los Angeles, 3Drexel University

W150. Effects of Target Self-Selection in an App-Based Contingency Management Intervention to Reduce Substance Use
Jesse Fletcher1, Win Turner2, Jody Kamon2, Laura Monico3, Maxine Stitzer3, Shannon Gwin Mitchell3
1Friends Research Institute, Inc., 2Center for Behavioral Health Integration, 3Friends Research Institute

W151. Heroin Use, Non-Medical Prescription Opioid Use, and Injection Drug Use among Urban High School Students Across the US
Himani Byregowda1, Terrinieka Powell1, Xinzi Wang1, Sabriya Linton1, Renee Johnson1
1Johns Hopkins Bloomberg School of Public Health

W152. Drug Use as a Risk Factor for Mortality From HIV, Cirrhosis, and Liver Cancer Among People 15-49 Years old in Uzbekistan
Sergey Soshnikov1, Azizbek Botaev2
1Frankfurt University of Applied Sciences, 2Human Research and Development Center “INSON”

W153. Establishing and Engaging Community Partner Boards That Generate the Research Ideas
Tess Drazdowski1, Patrick Hibbard1, Michelle Cruz1, JEAP Community Boards1, JEAP Initiative Investigators1
1Oregon Social Learning Center

W154. Peer Recovery Center of Excellence Needs Assessment of Minority AIDS Initiative Grantees’ Peer Worker Training Needs
Michelle Teti1, Laurie Krom2, Adam Viera2, Shannon Roberts2, Tanesha Burley2, Lena Marceno3
1University of Missouri, 2University of Missouri- Kansas City, 3Altarum Institute

W155. Preparing the Addiction Workforce to Practice Informed Eclecticism Through Integration of Motivational Interviewing and Cognitive-Behavioral Therapy
Bryan Hartzler1, Alanna Feltner1
1University of Washington

W156. HIV Prevention Intervention Delivery via Facebook With Rural Appalachian Women who Use Drugs: Risk-Related Outcomes During Community Re-Entry Following Incarceration
Megan Dickson1, Erika Pike1, Michele Staton2
1University of Kentucky, 2University of Kentucky, College of Medicine

W157. Identifying Common Drug Abuse Products in Polysubstance and Serious Adverse Events
Paula Bernander1, Gabrielle Bau1, Karilynn Rockhill1, Jennifer Jewell1, Matthew Ellis2, Richard Dart1, Joshua Black1, Joshua Black3
1Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, CO, USA, 2Washington University in St. Louis, 3Rocky Mountain Poison and Drug Safety
W158. A Systematic Mapping Review of Treatment for Persons who Use Drugs and Alcohol With Histories of Violence: Gaps in Treatment and Future Directors for Research
Sara Beeler¹, Olivia Gerrish³, Benjamin Aldred²
¹Jane Addams College of Social Work, UIC, ²University Library, UIC

W159. The Use of LSD by Major Depression Status in the U.S.: 2008-2019 Time Trends and Sociodemographic Associations
Claire Walsh¹, Lauren Gorfinkel², Dvora Shmulewitz³, Deborah Hasin³
¹New York State Psychiatric Institute, ²The University of British Columbia, ³Columbia University

W160. Associations Between Harm Reduction Strategy Use and Acute Psychedelic Effects in Spanish Speakers who Used LSD or Psilocybin
Rafael Lancelotta², Christopher Timmerman², Ana Maria Ortiz Bernal³, Sandeep Nayak⁴, Nathan D. Sepeda⁴, Aki Nikolaidis⁵, Roland R. Griffiths⁶, Alan K. Davis⁶
¹The Ohio State University, ²Imperial College, ³University of Wisconsin-Madison, ⁴Johns Hopkins University, ⁵Child Mind Institute, ⁶Ohio State University

W161. Differing Approaches to Investigating the Therapeutic Efficacy of Psilocybin Across Diverse Indications
Ryan Lanier¹, Michael Bogenschutz², Emmanuelle Schindler³, Benjamin Kelmendi⁴, Caitlyn Durgin⁵, Judy Ashworth⁵
¹Pinney Associates, ²New York University Grossman School of Medicine, New York, NY, USA, ³VA Connecticut Healthcare System, West Haven, CT, USA, ⁴Yale School of Medicine, New Haven, CT, USA, ⁵Pinney Associates, Inc., Bethesda, MD

W162. Psychiatrists’ Personal Use and Social Proximity to Psychedelics Predicts Attitudes Towards Drugs and Drug Users
Adam Levin¹, Paul Nagib¹, Alan K. Davis²
¹Ohio State University, College of Medicine, ²Ohio State University

W163. Hyperarousal/Sleep Disturbance and Inability to Discontinue Chronic Hypnotic Use
Timothy Roehrs¹, Gail Koshorek¹, Thomas Roth¹
¹Henry Ford Health System

W164. Pregnancy and Childbirth in Relation to Receiving the Deferred Prosecution for Amphetamine-Type Substance-Involved Female Offenders in Taiwan
Chuan-Yu Chen¹, Tan-Wen Hsieh², Rosetta Siew³, Wenmay Rei³, Sheng-Chang Wang²
¹National Yang Ming Chiao Tung University, ²National Health Research Institutes

W165. Prevalence, Geographic Variation and Racial/Ethnic Disparities in Methamphetamine Associated Heart Failure Among Veterans
Veena Manja¹, Cheng Chen², Alex Sandhu³, Steven Asch⁴, Susan Frayne⁴, Mark McGovern², Paul Heidenreich⁴
¹Center for Innovation to Implementation, VA Palo Alto Health Care System; Stanford University, ²Center for Innovation to Implementation, VA Palo Alto Health Care Services, ³Stanford University, ⁴Center for Innovation to Implementation, VA Palo Alto Health Care Services; Stanford University
W166. A Pilot Study of 16-Week Intensive Outpatient Treatment for Gay and Bisexual Men With Methamphetamine Use Disorder in Taiwan
Yen-Chun Kou¹, Han-Ting Wei², Yu-Hsiung Chen¹, Chao-Hui Lee³, Sheng-Chang Wang⁴
¹Department of Psychiatry, Linsen, Chinese Medicine, and Kunming Branch, Taipei City Hospital, Taiwan, ²Kunming Prevention and Control Center, Taipei City Hospital, Taiwan, ³Blossom Clinic of Psychosomatic Medicine, Taiwan, ⁴National Health Research Institutes

W167. Hub Disruption in HIV Disease and Cocaine Use Disorder.
Kareem Al-Khalil¹, Ryan Bell², Sheri Towe², Jessica Cohen³, Syam Gadde², Shana Hall², Christina Meade²
¹Duke University, ²Duke University School of Medicine, ³University of North Carolina at Chapel Hill

W168. Open Board

W169. Co-Occurrence of Gaming Disorder and Drug Dependence in People who Use Stimulants During the Era of COVID-19 Pandemic in Taiwan
Tony Szu-Hsien Lee¹, Ming-Chyi Huang², Lian-Yu Chen², Kuen-Hong Wu³, Su-Chen Fang⁴, Cheng-Yi Huang⁵, Chun Lin², Chuan-Hsi Chen⁶, Lien-Wen Su⁷, Yang-Lin Lin³, Yi-Jia Wu², Chia-Chun Hung⁵
¹National Taiwan Normal University, ²Taipei City Hospital, ³Taoyuan Psychiatric Center, ⁴Mackay Medical College, ⁵Bali Psychiatric Center, ⁶National Taipei University, ⁷Taipei Medical University-Shuang Ho Hospital
<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calihan, Jessica</td>
<td>80</td>
</tr>
<tr>
<td>Campbell, Kaytryn</td>
<td>133</td>
</tr>
<tr>
<td>Carbonaro, Theresa</td>
<td>111</td>
</tr>
<tr>
<td>Carlon, Hannah</td>
<td>69</td>
</tr>
<tr>
<td>Carreiro, Stephanie</td>
<td>78</td>
</tr>
<tr>
<td>Carrico, Adam</td>
<td>50</td>
</tr>
<tr>
<td>Carter, Jordan</td>
<td>58, 94</td>
</tr>
<tr>
<td>Castillo, Felipe</td>
<td>61</td>
</tr>
<tr>
<td>Cavazos, Patricia</td>
<td>93</td>
</tr>
<tr>
<td>Cazares, Leticia</td>
<td>73</td>
</tr>
<tr>
<td>Cerdà, Magdalena</td>
<td>21</td>
</tr>
<tr>
<td>Chai, Peter</td>
<td>77</td>
</tr>
<tr>
<td>Chandler, Corinne</td>
<td>115</td>
</tr>
<tr>
<td>Chang, Andy</td>
<td>77</td>
</tr>
<tr>
<td>Chao, Thomas Wen-Chi</td>
<td>131</td>
</tr>
<tr>
<td>Charron, Elizabeth</td>
<td>102</td>
</tr>
<tr>
<td>Chatterjee, Avik</td>
<td>66</td>
</tr>
<tr>
<td>Chattopadhyay, Ankita</td>
<td>89</td>
</tr>
<tr>
<td>Chen, Catherine</td>
<td>84</td>
</tr>
<tr>
<td>Chen, Chi-Ya</td>
<td>132</td>
</tr>
<tr>
<td>Chen, Chuan-Yu</td>
<td>138</td>
</tr>
<tr>
<td>Chen, Lian-Yu</td>
<td>95</td>
</tr>
<tr>
<td>Chen, Shaw-Ji</td>
<td>136</td>
</tr>
<tr>
<td>Chen, Tianzhen</td>
<td>91</td>
</tr>
<tr>
<td>Chen, Wei J.</td>
<td>101</td>
</tr>
<tr>
<td>Cheng, Hui</td>
<td>99</td>
</tr>
<tr>
<td>Chilcoat, Howard</td>
<td>24</td>
</tr>
<tr>
<td>Christine, Paul</td>
<td>60</td>
</tr>
<tr>
<td>Chung, An-Nie</td>
<td>131</td>
</tr>
<tr>
<td>Chung, Yu-Chu</td>
<td>93</td>
</tr>
<tr>
<td>Gioffi, Camille</td>
<td>124</td>
</tr>
<tr>
<td>Claborn, Kasey</td>
<td>35</td>
</tr>
<tr>
<td>Clingan, Sarah</td>
<td>72</td>
</tr>
<tr>
<td>Cloutier, Renee</td>
<td>20</td>
</tr>
<tr>
<td>Cochran, Gerald</td>
<td>105</td>
</tr>
<tr>
<td>Coffin, Phillip</td>
<td>43, 124</td>
</tr>
<tr>
<td>Colledge-Frisby, Samantha</td>
<td>88</td>
</tr>
<tr>
<td>Coll, Neasa</td>
<td>92</td>
</tr>
<tr>
<td>Comer, Sandra</td>
<td>30, 49</td>
</tr>
<tr>
<td>Conn, Bridgid</td>
<td>137</td>
</tr>
<tr>
<td>Conner, Brad</td>
<td>32</td>
</tr>
<tr>
<td>Conway, Caitlin</td>
<td>126</td>
</tr>
<tr>
<td>Cook, Christopher</td>
<td>130</td>
</tr>
<tr>
<td>Cook, Robert</td>
<td>56</td>
</tr>
<tr>
<td>Cooper, Clinton</td>
<td>90</td>
</tr>
<tr>
<td>Cope, Lora</td>
<td>96</td>
</tr>
<tr>
<td>Copenhagen, Michael</td>
<td>104</td>
</tr>
<tr>
<td>Cordoba-Grueso, Whitney</td>
<td>56</td>
</tr>
<tr>
<td>Coughlin, Lara</td>
<td>82</td>
</tr>
<tr>
<td>Craft, William</td>
<td>65</td>
</tr>
<tr>
<td>Crane, Nata尼亚</td>
<td>80</td>
</tr>
<tr>
<td>Crimmins, Lauren</td>
<td>63</td>
</tr>
<tr>
<td>Cropsey, Karen</td>
<td>90</td>
</tr>
<tr>
<td>Crowley, Christina</td>
<td>87</td>
</tr>
<tr>
<td>Cruz, Rick</td>
<td>19</td>
</tr>
<tr>
<td>Cservenka, Anita</td>
<td>81</td>
</tr>
<tr>
<td>Cunningham, Kathryn</td>
<td>40, 41</td>
</tr>
<tr>
<td>Curtis, Brenda</td>
<td>38, 39</td>
</tr>
<tr>
<td>Cyr, Kevin</td>
<td>108</td>
</tr>
<tr>
<td>Daniulaityte, Raminta</td>
<td>69</td>
</tr>
<tr>
<td>Datta, Abhishek</td>
<td>34</td>
</tr>
<tr>
<td>Davis, Alan</td>
<td>116</td>
</tr>
<tr>
<td>Davis, Chrysanthia</td>
<td>105</td>
</tr>
<tr>
<td>Davis, Danielle</td>
<td>37, 133</td>
</tr>
<tr>
<td>DeGennhardt, Louisa</td>
<td>106</td>
</tr>
<tr>
<td>DeLucia, Alexandra</td>
<td>26</td>
</tr>
<tr>
<td>de Martell, Sierra Castedo</td>
<td>133</td>
</tr>
<tr>
<td>Denis, Cecile</td>
<td>105</td>
</tr>
<tr>
<td>Denson, Rebecca</td>
<td>120</td>
</tr>
<tr>
<td>Derminassian, Andrew</td>
<td>97</td>
</tr>
<tr>
<td>DeVeauh-Geiss, Angela</td>
<td>82</td>
</tr>
<tr>
<td>Devi, Lakshmi</td>
<td>44</td>
</tr>
<tr>
<td>Dewey, Jodie</td>
<td>66</td>
</tr>
<tr>
<td>Dewey, William</td>
<td>17</td>
</tr>
<tr>
<td>Dickson, Megan</td>
<td>137</td>
</tr>
<tr>
<td>Diggs, Bria-Necole</td>
<td>56</td>
</tr>
<tr>
<td>Dong, Huiru</td>
<td>122</td>
</tr>
<tr>
<td>Drazdowski, Tess</td>
<td>137</td>
</tr>
<tr>
<td>Driezen, Peter</td>
<td>72</td>
</tr>
<tr>
<td>Dugosh, Karen</td>
<td>85</td>
</tr>
<tr>
<td>Duncan, Alexandra</td>
<td>38</td>
</tr>
<tr>
<td>Dunn, Kelly</td>
<td>41, 42, 46</td>
</tr>
<tr>
<td>Durgin, Caitlyn</td>
<td>62</td>
</tr>
<tr>
<td>Dwoskin, Linda</td>
<td>42</td>
</tr>
<tr>
<td>Dwyer, Candice</td>
<td>72</td>
</tr>
<tr>
<td>Eaton, Ellen</td>
<td>113</td>
</tr>
<tr>
<td>Ebrahami, Chantal</td>
<td>117</td>
</tr>
<tr>
<td>Eggert, Kathryn</td>
<td>64</td>
</tr>
<tr>
<td>Eglovitch, Michelle</td>
<td>89</td>
</tr>
<tr>
<td>Eisenstein, Toby</td>
<td>17</td>
</tr>
<tr>
<td>Ekhtiari, Hamed</td>
<td>44, 45, 62</td>
</tr>
<tr>
<td>Elbaz, Hosam</td>
<td>56</td>
</tr>
<tr>
<td>Elliott, Luther</td>
<td>127</td>
</tr>
<tr>
<td>Ellis, Jennifer</td>
<td>111</td>
</tr>
<tr>
<td>Ellis, Robyn</td>
<td>82</td>
</tr>
<tr>
<td>Ely, Alice</td>
<td>96</td>
</tr>
<tr>
<td>Endres-Dighe, Stacy M.</td>
<td>123</td>
</tr>
<tr>
<td>Estad, Angela</td>
<td>71</td>
</tr>
<tr>
<td>Evans, Rachel</td>
<td>21</td>
</tr>
<tr>
<td>Evins, Anne Eden</td>
<td>15</td>
</tr>
<tr>
<td>Evonko, Christopher</td>
<td>76</td>
</tr>
<tr>
<td>Fahey, Margaret</td>
<td>33</td>
</tr>
<tr>
<td>Fairbairn, Nadia</td>
<td>122</td>
</tr>
<tr>
<td>Fairman, Brian</td>
<td>58</td>
</tr>
<tr>
<td>Fallise, Alyssa</td>
<td>86</td>
</tr>
<tr>
<td>Falls, Zackary</td>
<td>114</td>
</tr>
<tr>
<td>Fanucci, Laura</td>
<td>53, 54</td>
</tr>
<tr>
<td>Feaster, Daniel</td>
<td>53, 116</td>
</tr>
<tr>
<td>Feder, Kenneth</td>
<td>93</td>
</tr>
<tr>
<td>Feeley, Jonathan</td>
<td>91</td>
</tr>
<tr>
<td>Feinstein, Marc Jerome</td>
<td>121</td>
</tr>
<tr>
<td>Fendrich, Michael</td>
<td>124</td>
</tr>
<tr>
<td>Fenton, Melissa</td>
<td>119</td>
</tr>
<tr>
<td>Ferreiro, Andrea Vasquez</td>
<td>61</td>
</tr>
<tr>
<td>Ferretti, Morgan</td>
<td>119</td>
</tr>
<tr>
<td>Fidalgo, Thiago</td>
<td>23</td>
</tr>
<tr>
<td>Fields, Logan</td>
<td>84</td>
</tr>
<tr>
<td>Fink, David</td>
<td>83</td>
</tr>
<tr>
<td>Fitzgerald, Nicole</td>
<td>99</td>
</tr>
<tr>
<td>Flannagan, Kerry</td>
<td>119</td>
</tr>
<tr>
<td>Author</td>
<td>Page</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Fletcher, Jesse</td>
<td>137</td>
</tr>
<tr>
<td>Fockele, Callan</td>
<td>106</td>
</tr>
<tr>
<td>Fogelman, Nia</td>
<td>72</td>
</tr>
<tr>
<td>Forati, Amir Masoud</td>
<td>123</td>
</tr>
<tr>
<td>Foster, Daniel</td>
<td>22</td>
</tr>
<tr>
<td>Foster, Katrina</td>
<td>34</td>
</tr>
<tr>
<td>Fox, Evelyn</td>
<td>86</td>
</tr>
<tr>
<td>France, Charles</td>
<td>34</td>
</tr>
<tr>
<td>Franciotti, Kevin</td>
<td>24</td>
</tr>
<tr>
<td>Fredericksen, Rob</td>
<td>115</td>
</tr>
<tr>
<td>Freeman, Kevin</td>
<td>37</td>
</tr>
<tr>
<td>Freeman, Patricia</td>
<td>65</td>
</tr>
<tr>
<td>Freibott, Christina</td>
<td>136</td>
</tr>
<tr>
<td>Freisthler, Bridget</td>
<td>117</td>
</tr>
<tr>
<td>Friend, Lindsey</td>
<td>13</td>
</tr>
<tr>
<td>Frohe, Tessa</td>
<td>36</td>
</tr>
<tr>
<td>Frost, Madeline</td>
<td>107</td>
</tr>
<tr>
<td>Frye, Emma</td>
<td>94</td>
</tr>
<tr>
<td>Fuster, Daniel</td>
<td>75</td>
</tr>
<tr>
<td>Gaalema, Diann</td>
<td>45, 84</td>
</tr>
<tr>
<td>Gagonon, Kelly</td>
<td>85</td>
</tr>
<tr>
<td>Gainey, Sarah</td>
<td>62</td>
</tr>
<tr>
<td>Galaj, Ewa</td>
<td>94</td>
</tr>
<tr>
<td>Gallivan, Molly</td>
<td>92</td>
</tr>
<tr>
<td>García, Erik</td>
<td>19</td>
</tr>
<tr>
<td>García-Romeu, Albert</td>
<td>43</td>
</tr>
<tr>
<td>Gatch, Michael</td>
<td>94</td>
</tr>
<tr>
<td>Gazzola, Marina Gaeta</td>
<td>91</td>
</tr>
<tr>
<td>Gebru, Neo</td>
<td>19, 120</td>
</tr>
<tr>
<td>Gehlert, Don</td>
<td>77</td>
</tr>
<tr>
<td>Gex, Kathryn</td>
<td>57</td>
</tr>
<tr>
<td>Giannini, Jillian</td>
<td>105</td>
</tr>
<tr>
<td>Giardino, William</td>
<td>44</td>
</tr>
<tr>
<td>Gicquelais, Rachel</td>
<td>123</td>
</tr>
<tr>
<td>Gilbert, Paul</td>
<td>22</td>
</tr>
<tr>
<td>Giles, Michael</td>
<td>76</td>
</tr>
<tr>
<td>Gilman, Jodi</td>
<td>97</td>
</tr>
<tr>
<td>Glatfelter, Grant</td>
<td>95</td>
</tr>
<tr>
<td>Glynn, Tiffany</td>
<td>112</td>
</tr>
<tr>
<td>Golde, Jake</td>
<td>78</td>
</tr>
<tr>
<td>Gomez, Alejandro De La Hoz</td>
<td>115</td>
</tr>
<tr>
<td>Gonçalves, Priscila</td>
<td>19, 96</td>
</tr>
<tr>
<td>Gopaldas, Manesh</td>
<td>36, 104</td>
</tr>
<tr>
<td>Gordon, Ellie</td>
<td>76</td>
</tr>
<tr>
<td>Gorfinkel, Lauren</td>
<td>73</td>
</tr>
<tr>
<td>Gosden, Jane</td>
<td>116</td>
</tr>
<tr>
<td>Gould, Errol</td>
<td>68</td>
</tr>
<tr>
<td>Grasing, Ken</td>
<td>94</td>
</tr>
<tr>
<td>Greiner, Miranda</td>
<td>89</td>
</tr>
<tr>
<td>Gross, Ariana</td>
<td>70</td>
</tr>
<tr>
<td>Grossman, Daniel</td>
<td>58</td>
</tr>
<tr>
<td>Grunevski, Sergej</td>
<td>125</td>
</tr>
<tr>
<td>Gryczynski, Jan</td>
<td>87</td>
</tr>
<tr>
<td>Guerin, Alexandre</td>
<td>82</td>
</tr>
<tr>
<td>Gukasyan, Natalie</td>
<td>116</td>
</tr>
<tr>
<td>Gupta, Abhishek</td>
<td>118</td>
</tr>
<tr>
<td>Gust, Steve</td>
<td>16</td>
</tr>
<tr>
<td>Gutfkind, Sarah</td>
<td>131</td>
</tr>
<tr>
<td>Gutowski, Stacie</td>
<td>46</td>
</tr>
<tr>
<td>Guttman, Jeremy</td>
<td>76</td>
</tr>
<tr>
<td>Habersham, Leah</td>
<td>68</td>
</tr>
<tr>
<td>Habib, Mohammad</td>
<td>119</td>
</tr>
<tr>
<td>Haddad, Stephanie</td>
<td>79</td>
</tr>
<tr>
<td>Hagle, Holly</td>
<td>133</td>
</tr>
<tr>
<td>Hai, Audrey</td>
<td>110</td>
</tr>
<tr>
<td>Hammerslag, Lindsey</td>
<td>89</td>
</tr>
<tr>
<td>Hammond, Christopher</td>
<td>49</td>
</tr>
<tr>
<td>Hammond, David</td>
<td>32</td>
</tr>
<tr>
<td>Han, Benjamin</td>
<td>129</td>
</tr>
<tr>
<td>Hanbury, Richard</td>
<td>28</td>
</tr>
<tr>
<td>Hand, Dennis</td>
<td>60</td>
</tr>
<tr>
<td>Haney, Margaret</td>
<td>15</td>
</tr>
<tr>
<td>Hansson, Jocelyn</td>
<td>58</td>
</tr>
<tr>
<td>Haque, Lamia</td>
<td>121</td>
</tr>
<tr>
<td>Harfmann, Roxanne</td>
<td>90</td>
</tr>
<tr>
<td>Harris, Joshua</td>
<td>78</td>
</tr>
<tr>
<td>Harris, Miriam</td>
<td>68</td>
</tr>
<tr>
<td>Harrison, Eric</td>
<td>123</td>
</tr>
<tr>
<td>Harton, Moriah</td>
<td>113</td>
</tr>
<tr>
<td>Hartung, Daniel</td>
<td>125</td>
</tr>
<tr>
<td>Hartwell, Karen</td>
<td>133</td>
</tr>
<tr>
<td>Hartzler, Bryan</td>
<td>137</td>
</tr>
<tr>
<td>Hasin, Deborah</td>
<td>30</td>
</tr>
<tr>
<td>Hatch, Mary</td>
<td>135</td>
</tr>
<tr>
<td>Heges, Elizabeth</td>
<td>58</td>
</tr>
<tr>
<td>Hawk, Kathryn</td>
<td>127</td>
</tr>
<tr>
<td>Hayley, Amie</td>
<td>52</td>
</tr>
<tr>
<td>Heads, Angela</td>
<td>50</td>
</tr>
<tr>
<td>Heald, David</td>
<td>95</td>
</tr>
<tr>
<td>Heidari, Omeid</td>
<td>122</td>
</tr>
<tr>
<td>Hendricks, Peter</td>
<td>24, 43</td>
</tr>
<tr>
<td>Henningfield, Jack</td>
<td>30, 74</td>
</tr>
<tr>
<td>Henry, Maxine</td>
<td>110</td>
</tr>
<tr>
<td>Hernandez-Casas, Daisy</td>
<td>115</td>
</tr>
<tr>
<td>Herrera, Maria</td>
<td>60</td>
</tr>
<tr>
<td>Hester, Robert</td>
<td>36</td>
</tr>
<tr>
<td>Hides, Leanne</td>
<td>49</td>
</tr>
<tr>
<td>Hill, Justine</td>
<td>84</td>
</tr>
<tr>
<td>Hinckley, Jesse</td>
<td>51</td>
</tr>
<tr>
<td>Hindmarch, Grace</td>
<td>51</td>
</tr>
<tr>
<td>Hiranita, Takato</td>
<td>66</td>
</tr>
<tr>
<td>Hite, Desislava</td>
<td>75</td>
</tr>
<tr>
<td>Hite, Michael</td>
<td>46</td>
</tr>
<tr>
<td>Hobin, Jennifer</td>
<td>21</td>
</tr>
<tr>
<td>Hochheimer, Martin</td>
<td>71</td>
</tr>
<tr>
<td>Hochstatter, Karlí</td>
<td>75</td>
</tr>
<tr>
<td>Hodgson, Kate</td>
<td>64</td>
</tr>
<tr>
<td>Hoffman, Kim</td>
<td>79</td>
</tr>
<tr>
<td>Homsted, Felicity</td>
<td>66</td>
</tr>
<tr>
<td>Hoover, Daniel</td>
<td>128</td>
</tr>
<tr>
<td>Horigian, Viviana</td>
<td>132</td>
</tr>
<tr>
<td>Houghton, David</td>
<td>86</td>
</tr>
<tr>
<td>Howell, Benjamin</td>
<td>102</td>
</tr>
<tr>
<td>Huhn, Andrew</td>
<td>41, 42</td>
</tr>
<tr>
<td>Humphrey, Jamie</td>
<td>25</td>
</tr>
<tr>
<td>Hung, Chia-Chun</td>
<td>74</td>
</tr>
<tr>
<td>Huskinson, Sally</td>
<td>37</td>
</tr>
<tr>
<td>Ibrahim, Layan</td>
<td>81</td>
</tr>
<tr>
<td>Idrisov, Bulat</td>
<td>124</td>
</tr>
<tr>
<td>Ilgen, Mark</td>
<td>57</td>
</tr>
</tbody>
</table>
Islam, Kendall
Israel, Josh
Jackson, Logan
Jain, Jennifer
James, G. Andrew
Janes, Amy
Jarlais, Don Des
Jeansonne, Scott
Jemberie, Wossenseged Birhane
Jimes, Cynthia
Johnson, Carla
Johnson, Matthew
Johnson, Micah
Jones, Abenaa
Jones, Christopher
Jones, Jermaine
Jones, Joseph
Jones, Marissa
Joseph, Verlin
Joshi, Vandana
Kahler, Christopher
Kalmn, Mariah
Kan, Emily
Kang, Augustine
Kang, Kai-Hsiang
Karamouzian, Mohammad
Karavolis, Zoe
Karns-Wright, Tara
Karoly, Hollis
Karunakaran, Thiruventhan
Kasinather, Vicknasingam
Kasson, Erin
Katz, Brian
Kaufman, Marc
Kearney-Ramos, Tonisha
Keen, Larry
Kehne, Adrienne
Kelsch, Jordan
Kenesfick, Leslie
Kennedy-Hendricks, Alene
Kepner, Wayne
Khairy, Lisa
Khalsa, Rama
Khodaparast, Navid
Khokhar, Jibran
Khotimchenko, Maksim
King, Carla
King, Thomas
Kiraly, Drew
Kirk, Mia
Kirtadze, Irma
Kleykamp, Bethea
Knox, Justin
Knudsen, Hannah
Kock, Loren
Kong, Grace
Koob, George
Korthuis, P. Todd
Kosgolla, Janaka
Kouri, Nicole
Kou, Yen-Chun
Krause, Alexis
Krawczyk, Noa
Kritikos, Brooke E.
Krueger, Evan
Kulak, Jessica
Kusi-Boadum, Nana Kofi
Kuzniewicz, Michael
Lacy, Ryan
Lagisetty, Pooja
Lake, Stephanie
Lancaster, Kathryn
Lancelotta, Rafael
Lane, Suzanne
Langois, Jenna
Lanier, Ryan
Lankenau, Stephen
Lapham, Gwen
Larochelle, Marc
Lauckner, John
Lavin, Antonieta
Le, Mylinese
Ledgerwood, David
Lee, Dustin
Lee, Elizabeth
Lee, Kenneth
Lee, Tony Szu-Hsien
Levin, Adam
Levin, Frances
Levine, Emily A.
Levitsky, Igor
Li, Anna
Li, Shuwen
Li, Wei
Li, Yang
Liew, Megan
Lile, Joshua
Lin, Chunqing
Lin, Lewei (Allison)
Linden-Carmichael, Ashley
Lippi, Stephen
Livne, Ofrin
Lofwall, Michelle
London, Edythe
Lopes, Snehal
Lopez, Alexa
Lopez-Quintero, Catalina
Loree, Amy
Loya, Jennifer
Luba, Rachel
Ludwig-Barron, Natasha
Lukas, Scott
Lundahl, Leslie
Luo, Ting
Lyons, Myla
Macias, Miracle
Mackesy-Amiti, Mary
MacLean, Robert
Madden, Lynn
Mallahan, Stephanie
Malone, Natalie 65
Malone, Samantha 64
Manja, Veena 138
Mannes, Zachary 119
Marchette, Renata 66
Marcus, Olivia 74
Marino, Elise 35
Marks, Katherine 104
Marotta, Phil 123
Marra, Ashton 29
Martin, Caitlin 124
Martin, Erin 98
Martinez, Suky 66
Martins, Daniel 121
Martins, Silvia 88
Matheson, Justin 120
Mathur, Rahul 100
Mauro, Pia 71
Maxwell, Andrea 86
Mbichila, Tinkhani 87
McCabe, Andrew 88
McCleire, Erin 82
McCulstian, Caravella 24, 61
McCurdy, Li Yan 136
McGinty, Jacqueline 40
McGriff, Shelby 95
McKendrick, Greer 90
McLellan, A Thomas 28
McLeman, Bethany 128
McMahan, Vanessa 129
McNeely, Jennifer 54, 110
McPherson, Sterling 127
Meacham, Meredith 26, 57
Meade, Christina 119
Meadows, Diamond 71
Medina, Maritza Perez 39
Meredith, Lisa 51
Merritt, Christina 127
Mestre, Luis 99
Metz, Verena 109
Mian, Maha 98
Mihic, Tamara 60
Miller, Thomas 78
Miloslavich, Krista 67
Mitchell, Jennifer 24
Mitchell, Shannon 64
Mitra, Sanjana 69
Mixon, Lyndsey 109
Moeller, F. Gerard 40
Moffitt, Trevor 108
Mohebbi, Fahimeh 123
Moline, Margaret 114
Montgomery, Barrett 47, 102
Moore, Debra 20
Moore, Kelly 126
Moreira, Eliseu 74
Moreland, Angela 23, 105
Moriceau, Sarah 55
Morris, Alexis 83
Morrison, Filomene 67
Morse, Sophie 65
Moses, Tabitha 55
Motemayor, Ana Chapa 97
Moyers, Susette 35
Mulford, Carrie 51
Murnane, Kevin 43
Murphy, Zoe 73
Murray, Conor 82
Murray, Laura 100
Myers, Amanda 92
Myers, Matthew 81
Nader, Michael 37
Nelson, Erik 25
Nesoff, Elizabeth 101
Nguyen, Anh 102
Nguyen, Diep Bich 106
Nguyen, Tam 78
Nielsen, Suzanne 23, 65
Noggle, Brendan 121
Nordeck, Courtney 103
Novak, Matthew 45, 117
Obekpa, Elizabeth 106
Obel, Geoffrey 24
Oberlin, Brandon 75
Ochal, Domenic 125
Ochalek, Taylor 90
O’Dell, Nicole 81
Odom, Gabriell 53
Oesterle, Tyler 114
Okita, Kyoji 55
Oliva, Henrique 62, 94
Oliver, Jeffrey 75
Olszewski, Nathan 85
Onigbogi, Olanrewaju 84
Oon-arom, Awirut 113
Opara, Onumara 85
Ortiz, Cynthia 83
Oser, Carrie 63
Oviedo-Joekes, Eugenia 22
Palmasano, Alexandra 58
Pang, Raina 84
Papa, Carrie 126
Pareek, Tanya 80
Parker, Maria 24, 85
Parks, Michael 79
Parlier-Ahmad, Anna 105
Parms, Tiffany 121
Paschke, Maria 26
Pasternak, Annie 77
Patton, Thomas 107
Pearlman, Morgan 82
Peck, Kelly 61
Peles, Einat 85
Perez-Carreno, Juan G 97
Perez, Patricio Viera 100
Perez-Pedrogo, Coralee 72
Perron, Lauren 106
Perse, Artin 79
Peters, Erica 38
<table>
<thead>
<tr>
<th>Author</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pham, Huyen</td>
<td>61</td>
</tr>
<tr>
<td>Phillips, Kristina</td>
<td>130</td>
</tr>
<tr>
<td>Pho, Mai</td>
<td>27</td>
</tr>
<tr>
<td>Picco, Louisa</td>
<td>107</td>
</tr>
<tr>
<td>Pickering, Eleanor</td>
<td>92</td>
</tr>
<tr>
<td>Plaitano, Enzo</td>
<td>131</td>
</tr>
<tr>
<td>Pollock, Jonathan</td>
<td>41</td>
</tr>
<tr>
<td>Potter, Jennifer</td>
<td>34</td>
</tr>
<tr>
<td>Pravetoni, Marco</td>
<td>49</td>
</tr>
<tr>
<td>Preston, Thomas</td>
<td>98</td>
</tr>
<tr>
<td>Pridgen, Bailey</td>
<td>126</td>
</tr>
<tr>
<td>Pringle, Janice</td>
<td>20</td>
</tr>
<tr>
<td>Proferes, Nicholas</td>
<td>27</td>
</tr>
<tr>
<td>Purdon, Patrick</td>
<td>46</td>
</tr>
<tr>
<td>Pytell, Jarratt</td>
<td>101</td>
</tr>
<tr>
<td>Quarles, Emma</td>
<td>57</td>
</tr>
<tr>
<td>Quddos, Fatima</td>
<td>74</td>
</tr>
<tr>
<td>Rahman, Tahsin</td>
<td>31</td>
</tr>
<tr>
<td>Rains, Alex</td>
<td>27, 134</td>
</tr>
<tr>
<td>Ralte, Lalchhanhima</td>
<td>96</td>
</tr>
<tr>
<td>Ramaekers, Jan</td>
<td>52</td>
</tr>
<tr>
<td>Ramirez, Miranda</td>
<td>119</td>
</tr>
<tr>
<td>Ramsey, Kelly</td>
<td>33</td>
</tr>
<tr>
<td>Randall-Thompson, Jovita</td>
<td>38</td>
</tr>
<tr>
<td>Rao, Deepika</td>
<td>60</td>
</tr>
<tr>
<td>Ray, Lara</td>
<td>45</td>
</tr>
<tr>
<td>Reed, Brian</td>
<td>18</td>
</tr>
<tr>
<td>Reed, Derek</td>
<td>40</td>
</tr>
<tr>
<td>Reed, Megan</td>
<td>128</td>
</tr>
<tr>
<td>Reeser, David</td>
<td>46</td>
</tr>
<tr>
<td>Regan, Timothy</td>
<td>55</td>
</tr>
<tr>
<td>Regier, Paul</td>
<td>112</td>
</tr>
<tr>
<td>Regnier, Sean</td>
<td>77, 117</td>
</tr>
<tr>
<td>Reich, Jeffrey</td>
<td>79</td>
</tr>
<tr>
<td>Reif, Sharon</td>
<td>67</td>
</tr>
<tr>
<td>Richardson, Julia</td>
<td>71</td>
</tr>
<tr>
<td>Ridenour, Ty</td>
<td>46, 47</td>
</tr>
<tr>
<td>Robinson, Athena</td>
<td>78</td>
</tr>
<tr>
<td>Rocha, Beatriz</td>
<td>30</td>
</tr>
<tr>
<td>Roehrs, Timothy</td>
<td>138</td>
</tr>
<tr>
<td>Roman, Benjamin</td>
<td>120</td>
</tr>
<tr>
<td>Ross, Che</td>
<td>102</td>
</tr>
<tr>
<td>Ross, J. Megan</td>
<td>118</td>
</tr>
<tr>
<td>Rouhani, Saba</td>
<td>67</td>
</tr>
<tr>
<td>Rowlett, James</td>
<td>36, 37</td>
</tr>
<tr>
<td>Roy, Payel</td>
<td>61</td>
</tr>
<tr>
<td>Russell, Lauren</td>
<td>56</td>
</tr>
<tr>
<td>Ruth, Avaion</td>
<td>128</td>
</tr>
<tr>
<td>Ryan, Jennie</td>
<td>135</td>
</tr>
<tr>
<td>Ryan-Pettes, Stacy</td>
<td>19</td>
</tr>
<tr>
<td>Rzeszutek, Mark</td>
<td>118</td>
</tr>
<tr>
<td>Saavedra, Lissette</td>
<td>46</td>
</tr>
<tr>
<td>Sadler, Richard</td>
<td>25</td>
</tr>
<tr>
<td>Sahlem, Gregory</td>
<td>120</td>
</tr>
<tr>
<td>Sakai, Joseph</td>
<td>34</td>
</tr>
<tr>
<td>Salow, Katheryn</td>
<td>113</td>
</tr>
<tr>
<td>Samples, Hillary</td>
<td>59</td>
</tr>
<tr>
<td>Sancho-Domingo, Clara</td>
<td>118</td>
</tr>
<tr>
<td>Santos, Glenn-Milo</td>
<td>50</td>
</tr>
<tr>
<td>Santo, Thomas</td>
<td>59</td>
</tr>
<tr>
<td>Saraiya, Tanya</td>
<td>100</td>
</tr>
<tr>
<td>Satybaltiyeva, Nora</td>
<td>135</td>
</tr>
<tr>
<td>Saunders, Elizabeth</td>
<td>100</td>
</tr>
<tr>
<td>Scarpetta, Maia</td>
<td>112</td>
</tr>
<tr>
<td>Schacht, Joseph</td>
<td>45</td>
</tr>
<tr>
<td>Scheidell, Joy</td>
<td>59</td>
</tr>
<tr>
<td>Schepis, Ty</td>
<td>95</td>
</tr>
<tr>
<td>Schermitzer, Brandon</td>
<td>120</td>
</tr>
<tr>
<td>Schmitz, Joy</td>
<td>14, 50</td>
</tr>
<tr>
<td>Schow, Nicole</td>
<td>123</td>
</tr>
<tr>
<td>Schranz, Asher</td>
<td>111</td>
</tr>
<tr>
<td>Scott, Pamela</td>
<td>34</td>
</tr>
<tr>
<td>Searcy, Carly</td>
<td>118</td>
</tr>
<tr>
<td>Seegulam, Vijaya</td>
<td>98</td>
</tr>
<tr>
<td>Serrano, Vanessa</td>
<td>114</td>
</tr>
<tr>
<td>Sessler, Nelson</td>
<td>96</td>
</tr>
<tr>
<td>Shah, Hridika</td>
<td>68</td>
</tr>
<tr>
<td>Shakhshir, Ali</td>
<td>114</td>
</tr>
<tr>
<td>Shakyta, Pooja</td>
<td>61</td>
</tr>
<tr>
<td>Sharma, Anjalee</td>
<td>110</td>
</tr>
<tr>
<td>Shearer, Riley</td>
<td>100</td>
</tr>
<tr>
<td>Shepherd, Justin</td>
<td>84</td>
</tr>
<tr>
<td>Shetty, Shekar</td>
<td>78</td>
</tr>
<tr>
<td>Shulman, Matisyahu</td>
<td>97</td>
</tr>
<tr>
<td>Shurtleff, David</td>
<td>16</td>
</tr>
<tr>
<td>Siegel, Gregg</td>
<td>76</td>
</tr>
<tr>
<td>Silverstein, Sydney</td>
<td>128</td>
</tr>
<tr>
<td>Silwal, Anita</td>
<td>108</td>
</tr>
<tr>
<td>Singh, Vasudha</td>
<td>92</td>
</tr>
<tr>
<td>Skewes, Monica</td>
<td>26</td>
</tr>
<tr>
<td>Skinstad, Anne</td>
<td>21</td>
</tr>
<tr>
<td>Skogseth, Emma</td>
<td>101</td>
</tr>
<tr>
<td>Slavin, Melissa</td>
<td>132</td>
</tr>
<tr>
<td>Slosky, Lauren</td>
<td>43</td>
</tr>
<tr>
<td>Smid, Marcela</td>
<td>68</td>
</tr>
<tr>
<td>Smith, Danielle</td>
<td>134</td>
</tr>
<tr>
<td>Smith, Kirsten</td>
<td>68</td>
</tr>
<tr>
<td>Smith, Rachel</td>
<td>122</td>
</tr>
<tr>
<td>Smith, Sharon</td>
<td>95</td>
</tr>
<tr>
<td>Smoker, Michael</td>
<td>132</td>
</tr>
<tr>
<td>Snyder, Hannah</td>
<td>96</td>
</tr>
<tr>
<td>Snyder, Matthew</td>
<td>135</td>
</tr>
<tr>
<td>Sokolowska, Marta</td>
<td>30</td>
</tr>
<tr>
<td>Sorg, Barbara</td>
<td>40</td>
</tr>
<tr>
<td>Sorkhou, Maryam</td>
<td>118</td>
</tr>
<tr>
<td>Soshnikov, Sergey</td>
<td>137</td>
</tr>
<tr>
<td>Sosnowski, David</td>
<td>134</td>
</tr>
<tr>
<td>Sousa, Jason</td>
<td>49</td>
</tr>
<tr>
<td>Spindle, Tory</td>
<td>52</td>
</tr>
<tr>
<td>Spitz, Stephanie</td>
<td>115</td>
</tr>
<tr>
<td>Sproule, Beth</td>
<td>103</td>
</tr>
<tr>
<td>Stanton, Cory</td>
<td>73</td>
</tr>
<tr>
<td>Stanton, Michele</td>
<td>86</td>
</tr>
<tr>
<td>Steine, Steven</td>
<td>22</td>
</tr>
<tr>
<td>Stein, Lynda</td>
<td>107</td>
</tr>
<tr>
<td>Stevens-Watkins, Danelle</td>
<td>26</td>
</tr>
<tr>
<td>Stoltman, Jonathan</td>
<td>29</td>
</tr>
<tr>
<td>Strait, Matthew</td>
<td>17</td>
</tr>
<tr>
<td>Strickland, Justin</td>
<td>39, 40</td>
</tr>
<tr>
<td>Striley, Catherine</td>
<td>111</td>
</tr>
</tbody>
</table>
AUTHOR INDEX

Strong-Jones, Sienna 122  
Struble, Cara 30, 31  
Stull, Samuel 125  
Sugarman, Dawn 108  
Sullivan, John 80  
Sullivan, Kyle 41  
Surratt, Hilary 70  
Suzuki, Joji 104  
Svikis, Dace 69  
Sweeney, Kaylin 91  
Szlyk, Hannah 62  
Takano, Ayumi 117  
Tatangelo, Mark 103  
Terashima, Javier Ponce 106  
Teti, Michelle 137  
Thiessen, Karina 97  
Thompson, Ronald 28  
Thrul, Johannes 71  
Tilhou, Alyssa 60  
Tillson, Martha 63  
Timberlake, John 77  
Timmons, Patricia 117  
Tiouririne, Nassima Ait-Daoud 34  
Todesco, Stefanie 131  
Tofighi, Babak 66  
Tomko, Catherine 70, 92  
Tomlinson, Devin 122  
Tonigan, Alexandra 47  
Torralva, Phillip 42  
Towers, Eleanor 67  
Towe, Sheri 82  
Townsend, Drew 49  
Traxler, Haily 96  
Treitler, Peter 130  
Tross, Susan 135  
Tsui, Judith 27, 88  
Unterwald, Ellen 17, 18  
Valeri, Jake 80  
Vallender, Eric 118  
Van Dyne, Angelina 112  
Vemuri, Kiran 47  
Vest, Bonnie 67  
Vest, Noel 36, 110  
Vidal, Carol 80  
Vidot, Denise 37, 112  
Viera, Adam 107  
Vitaliano, Gordana 79  
Volkow, Nora 13, 15, 28  
Vo, Quynh 99  
Vroom, Enya 89  
Wagner, Karla 74  
Wahab, Suzaily 111  
Walsh, Claire 138  
Wang, Anna 86  
Wang, Danny 115  
Wang, Hannah 94  
Wang, Jia Bei 76  
Wang, Jijiang 56  
Ware, Orrin 72  
Warren, Katherine 129  
Wartko, Paige 108  
Washio, Yukiko 58  
Weaver, Nicholas 89  
Webber, Heather 74  
Webster, Matt 91  
Weiss, Roger 127  
Weiss, Susan 16  
Wesley, Michael 126  
West, Brooke 88  
Whistler, Jennifer 48  
White, Augustus 124  
Whiteside, Lauren 126  
Wiese, Anna 120  
Wightman, Rachel 98  
Wiley, Rhiannon 100  
Wilkerson, J. Michael 63  
Williams, Arthur Robin 125  
Williams, Emily 88  
Williams, Michael 91  
Windsor, Liliane 115  
Winstanley, Erin 101  
Witcraft, Sara 104  
Withey, Sarah 83, 106  
Wolinsky, David 56  
Wolkowicz, Noah 127  
Won, Hyejung 41  
Won, Nae 68  
Won, Carolyn 97  
Wong, Jennifer 34  
Woody, George 62  
Wright, Madison 57  
Wright, Susan 47  
Wu, Shang-Chi 134  
Wyse, Jessica 128  
Xenakis, Stephen 24  
Xin, Yitong 74  
Xu, Kevin 87  
Yan, ‘Elise’ Xu 98  
Yanez, Jaime 42  
Yang, Yang 126  
Yasuma, Naonori 81  
Yeh, Yu-Hua 73  
Yip, Sarah 44, 45  
Young, Samantha 103  
Zamarripa, Carlos 52  
Zeid, Dana 94  
Zhang, Chenming 49  
Zhao, Yihong 57  
Zhou, Yanjiao 48  
Zhu, Yuhui 114
<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Merideth Addicott</td>
<td>Dr. Jermaine Jones</td>
</tr>
<tr>
<td>Dr. Judy Ashworth</td>
<td>Dr. Scott Lane</td>
</tr>
<tr>
<td>Dr. Sudie Back</td>
<td>Dr. Scott Lukas</td>
</tr>
<tr>
<td>Dr. Jack Bergman</td>
<td>Dr. Wendy Lynch</td>
</tr>
<tr>
<td>Dr. Qiana Brown</td>
<td>Dr. Bertha Madras</td>
</tr>
<tr>
<td>Dr. Kathleen Bucholz</td>
<td>Dr. Paolo Mannelli</td>
</tr>
<tr>
<td>Dr. Alan Budney</td>
<td>Dr. Silvia Martins</td>
</tr>
<tr>
<td>Dr. Sandra Comer</td>
<td>Dr. Deborah Mash</td>
</tr>
<tr>
<td>Dr. James Cook</td>
<td>Dr. Shayna Mazel</td>
</tr>
<tr>
<td>Dr. Andrew Coop</td>
<td>Dr. Heidi Melbostad</td>
</tr>
<tr>
<td>Dr. Ziva Cooper</td>
<td>Dr. John Mendelson</td>
</tr>
<tr>
<td>Dr. Linda Cottler</td>
<td>Dr. Angela Moreland</td>
</tr>
<tr>
<td>Dr. Richard De La Garza</td>
<td>Dr. Jason Paris</td>
</tr>
<tr>
<td>Evan Dickert</td>
<td>Dr. Robert Pechnick</td>
</tr>
<tr>
<td>Dr. Kelly Dunn</td>
<td>Dr. Tasha Perdue</td>
</tr>
<tr>
<td>Dr. Linda Dwoskin</td>
<td>Dr. Marco Pravetoni</td>
</tr>
<tr>
<td>Dr. Linda Dykstra</td>
<td>Dr. James Rowlett</td>
</tr>
<tr>
<td>Dr. Reginald Fant</td>
<td>Dr. Sidney Schnoll</td>
</tr>
<tr>
<td>Dr. Francesca Filbey</td>
<td>Dr. Brian Sherman</td>
</tr>
<tr>
<td>Dr. Albert Garcia-Romeu</td>
<td>Dr. Stacey Sigmon</td>
</tr>
<tr>
<td>Dr. Ellen Geller</td>
<td>Dr. Mark Smith</td>
</tr>
<tr>
<td>Dr. Jillian Giannini</td>
<td>Dr. Lindsay Snyder</td>
</tr>
<tr>
<td>Johns Hopkins University Behavioral Pharmacology Research Unit</td>
<td>Dr. William Stoops</td>
</tr>
<tr>
<td>Dr. Cassandra Gipson-Reichardt</td>
<td>Dr. Eric Strain</td>
</tr>
<tr>
<td>Dr. Charles Gorodetzky</td>
<td>Dr. John Strang</td>
</tr>
<tr>
<td>Dr. Shelly Greenfield</td>
<td>Dr. Yung-Fong Sung-Holtzman</td>
</tr>
<tr>
<td>Dr. Margaret Haney</td>
<td>Dr. Dace Svikis</td>
</tr>
<tr>
<td>Dr. Deborah Hasin</td>
<td>Dr. Michael Taffe</td>
</tr>
<tr>
<td>Dr. Richard Hawks</td>
<td>Dr. D. Andrew Tompkins</td>
</tr>
<tr>
<td>Dr. Angela Heads</td>
<td>Dr. Judith Tsui</td>
</tr>
<tr>
<td>Dr. Jack Henningfield</td>
<td>Dr. Annie Umbricht</td>
</tr>
<tr>
<td>Dr. Denise Hien</td>
<td>Dr. Patricio Viera Perez</td>
</tr>
<tr>
<td>Dr. Frederic Hopf</td>
<td>Dr. Wendee Wechsberg</td>
</tr>
<tr>
<td>Jesse Howard</td>
<td>Dr. Erin Winstanley</td>
</tr>
<tr>
<td>Dr. Amy Janes</td>
<td>Dr. George Woody</td>
</tr>
</tbody>
</table>